ANTI-CANCER PROPERTIES OF TAT-RasGAP317_326 AND MOLECULAR MECHANISMS OF RESISTANCE TO SORAFENIB by Chevalier, Nadja
Unicentre 
CH-1015 Lausanne 
http://serval.unil.ch 
RRYear : 2017 
ANTI-CANCER PROPERTIES OF TAT-RasGAP317-326 AND 
MOLECULAR MECHANISMS OF RESISTANCE TO SORAFENIB 
Chevalier Nadja 
Chevalier Nadja, 2017, ANTI-CANCER PROPERTIES OF TAT-RasGAP317-326 AND 
MOLECULAR MECHANISMS OF RESISTANCE TO SORAFENIB 
Originally published at : Thesis, University of Lausanne 
Posted at the University of Lausanne Open Archive http://serval.unil.ch 
Document URN : urn:nbn:ch:serval-BIB_02F0A2758C821 
Droits d’auteur 
L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les 
documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la 
loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir 
le consentement préalable de l'auteur et/ou de l’éditeur avant toute utilisation d'une oeuvre ou 
d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la 
LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette 
loi. Nous déclinons toute responsabilité en la matière. 
Copyright 
The University of Lausanne expressly draws the attention of users to the fact that all documents 
published in the SERVAL Archive are protected by copyright in accordance with federal law on 
copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the 
author and/or publisher before any use of a work or part of a work for purposes other than 
personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose 
offenders to the sanctions laid down by this law. We accept no liability in this respect.
Département de Physiologie 
ANTI-CANCER PROPERTIES OF TAT-RasGAP317-326 AND 
MOLECULAR MECHANISMS OF RESISTANCE TO SORAFENIB 
Thèse de doctorat 
MD - PhD 
présentée à la 
Faculté de biologie et de médecine 
de l’Université de Lausanne 
par 
Nadja CHEVALIER 
Médecin diplômée de la Confédération Helvétique 
Jury 
Prof. Ivan Stamenkovic, Président  
Prof. Christian Widmann, Directeur de thèse 
Dr. Nicole Gross, Co-directrice de thèse 
Dr. Isabelle Janoueix-Lerosey, Experte 
Prof. Fabio Martinon, Expert 
Prof. Jean Gruenberg, Expert 
Lausanne 2017 

  
 
 
 
 
 
 
La science efface l'ignorance d'hier et révèle l'ignorance de demain.  
David Gross 
 
  
  
TABLE OF CONTENTS 
  3 
TABLE OF CONTENTS 
 
SUMMARY ............................................................................................................................. 5  
RESUME ................................................................................................................................ 6  
ABBREVIATIONS .................................................................................................................. 9  
INTRODUCTION .................................................................................................................. 13 
Cancer ................................................................................................................................. 13 
Origin of cancer ................................................................................................................................. 13 
Hallmarks of cancer .......................................................................................................................... 14 
Anti-cancer therapeutics ................................................................................................................... 17 
Hepatocellular carcinoma .................................................................................................................. 20 
 Epidemiology .............................................................................................................................. 20 
Pathogenesis .............................................................................................................................. 21 
Diagnosis .................................................................................................................................... 22 
Treatment ................................................................................................................................... 23 
Sorafenib resistance .................................................................................................................... 24 
Pediatric cancers ............................................................................................................................... 25  
Cell death ............................................................................................................................. 27 
Apoptosis ........................................................................................................................................... 27 
Necroptosis ....................................................................................................................................... 28 
Parthanatos ....................................................................................................................................... 29 
Pyroptosis .......................................................................................................................................... 29 
Autophagy ......................................................................................................................................... 30 
Ferroptosis ........................................................................................................................................ 30  
The TAT-RasGAP317-326 peptide ........................................................................................... 33 
Origin of TAT-RasGAP317-326 ............................................................................................................. 33 
Peptide-based drugs ......................................................................................................................... 35 
Cell-penetrating peptides .................................................................................................................. 35  
AIMS OF THE PROJECTS .................................................................................................. 41 
 
RESULTS ............................................................................................................................ 43 
Part I .................................................................................................................................... 43 
Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers .... 43 
Publication ......................................................................................................................................... 45  
Part II ................................................................................................................................... 61 
The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and 
necroptosis-independent manner  ........................................................................................ 61 
 
Publication ......................................................................................................................................... 63 
Related unpublished data ..................................................................................................... 87 
Part III .................................................................................................................................. 91 
TABLE OF CONTENTS 
  4 
Genome-wide CRISPR/Cas9 identifies the involvement of potassium channels and the 
Na+/K+-ATPase pump in the cytosolic access of TAT-constructs and viruses  ...................... 93 
 
Introduction ........................................................................................................................................ 93 
Materials and methods ...................................................................................................................... 94 
Results ............................................................................................................................................ 100 
Discussion ....................................................................................................................................... 115 
Supplementary table and figures .................................................................................................... 118 
 
Related data ....................................................................................................................... 125 
Part IV ................................................................................................................................ 137 
Identification of genes involved in acquired sorafenib resistance in hepatocellular    
carcinoma........................................................................................................................... 139 
 
Introduction ...................................................................................................................................... 139 
Materials and methods .................................................................................................................... 140 
Results ............................................................................................................................................ 143 
Discussion ....................................................................................................................................... 151 
Supplementary table and figures .................................................................................................... 154  
DISCUSSION ..................................................................................................................... 157  
REMERCIEMENTS ............................................................................................................ 163  
REFERENCES ................................................................................................................... 165  
ANNEX I ............................................................................................................................ 185  
A WxW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide ........ 187  
ANNEX II............................................................................................................................ 199 
Aldehyde dehydrogenase activity plays a key role in the aggressive phenotype of 
neuroblastoma ................................................................................................................... 201         
 
  
  
SUMMARY 
  5 
SUMMARY 
 
Although some types of tumours are now considered curable, cancer remains one of the deadliest 
diseases in the world. While various therapeutic strategies exist to treat malignant disease, too many 
tumours are refractory to current treatments. To improve cancer outcome several approaches can be 
undertaken, including the amelioration of the current anti-cancer therapies, the development of novel 
and more efficient drugs, or the reduction of treatment associated long-term side effects. 
 
Our laboratory previously developed an anti-cancer peptide called TAT-RasGAP317-326. This ten amino 
acid peptide, derived from the RasGAP protein and coupled to the TAT cell-penetrating peptide, 
sensitizes adult cancer cells to various chemotherapies and radiotherapy. In addition, it possesses the 
ability to prevent metastasis formation by hampering cell migration and invasion.  
In the present study, we report the identification of two new features of TAT-RasGAP317-326: its 
capacity to sensitize pediatric tumours to several chemotherapeutic agents and its ability to directly kill 
some cancer cells. The former property may be of considerable benefit to children by increasing the 
efficacy of anti-cancer therapies, which could allow to lower their dosage and associated side-effects. 
The second feature gave us the opportunity to investigate the mechanism of action of the peptide, 
which remained to be precisely determined, through the characterization of the mode of cell death 
triggered by it. Using pharmacological and genetic strategies, we demonstrated that cell death was not 
fully prevented when regulated forms of death including apoptosis, necroptosis, autophagy, 
parthanatos, and pyroptosis were inhibited. In addition, we performed CRISPR/Cas9 screens to 
identify genes that were required for the peptide to kill. The top candidates highlighted by the screens 
were mostly regulators of potassium flux including three potassium channels (KCNQ5, KCNN4, and 
KCNK5) as well as a subunit of the Na+/K+-ATPase pump (ATP1B3). However, instead of being 
required in the death induction process per se, we demonstrated that they were involved in the 
cytosolic access of TAT-RasGAP317-326. Although the mode of action of the peptide is still not fully 
understood, the RasGAP-derived peptide could be used to fight cancer on several fronts as a 
sensitizer or a direct cancer cell killer. 
 
At present, a major concern in anti-cancer therapies is treatment resistance leading to the relapse of 
the tumour. Despite the use of a multi-kinase inhibitor named sorafenib, advanced hepatocellular 
carcinoma has a poor prognosis, mainly due to intrinsic and acquired resistances. As the exact 
mechanisms of resistance to sorafenib are still incompletely understood, we performed exome 
sequencing analyses and CRISPR/Cas9 screening to identify novel pathways that lead to sorafenib 
resistance. Although we are still analysing and validating the data, preliminary results highlighted 
already known genetic alterations, such as p53 Y220C structural mutation and EGFR amplification. A 
better knowledge of sorafenib resistance could ultimately lead to the development of alternative 
therapies. 
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RESUME  
 
Bien qu’il soit aujourd’hui possible de guérir certaines tumeurs, le cancer demeure une des maladies 
les plus meurtrières dans le monde. Si différentes stratégies thérapeutiques ont été développées, un 
grand nombre de tumeurs restent encore réfractaires aux traitements. Le développement de 
nouveaux médicaments plus efficaces, la potentialisation des thérapies anti-cancéreuses existantes, 
ainsi que la réduction des effets secondaires inhérents à la toxicité des traitements offrent l’espoir 
d’améliorer considérablement le pronostique du cancer. 
 
Notre laboratoire a développé un peptide anti-cancéreux nommé TAT-RasGAP317-326. Ce dernier est 
capable de pénétrer dans les cellules cancéreuses et de les sensibiliser à différentes chimiothérapies, 
ainsi qu’à la radiothérapie. Il possède également la capacité d’empêcher la formation de métastases 
en inhibant la migration et l’invasion des cellules tumorales.    
La présente étude identifie deux nouvelles propriétés de TAT-RasGAP317-326 : celle de sensibiliser les 
tumeurs pédiatriques à plusieurs chimiothérapies, afin d’en augmenter l’efficacité, et celle de tuer 
directement certaines lignées cancéreuses. Cette dernière propriété a permis l’investigation du 
mécanisme d’action de ce peptide anti-cancéreux par la caractérisation du type de mort qu’il 
engendrait. L’utilisation d’antagonistes pharmacologiques et l’inhibition génétique des différentes 
modalités de mort cellulaire ont montré que TAT-RasGAP317-326 déclenche une nouvelle forme de mort 
ne correspondant à aucune de celles que nous avions testées. Une seconde approche a été utilisée, 
qui est capable de cribler le génome entier afin d’identifier les gènes nécessaires à la toxicité du 
peptide. Les meilleurs candidats générés par cette méthode sont principalement des régulateurs du 
flux potassique, comprenant trois canaux potassiques (KCNN4, KCNQ5 et KCNK5) et une sous-unité 
de la pompe Na+/K+-ATPase (ATP1B3). Cependant, nous avons démontré que ces gènes n’étaient 
pas impliqués dans l’induction de la mort cellulaire, mais dans l’accès cytoplasmique de TAT-
RasGAP317-326. Bien que le mode d’action de ce peptide n’ait été que partiellement élucidé, il possède 
la qualité de pouvoir combattre le cancer de deux manières : en l’éradiquant directement ou en le 
sensibilisant à d’autres traitements anti-cancéreux.  
Une des causes majeures d’échec des thérapies anti-cancéreuses est le développement de 
résistances par les cellules néoplasiques, induisant la rechute de la maladie. Le carcinome 
hépatocellulaire illustre idéalement ce phénomène. En effet, le pronostique désastreux de ce cancer 
est principalement dû aux résistances intrinsèques et acquises contre le sorafenib, seule molécule 
actuellement disponible pour traiter cette pathologie à un stade avancé. Les mécanismes de 
résistance étant incomplètement élucidés, le second volet de cette thèse repose sur l’identification de 
nouvelles voies moléculaires utilisées par les cellules hépatiques malignes pour contrer la toxicité du 
sorafenib. Le séquençage des exomes de lignées cellulaires résistantes à ce traitement a révélé des 
altérations génétiques déjà décrites dans la littérature, telles que la mutation Y220C de p53 et 
l’amplification d’EGFR. Nous sommes actuellement toujours en cours d’analyse des données 
générées par le séquençage, afin de mettre en évidence d’autres mutations impliquées dans la 
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résistance au sorafenib. En effet, une meilleure connaissance de ces altérations pourrait conduire au 
développement de thérapies alternatives. 
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7-AAD   7-AminoActinomycin D 
ACD   Accidental cell death 
ACT   Adoptive cellular therapy  
AFP   Alpha-fetoprotein 
AIF   Apoptosis-inducing factor 
AP2   Adaptor protein 2 
APAF1   Apoptotic protease activating factor 1 
APG-2   Asante Potassium Green 2 
ATG   Autophagy-related 
ATP   Adenosine triphosphate  
Bcl-2   B-cell lymphoma-2 
BCLC   Barcelona Clinic Liver Cancer 
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INTRODUCTION 
 
Cancer 
 
In 2012, 8.2 million people died from cancer worldwide and the global burden was grown to 14 million 
newly diagnosed cases [1]. By 2030, 13 million cancer-related deaths and 22 million new cancer 
cases are predicted to occur all over the world [2]. Cancer is the first leading cause of death in 
developed countries and the second one in developing countries. On a global scale, one in seven 
deaths is due to cancer [3].  
 
 
ORIGIN OF CANCER 
 
The oldest description of cancer comes from Egypt and dates back to about 3000 B.C. An ancient 
manuscript, the Edwin Smith Papyrus, describes that some cases of breast and bone tumours were 
found in human mummies in ancient Egypt [4]. Though, it is Hippocrates (460-370 B.C.), the “Father of 
Medicine”, who first established the word cancer (karkinos in ancient Greek). It means crab, referring 
most likely to the morphology of tumours with an irregular shape and some finger-like spreading 
projections [5]. At that time, the pathogenesis and the causes of cancer were not yet established. We 
had to wait until the 20th century to understand that cancer is a generic name for a heterogeneous 
group of diseases, which are caused by somatic mutations mainly in tumour-suppressor genes, 
oncogenes, and microRNA genes. These acquired alterations confer competitive advantages over the 
non-mutated cells, characterized by an uncontrolled growth and spread of abnormal cells. The 
transformation from a normal into a cancer cell is rarely a single genetic change, but most often a 
multistage process of sequential alterations in several genes that regulate cell homeostasis [6]. Only a 
few genomic mutations have the ability to induce tumorigenicity. There are driver mutations that 
directly or indirectly induce the oncogenic transformation, and the so-called passenger mutations that, 
for instance, lie in non-exonic regions or in regions that are not crucial for the protein function [7]. The 
latter do not contribute to cancer progression. Some mutations confer high genomic instability to 
cancer cells which in turn results in the accumulation of several other mutations. This genomic 
instability leads to the formation of cytogenetically different clones that arise from multiple secondary 
or tertiary mutations. This high heterogeneity is responsible for variations in clinical behaviour and 
responses to treatment of tumours originating from the same diagnostic type. In addition to genetic 
modifications, the state of a cell can be affected by epigenetic processes. Almost all human cancers 
bear epigenetic dysregulation including DNA methylation, histone modifications, and signalling by non-
coding RNAs. Epigenetic transformation is a major contributing factor for tumour heterogeneity [8]. 
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Our knowledge of the exact mutational processes, that induce somatic mutations, remains limited. 
However, some tumour types were found to be characterized by specific mutational signatures that 
could be the consequence of viral, chemical, or physical carcinogen exposures, such as hepatitis B or 
C virus (HBV/HCV) infections in hepatocellular carcinoma, tobacco smoking in lung tumours, or 
ultraviolet light in skin cancers, respectively. Moreover, around 15% of malignancies are due to 
inherited mutations. Finally, aging increases the probability to develop cancers, most likely because 
cellular repair mechanisms tend to be less effective and due to a build-up of risks for specific tumours 
[9].  
 
 
HALLMARKS OF CANCER 
 
Despite the remarkable biological heterogeneity of cancers in human, these diseases share common 
biological traits acquired during their multistage development. These distinctive and complementary 
hallmarks enable the driving of a population of normal cells to become a tumour. In 2011, Doug 
Hanahan and Robert Weinberg published “Hallmarks of cancer: the next generation”, a report of 
principles that points out eight hallmarks of cancer, which are sustaining proliferative signalling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis, reprogramming of energy metabolism, and evading 
immune destruction (Figure 1) [10]. The acquisition of these functions comes out at different times and 
via diverse mechanisms during malignant progression.  
INTRODUCTION 
  15 
 
Figure 1. The hallmarks of cancer and their therapeutic targeting. The hallmarks of cancer are 
required for tumor progression and expansion. Targeted therapies against these abilities are promising strategies 
to fight cancer. Some of the illustrative examples of drugs depicted in this figure are in clinical trials or currently 
used in the clinic.  From Hanahan and Weinberg, Cell, 2011 [10].  
 
Sustaining proliferative signalling and evading growth suppressors 
Normal cell proliferation is regulated both by proliferative signals and by growth arrest signals to 
maintain homeostasis and tissue architecture. Cell growth and proliferative signals are mainly 
conveyed by growth factors that bind cell-surface receptors, such as epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor (PDGFR), or vascular endothelial growth factor 
receptor (VEGFR) [11]. Cancer cells can modulate their paracrine and autocrine proliferative 
stimulation to maintain constant proliferation. They can reprogram normal cells within the tumour 
microenvironment to release growth factors or they can be autonomous by producing their own growth 
factors. Finally, tumor cells can acquire growth factor independence, either by structural alterations in 
the growth factor receptor that can render it constitutively active independently of the ligand binding, or 
by generating persistent activation of constituents downstream of the receptor signalling pathways 
[12].  
In addition, cancer cells can evade the growth arrest signals through genetic changes in tumour 
suppressor genes. These genes are responsible for slowing down cell division, controlling apoptosis, 
and repairing DNA damage. This is exemplified by some genes like tumour protein 53 (p53), 
phosphatase and tensin homolog (PTEN), and retinoblastoma-associated (RB) that are three tumour 
suppressors that are often down-regulated in cancers [13].  
 
Resisting cell death 
One natural barrier to cancer progression is programmed cell death. When the cell is subjected to high 
level of stress, such as DNA damage due to hyperproliferation or elevated levels of oncogene 
signalling, a normal cell can commit suicide through a process called apoptosis. The physiologic 
regulation of apoptosis is driven by an equilibrated balance between anti- and pro-apoptotic proteins. 
To circumvent cell death, tumour cells upregulate anti-apoptotic factors (Bcl-2, Bcl-xL) or repress pro-
apoptotic regulators (Bax, Bim, Puma) [14]. There is a diversity of mechanisms that tumour cells use 
to counteract cell death, illustrating the complexity and multiplicity of ways for a cell to die.  
 
Enabling replicative immortality 
Normal cells pass through a limited number of replication cycles before dying or entering into a 
quiescent but viable state called senescence. This process is regulated by progressive telomere 
shortening at each cell division, which induces the loss of their protective effect on chromosomal ends 
and eventually cell death or senescence [15]. These definite growth-and-division cycles represent 
another barrier to tumour development. Indeed, cancer cells have to become immortalized in order to 
generate macroscopic tumours. To counteract this obstacle, almost all malignant cells (but not normal 
cells) express the telomerase enzyme, which is a DNA polymerase that circumvents telomere erosion 
by adding DNA segments to the end of the telomeres [16].  
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Inducing angiogenesis 
Angiogenesis, the sprouting of new vasculature, is a physiological process that takes place during 
embryogenesis, but also transiently during adulthood as part of wound healing process and female 
reproductive cycling. In the context of tumour progression, the fast growing and expansion of cancer 
cell requires an important and continuous supply of oxygen and nutrients. Consequently, in malignant 
diseases, the angiogenic program is constitutively on to sustain neoplastic development. This 
angiogenic switch is orchestrated by countervailing factors, such as thrombospondin-1 (TSP-1) and 
vascular endothelial growth factor-A (VEGF-A) that inhibit and induce angiogenesis, respectively [17]. 
Unsurprisingly, VEGF and its associated tyrosine kinase receptors (VEGFR1-3) are often found 
upregulated in cancers [18].  
 
Activating invasion and metastasis 
Ninety percent of deaths from cancer are due to the metastatic spread of the disease [19]. The 
invasion-metastasis cascade includes several steps beginning with the local invasion of cancer cells 
into the extracellular matrix (ECM). Although currently debated, this initial event driving metastasis is 
probably directed by the so-called “epithelial-mesenchymal transition” (EMT). EMT is a developmental 
regulatory program, which takes place at various stages of embryonic morphogenesis and during 
wound healing. It is characterized by the loss of cell polarity and cell-to-cell adhesion, and the gain of 
mesenchymal phenotype, such as enhanced migratory capacity, increased resistance to apoptosis, 
and invasiveness [20]. Tumour cells can activate transcriptional regulators of EMT during the course 
of the metastatic process. After having evaded the ECM, cancer cells intravasate through the basal 
membrane into a blood or lymphatic vessel. Tumour cells can then transit through the haematogenous 
or lymphatic systems, evade from the vessel through a process called extravasation, to eventually 
colonize a new site and form a metastasis [21].  
 
Reprogramming of energy metabolism 
To fuel the growing need of energy due to their high proliferation rate, cancer cells have to adapt their 
energy metabolism. Among the heterogeneity of metabolic alterations characterizing tumor cells, 
increased glucose uptake and glycolysis have been described. In normal situation, healthy cells 
metabolize a glucose molecule in the presence of oxygen via glycolysis, which results in the 
production of two pyruvates, two adenosine triphosphates (ATP) and two reduced nicotinamide 
adenine dinucleotide (NADH) molecules.  Pyruvate is then oxidized to carbon dioxide (CO2) in the 
mitochondria, producing approximately 36 molecules of ATP. Under anaerobic conditions, pyruvate is 
mostly reduced to lactate away from the mitochondria. However, cancer cells metabolize glucose to 
lactate even in aerobic conditions, despite the poor efficiency regarding ATP production (~18 fold less 
efficient). This paradigm is known as the aerobic glycolysis or Warburg effect [22]. This glycolytic 
switch acidifies the tumour microenvironment resulting in several selective advantages for the cancer 
cells, including the acquisition of resistance to chemical drugs or an increased invasiveness [23, 24]. 
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Evading immune destruction 
Immune surveillance operates as a barrier towards cancer progression by recognizing and eradicating 
the emerging cancer cells. To escape elimination by the immune system, cancer cells undergo 
immunoediting process, characterized by changes in the immunogenicity profile of tumours to produce 
immune-resistant clones. However, the immune system plays a dual role in the tumorigenic process, 
by being implicated in the tumour-associated inflammatory response. Indeed, inflammation can 
contribute to cancer growth and survival [25].   
 
The knowledge of these hallmarks of cancers allowed scientists to design new strategies to fight 
cancer (Figure 1). Targeted therapies against these capabilities required for tumour progression are 
promising strategies to fight cancer. Some of them are in clinical trials or currently used in the clinic.  
 
 
ANTI-CANCER THERAPEUTICS 
 
Early in the 20th century, surgery was the unique way to cure cancer. Only small and localized tumours 
were completely removable. Later, the discovery of radiations as an anti-cancer therapy allowed to 
better control cancers that were not or only partially removed. Finally, the discovery of chemotherapy 
allowed to destroy the remaining small tumour growths that had spread beyond the reach of surgery or 
radiations. Since the discovery of the first chemotherapies, such as nitrogen mustard during World 
War II or aminopterin that was demonstrated by Sidney Farber to induce remissions in children with 
acute leukemia in 1947 [26], great advances have been made in the field of anti-cancer therapeutics.  
Nowadays, surgery remains the primary therapeutic approach and the most effective single modality 
to cure cancer. The goal of cancer surgery is to excise the tumour with a clear margin of healthy 
tissue, while preserving the form and function of the organ, thereby improving the quality of life. 
Surgical mortality and morbidity rates have declined thanks to technological advances, minimally 
invasive techniques such as laparoscopy, and the use of neoadjuvant and adjuvant therapies [27]. 
Neoadjuvant therapy aims to reduce the extent of the tumour using radiation-, chemo-, immune-, or 
hormonal therapy prior to cancer resection. Whereas, adjuvant therapy is any treatment given after 
surgical resection to decrease the need for more radical surgery and maximized its effectiveness.   
The majority of the existing nonsurgical anti-cancer strategies are designed to induce cancer cell 
death mostly via apoptosis. Radiation therapy is prescribed to treat cancer in about 50% of all cancer 
patients [28]. Its purpose is to deliver the maximal ionizing radiation dose to the tumour whilst sparing 
healthy tissue. Radiations deposit energy in cells inducing DNA damage and cell death. Accurate 
delivery of radiation can be achieved through two different ways; external beam radiation (the most 
common approach) or brachytherapy. The latter is internal radiations delivered from a sealed radiation 
source placed inside or close to the tumour [29]. 
 
Chemotherapy, as surgery and radiotherapy, is a mainstay of cancer treatment. More than 100 
chemotherapeutical agents exist. Although their chemical composition, their mechanism of action, 
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their route of administration, and their secondary effects vary widely from one to another, their 
principal goal is to eradicate cells with high division capacities. The rationale being that the 
proliferative rate of cancer cells is higher than the proliferative rate of normal cells. Accordingly, 
malignant cells acquired stronger dependency on DNA replication than healthy cells.  
Cytotoxic drugs can be classified according to their mode of action into five main groups: alkylating 
agents, antimetabolites, cytotoxic antibiotics, topoisomerase inhibitors and anti-microtubule agents. 
Alkylating agents: They induce DNA damage by covalent binding of their alkyl group to DNA. The 
resulting intra- or inter-strand crosslink interferes with DNA replication, which prevents the cell division 
and leads to apoptosis (e.g. cyclophosphamide) [30]. As alkylating agents target DNA, they can also 
induce long-term damage to the bone marrow. This can increase the risk of acute leukemia, as a 
secondary effect, about 5 to 10 years post-chemotherapy. 
Antimetabolites: They are structurally similar to nucleosides. They compete for binding sites of natural 
substrates that are essential for biosynthetic processes or they directly incorporate into DNA or RNA. 
This prevents mitosis or induces DNA damage, eventually triggering apoptosis (e.g. methotrexate) 
[31]. 
Cytotoxic antibiotics: They affect the function and the synthesis of nucleic acids by multiple 
mechanisms, such as intercalation with DNA, inhibition of DNA transcription, DNA fragmentation, or 
inhibition of DNA synthesis (e.g. doxorubicin). A major concern with some of these drugs is 
cardiotoxicity, which can be irreversible [32].  
Topoisomerase inhibitors: They affect topoisomerase I or II activity, resulting in the inhibition of DNA 
replication (e.g. etoposide) [33]. They can cause secondary cancer (mostly acute myelogenous 
leukemia) as early as 2 to 3 years after the treatment. 
Anti-microtubule agents: They work by binding to tubulin, the building block of microtubules. This 
prevents mitosis by inhibiting assembly of the spindle during metaphase (e.g. vincristine) [34].  
 
As chemotherapeutic agents do not specifically target cancer cells, one of the major limitations is the 
safety profile with a high incidence of adverse effects. Though, a better understanding of molecular 
cancer cell biology in the late 1990s has allowed the development of novel agents, called molecular 
targeted therapies.  
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Figure 2. Anti-cancer therapeutic strategies. Whereas surgery, chemotherapy, and radiotherapy are the 
mainstays of cancer treatment, other strategies have been designed to eradicate malignant diseases, such as 
immunotherapy, targeted therapy, or antiangiogenic therapy (which is also classified as targeted therapy). 
Modified from Walther et al., Nat Rev Clin Oncol., 2015 [35]. 
 
Targeted therapeutics include the use of monoclonal antibodies or small molecule inhibitors aiming at 
the inhibition of a well-defined target or hallmark of cancer essential for the biology of the tumour [36]. 
As targeted cancer therapies affect tumour cells but not normal cells, they are less prone to serious 
side effects. Some of the targets in cancer therapy are depicted in Figure 1. Most of targeted agents 
act on angiogenesis or on signalling pathways directing cell survival, proliferation and growth [10]. 
While monoclonal antibodies interfere with extracellular components of these pathways (i.e. ligands 
and receptor-binding domain due to their large molecular weight of approximately 150,000 Da), small 
molecule inhibitors (molecular weight of around 500 Da) are able to act within the cancer cell by 
blocking receptor signalling and by inhibiting downstream intracellular molecules. Most commonly they 
interfere with tyrosine kinases (e.g. EGFR, VEGFR) because of their central role in tumorigenesis, as 
cell growth, proliferation, migration and angiogenesis signalling initiators [36]. Since these targeted 
drugs may be effective only in patients whose cancers bear a specific molecular target, such therapies 
raised the new concept of personalized cancer medicine. Nowadays, the therapeutic management of 
patients with cancer is dictated by a specific molecular and genetic signature of the tumour, and not 
only by the type, histology, and localization of the disease.  
 
INTRODUCTION 
  20 
More recently, new insights about the crucial role of the immune system in the tumorigenic process led 
to the development of immunotherapeutic agents that modulate anti-tumour immune response. The 
immune system can sustain an anti-cancer response through the activation of immune cells (e.g. 
natural killer cells (NK), cytotoxic T lymphocyte (CTL), dendritic cells (DC) or T helper cells (Th cells)) 
that are able to detect the foreign neo-antigens presented by the tumour cells and consequently target 
them for destruction. The two most effective strategies are immune-cell-targeted monoclonal antibody 
(mAb) and adoptive cellular therapy (ACT). Immunomodulatory mAb can activate T-cells by blocking 
their inhibitory receptors (checkpoint blockade) or by targeting their stimulatory receptors (T-cell co-
stimulation). ACT relies on the ex vivo selection and manipulation of T cells for their ability to attack 
tumour cells. The best killers are then amplified and infused back into the vein of the patients [37].  
 
Thanks to all the various therapeutic strategies summarized in Figure 2, cancer outcome still 
improves, while minimizing the impact of cancer management on quality of life. However, primary and 
acquired resistances to these treatments remain considerable challenges. Whereas primary 
resistance means that resistance-conferring factors pre-exist in the bulk of cancer cells prior to initial 
therapy, acquired resistance ensues from the genetic instability, heterogeneity and high mutational 
rate of tumour cells that induce high risk of selection for drug-resistant cell clones [38]. The acquired 
mechanisms of resistance are vast and illustrate the ability of cancer cells for eluding death. This 
aptitude to evade apoptosis, which is the main cell death pathway activated by most anti-tumour 
therapies, leads to cancer cell survival and the relapse of the disease. Therefore, the development of 
novel, low-toxicity, better targeted and efficient therapeutic strategies is a priority to improve cancer 
prognosis. Strategies to circumvent such obstacles include triggering alternate forms of death, 
combining the different anticancer modalities, but also improving the sensitivity of treatments currently 
used in clinical practice. 
 
However, prevention is better than cure. One of the strategies to reduce the burden of cancer is to 
decrease the risk and incidence of the disease. Avoiding exposure to key risk factors, including 
tobacco use, alcohol abuse, unhealthy diet, lack of physical activity, or ionizing and non-ionizing 
radiations, could prevent more than 30% of cancer deaths. 
 
 
HEPATOCELLULAR CARCINOMA 
 
EPIDEMIOLOGY 
Worldwide, liver cancer is the second most common cause of cancer mortality and the fifth most 
common cancer type [39]. Liver cancer is a general term including various kinds of primary tumours 
according to their cellular origin, such as intrahepatic cholangiocarcinoma, angiosarcoma, 
hepatoblastoma, and hepatocellular carcinoma (HCC). The latter is the most frequent form of liver 
cancer (80% of total liver cancer cases) and one of the deadliest cancers, with a five-year survival rate 
averaging 10% [40]. The global mortality rate is proportional to the global incidence, highlighting the 
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poor efficacy of current therapies and the aggressiveness of the tumour. While HCC incidence has 
decreased in developing countries thanks to national HBV vaccination programs, it remains the most 
common type of cancer in many countries in Sub-Saharan Africa and Southeast Asia. Furthermore, in 
western countries, the rate of occurrence is increasing steadily over the last 30 years because of an 
augmented emergence of obesity, type II diabetes, alcohol and drug abuse [41]. Consequently, HCC 
is a major and universal health problem which emphasizes the need for better understanding of its 
biology and improved therapeutic management.  
 
PATHOGENESIS 
Chronic infections with HBV or HCV contribute to the greatest number of HCC all over the world. 
Metabolic syndrome with nonalcoholic steatohepatitis (NASH), chronic alcohol consumption, iron 
overload (hemochromatosis) and aflatoxin-B1-contaminated food exposition are additional risk factors. 
All of them are known to induce an inflammatory microenvironment that facilitates 
hepatocarcinogenesis. Sustained inflammation predisposes the liver to fibrogenesis and subsequently 
cirrhosis, which often progresses to dysplasia and finally malignant transformation [42]. This complex 
multistep process generates a large landscape of genetic and epigenetic alterations. The various 
causes, the multistage pathogenesis, and the multistep sequence of molecular modifications of HCC 
explain the highly heterogeneous phenotype of this disease. The most frequent genetic modifications 
induce telomere maintenance (TERT), cell cycle dysregulation (e.g. TP53, RB1), aberrant activation of 
the WNT/β-Catenin signalling pathway (e.g. CTNNB1; AXIN1/2; APC), mutations of epigenetic 
regulators (e.g. ARID1A, ARID2, MLL) and oxidative stress alterations (e.g. NRF2, KEAP1). Less 
often, receptor tyrosine kinases (RTKs) are upregulated (e.g. EGFR, VEGFR, MET) or the activation 
of their downstream elements (e.g. PTEN) is modified (Figure 3) [43-46]. All these somatic alterations 
enable tumour cells to acquire the phenotypic hallmark of cancer. Moreover, the tissue 
microenvironment is critical in HCC pathogenesis.  Cancer-associated fibroblasts (CAFs), endothelial 
cells, pericytes, hepatic stellate cells and invading inflammatory cells interact with each other to 
produce factors contributing to liver fibrosis and malignancy growth [47]. 
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Figure 3. Pathogenesis of HCC. Several risk factors, such as HCV, HBV, alcohol, or aflatoxin-B1 can trigger 
hepatocarcinogenesis through various mechanisms depicted in this figure. The core oncogenic pathways in HCC 
are genomic instability (p53, ATM), growth factor signalling (PDGFR, c-Kit, RET, VEGFR, EGFR), oxidative stress 
(NRF2, KEAP1), and WNT signalling (CTNNB1, AXIN1, APC). However, other pathways can be involved in the 
disease, including cell cycle regulation (RB1, MYC, CCND1), immortalization (TERT), or chromatin regulation 
(ARID1A). HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma. 
 
 
DIAGNOSIS 
Clinically, patients suffering from HCC usually have only the symptoms related to their chronic liver 
disease, such as loss of appetite, weight loss, hepatosplenomegaly, and itching. This absence of 
pathognomonic symptoms delays the diagnosis of HCC. As a result, when the tumour is detected, its 
size is often bigger than 2 cm rendering the tumour incurable. However, cirrhotic decompensation, 
including ascites, encephalopathy, variceal bleeding, and upper abdominal pain, should induce 
suspicion for HCC. Laboratory examination lacks reliable biomarkers. A rising serum alpha-fetoprotein 
(AFP) level is usually present, although it has poor sensitivity and specificity values. HCC diagnosis 
can be made purely by radiology on the basis of the presence of a classic vascular pattern on 
computerized tomography (CT) scans (early arterial enhancement and delayed washout) or in 
dynamic contrast-enhanced magnetic resonance imaging (MRI). If there is a diagnostic doubt, an 
image-guided biopsy should be considered [41]. Nevertheless, the best way to diagnose HCC 
efficiently and in a timely fashion is to screen, using ultrasonography (US) at 6 monthly intervals, 
individuals who are at high risk for development of HCC, such as patients with established liver 
cirrhosis [39]. 
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Figure 4. BCLC staging and therapeutic. BCLC staging classifies HCC in five stages according to the 
extent of the disease, the Child-Pugh score, and the performance status. It suggests the first line treatment 
strategy for each stage and enables prognostication. BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular 
carcinoma; PST, performance status; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, 
transarterial chemoembolization; OS, overall survival. Modified from Forner et al., The Lancet, 2012 [48]. 
 
 
TREATMENT 
Once the diagnosis is made, the treatment procedure is driven by the cancer stage as shown in Figure 
4. Barcelona Clinic Liver Cancer (BCLC) staging is a useful classification tool that takes into account 
data on the patient’s performance status, number and size of nodules, cancer symptoms, and liver 
function, as determined by the Child-Pugh scoring system [49]. The latter rates the severity of the liver 
disease according to five clinical measures (ascites, bilirubin, albumin, prothrombin time and 
encephalopathy). Each measure is scored 1 to 3 points, with 3 points indicating the most serious 
derangement. Liver disease is then classified into three Child-Pugh classes (A, B, and C), employing 
the added score from the five measures [50]. According to BCLC system, HCC is divided into five 
stages: very early, early, intermediate, advanced and terminal (Figure 4). Patients presenting with 
very-early-stage HCC are rare because of late diagnosis of HCC due to the paucity of symptoms at 
earlier stages. They can benefit from surgical resection which is associated with an overall survival 
rate of 90%. Liver transplantation is the most appropriate therapy for early-stage HCC patients, who 
are not suitable to undergo liver resection or who present underlying cirrhosis. If transplantation is not 
suitable, percutaneous ablation using radiofrequency ablation is the next best therapeutic strategy. For 
patients with an intermediate-stage disease, transarterial chemoembolization (TACE) is the 
recommended palliative treatment. Finally, sorafenib (Nexavar®), an oral multi-kinase inhibitor 
(VEGFR, PDGFR, RET, c-KIT, C-Raf, B-Raf), is the sole Food and Drug Administration (FDA)-
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approved drug for patients with advanced-stage HCC [51]. However, in spite of clinical trials showing 
that the median overall survival time with sorafenib is higher than with placebo (10.7 mo vs 7.9 mo), 
the outcomes are far from satisfactory [52]. Genetic heterogeneity of HCC and primary and acquired 
resistance to sorafenib are part of the explanations for the poor prognosis. Patients with terminal-stage 
disease do not benefit from the therapies mentioned above. The 1-year survival rate is less than 10% 
with supportive care alone.  
 
SORAFENIB RESISTANCE 
Usual genotoxic agents are not frequently used in HCC therapeutic strategy because of several 
reasons. First, tolerance to systemic chemotherapy is limited due to the significant underlying hepatic 
dysfunction. Then, HCCs are highly genotoxic refractory tumours, mostly because of the high 
expression of drug resistance genes. Finally, the immunosuppressive state induces by these 
compounds may reactivate chronic HBV or HCV infections [53]. In this context, data from two different 
clinical trials, showing that sorafenib monotherapy prolonged life expectancy by nearly three months in 
advanced-stage HCC patients, were of great interest and enthusiasm [54, 55]. 
As mentioned above, dysregulation of several signalling pathways is implicated in 
hepatocarcinogenesis (Figure 3). Consequently, there is no dominating pathway or no prototypical 
oncogene addiction that could be targeted by one specific agent. Indeed, in HCC, a potent targeted 
molecular therapy should inhibit more than one signalling pathway and ideally more than one step in 
the targeted pathways. Sorafenib possesses these required characteristics. It simultaneously blocks 
several cell surface and downstream kinases, which are often deregulated during 
hepatocarcinogenesis, such as components of the mitogen-activated protein kinase/extracellular-
signal-regulated kinase (RAF/MEK/ERK). In parallel, this drug can abrogate angiogenesis through the 
inhibition of VEGFR and PDGFR. VEGFR plays a dual role in HCC tumorigenesis, which is one of the 
most vascularized tumours. Indeed, in addition to its involvement in angiogenesis, VEGFR signalling 
may also favor metastasis by increasing vascular permeability. The effectiveness of sorafenib can be 
attributed to its capacity to target tumour microenvironment in addition to cancer cells [56]. 
Furthermore, as a targeted therapy, the safety profile of sorafenib is favourable with a limiting 
widespread systemic toxicity and a good tolerance. Most common side effects include diarrhea, 
fatigue, hand-foot skin reaction and loss of appetite.  
Despite all these abilities, sorafenib only improves moderately the overall survival of patients, 
suggesting the existence of primary and acquired resistance mechanisms. HCC molecular 
heterogeneity and genetic instability are both responsible for resistance to this antiangiogenic and 
anti-proliferative agent. To date, many mechanisms have been implicated in the failure to respond to 
sorafenib [57]. One of them is activation of the escape pathway of canonical RAF/MERK/ERK 
cascade. In addition, EGFR aberrant activation and the subsequent stimulation of PI3K/AKT pathway 
are such examples [58]. In this context, other mechanisms, such as JNK, Mcl-1, Mapk14, SDF-1α, 
Galectin-1, and Sirtuin 1 activations, have been reported as well [59-64]. Sorafenib resistance can 
also be acquired through its antiangiogenic activity as sustained sorafenib treatment induces an 
increased intratumour hypoxia, which leads to cell survival in a HIF-1α-dependent manner [65]. 
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Despite the fact that several signalling pathways have been described to be implicated in sorafenib 
primary and acquired resistance, the exact mechanisms are still incompletely understood. A better 
knowledge and overcoming chemoresistance to this drug are primordial to improve the outcome of 
advanced-stage HCC patients.  
 
 
PEDIATRIC CANCERS 
 
The biologic nature of pediatric cancers is clinically, histopathologically and biologically distinct from 
adult cancers. Childhood malignancies have shorter latency periods, are often rapidly growing and 
aggressively invasive. Moreover, they are rarely associated with exposure to carcinogens, have fewer 
somatic mutations per tumour, and are generally more responsive to standard modalities of treatments 
than adulthood cancers [9]. Finally, epigenetic alterations play a critical role in the pathogenesis of 
pediatric tumours. Prenatal period is very important for epigenetic mechanisms because they are reset 
during early in utero development [66]. It is also during this period that the initiation of many pediatric 
malignancies occurs [67]. Indeed, disruptions to normal development have been suggested to be 
involved in the genesis of most of the childhood cancers [68].  
Although children are affected by cancer at a lower frequency compared to adults, this disease 
represents the second cause of death after accidents in Europe [69]. Globally, more than 160,000 new 
pediatric cancer cases occur per year among patients before 15 years of age and almost 100,000 
children die from their disease every year [70]. The causes of the majority of childhood malignancies 
are unknown. In a small percentage, some cases are attributable to inherited genetic conditions (e.g. 
RB1, FWT1/2, APC mutations are risk factors for retinoblastoma, Wilm’s tumour, and hepatoblastoma 
respectively) [71-73]. Moreover, known environmental exposures or exogenous factors, such as 
ionizing radiations or viral infections, have been identified as risk factors for some types of cancers, 
including leukemias (ionizing radiations), liver carcinoma (HBV), Kaposi sarcoma (HHV8), Burkitt 
lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma (all associated with EBV)[73].  
Childhood cancers have clearly benefited from advances in research in the last 30 years. 
Chemotherapy and radiotherapy have revolutionized cancer treatment and more than 80% of 
leukemias and lymphomas can now be cured, yet approximately 30% of solid and embryonic tumours 
are refractory to known treatments [74]. Additionally, the treatment-associated long-term side effects 
induced by damage to non-tumour cells remain a challenging problem. Currently, beyond 5-year 
survival, the mortality rate from recurrence decreases. However, the risk of death from second primary 
cancers and non-neoplastic conditions, such as circulatory or respiratory diseases, due to high dose 
administration of chemo- or radiotherapy, continues to be elevated compared with the general 
population (Figure 5) [75]. As children are by definition long-term survivors, there is a strong need for 
the development of low-toxicity, better targeted and efficient new therapeutic strategies for all types of 
childhood cancers. 
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Figure 5. Cumulative mortality of causes of death among survivors of childhood cancer. 
Observed cumulative mortality of causes of death other than recurrence was 19.0% at 50 years from initial 
diagnosis, whereas 6.3% was expected based on rates from the general population. For example, in the case of 
second primary cancer, cumulative mortality increased gradually with time to 2.4% by 30 years but then 
expanded rapidly to 8.6% by 50 years. From Reulen et al., JAMA, 2010 [75]. 
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Cell death 
 
Ironically, life depends on death. Mammalian development and tissue homeostasis require the 
controlled death of cells, mostly through apoptosis. The stability of the body is maintained by the 
balance between stimuli that regulate the proliferation and the death of cells [76]. However, cell death 
plays also a key role in pathogenesis [77]. Too much or too little activation of death can induce 
diseases, such as autoimmunity or neurodegeneration [78, 79]. Moreover, defects in the apoptotic 
machinery occur in the majority of cancers, allowing them to escape cell death and thus survive. As 
most chemotherapeutic compounds trigger apoptosis in malignant cells, tumour resistance to this cell 
death pathway remains a major clinical problem, leading to cancer cell survival and finally the relapse 
of the disease. Henceforth, triggering non-apoptotic cell death pathways could be a route for effective 
targeted therapy in cancers resistant to apoptosis. 
Classification of mammalian cell death is divided into two main categories: accidental cell death (ACD) 
and regulated cell death (RCD) [80]. ACD, such as necrosis, is mainly promoted by exposure to 
intense mechanical or chemical insults, but does not require the signalling machinery of cells. On the 
contrary, cell death is regulated if there is a genetically encoded molecular signalling pathway. 
Consequently, pharmacologic agents and genetic modulations can initiate or inhibit RCD. Apoptosis 
and necroptosis are the fundamental forms of RCD, but there are also less known modalities of death, 
such as parthanatos, pyroptosis, or ferroptosis [80].  
Distinctions between the various types of death entail differences in the morphological, biochemical 
and molecular attributes [81]. The different mode of cell death and their associated molecular 
cascades are reviewed here below. 
 
 
APOPTOSIS 
 
Apoptosis aims at the destruction of damage and harmful cells. The principal morphologic features of 
apoptosis are cell shrinkage, nuclear and DNA fragmentation, chromatin condensation and blebbing 
into membrane-bound apoptotic bodies [82]. The plasma membrane integrity is maintained until late 
stage of cellular disintegration [83].  Apoptosis can be triggered by intracellular or extracellular ligands, 
resulting in the activation of one of the two distinct but convergent pathways called intrinsic (or 
mitochondrial pathway) or extrinsic (or death receptor pathway) apoptosis (Figures 6B and 6C).  
External stimulation of the extrinsic pathway happens through activation of death receptor family 
members exposed on the cell surface, including tumour necrosis factor (TNF) receptor, TNF-related 
apoptosis-inducing ligand (TRAIL) receptor, or FAS receptor. Once the ligand has bound to the death 
receptor, this elicits the clustering of activated receptors and the recruitment of intracellular adapter 
proteins, such as Fas-Associated protein with Death Domain (FADD) and caspase-8, to form the 
death-inducing signalling complex (DISC)[84]. Caspase-8 belongs to the family of cysteine-aspartic 
proteases, called caspases that are expressed ubiquitously as zymogens. Apoptosis is mainly 
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orchestrated by the sequential activation of caspases. Caspase-8 and -9 are initiator caspases that 
cleave inactive forms of executioner caspases (caspase-3, -6, and -7). The latter trigger proteolytic 
events inducing cell death [85]. Caspase-8 specifically activates caspase-3 and -7, provoking 
substrate proteolysis and the elimination of the cell (Figure 6C). Caspase-8 can also indirectly induce 
apoptosis through the cleavage of the pro-apoptotic protein BH3-Interacting domain Death agonist 
(BID) (Figures 6B and 6C) [86].  
In the intrinsic apoptotic program, cellular stress signals, such as DNA damage, increased reactive 
oxygen species (ROS), the withdrawal of growth factors, or the unfolded protein response (UPR), 
induced by radiation, toxins, or viral infections for instance, disturb the physiological equilibrium of B-
cell lymphoma-2 (Bcl-2) family proteins [87]. This family plays a crucial role in the regulation of the 
mitochondrial membrane integrity. The Bcl-2 family is divided into pro-apoptotic members, including 
BAX, BAK, BOK, and BH3-only protein family (BID, BAD, BIM, BMF, NOXA, PUMA, and HRK) and 
anti-apoptotic members (BCL-XL, MCL1, BCL2A1, BCL-W, and BCL-B) [85]. The interplay between 
players of these two sub-groups determines whether apoptosis is elicited or not. In the presence of 
apoptotic stimuli, the activation of BH3-only proteins promotes the mitochondrial outer membrane 
permeabilization (MOMP) via the oligomerization of BAX and BAK in the outer mitochondrial 
membrane. This creates channels that mediate the release of proteins, such as cytochrome c or 
second mitochondria-derived activator of caspases (SMAC), into the cytoplasm [88]. Cytochrome c 
can then interact with apoptotic protease activating factor 1 (APAF1), promoting apoptosome 
assembly, which activates the caspase cascade through the executioner caspase-9, leading to 
apoptosis (Figure 6B) [89].   Among the other mitochondrial proteins that are discharged into the 
cytoplasm secondary to MOMP, apoptosis-inducing factor (AIF) and endonuclease G (EndoG) can 
trigger caspase-independent cell death [90].  
 
 
NECROPTOSIS 
 
Unlike apoptosis, early loss of integrity of the plasma membrane happens during necroptosis (also 
named regulated necrosis). This causes the release of cellular contents into the extracellular space 
but also the influx of extracellular ions and fluid, inducing an increase of cell volume with cell rounding 
and organelle swelling [91]. Necroptosis occurs when the caspase activity is suppressed and in the 
presence of tumour necrosis factor alpha (TNF-α) stimulation [92]. However, many other triggers of 
necroptosis have been identified, including TRAIL, FASL, or TNF-related weak inducer of apoptosis 
(TWEAK) among others [93]. Regulated necrosis is involved in several clinical disorders, such as 
myocardial infarction, inflammatory bowel diseases, or viral infection [94]. For instance, in the context 
of viral aggression, TNF-α secretion induces its receptor TNFR1 activation and the formation of a 
protein complex called necrosome. The latter, composed of receptor-interacting protein kinase-1 
(RIPK1), -3 (RIPK3), FADD, and inactive caspase-8, activates mixed lineage kinase domain-like 
(MLKL) protein. MLKL phosphorylation drives its own oligomerization and translocation from the 
cytosol to the plasma membrane, leading to the formation of membrane-disrupting pores [95-97]. 
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Necroptosis can be pharmacologically repressed using necrostatin-1 (Nec-1), an inhibitor of RIPK1, 
and the MLKL blocker necrosulfonamide (NSA) (Figure 6D) [96, 98]. 
 
 
PARTHANATOS 
 
Parthanatos is a form of regulated cell death characterized by an overactivation of poly(ADP-ribose) 
polymerase protein-1 (PARP-1), due to a wide array of stress signals, such as ultraviolet (UV), ROS, 
or alkylating agents. PARP-1, one of the PARP family proteins, is implicated in DNA repair, 
chromosome stability, and the inflammatory response [99]. To maintain genomic homeostasis, PARP-
1 detects single strand DNA breaks, binds to DNA, and uses nicotinamide adenine dinucleotide 
(NAD+) to synthesize poly(ADP-ribose) (PAR). The latter triggers the recruitment of other DNA-
repairing enzymes, such as DNA ligase III (LigIII) or DNA polymerase beta (polβ) [100]. Once the 
repair is made, the PAR chains are degraded. However, in some pathological conditions, 
hyperactivation of PARP-1 contributes to NAD+ and ATP depletion, and to the translocation of AIF 
from the mitochondria to the nucleus [101, 102]. PARP-1-induced AIF release elicits cell demise 
(Figure 6A). Parthanatos is a regulated necrotic-like cell death. It means that its regulation occurs 
independently of RIPK1 or RIPK3, but it has similar morphologic features of regulated necrosis (cell 
swelling and loss of plasma membrane integrity) [93]. However, nuclear translocation of AIF leads to 
large-scale DNA fragmentation and chromatin condensation, which are morphological features of 
apoptotic death [103]. 
 
 
PYROPTOSIS 
 
Execution of pyroptosis requires caspase-1 activation. Like parthanatos, pyroptosis is a necrotic-like 
cell death morphologically characterized by cell swelling and rapid plasma membrane disruption [104]. 
Caspase-1 is a pro-inflammatory molecule that processes interleukin 1β (IL-1β) and IL-18 precursors 
into active inflammatory cytokines. Various pathological stimuli, including stroke, cancer, or microbial 
infection, can stimulate caspase-1 [105]. Its activation generates the formation of plasma membrane 
pores, inducing the release of inflammatory cytoplasmic contents and water influx into the cell (Figure 
6E). Nevertheless, the exact mechanism of how caspase-1 induces death remains incompletely 
understood. Although pyroptosis requires the activation of a caspase, it differs from apoptosis in 
several ways. Indeed, mitochondrial membrane permeabilization does not occur during pyroptosis, 
and the substrates of caspase-1 differ from those of pro-apoptotic caspases [104].  
 
 
 
INTRODUCTION 
  30 
 
AUTOPHAGY 
 
Autophagy is a process of self-degradation induced in response to starvation. In most cases, 
autophagy protects cells from death by recycling organelles and cytoplasmic constituents to fulfill its 
need of energy. Autophagy is characterized by the formation of double-membrane bound vesicles, 
named autophagosomes that sequester cytoplasmic components. These vesicles are then trafficked 
to lysosomes, where the engulfed cargos are degraded. The autophagosome formation requires 
autophagy regulators called autophagy-related (ATG) proteins, including ATG5 and ATG6, as well as 
the lipidation of the microtubule-associated protein light chain 3 (LC3). However, under specific 
conditions, it has been suggested that autophagy can mediate cell death (Figure 6G) [106].   
 
 
FERROPTOSIS 
 
Ferroptosis was recently described as a new form of cell death mediated by the inhibition of the 
system xc- antiporter [107]. The system xc- is a glutamate/cystine antiporter, allowing the import of 
cystine into the cell. Depletion of the intracellular cysteine pool, due to the decrease of cystine uptake, 
induces a reduction of glutathione. Subsequently, inhibition of glutathione-dependent enzymes, such 
as the repair lipid enzyme glutathione peroxidase 4 (GPX4), as well as the loss of cellular antioxidant 
ability result in the accumulation of lipid-based ROS [108-110]. Ferroptosis requires abundant cellular 
iron, as demonstrated by inhibition of ferroptosis-induced cell death in the presence of iron chelators 
[111]. Erastin and sorafenib are compounds able to induce ferroptosis, by inhibiting the system xc- 
antiporter (Figure 6F) [112, 113].  
 
A cell has other multiple and distinct ways to die than the ones described above, such as anoikis, 
cornification, entosis, mitotic catastrophe, and netosis. Various cell death pathways can be 
interconnected. This interplay needs to be taken into account to improve pharmacological strategies to 
fight cancer cells and to reduce anti-cancer treatment resistance (Figure 6).  
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Figure 6. The interplay of cell death modalities. There are many ways for a cell to die that can, 
sometimes, be interconnected. A. PARP1 hyperactivation, mostly due to DNA damage, causes the accumulation 
of PAR polymers into the cytosol. The latter PARylate several proteins, leading to the depletion of NAD+ and, 
consequently, ATP. In addition, PAR polymers induce the translocation of AIF from the mitochondria to the 
nucleus and the cytoplasm, eliciting cell demise. B. Mitochondrial damage, induced by various cellular stress 
signals, disturb the physiological equilibrium of Bcl-2 family proteins, leading to MOMP and, consequently, the 
release of pro-apoptotic proteins, such as cytochrome c. The latter promotes the apoptosome assembly and the 
subsequent activation of the caspase cascade, provoking cell death via the intrinsic apoptotic program. C. 
Extrinsic apoptosis is triggered by the activation of death receptor family members, such as TNFR1. Activation of 
caspase-8 is the key event of this pathway. It can lead to the stimulation of caspase-3 and -7 as well as to the 
cleavage of BID, eliciting cell death. D. The activation of TNFR1 can also trigger necroptosis, through the 
formation of the necrosome composed of RIPK1, RIPK3, FADD, and inactive caspase-8. This complex recruits 
and phosphorylates MLKL, driving the oligomerization and translocation to the plasma membrane of this activated 
protein. This leads to the creation of membrane-disrupting pores and cell demise. E. Caspase-1 is the key 
element of pyroptosis execution. Caspase-1 activation, elicited by pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs), provokes the rapid formation of plasma 
membrane pores, inducing the release of inflammatory cytoplasmic contents and water influx into the cell. F. 
Inhibition of the glutamate/cystine antiporter reduces the level of GSH and subsequently GPX4 as well as the 
cellular antioxidant capacity. In presence of abundant cellular iron, this results in the accumulation of lipid-based 
ROS and cell death through ferroptosis. G. In cell death with autophagy, the pro-death stimulus induces the 
formation of autophagosome, which requires ATG5, ATG6, and the lipidation of LC3 protein. PARP1, poly(ADP-
ribose) polymerase protein-1; PAR, poly(ADP-ribose); NAD+, nicotinamide adenine dinucleotide; ATP, adenosine 
triphosphate; AIF, apoptosis-inducing factor; UV, ultraviolet; ROS, reactive oxygen species; Bcl-2, B-cell 
lymphoma-2; MOMP, mitochondrial outer membrane permeabilization; SMAC, second mitochondria-derived 
activator of caspases; TNFR1, tumour necrosis factor receptor 1; TNF, tumour necrosis factor; DISC, death-
inducing signalling complex; NEC1, necrostatin-1; RIPK1/3, receptor-interacting protein kinase-1/3; FADD, Fas-
Associated protein with Death Domain; MLKL, mixed lineage kinase domain-like; NSA, necrosulfonamide; 
PAMPs, pathogen-associated molecular patterns ; DAMPs, damage-associated molecular patterns; Glu, 
glutamate; GSH, glutathione; GPX4, glutathione peroxidase 4; ATG5/6, autophagy-related protein-5/6; LC3, 
microtubule-associated protein light chain 3.Modified from Marino et al., Nat Rev Mol Cell Biol., 2014 [88], 
Vanden Berghe et al., Nat Rev Mol Cell Biol., 2014 [114], Taylor et al., Nat Rev Mol Cell Biol., 2008 [115], and 
Kroemer et al., Nat Rev Mol Cell Biol., 2008 [116].  
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The TAT-RasGAP317-326 peptide 
 
 
ORIGIN OF TAT-RASGAP317-326 
 
TAT-RasGAP317-326 is a cell-permeable peptide derived from the p120 Ras GTPase-activating protein 
(RasGAP). The p120 RasGAP protein is an ubiquitously expressed multi-domain protein that acts as a 
regulator of Ras and Rho GTP-binding proteins. It contains two conserved caspase-3 cleavage sites 
[117]. When a cell faces a stress, RasGAP is cleaved at position 455, generating a N-terminal 
fragment that bears potent anti-apoptotic activities. This process allows the cell to survive in mild 
stress situations through the stimulation of Ras/PI3K/Akt pathway (Figure 7A) [118, 119]. In the 
presence of apoptotic stimuli, when caspase-3 activity levels are high, the N-terminal fragment is 
further cleaved. The smaller fragments resulting from this second cleavage (in particular fragment N2 
[RasGAP 158-455]) regulate tumour cell death by sensitizing them to stress-induced apoptosis which 
is thought to be a natural mechanism to make a cell die when facing high stress situations [120, 121].  
The sensitizing activity of fragment N2 was also shown to occur for anti-cancer agents like 
chemotherapies and this biological activity lies in a 10 amino acid sequence (WMNVTNLRTD) that 
corresponds to amino acid 317-326 of the human p120 RasGAP protein sequence (Figure 7B) [122]. 
This sequence, when fused to a cell-penetrating peptide derived from the human immunodeficiency 
virus (HIV), HIV-TAT48-57 (the so-called TAT-RasGAP317-326 peptide), efficiently sensitizes adulthood 
tumour cell lines of various origins to chemotherapies. This effect seems to be specific for cancer cells 
as non-transformed human endothelial cells and human keratinocytes had their sensitivity to anti-
cancer agents unaffected by TAT-RasGAP317-326 [122]. 
The stability of the RasGAP-derived peptide could then be increased by using D-amino acids for its 
synthesis. When used in vivo, this stable form of TAT-RasGAP317-326 potentiates the anti-tumoral 
growth efficacy of cisplatin, doxorubicin, and radiotherapy [123]. Once injected intraperitoneally in 
mice, TAT-RasGAP317-326 is delivered to various organs and can thereby reach tumours. Importantly, 
doses that are >100 fold below the lethal doses (the LD50 is between 2.5 and 5.0 mg/kg) still exert 
sensitization activity and no toxicity has been observed. However, one weakness of this peptide is its 
non-optimal bioavaibility with a high excretion rate via renal and hepatic routes [123].  
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Figure 7. p120 RasGAP cleavage upon stress (A) and the TAT-RasGAP317-326 sequence (B). A. 
RasGAP bears two cleavage sites with different sensitivities towards caspase-3 activity. In situations of mild 
stress, low caspase-3 activity cleaves RasGAP into fragment C and fragment N. The latter promotes cell survival. 
In the presence of a strong stress, caspase-3 is more activated, resulting in further cleavage of fragment N into 
fragment N1 and fragment N2. This favours cell death. B. Fragment N2 was narrowed down to a 10 amino acid 
sequence (WMWVTNLRTD). This sequence was then fused to the cell permeable peptide HIV-TAT 
(GRKKRRQRRR) to generate the TAT-RasGAP317-326 peptide. 
 
 
Moreover, it was discovered that, besides its sensitizing activity in tumours, TAT-RasGAP317-326 
inhibits cell migration and invasion through extra-cellular matrices, which indicates that it has the 
potential to prevent the dissemination of primary tumours and thus to function as an antimetastatic 
compound [124]. 
Recently, it has been shown that the anti-cancer properties of TAT-RasGAP317-326 rely on two 
tryptophan residues at positions 317 and 319 (see Annex I [125]). However, the mechanism of action 
of TAT-RasGAP317-326 is not fully characterized yet. It has been previously shown that this peptide 
does not favour the death of tumour cells by modulating MAPK signalling pathways, NF-кB 
transcriptional activity, or Akt protein levels and phosphorylation status [120, 126]. As genotoxins are 
DNA-damaging substances that exert their anti-tumour activity by causing apoptosis in cancer cells 
mainly through the mitochondrial pathway, the involvement of Bcl-2 family members in TAT-
RasGAP317-326 –induced sensitization activity was investigated [127-129]. All the Bcl-2 family members 
that were tested were shown to be individually dispensable for the sensitizing activity of the peptide 
[130]. Consequently, the mode of action of TAT-RasGAP317-326 remains to be determined. 
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PEPTIDE-BASED DRUGS 
 
Peptides are short chains of amino acid monomers linked by covalent amide bonds [131]. They are 
distinguished from proteins on the basis of their size. An arbitrary cutoff of 50 amino acids is set up to 
describe peptides, although this limit can vary according to some authors [131, 132]. Peptides include 
hormones, growth factors, neurotransmitters, or ion channel ligands supporting key roles in human 
physiology. These extremely potent signal transduction molecules raised interest by the 
pharmaceutical companies. Their main advantages are their high selectivity, efficiency, and, at the 
same time, their relative safety and good tolerance. As a result, more than 60 FDA-approved peptide 
therapeutics are commonly used in the clinic, such as insulin, cyclosporine, and desmopressin. 
Besides, around 140 peptide-based drugs are currently in clinical trials and more than 500 are in 
preclinical development [133]. However, the use of natural peptides is also highly criticized for the 
following reasons: a short circulating plasma half-life, a low biodelivery, and a weak bioavailability. 
Nevertheless, these limitations can be circumvented by designing more stable synthetic peptides that 
are less prone to enzymatic degradation, using for instance unnatural amino acids (D-configuration 
instead of L-configuration), peptide cyclization, or binding peptide to the circulating protein albumin 
[134, 135]. In addition, to allow peptides to reach intracellular targets, they can be coupled to cell-
penetrating peptides (CPPs), or conjugated with antibodies or small molecules that take the role of the 
targeting unit, whereas the peptide is the effector entity.  
Peptides are commonly used in a diversity of therapeutic areas, including endocrinology, urology, 
ophthalmology, infectious disease, metabolic disease, and oncology [136]. In oncology, peptides are 
utilized as direct cytotoxic compounds (e.g. goserelin (Zoladex®), for prostate cancer) or as carriers of 
cytotoxic compounds and radioisotopes by targeting cancer cells (e.g. radiolabeled somatostatin 
analogs (Octreoscan®) to find carcinoid and other types of tumours) [137]. Besides peptides already 
available for cancer patients, other peptide-based treatments such as cancer vaccines or anti-
angiogenic peptides are currently in clinical trials [138, 139]. 
 
 
CELL-PENETRATING PEPTIDES 
 
Due to the selective permeability of the cell membrane, improving drug delivery into cells remains a 
challenge. For cellular internalization, a drug must be either lipophilic or very small. In order to 
increase the restricted repertoire of possible therapeutic molecules, CPPs can be conjugated to 
cargoes of interest to achieve their intracellular delivery. CPPs are short peptides (usually less than 30 
amino acids) able to spontaneously and ubiquitously transport various biochemically active molecules, 
such as proteins, peptides, DNA, or RNA inside living cells [140].  
In 1988, it was reported that the full-length Trans-Activator of Transcription (TAT) protein of HIV could 
efficiently enter cells in a non-toxic and receptor-independent manner [141]. Some years later, it was 
found that only a short sequence of the full-length TAT, TAT48-57 that bears arginine-rich motif (Table 
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1), was sufficient to deliver cargoes into cells [142]. Since this discovery, multiple other peptides with 
cell-penetrating abilities have been described including Penetratin, Transportan, or Polyarginine 
peptides (Table 1) [143-145]. They can be divided into three main categories: cationic CPPs, 
hydrophobic CPPs, and amphipathic CPPs. The former ones are the most common CPPs (e.g. TAT, 
Polyarginine) and are positively charged sequences of amino acids, such as lysine or arginine, 
whereas the latter contain both hydrophobic and hydrophilic residues (e.g. Penetratin) [146]. Finally, 
hydrophobic CPPs are characterized by either only non-polar residues, a low net charge, or a 
hydrophobic motif that is crucial for their uptake (e.g. Transportan) [140].  
 
Table 1. The representative cell-penetrating peptides. Amino acid sequences, origin, and the 
biochemical category of four representative CPPs are denoted in this table.  
 
 
Mechanisms of entry, trafficking routes, and degradation pathways of CPPs remain poorly 
characterized and greatly debated, rendering their clinical use limited. Indeed, there is inconsistency in 
the literature regarding uptake mechanisms that can be attributed to the fact that a CPP according to 
its sequence, structure, or amphipathicity enters cell via a singular mechanism. Moreover, cellular 
uptake of a single CPP is dependent on several factors such as peptide concentration, time of 
incubation, local lipid composition, or cargo characteristics [147]. According to these features, CPP 
internalization can be passive (cell energy-independent, such as direct translocation), active (cell 
energy-dependent, such as endocytosis) or both simultaneously [148].  
The first step of CPP entry is its interaction with the plasma membrane. The efficacy of this process 
varies according to amino acids constituting the CPP. For instance, the positive charges of cationic 
CPPs cluster which creates strong electrostatic interactions with the negatively charged membrane 
composed of proteoglycans and phospholipids. More precisely, it has been demonstrated that arginine 
residues are more efficient than lysines to undergo internalization into cells [145]. This is due to the 
guanidinium headgroup of the arginine side chain that binds to the cell surface in a more effective 
manner than ammonium cations in lysines [149]. Another key amino acid for CPP internalization is the 
hydrophobic and aromatic tryptophan residue. Tryptophan plays a crucial role in CPP interaction with 
the plasma membrane, due to its tendency to insert into biological membranes. Indeed, tryptophan 
can induce membrane destabilization processes and translocation mechanisms [150, 151]. 
Additionally, it was also reported that adding tryptophan residues to a CPP sequence improves its 
endocytosis [152-154]. These observations demonstrate that one amino acid can modify the uptake of 
a CPP.  
Once the peptide binds to the membrane, it may either directly penetrate into the cell or it undergo 
endocytosis. In some conditions, both processes can be achieved at the same time. 
Unlike endocytosis, direct translocation can occur at 4°C and in ATP depletion conditions. It requires 
Name Amino acid sequences  Origin Biochemical category 
TAT GRKKRRQRRR TAT protein of HIV-1 virus Cationic 
Penetratin RQIKIWFQNRRMKWKK Homeoproteins Amphipathic 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 
Chimeric peptide of galanin and 
mastoparan Hydrophobic 
Polyarginine (R)n; 6<n<12 Artificial peptide Cationic 
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the destabilization of the plasma membrane through different ways detailed below and illustrated in 
Figure 8 [155-157].  
• Transient toroidal pore formation: This translocation process occurs secondary to the 
accumulation of the positively charged peptides in the outer leaflet of the bilayer membrane. 
This causes the thinning of the membrane and formation of pores by some of the CPPs, 
allowing the other CPPs to diffuse [155]. 
• Barrel stave model: This is a model of pore formation by amphipathic α-helices CPPs. The 
latter bind to the bilayer surface in α-helical structures. Helices attach into the hydrophobic 
core of the membrane and recruit additional monomers to progressively increase the pore size 
[158].  
• Inverted micelle formation: CPP interaction with the plasma membrane leads to invagination 
of the membrane followed by the reorganization of neighbouring lipids. This induces the 
encapsulation of the CPP in the bilayer membrane. Ultimately, its release into the cytoplasm is 
due to subsequent membrane disruption [156]. 
• Carpet-like model: This is characterized by the binding of CPPs onto the bilayer surface 
covering it in a carpet-like manner. Above a critical threshold of local surface density, it leads 
to membrane disruption in a detergent-like manner [157]. 
 
 
Figure 8. Mechanisms of direct translocation of CPPs through the plasma membrane. Several 
mechanisms, including the toroidal pore model, the barrel stave model, the inverted micelle model, or the carpet 
model, are proposed to explain the direct translocation of CPPs through the bilayer surface. Modified from 
Ruczynski, Folia Histochem Cytiobiol., 2014 [159].  
 
 
 
In contrast to direct translocation, endocytosis is a generic name describing different processes that 
allow cells to absorb material via an ATP-depend manner [160]. CPPs can trigger endocytosis by the 
direct contact with the cell membrane, its binding to a receptor, or by their electrostatic interactions 
with the proteoglycans. There are several endocytic routes to reach the cytoplasm that are briefly 
described below and depicted in Figure 9 [161].  
INTRODUCTION 
  38 
• Macropinocytosis: It is initiated from membrane ruffling driven by dynamic remodeling of the 
actin cytoskeleton. It induces the extension of the bilayer surface to ingest large amounts of 
extracellular fluid and plasma membrane once the ruffles close off [162]. This gives rise to 
large (from 0.2 to 5 µm in diameter) and irregularly shaped vesicles named macropinosomes 
[160]. Macropinocytosis is in part regulated by Rac1 and Cdc42, two proteins that mediate 
actin cytoskeleton remodelling [163].  
• Clathrin-mediated endocytosis (CME): This is the most studied and well-characterized 
endocytic route. It occurs through the construction of clathrin-coated vesicles (CCVs) 
composed of the heavy and light chains of clathrin that form upon interaction with each other a 
polyhedral lattice. Those CCVs are also composed of the adaptor protein 2 (AP2) complex 
that binds to the cargo but also to the clathrin coats [164]. In addition, other cargo-specific 
adaptor proteins can constitute the CCVs to increase the repertoire of cargo that can be 
recognized. For instance, the cellular uptake of low-density lipoprotein (LDL) and transferrin 
occur through CME after binding to their respective receptors [165, 166]. Once the CCV is 
mature, the GTP hydrolysis of the GTPase dynamin is required to pinch off the vesicles from 
the plasma membrane by constricting their neck [167].  Finally, the vesicle is uncoated by the 
heat shock cognate 70 (HSC70) protein that disassembles the clathrin coat and allows its 
travel and fusion with endosomes [168]. 
• Caveolae-mediated endocytosis (CavME): Some regions in the plasma membrane, called 
caveolae, are highly hydrophobic, enriched in cholesterol and sphingolipids, and show an 
omega-shaped or flask invagination. Although present in most eukaryotic plasma membranes, 
some cells (e.g. various lymphoid cell lines) do not carry caveolae regions [169, 170]. 
Caveolae are composed of the caveolin protein family, whose the main member is caveolin-1. 
This protein is necessary for the internalization process. It is inserted into the inner leaflet of 
the plasma membrane, binding to cholesterol and to other important signalling molecules. To 
form carriers to transport cargoes, caveolins cluster with cytosolic coated proteins named 
cavins [171]. The latter process is regulated by kinases and phosphatases [172]. Finally, 
dynamin enables the detachment of the vesicles from the bilayer membrane [173]. 
• Clathrin- and caveolae-independent endocytosis: CLICs/GEEC pathway, IL-2, flotillin-, and 
Arf6-dependent endocytosis represent more recently described processes. They are all 
cholesterol-dependent mechanisms. Whereas IL-2 endocytosis requires dynamin for scission 
of the endocytic pit, Arf6 and CLICs/GEEC pathways undergo endocytosis via a dynamin-
independent mechanism [174-176]. Flotillin-mediated endocytosis supposedly functions as 
CavME, although flotillin proteins localize to membrane invagination other than caveolae 
[177].  
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Figure 9. Diverse routes of endocytosis. CPPs can be endocytosed by numerous mechanisms, whose the 
main ones are depicted in this figure. Clathrin-, caveolin-, and IL-2-dependent endocytosis are dynamin-mediated, 
whereas Arf6, Flotillin, and CLICs/GEEC pathways are dynamin-independent. Macropinocytosis, for which 
involvement of dynamin is debated, requires actin remodeling to form large vesicles called macropinosomes. 
Some endocytic routes may first traffic to intermediate compartments, such as caveosome, macropinosome, or 
GEEC, before reaching an endosome. Once the cargo has been trapped into an endosome, it can either be 
recycled back to the cytoplasmic membrane, escape the endosome to gain access to the cytoplasm, or be 
degraded by a lysosome. CPP, cell-penetrating peptide; CLICs/GEEC, clathrin-independent carriers and 
glycophosphatidylinositol-anchored protein-enriched endosomal compartments. Modified from Mayor et al., Nat 
Rev Mol Cell Biol., 2007, [178] and Soldati et al., Rev Mol Cell Biol., 2006, [179].  
 
Once the cargo is sequestered into a vesicle, it is then internalized and sorted into a series of 
tubulovesicular compartments named endosomes. The latter are subjected to maturation from early to 
late endosomes. The maturation step is characterized by the fall of the luminal pH, the recruitment and 
activation of sequential proteins such as the Rab family GTPases, and the alteration of 
phosphatidylinositol lipids by lipid kinases and phosphatases [180]. After being trapped to endosomes, 
cargoes can have various fates, e.g. recycled back to the cytoplasmic membrane, delivered and 
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degraded to lysosomes, or escaped to the cytosol (Figure 9) [180]. Endosomal escape is necessary 
for most of cargoes to reach their target and exert their function. Indeed, by escaping the final 
maturation steps of the endosomes, the cargo hampers its lysosomal destruction. Although, the exact 
mechanisms by which a cargo is released from endosomes are still not well-understood, there are 
evidences suggesting the involvement of endosomal acidification and lipid composition modifications 
in this process [181, 182]. 
 
Although the clinical application of CPPs is currently limited because their entry and endosomal 
escape mechanisms remain to be elucidated in details, some of them conjugated to therapeutic 
cargoes are under clinical trials to treat cancers among other diseases [183, 184]. In addition, a large 
number of preclinical studies have shown that proteins or nucleic acids such as siRNA, which are 
promising strategies to treat cancers, infectious diseases, and genetic disorders, have successful 
application when attached to a CPP [185]. Finally, coupling currently used small chemotherapeutic 
drugs, such as doxorubicin or methotrexate, improves the efficacy of the compound [186, 187]. 
However, no FDA approval has yet been delivered for the clinical application of the TAT CPP, 
although it was and is still studied in preclinical and clinical trials. This is explained by its lack of 
specificity for a defined cell type, the intrinsic weaknesses of peptide compounds (described above, in 
the part dedicated to peptide-based drugs), and its debated mechanism of entry into cells. Whereas 
some authors describe macropinocytosis as the primary mechanism of TAT entry, clathrin- and 
caveolae-mediated endocytosis are likely to be also involved [188-191]. Moreover, direct translocation 
of TAT has been shown at threshold concentration or when it is conjugated to a hydrophobic cargo 
[140, 192, 193]. The discrepancies between the studies highlight the complexity and variability of the 
mode of entry according to multiple experimental factors. Nevertheless, CPPs emerge as interesting 
tools to better understand the prime mechanisms of cellular entry and endosomal escape.     
Interestingly, many pathogens, such as viruses and bacteria, hijack the endocytic routes to mediate 
their internalization into the cytoplasmic compartment [194, 195]. Like CPPs, these microorganisms 
have to reach the cytoplasm for their survival and activity. Thus, they develop various mechanisms to 
escape endosomes once trapped into these vesicles [158]. Knowing that they use existing cellular 
pathways, a better understanding and knowledge of cellular uptake and endosomal escape 
mechanisms could allow a prophylactic inhibition of microorganisms infection. 
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AIMS OF THE PROJECTS 
 
This thesis work is articulated around two distinct projects. The first and major one aims at the 
investigation of the sensitization potential of TAT-RasGAP317-326 in pediatric tumours and its 
mechanism of action. This RasGAP-derived peptide, that bears anti-malignant properties, was 
developed in our laboratory. One of its anti-cancer capabilities is to inhibit cellular migration and 
invasion, indicating that it has the ability to function as an anti-metastatic compound. In addition, this 
peptide does not by itself affect non-tumoral cells, but it potently sensitizes adult cancer cells in vitro 
and in vivo to various anti-cancer therapies, including genotoxins and gamma radiations.  
 
The specific aims of the first project are:  
 
I. To assess the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers. 
Knowing that this peptide has the potential to increase the potency of anti-cancer 
therapies in adult tumour cells without affecting the sensitivity of healthy tissues to these 
treatments, it may, therefore, be of considerable benefit to children cancer patients. This 
could allow decreasing the efficacious dosage administration so that deleterious side 
effects can be reduced. If side-effects are not too problematic, the peptide would anyway 
exert a beneficial effect by increasing the killing efficiency of the treatment. 
 
II. To characterize which type of cell death is triggered by TAT-RasGAP317-326. While 
screening several cell lines for the chemosensitizing activity of the peptide (Aim I), I found 
out that some of them were directly killed by it. Indeed, previously to this work, TAT-
RasGAP317-326 was not found to affect cell viability alone. This gave us the opportunity to 
investigate the mode of death triggered by the peptide. As the mode of action of TAT-
RasGAP317-326 remains to be determined, this approach could help us to better 
understand how this peptide works. 
 
III. To identify proteins involved in TAT-RasGAP317-326-induced cell death. The other 
approach used to elucidate the mechanism of action of the peptide was to screen for 
genes that mediate the pro-death activity of the peptide alone. A CRISPR/Cas9 
(clustered regularly interspaced short palindromic repeats-Cas9) screening was 
performed and the top candidate genes were validated, followed by the study of the role 
of their proteins in the activity of TAT-RasGAP317-326.   
 
We took advantage of the well-implemented CRISPR/Cas9 technology in the lab to apply it to a new 
project about hepatocellular carcinoma (HCC) resistance to sorafenib. The latter, a multi-kinase 
inhibitor, is the sole approved drug for patients with advanced HCC. Despite this treatment, the 
outcome is far from satisfactory, in part due to primary and acquired resistance to sorafenib.  
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The specific aim of the second project is: 
 
IV. To identify novel sorafenib resistance pathways that could be targeted to treat 
HCC. Whereas some pathways have already been described to be implicated in intrinsic 
and acquired resistance, the exact resistance mechanisms are still incompletely 
understood. To this purpose, we performed exome sequencing analysis and 
CRISPR/Cas9 screening on HCC cell lines that were previously rendered resistant to 
sorafenib.  
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RESULTS 
 
PART I 
 
ASSESSMENT OF THE CHEMOSENSITIZING ACTIVITY OF TAT-RASGAP317-326 
IN CHILDHOOD CANCERS. 
 
Although current anti-cancer protocols are reasonably effective, treatment-associated long-term side 
effects induced by lack of specificity of the anti-cancer procedures remain a challenging problem in 
pediatric oncology. The TAT-RasGAP317-326 peptide may, therefore, be of considerable benefit to 
children cancer patients because it has the potential to increase the potency of anti-cancer therapies 
in tumour cells without affecting the sensitivity of healthy tissues to these treatments. This peptide 
could have a valuable effect by allowing the decrease of the efficacious dosage of chemotherapeutic 
agents so that side effects could be reduced. In addition, if the secondary deleterious effects of 
treatment are not too problematic, the peptide would anyway increase the killing efficiency of the 
therapeutic agents. However, it was previously unknown if the peptide can sensitize pediatric tumours 
as it does to adult cancers.  
The evaluation of the sensitizing property of the peptide in pediatric tumours led to a first author paper 
published in Plos One in March 2015: “Assessment of the chemosensitizing activity of TAT-
RasGAP317-326 in childhood cancers”. This work, entirely carried out by me, is attached in the following 
section. As discussed in this study, the effect of TAT-RasGAP317-326 was analyzed in several childhood 
cancer cell lines. All the tested pediatric tumours were sensitized by TAT-RasGAP317-326 in response to 
at least one genotoxin. Moreover, the RasGAP-derived peptide did not increase cell death of normal 
lymphocytes, alone or in combination with the majority of the tested chemotherapies. Consequently, 
TAT-RasGAP317-326 may benefit children with tumours by increasing the efficacy of anti-cancer 
therapies notably by allowing reductions in anti-cancer drug dosage and the associated drug-induced 
side effects. 
 
Interestingly, by screening several cell lines for the chemosensitizing activity of the peptide, we found 
that a neuroblastoma cell line was directly killed by the peptide alone. The mechanism of action of the 
RasGAP-derived peptide remains to be determined and the characterization of the cell death induced 
by this peptide will be very helpful to understand its mode of action. Consequently, the second part of 
the results of this thesis report is dedicated to the study of the type of cell death induced by TAT-
RasGAP317-326.
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Abstract
Although current anti-cancer protocols are reasonably effective, treatment-associated long-
term side effects, induced by lack of specificity of the anti-cancer procedures, remain a chal-
lenging problem in pediatric oncology. TAT-RasGAP317-326 is a RasGAP-derived cell-
permeable peptide that acts as a sensitizer to various anti-cancer treatments in adult tumor
cells. In the present study, we assessed the effect of TAT-RasGAP317-326 in several childhood
cancer cell lines. The RasGAP-derived peptide-induced cell death was analyzed in several
neuroblastoma, Ewing sarcoma and leukemia cell lines (as well as in normal lymphocytes).
Cell death was evaluated using flow cytometry methods in the absence or in the presence of
the peptide in combination with various genotoxins used in the clinics (4-hydroperoxycyclo-
phosphamide, etoposide, vincristine and doxorubicin). All tested pediatric tumors, in re-
sponse to at least one genotoxin, were sensitized by TAT-RasGAP317-326. The RasGAP-
derived peptide did not increase cell death of normal lymphocytes, alone or in combination
with the majority of the tested chemotherapies. Consequently, TAT-RasGAP317-326 may ben-
efit children with tumors by increasing the efficacy of anti-cancer therapies notably by allowing
reductions in anti-cancer drug dosage and the associated drug-induced side effects.
Introduction
Cancer represents the second cause of death in children after accidents in industrialized coun-
tries [1, 2]. Our understanding of childhood cancers has benefited from significant advances
over the four last decades. Standard treatments to cure pediatric tumor include surgery, radia-
tion therapy and intensive multi-agent chemotherapy such as etoposide, vincristine, doxorubi-
cin, and cyclophosphamide [3].
In developed countries, eighty percent of children who are diagnosed with cancer are ex-
pected to survive within 5 years following the treatment. However, most of them will suffer
from chronic diseases by 40 years of age [4]. Extended surveillance of pediatric cancer survivors
shows a high risk for life-threatening late effects from second malignancies, cardiac conditions
and pulmonary diseases [5, 6]. The risk of early mortality is mostly determined by treatment-
specific factors such as the cumulative dose of chemotherapy [7]. Therefore, treatment-
associated long-term side effects induced by damage to non-tumor cells are a challenging
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problem and remain largely unresolved. As children are by definition long-term survivors,
there is a strong need to develop low-toxicity, better targeted and efficient new therapeutic
strategies for all types of childhood cancers [8]. Strategies to circumvent such obstacles include
the improvement of anti-cancer drug sensitivity and specificity toward cancer cells [9–11].
In this context, we previously reported that a cell-permeable peptide derived from the p120
RasGAP protein, called TAT-RasGAP317-326, is a tumor-sensitizer to various anti-cancer drugs.
Indeed, although it does not show any toxicity toward cells on its own, it efficiently and specifi-
cally sensitizes adult tumor cells in vitro and in vivo to various anti-cancer therapies, including
chemotherapy [12,13], and photodynamic therapy [14]. Importantly, it displays specificity to
cancer cells as it does not sensitize non-tumor cells to genotoxin-induced apoptosis [12, 14].
TAT-RasGAP317-326 appears to have additional anti-cancer activities than tumor cell sensitiza-
tion as it has been recently demonstrated that this peptide can hamper cell migration and inva-
sion in vitro [15, 16] and that this activity can inhibit the metastatization process in vivo [17].
This indicates that the RasGAP-derived peptide has the ability to act as an anti-metastatic com-
pound on top of its tumor sensitization effects. Recently, it has been shown that the anti-cancer
properties of TAT-RasGAP317-326 are dependent on two tryptophan residues at position 317
and 319 [16]. However, the mode of action of TAT-RasGAP317-326 is not fully characterized. It
has been previously shown that this peptide does not favor the death of tumor cells by modu-
lating Ras activity, MAPK signaling pathways, NF-κB transcriptional activity, Akt protein lev-
els and phosphorylation status [18, 19]. Moreover, the Bcl-2 family members, which regulate
mitochondrial-dependent cell death, were shown to be individually dispensable for the sensitiz-
ing activity of the peptide [20].
The effect of this peptide in childhood cancer is however not known. The molecular biology
of pediatric tumors is distinct from cancers in adults in many ways. As the genesis of most
childhood cancers seems to come from disruptions of normal early development, they accumu-
late fewer mutations than adult tumors. On the other hand, it appears that development of pe-
diatric tumors rely heavily on epigenetic modifications [21–23]. In the present study, we have
therefore investigated whether TAT-RasGAP317-326 was able to render childhood tumors more
sensitive to clinically relevant anti-tumor drugs.
Methods
Cell lines and culture cells
The CCRF-CEM [24], THP-1 [25] and A673 [26] cell lines were obtained from the American
Type Culture Collection (ATCC) (references CRL-8436, TIB-202, CRL-1598 respectively). The
LAN-1 [27] and M-07e [28] cell lines were obtained from the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures (references ACC655, ACC104 respectively).
The EW-11 [29], TC252 [30] and NB1-derived [31] cell lines were described earlier. All cell
lines were cultured in 5% CO2 at 37°C. The neuroblastoma cell lines (LAN-1, NB1-FBS,
NB1-FBS-Re) and the EW-11 Ewing sarcoma cell line were grown in Dulbecco’s modified
Eagle Medium (DMEM) (Gibco, Paisley, UK) containing 10% fetal bovine serum (FBS)
(Gibco). The NB1-NBM neuroblastoma primary tumor cells were maintained in neural basic
medium made of DMEM/F12 (Gibco) supplemented with 2% B27 serum-free supplement
(Invitrogen, Carlsbad, CA), 20 ng/ml human recombinant basic fibroblast growth factor
(bFGF) (Peprotech), and 20 ng/ml human recombinant epidermal growth factor (EGF)
(Peprotech). The CCRF-CEM and THP-1 acute leukemia cell lines, and the A673 and TC252
Ewing sarcoma cells, were cultured in RPMI 1640 (Gibco) containing 10% FBS. M07e, an acute
myeloid leukemia cell line, was maintained in Minimum Essential Medium alpha (MEMα)
(Gibco) supplemented with 10% FBS and 5 ng/ml recombinant human granulocyte
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macrophage colony-stimulating factor (GM-CSF) (Peprotech). Human peripheral blood lym-
phocytes (PBLs) were isolated by density centrifugation over a Ficoll-Paque gradient (Lympho-
prep; Stemcell Technologies) from buffy coats of healthy human donors, obtained from the
state of Vaud blood transfusion service. The donors gave written consent for potential use of
their blood for medical research. PBLs were cultured in RPMI 1640 (Gibco) supplemented
with 8% of pooled human serum and supplemented with 100 U/ml recombinant human inter-
leukin-2 (Proleukin, Roche Pharma AG).
Chemicals
The drugs used were vincristine (Sigma-Aldrich, St Louis, USA), etoposide (Sigma-Aldrich),
4-hydroperoxycyclophosphamide (4-HC) (Niomech, Bielefeld, Germany) and doxorubicin
(Pfizer AG, Zurich, Switzerland). The staining used to perform flow cytometry were 7-ami-
noactinomycin D (7-AAD) and Annexin V-FITC (Annexin V-FITC/7-AAD kit, Beckman
Coulter, Miami, USA).
Peptide synthesis
TAT-RasGAP317-326 (GRKKRRQRRRGGWMWVTNLRTD), TAT48-57 (from now on referred to as
TAT) (GRKKRRQRRR), TAT-Scrambled (GRKKRRQRRRGGWLDMTTVNRW) and TAT-Mutated
(GRKKRRQRRRGGAMWVTNLRTD) were synthesized at the Department of Biochemistry, Uni-
versity of Lausanne, Switzerland as described previously [12].
Cytotoxic assay
For cells growing in suspension (THP-1, M07e, CCRF-CEM, and lymphocytes), three hundred
thousand cells were seeded in 6-well plates and directly treated with the indicated doses of
4-HC, etoposide, vincristine, or doxorubicin in the presence or in the absence of 10 μM
TAT-RasGAP317-326, TAT, TAT-Scrambled or TAT-Mutated. For adherent cell lines
(NB1-NBM, NB1-FBS, NB1-FBS-Re, LAN-1, EW-11, TC252, and A673), two hundred thou-
sand cells were allowed to adhere for 48 hours in 6-well plates and were then treated like cells
growing in suspension. Twenty-four hours after drug incubation, cells were subjected to flow
cytometry to evaluate cell death. Briefly, adherent cell lines were detached by trypsin-EDTA
(Gibco) and single-cell suspensions were processed and stained with 1 μg/ml 7-AAD and 50
ng/ml Annexin V-FITC in 500 μl binding buffer. A minimum of ten thousand cells were ana-
lyzed. The 7-AAD dye-derived signal could not be used when cells were treated with doxorubi-
cin because 7-AAD and doxorubicin have similar fluorescent properties (7-AAD emission
wavelength: 525 nm; doxorubicin emission wavelength: 530 nm [32]).
Statistical analysis
Unless otherwise mentioned, all experiments were derived from three or more independent ex-
periments. The results were expressed as mean ± 95% confidence intervals. Significance was as-
sessed using t-tests performed with Microsoft Excel 2010 followed by Bonferroni corrections
(i.e. differences were considered significant when p values< 0.05/n, where n is the number of
comparisons made). Asterisks represent statistically significant differences. In the last figure,
significance was assessed by one-way ANOVAs followed by Bonferroni (Dunn) t post-hoc
tests using the SAS 9.2 software (SAS Institute Inc., Cary, NC, USA).
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Results
In this study, three types of childhood cancers were analyzed: neuroblastoma, leukemia, and
Ewing sarcoma. Among childhood malignancies, neuroblastoma is the most frequent extracra-
nial solid cancer. Deaths resulting from neuroblastoma account for 15% of all tumor related
death in children [33]. Multidrug resistance, acquired during exposure to chemotherapies,
plays a major role in this poor outcome [34, 35]. Leukemia is the most common childhood can-
cer type and represents one third of all pediatric tumors [36]. Although less prevalent than leu-
kemia, Ewing sarcoma is an aggressive cancer with a poor prognosis and a high rate of relapse
with metastatic disease [37]. The drugs employed here are all used in the clinics. Their proper-
ties are presented in Table 1.
TAT-RasGAP317-326 sensitizes acute lymphoblastic and myeloid
leukemia cells to various chemotherapeutic agents without showing any
effect toward tumor cells by itself
To investigate the sensitization effect of TAT-RasGAP317-326 in leukemia cells, three different
cell lines were subjected to increasing concentrations of cytostatic agents in the absence or in
the presence of 10 μM TAT-RasGAP317-326. Etoposide, vincristine, doxorubicin, and 4-hydro-
peroxycyclophosphamide (4-HC), the active form of cyclophosphamide, were the drugs used
here and are each currently employed in the clinic. Cell death was assessed using 7-AAD that
labels dead cells that have permeabilized plasma membrane and with Annexin V that binds to
phosphatidylserine exposed on dead cells. Some of the anti-cancer drugs used here induced a
concomitant appearance of the 7-AAD and Annexin V signals (Fig 1A shows the representa-
tive case of 4-HC). In other words, as soon as a cell became Annexin V-positive it also picked
up the 7-AAD dye. Hence, in our hands, anti-cancer drugs such as 4-HC induced a necrosis-
like type of death. In the next figures, the 7-AAD data are reported as we found them to be as-
sociated with a lower variance than those obtained with Annexin V staining (Fig 1B). The only
exception was when doxorubicin was used. Indeed, this dye fluoresces at similar wavelengths
as 7-ADD. In this case therefore, the Annexin V data are presented. These experiments re-
vealed that TAT-RasGAP317-326 significantly sensitizes leukemia cells to almost all tested drugs
(Fig 2A). However, in some conditions (for example when THP-1 cells are treated with vincris-
tine) tumor cells did not respond well to TAT-RasGAP317-326. A limited sensitization effect of
the RasGAP-derived peptide is not necessarily a consequence of intrinsic resistance to a drug
as the CCRF-CEM cell line, which is vincristine-resistant, was efficiently sensitized by
TAT-RasGAP317-326. This point is of particular clinical relevance as it indicates that TAT-Ras-
GAP317-326 can exert a sensitization effect in chemo-resistant cells.
Table 1. Mechanism of action and clinical use of cyclophosphamide, doxorubicin, etoposide and vincristine.
Drugs Class Mechanism of action Clinical use
Cyclophosphamide Alkylating agent Interstrand DNA crosslinker NB, ES, ALL, AML
Doxorubicin Antracycline DNA intercalation and inhibition of the progression of topoisomerase II enzymes NB, ES, ALL, AML
Etoposide Topoisomerase inhibitor Single or double strand breaks by trapping topoisomerase II enzymes on DNA NB, ES, AML
Vincristine Mitotic inhibitor Inhibition of assembly of microtubule structures NB, ES, ALL, AML
Only the tumor types that were analyzed in this study are mentioned here. The listing was based on the protocols of the Children’s Oncology Group and
the International Society of the Pediatric Oncology (EURO-E.W.I.N.G. 99; AALL0232; HR-NBL-1.5/SIOPEN). NB, neuroblastoma; ES, Ewing sarcoma;
ALL, acute lymphoblastic leukemia; AML: acute myeloid leukemia.
doi:10.1371/journal.pone.0120487.t001
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TAT-RasGAP317-326 by itself did not induce cell death in the tested leukemia cell lines, even
at a two-fold higher concentration (20 μM) than the one used to induce a sensitization effect
(10 μM) (Fig 2A).
TAT-RasGAP317-326 does not display toxicity toward non-tumor
lymphocytes from healthy subjects.
It was shown previously using non-tumor immortalized human keratinocytes (HaCaT) and
umbilical vascular endothelium (HUV-EC-C) cells that TAT-RasGAP317-326, in combination
Fig 1. Necrosis-like death induced by 4-HC in CCRF-CEM cells. A. Three hundred thousand CCRF-CEM cells were seeded in 6-well plates and directly
treated with 50 μM 4-HC. Cell death was evaluated after several time points (0, 3, 6, 12 and 24 hours) using 7-AAD and Annexin V-FITC staining. B.
CCRF-CEM cells were seeded in 6-well plates and directly treated with the indicated doses of 4-HC, etoposide or vincristine in the presence or in the
absence of 10 μM TAT-RasGAP317-326. After 24 hours of drug incubation, 7-AAD and Annexin V-FITC staining was performed to evaluate cell death. 4-HC,
4-hydroperoxycyclophosphamide.
doi:10.1371/journal.pone.0120487.g001
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with various genotoxins, did not sensitize non-tumor cells [12]. In the present study, we used
isolated lymphocytes from whole blood of healthy patients to investigate the selectivity of the
RasGAP-derived peptide toward cancer cells. We used the same dosages of chemotherapeutic
agents to treat healthy lymphocytes as those used to treat the CCRF-CEM T-acute
Fig 2. The effect of TAT-RasGAP317-326 as a chemosensitizer of leukemia cells and non-tumor lymphocytes. A. Two acute myeloid leukemia cell lines
(THP-1 and M-07e) and one T acute lymphoblastic leukemia cell line (CCRF-CEM) were seeded in 6-well plates and directly treated with 4-HC, etoposide,
vincristine or doxorubicin at the indicated concentrations in the presence or in the absence of 10 μM TAT-RasGAP317-326. After 24 hours of drug incubation,
7-AAD or Annexin V-FITC staining was performed to evaluate cell death (last four columns). Alternatively (first column), the cells were treated with increasing
concentrations of TAT or TAT-RasGAP317-326 alone. After 24 hours, the evaluation of cell death was carried out using 7-AAD staining.B. Isolated
lymphocytes from three distinct healthy subjects were treated as described in Fig. 2A. The dosages of chemotherapeutic agents used to treat the healthy
lymphocytes from the three subjects are similar to those used to treat the T-ALL CCRF-CEM cells. Note that the graphs are derived from single experiments
where lymphocytes are immediately used after their isolation (if cultured in vitro, they would experience high levels of spontaneous apoptosis that would
prevent accurate measurement of anti-cancer drug- and peptide-induced death). T-ALL, T-acute lymphoblastic leukemia; AML, acute myeloid leukemia;
4-HC, 4-hydroperoxycyclophosphamide. * p<0.05 t-test after Bonferroni correction.
doi:10.1371/journal.pone.0120487.g002
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lymphoblastic leukemia (T-ALL) cell line (Fig 2A). Fig 2B shows the response of peripheral
blood lymphocytes (PBLs) derived from three different healthy subjects (subjects A-C) to the
RasGAP-derived peptide in combination or not with the genotoxins used in Fig 2A. The Ras-
GAP-derived peptide by itself did not display any toxicity toward the PBLs. The sensitivity of
the non-tumor lymphocytes for the tested chemotherapies alone was similar to the sensitivity
of the CCRF-CEM cell line (even slightly increased in the case of doxorubicin for the healthy
subjects A and C). The observation that cancer and normal lymphocytes were similarly sensi-
tive to genotoxins was somehow surprising because the rationale to use a given chemotherapy
is that it will target preferentially the malignant cells. Nevertheless, the important information
drawn from Fig 2B is that TAT-RasGAP317-326 does not sensitize PBLs to etoposide-, vincris-
tine- and doxorubicin-mediated death. The peptide however did sometimes sensitize PBLs to
4-HC (Fig 2B), suggesting that TAT-RasGAP317-326 can affect the viability of normal cells in
some treatment combinations.
TAT-RasGAP317-326 can potentiate genotoxin-induced cell death in
Ewing sarcoma
To extend the investigation on TAT-RasGAP317-326 in non-leukemia childhood cancer, the ef-
ficacy of TAT-RasGAP317-326 was also tested in Ewing sarcoma cells. The results show that the
RasGAP-derived peptide is also able to sensitize these cells to various genotoxins, although to a
lower extent than in leukemias (Fig 3). In some cases, no sensitization was observed (e.g. when
vincristine was used in the A673 and TC252 cell lines). Here again, TAT-RasGAP317-326 alone
did not display any toxicity toward the Ewing sarcoma cells (Fig 3).
Fig 3. TAT-RasGAP317-326 potentiates genotoxin-induced cell death in Ewing sarcoma. Three Ewing sarcoma cell lines (EW-11, A673 and TC252)
were seeded in 6-well plates and after 24 hours were treated with 4-HC, etoposide, vincristine, or doxorubicin at the indicated concentrations in the presence
or in the absence of 10 μM TAT-RasGAP317-326. One day later, cell death was evaluated. 4-HC, 4-hydroperoxycyclophosphamide. * p<0.05 t-test after
Bonferroni correction.
doi:10.1371/journal.pone.0120487.g003
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The NB1 neuroblastoma derived-cell lines are directly killed by
TAT-RasGAP317-326
Acquired chemoresistance is an important cause of failure of treatment of neuroblastoma. To
assess the effect of TAT-RasGAP317-326 in cells that were exposed to high doses of chemothera-
pies and therefore that potentially have acquired resistance to these cytotoxic agents, we select-
ed primary tumor cells of a single patient at different stages of the disease. The NB1 cells are
high risk stage 4 primary neuroblastoma cells derived from bone marrow samples that were es-
tablished at initial diagnosis (NB1-NBM and NB1-FBS) and at subsequent relapse after multi-
agent chemotherapy (NB1-FBS-Re) (Fig 4A). NB1-FBS and NB1-FBS-Re cell lines were cul-
tured in 10% fetal bovine serum (FBS)-containing DMEMmedium, while NB1-NBM cells
were established in neural basic medium (NBM). NBM is a stem cell permissive serum-free,
bFGF-, EGF- and B27-supplemented medium to support the growth of neural crest cells, the
tissue of origin of neuroblastoma [38, 39].
Fig 4A shows that the NB1-NBM and NB1-FBS cell lines do not display the same sensitivity
toward the tested chemotherapies. Moreover, the efficacy of TAT-RasGAP317-326 to improve
the killing efficiency of 4-HC varies between these two cell lines: the NB1-FBS cells were found
to be very sensitive to the sensitization effect of the peptide, while the NB1-NBM cells were not
affected by the presence of TAT-RasGAP317-326. As the only difference between the NB1-NBM
and NB1-FBS cell lines is the medium in which they are cultured, one could hypothesize that
the metabolism of the NB1 cells varies from one culture condition to the other and that this dif-
ferentially modulates the sensitivity of the tumor cells to TAT-RasGAP317-326.
To investigate whether the sensitization effect of TAT-RasGAP317-326 was still efficient on
relapsed neuroblastoma cells, we compared its efficacy between the NB1-FBS cells and the
NB1-FBS-Re cells. Both cell lines are cultured in the same culture medium. The treatment regi-
men that was used to treat the patient is illustrated in Fig 4A. The patient, the relapsed cells of
which were derived, was exposed to the four drugs (4-HC, etoposide, vincristine and doxorubi-
cin) tested in this study. However, except for the 4-HC-treated conditions where we can ob-
serve a slight resistance to this drug in the NB1-FBS-Re cells, the relapsed cells are not more
resistant to etoposide, vincristine and doxorubicin than the cells derived from initial diagnosis
(Fig 4A). On the contrary, NB1-FBS-Re cells show an increased sensitivity to doxorubicin com-
pared to the NB1-FBS cells. Nevertheless, TAT-RasGAP317-326 sensitizes the three primary
NB1-derived cell lines, although to a different level of efficacy according to the cell line and the
tested chemotherapy (Fig 4A).
In most cases, TAT-RasGAP317-326 does not induce tumor cell death by itself. However, we
found out that the three NB1 derived-cell lines can be directly killed by the RasGAP-derived
peptide (Fig 4A). The dose needed to induce cell death (20 μM) is nevertheless higher than the
dose used to sensitize the cells to genotoxins (10 μM).
To complete the investigation of the effect of TAT-RasGAP317-326 in neuroblastoma tumor
type, we also tested the peptide on LAN-1, another neuroblastoma cell line derived from an ag-
gressive stage 4 neuroblastoma. Fig 4B shows that the RasGAP-derived peptide displays a slight
sensitization effect toward this cell line. Unlike the NB1 derived-cell lines, TAT-RasGAP317-326
alone was not able to kill LAN-1 cells (Fig 4B), meaning that TAT-RasGAP317-326-induced cell
death is not a specificity shared by all neuroblastomas.
The sensitizing activity of TAT-RasGAP317-326 is carried by the RasGAP-
derived sequence
To assess the specificity of the chemo-sensitizing activity of TAT-RasGAP317-326, three differ-
ent control peptides were tested: a peptide composed of the TAT sequence only (TAT), a
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Fig 4. TAT-RasGAP317-326 sensitizes neuroblastoma cells to chemotherapy and displays a direct killing effect on NB1-derived cell lines. A. The light
grey thick arrow on top of the figure represents the treatment regimen administrated to the patient from whom the three NB1-derived cell lines were
established. The NB1 cells are derived from primary high risk neuroblastoma bone marrow samples. NB1-NBM and NB1-FBS were established at initial
diagnosis and cultured in NBM and DMEMmedia, respectively. NB1-NBM-Re was established at a subsequent relapse and cultured in DMEM. The three
NB1-derived cell lines were treated as described in Fig 3. B. The LAN-1 cell line is derived from a high risk neuroblastoma. LAN-1 cells were treated as
described in Fig 3. M, month; BM, bone marrow; 4-HC, 4-hydroperoxycyclophosphamide. * p<0.05 t-test after Bonferroni correction.
doi:10.1371/journal.pone.0120487.g004
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peptide in which the RasGAP sequence was scrambled (TAT-Scrambled), and a peptide in
which the first tryptophan of the RasGAP sequence was substituted into an alanine residue
(TAT-Mutated). This tryptophan was recently shown to be essential for the sensitizing activity
of TAT-RasGAP317-326 in adult tumors [16]. The effect of TAT-RasGAP317-326 and the three
control peptides was tested in CCRF-CEM cells in combination with various anti-cancer drugs
at doses that allowed the greatest sensitization activity to be detected. CCRF-CEM cells were
used because this leukemia cell line was the one most efficiently sensitized by the RasGAP-de-
rived peptide. Fig 5A shows that all three control peptides had a tendency to slightly favor the
death of CCRF-CEM cells when combined with the different anti-cancer drugs but in most
cases this did not reach statistical significance. In contrast, TAT-RasGAP317-326 markedly, and
always significantly, sensitized these cells to the drugs. The slight sensitization effect of the con-
trol peptides is most likely due to the cell penetrating activity of the TAT moiety, which has the
potential to negatively affect cellular homeostasis [40]. Similar results were obtained when the
TC252 Ewing sarcoma cell line and the NB1-FBS neuroblastoma cell line were used: TAT-Ras-
GAP317-326 significantly increased their sensitivity to 4-HC, while the three control peptides
did not, or only minimally (Fig 5B and 5C). These data indicate that the tumor sensitizing ac-
tivity of TAT-RasGAP317-326 only marginally relies on its ability to penetrate cells via the TAT
cell-permeable sequence. Therefore, it can be concluded that the sensitizing activity of
TAT-RasGAP317-326 is mainly carried by the RasGAP-derived sequence.
Discussion
The currently applied therapies to treat childhood solid cancers, such as neuroblastoma and
Ewing sarcoma, need to be more efficient and specific to improve clinical outcome. Leukemia
has usually a better 5-year survival rate than pediatric solid tumors, but long-term effects of the
therapy remain an important cause of morbidity and mortality. Furthermore, acquired resis-
tance to the conventional treatments is responsible for relapses and poor outcome. According-
ly, finding less toxic and more efficient therapeutic agents to treat pediatric cancers is a
necessity to decrease drug-induced deleterious side effects and the associated mortality [3].
In the present study, we assessed the effect of TAT-RasGAP317-326 in several childhood can-
cer cell lines. This RasGAP-derived peptide was already known to sensitize adult tumor cells in
vitro and in vivo to various anti-cancer therapies [12]. Our results show that TAT-RasGAP317-
326 significantly sensitizes childhood cancer cells in the majority of the tested conditions. How-
ever, in some cases, tumor cells did not, or minimally, respond to the peptide. The pediatric
tumor-sensitizing effect illustrated in this study was reached using half of the peptide concen-
tration used previously to sensitize adult cancer cells (10 μMTAT-RasGAP317-326 in this study
instead of 20 μM in the paper of Michod et al. [12]). Possibly, the dose of TAT-RasGAP317-326
could be doubled to increase the sensitizing efficacy of the peptide in the conditions where it
was less efficient. Since primary tumor cells represent a more clinically relevant condition, we
also tested the peptide in primary neuroblastoma cells derived from bone marrow samples
from a single patient (the three NB1-derived cell lines showed in Fig 4). The results show that
the RasGAP-derived peptide sensitizes primary tumor cells, suggesting that it could exert its
anti-cancer activity on tumors in an in vivo context.
The mechanism of action of TAT-RasGAP317-326 remains to be precisely determined [18–
20]. We initially assumed that working with a large panel of cell lines and cytotoxic agents
would allow us to draw a pattern that could be used to predict which type of childhood tumors
display sensitivity to TAT-RasGAP317-326 in response to a given drug. Such information would
be helpful to decipher the mode of action of TAT-RasGAP317-326. For this purpose, we analyzed
how the half maximal inhibitory concentration (IC50) for each chemotherapeutic agent was
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modified by the presence of TAT-RasGAP317-326 for a given cell line (Table 2). The RasGAP-
derived peptide decreased the IC50 for most genotoxins in most cell lines. However, no specific
pattern based on tumor origin or drug type could be deduced from the data presented in
Table 2. We also looked whether there were some common specific mutations in well-known
oncogenes or tumor suppressor genes (e.g. HRAS, KRAS, NRAS, HDM2, N-MYC, C-MYC,
TAL1, FLI-1, MLL, p53 and Rb1) in the analyzed cell lines. Again, no association could be
Fig 5. The RasGAPmoiety carries the tumor sensitizing activity of TAT-RasGAP317-326. A. CCRF-CEM cells were seeded in 6-well plates and directly
treated with 10 μM TAT-RasGAP317-326, TAT, TAT-Scrambled or TAT-Mutated in the absence or in the presence of 4-HC, etoposide, vincristine or
doxorubicin at the indicated concentrations. After 24 hours of drug incubation, 7-AAD or Annexin V-FITC staining was performed to evaluate cell death.B-C.
The TC252 (B) and NB1-FBS (C) cell lines were treated similarly but in combination with 4-HC only. P10, TAT-RasGAP317-326; TAT-S, TAT-Scrambled;
TAT-M, TAT-Mutated; 4-HC, 4-hydroperoxycyclophosphamide. Means with the same letter are not significantly different.
doi:10.1371/journal.pone.0120487.g005
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Table 2. Sensitizing effect of the TAT-RasGAP317-326 toward childhood tumors.
Cell line Tumor type Chemotherapy IC50 (without peptide) IC50 (with 10 μM
TAT-RasGAP317-326)
Effect of TAT-
RasGAP317-326 on IC50
THP-1 AML 4-HC [μM] 38 25 Decrease
Etoposide [μg/ml] >20 10 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 0.3 0.3 No change
M-07e AML 4-HC [μM] 20 11 Decrease
Etoposide [μg/ml] >150 150 Decrease
Vincristine [μM] >10 1 Decrease
Doxorubicin [μg/ml] 2 2 No change
CEM T-ALL 4-HC [μM] 25 12.5 Decrease
Etoposide [μg/ml] >100 25 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] >10 >10 -
EW-11 Ewing sarcoma 4-HC [μM] 40 35 Decrease
Etoposide [μg/ml] >200 >200 -
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 3 1 Decrease
A673 Ewing sarcoma 4-HC [μM] 20 10 Decrease
Etoposide [μg/ml] >200 >200 -
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 2 0.4 Decrease
TC252 Ewing sarcoma 4-HC [μM] 27 10 Decrease
Etoposide [μg/ml] >200 25 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] >10 3 Decrease
NB1-NBM Neuroblastoma 4-HC [μM] 27 27 No change
Etoposide [μg/ml] 25 1 Decrease
Vincristine [μM] 10 0.04 Decrease
Doxorubicin [μg/ml] 0.3 0.07 Decrease
NB1-FBS Neuroblastoma 4-HC [μM] 10 3 Decrease
Etoposide [μg/ml] 2.5 1 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] >10 >10 -
NB1-FBS-Re Neuroblastoma 4-HC [μM] 15 2.5 Decrease
Etoposide [μg/ml] 2.5 1 Decrease
Vincristine [μM] >10 >10 -
Doxorubicin [μg/ml] 0.05 0.004 Decrease
LAN-1 Neuroblastoma 4-HC [μM] 26 24 Decrease
Etoposide [μg/ml] 200 50 Decrease
Vincristine [μM] 0.1 0.02 Decrease
Doxorubicin [μg/ml] 0.3 0.3 No change
This table summarizes the effect of TAT-RasGAP317-326 in combination with 4-HC, etoposide, vincristine or doxorubicin on the IC50 of the cell lines studied
in this paper. IC50 were calculated for each chemotherapeutic agent in the absence or in the presence of 10 μM TAT-RasGAP317-326. AML, acute myeloid
leukemia; T-ALL, T-acute lymphoblastic leukemia; 4-HC, 4-hydroperoxycyclophophamide.
doi:10.1371/journal.pone.0120487.t002
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found between the presence of specific mutations in a cancer cell line and its ability to be sensi-
tized by the RasGAP-derived peptide.
An interesting aspect of this research is that the sensitization effect of TAT-RasGAP317-326
can be differentially modulated by the cell culture conditions. This feature is illustrated by the
fact that the NB1-FBS cells, but not the NB1-NBM cells, are sensitive to the effect of the peptide.
These two cell lines are derived from the same neuroblastoma tumor at initial diagnosis (see Fig
4) but they were cultured in different media. These two cell lines appear to have the same geno-
mic alterations. Indeed, they possess identical array-CGH profiles with the same typical neuro-
blastoma-associated segmental chromosomic alterations (unpublished data). So if these two cell
lines have identical array-CGH profiles, what could explain their different sensitivity to
TAT-RasGAP317-326? One possibility is that the medium in which they are grown modulate
their metabolism differentially. This might in turn affect their sensitivity to anti-cancer treat-
ments. There are indeed accumulating evidence that the metabolic state of cancer cells play an
important role in the way they respond to anti-cancer drugs [41]. Another hypothesis is that
different cell populations are selected upon passages in different medium. Unlike the FBS-con-
taining DMEMmedium, the NBMmedium blocks cell differentiation. Consequently, the
NB1-FBS cells are potentially more differentiated than the NB1-NBM cells. The state of differ-
entiation of the cells could explain their different behavior in response to TAT-RasGAP317-326.
Alternatively, passage in different medium may induce differential epigenetic modifications or
mutations that impact on the sensitivities of the NB1-FBS and NB1-NBM cell lines toward the
RasGAP-derived peptide.
We have previously shown that the genotoxin sensitivity of non-tumor cells is not affected
by TAT-RasGAP317-326 [12]. Moreover, doses that induce tumor sensitization in vivo do not
exert any detectable toxic side effects [13]. In the present study, we tested the effect of the pep-
tide in isolated lymphocytes from blood of healthy patients. We confirmed the non-toxic effect
of the RasGAP-derived peptide in these cells. The peptide was also unable to sensitize the iso-
lated lymphocytes to etoposide, vincristine or doxorubicin. However, TAT-RasGAP317-326 was
found sometimes to sensitize non-malignant lymphocytes to 4-HC-induced death. This finding
is clinically relevant because one of the most frequent dose-limiting side effect of chemotherapy
is hematological toxicity [42]. Consequently, if TAT-RasGAP317-326 increases genotoxin-in-
duced side effects toward non-tumor cells, it would lose its attractivity as an anti-cancer candi-
date to treat childhood tumors. However, cyclophosphamide (and consequently its active form
4-HC) possesses hematologic toxic effects. This toxicity depends of the cellular expression level
of aldehyde dehydrogenase (ALDH), an enzyme responsible for cyclophosphamide detoxifica-
tion. The expression level of ALDH is very low in mature hematopoietic cells such as lympho-
cytes, while in hematopoietic stem cells, ALDH is expressed at high levels. Thus, the later are
relatively resistant to cyclophosphamide, whereas this alkylating agent is toxic toward mature
lymphocytes [43]. This feature explains why white blood cell counts drop in patients treated
with cyclophosphamide [44]. However this drop is transient and a rapid hematologic recovery
invariably occurs after cyclophosphamide therapy. Consequently, the observed sensitizing ef-
fect of TAT-RasGAP317-326 in combination with 4-HC in healthy lymphocytes may not be clin-
ically incompatible, provided that the negative effect of the peptide is limited to mature
hematopoietic cells and does not affect hematopoietic stem cells.
Although in most cases TAT-RasGAP317-326 by itself does not kill tumor cells, we found out
that it induced the cell death of the three NB1-derived cell lines tested here. This newly discov-
ered feature has two consequences. First, it will give us the opportunity to study the pro-death
activity of the peptide alone. This possibly may facilitate deciphering its mode of action by, for
example, using genome-scale knockout screenings [45, 46]. Second, it indicates that the Ras-
GAP-derived peptide, in its own right, corresponds to a new cytotoxic agent in certain tumors.
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In conclusion, our work shows that in most cases TAT-RasGAP317-326 sensitizes childhood
cancer cells to genotoxins. However, it was not possible to predict the efficacy of this sensitiza-
tion based on the tumor type and the drug used. Additional investigation is therefore required
to increase our understanding on how TAT-RasGAP317-326 works and to determine the indica-
tions for which it might be useful in the clinic.
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PART II 
 
THE TAT-RASGAP317-326 ANTI-CANCER PEPTIDE CAN KILL IN A CASPASE-, 
APOPTOSIS-, AND NECROPTOSIS-INDEPENDENT MANNER. 
 
Cancer cell resistance to apoptosis, which is triggered by many anti-tumour therapies, remains a 
major clinical problem. Henceforth, the development of novel and more efficient therapies is a priority 
to improve cancer prognosis. We have previously shown that TAT-RasGAP317-326 bears anti-malignant 
activities in vitro and in vivo, such as inhibition of metastatic progression and tumour cell sensitization 
to cell death induced by anti-cancer therapies. Recently, we have discovered that this RasGAP-
derived peptide possesses the ability to directly kill some cancer cells (e.g. the NB1 neuroblastoma 
and the Raji Burkitt lymphoma cell lines).  
The characterization of the type of cell death triggered by the peptide is the subject of a first author 
paper published in Oncotarget in September 2016: “The TAT-RasGAP317-326 anti-cancer peptide can 
kill in a caspase-, apoptosis-, and necroptosis-independent manner”. Of note, this study was carried 
out in collaboration with Mathieu Heulot. We equally contributed to the data presented in this section. I 
performed all the experiments in NB1 cells.  
Our results showed that TAT-RasGAP317-326 can activate both caspase-dependent and caspase-
independent cell death. Indeed, TAT-RasGAP317-326-induced cell death was not or only partially 
prevented when apoptosis was inhibited, either genetically or pharmacologically. Moreover, blocking 
other forms of cell death, such as necroptosis, autophagy, parthanatos, or pyroptosis, did not hamper 
the killing activity of the peptide. TAT-RasGAP317-326 is, therefore, able to trigger a type of cell death, 
which is distinct from those known forms of regulated death. Our finding has potentially important 
clinical relevance because uncovering a newly described form of death in tumour cells could lead to 
the generation of anti-cancer drugs that target pathways not yet considered for cancer treatment. 
 
Although these results allow a better understanding of the mode of action of the peptide, additional 
investigations were required to decipher the mechanisms involved in TAT-RasGAP317-326 toxicity. For 
this purpose, CRISPR/Cas9-based screens were performed to identify genes that are required for the 
peptide to kill. The validation and the study of the role of the various candidates highlighted by these 
screenings are exposed in the next part of this manuscript.  
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ABSTRACT
Tumor cell resistance to apoptosis, which is triggered by many anti-tumor 
therapies, remains a major clinical problem. Therefore, development of more efficient 
therapies is a priority to improve cancer prognosis. We have previously shown that a 
cell-permeable peptide derived from the p120 Ras GTPase-activating protein (RasGAP), 
called TAT-RasGAP317-326, bears anti-malignant activities in vitro and in vivo, such as 
inhibition of metastatic progression and tumor cell sensitization to cell death induced 
by various anti-cancer treatments. Recently, we discovered that this RasGAP-derived 
peptide possesses the ability to directly kill some cancer cells. TAT-RasGAP317-326 can 
cause cell death in a manner that can be either partially caspase-dependent or fully 
caspase-independent. Indeed, TAT-RasGAP317-326-induced toxicity was not or only 
partially prevented when apoptosis was inhibited. Moreover, blocking other forms 
of cell death, such as necroptosis, parthanatos, pyroptosis and autophagy did not 
hamper the killing activity of the peptide. The death induced by TAT-RasGAP317-326 
can therefore proceed independently from these modes of death. Our finding has 
potentially interesting clinical relevance because activation of a death pathway that 
is distinct from apoptosis and necroptosis in tumor cells could lead to the generation 
of anti-cancer drugs that target pathways not yet considered for cancer treatment.
INTRODUCTION
Cancer ranks among the leading causes of death 
worldwide [1]; this makes the development of novel 
and improved anti-cancer treatment a priority. Current 
oncological therapeutics aim to activate apoptosis to 
achieve disease control. However, cancer cells can 
adapt and become refractory to therapy by mutating 
and acquiring the ability to resist apoptotic stimuli [2]. 
The ability to evade apoptosis is one of the hallmarks of 
cancer [3]. Resistance leads to cancer cell survival and 
relapse. Consequently, development of treatments able 
to trigger non-apoptotic forms of death in cancer cells is 
of prime interest. There are many ways for mammalian 
cells to die, which could be divided into two main 
categories: accidental cell death (ACD) or regulated 
cell death (RCD) [4-6]. ACD is a form of death that 
is not induced by physiological or pathological insults 
and that does not involve the signaling machinery of 
cells. For example, ACD can result from exposure to 
extreme mechanical or chemical stimuli. In contrast, 
RCD requires genetically encoded molecular signaling 
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pathways and consequently can be modulated by genetic 
or pharmacologic interventions. Regulated forms of 
cell death include the intensively studied apoptosis, 
necroptosis and autophagy but also less known forms 
of death such as pyroptosis and parthanatos. These 
different types of cell death diverge at the level of 
the morphological changes and biochemical features 
triggered by death stimuli [4-6].
TAT-RasGAP317-326, a cell-permeable peptide derived 
from the p120 GTPase-activating protein (RasGAP), bears 
anti-malignant activities, including inhibition of metastatic 
progression and tumor cell sensitization to cell death 
induced by anti-cancer therapies [7-12]. This compound, 
in the initial tumor cell lines tested and at the given doses 
assessed was not found to affect their viability [7]. By 
screening additional tumor cells, however, we discovered 
that some cancer cell lines are directly killed by the 
RasGAP-derived peptide. The aim of the present study 
was to investigate which type of death was activated by 
TAT-RasGAP317-326 in the cells that are directly eliminated 
by the peptide.
RESULTS
TAT-RasGAP317-326 directly kills a subset of 
cancer cells
By screening a variety of cancer cell lines for their 
ability to become more sensitive to genotoxins in the 
presence of TAT-RasGAP317-326, we found 13 tumor cell 
lines that were directly killed by the peptide (Table 1). 
Among these, five are B-cell-derived cell lines (Daudi, 
Namalwa, Raji, Ramos and SKW6.4). To determine if 
non-transformed B cells were affected by the peptide, 
purified B cells (CD19+ cells) from healthy donors were 
tested. Supplementary Figure S1 shows that normal B cells 
were killed by TAT-RasGAP317-326 while peripheral blood 
lymphocytes (PBL) were barely affected. This indicates 
that the RasGAP-derived peptide can be detrimental to a 
fraction of immune circulating cells and this will have to 
be taken into account in case the peptide is therapeutically 
used.
Two of the tumor cells that were efficiently killed 
by the peptide, the Raji Burkitt lymphoma and the 
NB1 neuroblastoma cell lines, were used to investigate 
the manner by which the peptide induced death. 
Supplementary Figure S2 shows that the peptide did not 
alter the proportion of cells in a given cell cycle stage, 
suggesting that cell cycle regulators are not targeted by 
the peptide. When treated with an inactive point mutant of 
the peptide [TAT-RasGAP317-326 (W317A)] [13], or with the 
TAT cell-penetrating peptide alone, viability of Raji and 
NB1 cells was not affected (Figure 1A). This demonstrates 
that the direct killing ability of TAT-RasGAP317-326 is 
not carried solely by the TAT moiety but depends on 
specific RasGAP sequences. TAT-RasGAP317-326 induced 
membrane permeabilization in a dose-dependent manner 
in both Raji and NB1 cells (Supplementary Figure S3A). 
The kinetic of death, induced by the peptide was assessed 
using Annexin-V and 7AAD staining. Annexin-V binds 
to phosphatidylserine (PS) exposed at the cell surface, a 
phenomenon that is generally characteristic of apoptosis. 
The 7AAD dye is plasma membrane impermeable and 
thus only labels cells with compromised cell permeability, 
which is typically seen in necrotic cells. Apoptotic cells 
bind Annexin-V but remain initially 7AAD negative 
[14]. Figure 1B-1C shows that Annexin-V and 7AAD 
positivity occurred concomitantly in Raji and NB1 cells 
when incubated with TAT-RasGAP317-326. In contrast and 
as expected, apoptotic inducers in these cells (e.g. Fas 
ligand (FasL) or etoposide) induced PS exposure before 
membrane impermeability was compromised (Figure 1D). 
Of note, in both Raji and NB1 cells, TAT-RasGAP317-326 
induced a drop in mitochondrial membrane potential 
(Supplementary Figure S3B).
Reactive oxygen species (ROS) production upon 
peptide treatment was investigated. Intracellular hydrogen 
peroxide (H2O2) and cytosolic superoxide (CO2
.-) were not 
augmented by TAT-RasGAP317-326 (Supplementary Figure 
S4A). The sensors for these ROS were functional as 
shown in Jurkat cells treated with APO866, a nicotinamide 
phosphoribosyltransferase inhibitor (Supplementary 
Figure S4B). In contrast to hydrogen peroxide and 
cytosolic superoxide, mitochondrial superoxide (mO2
.-) 
was increased in NB1 and, less markedly, in Raji cells in 
response to TAT-RasGAP317-326 treatment (Supplementary 
Figure S4A). To assess the impact of mitochondrial 
ROS production on the viability of these cells, they were 
incubated with MitoTEMPO, a mitochondria-specific 
ROS scavenger. Supplementary Figure S4C shows that 
MitoTEMPO efficiently reduced TAT-RasGAP317-326-
induced mO2
.- production in NB1 cells and this lowered 
death induced by the peptide. However, in Raji cells, 
MitoTEMPO did neither reduce the level of mO2
.- 
nor TAT-RasGAP317-326-induced death. While it is not 
clear why MitoTEMPO failed to inhibit mitochondrial 
superoxide production in Raji cells, the data obtained in 
NB1 cells indicate that TAT-RasGAP317-326 might kill some 
cells via production of mitochondrial ROS.
As the RasGAP-derived peptide impacted the 
functionality of mitochondria, we determined if it 
modulated cellular ATP levels. As shown in Supplementary 
Figure S4D, the peptide induced a drop in ATP levels 
in Raji and NB1 cells. Intriguingly, this drop started to 
occur before any detectable cell death, suggesting that 
the peptide impacts cellular metabolism before inducing 
membrane permeabilization.
To evaluate the morphological changes involved 
in TAT-RasGAP317-326-induced cell death, we performed 
ultrastructural analyses in Raji and NB1 cells using 
electron microcopy (Figures 2 and 3). To have a 
comparison with apoptosis, we also treated Raji cells 
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Table 1: Cell lines tested for their sensitivity to TAT-RasGAP317-326.
TAT-RasGAP317-326 (µM)
Cell line 10 20 40 60 80 Ref
293T (embryonic kidney) ND - - ND + Unpublished
501Mel (melanoma) ND - - ND ND Unpublished
A375 (melanoma) - - ++ ++ ND Unpublished
A673 (Ewing sarcoma) - ND ND ND ND [12]
CCRF-CEM (acute T cell 
leukemia) - ND ND ND ND [12]
Daudi (Burkitt lymphoma) - ++ ++ ND ND Unpublished
EW-11 (Ewing sarcoma) - ND ND ND ND [12]
H1299 (non-small cell lung 
carcinoma) ND - ND ND ND [46]
HaCat (non-tumor keratinocyte) ND - ND ND ND [7]
HCT116 (colorectal carcinoma) ND - ND ND ND [7]
HeLa (cervical cancer) - - + ND ++ [7] / Unpublished
H-meso1 (lung mesothelioma) ND - ND ND ND [7]
HUVECC (non-tumor endothelial 
cells) ND - ND ND ND [7]
IGr37 (melanoma) ND - - ND ND Unpublished
IPC298 (melanoma) ND - - ND ND Unpublished
Jurkat (acute T cell leukemia) - - ND ND ND Unpublished
LAN-1 (neuroblastoma) - ND ND ND ND [12]
Lymphocytes (human PBL) - - + ND + [12] / Unpublished
MCF-7 (breast cancer) ND - ND ND ND [7]
MEF (mouse embryo fibroblast) ND - ND ND ND [44]
MelJuso (melanoma) ND - - ND ND Unpublished
MO7e (acute myeloid leukemia) - ND ND ND ND [12]
Namalwa (Burkitt lymphoma) - - - + ++ Unpublished
NB1 (neuroblastoma) - ++ ++ ++ ++ [12]/This study
PC3 (prostate cancer) ND - ND ND ND Unpublished
Raji (Burkitt lymphoma) - ++ ++ ++ ++ This study
Ramos (Burkitt lymphoma) - + ++ ND ++ Unpublished
RPMI-8226 (myeloma) - - ND ND ND Unpublished
SAOS (osteosarcoma) ND - ND ND ND [46]
SkMel30 (melanoma) ND - - ND ND Unpublished
SK-N-Be(2)c (neuroblastoma) - ND ND ND ND [12]
SKW6.4 (transformed 
B-lymphoblastoid) - ++ ++ ++ ++ Unpublished
(Continued )
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with FasL, a well-known apoptotic inducer (Figure 2). 
FasL treatment induced apoptotic cell death with classical 
morphological criteria including nuclear and cytoplasmic 
condensation, chromatin condensation throughout the 
nucleus (pyknosis), nuclear fragmentation, and minimal 
alterations of organelles (including mitochondria). TAT-
RasGAP317-326-treated Raji cells displayed different 
morphological features than those seen in FasL-treated 
cells (Figure 2). At first, slight and heterogeneous 
chromatin condensation without nuclear fragmentation, 
shrinkage of the cytoplasm and accumulation of 
cytoplasmic materials around the nucleus were observed. 
Organelles aggregated in distinct portions of the cytoplasm 
whereas some cytoplasmic areas seemed to be devoid 
of organelles. Organelles displayed a relatively good 
preservation but some mitochondria showed condensed 
features. Then, at later stages, Raji cells displayed a 
necrotic-like phenotype such as huge organelle swelling 
and loss of plasma membrane integrity. The inactive 
TAT-RasGAP317-326 (W317A) mutant did not alter the 
ultrastructural morphology of Raji cells.
Whereas TAT-RasGAP317-326-induced Raji cell 
death displayed a non-canonical morphological 
phenotype, TAT-RasGAP317-326-induced NB1 cell death 
showed some morphological features of apoptosis 
including chromatin condensation, nuclear fragmentation 
and condensed mitochondria at early stage and then 
secondary necrosis morphological features at later stage 
(Figure 3). Morphological features in TAT-RasGAP317-326-
induced NB1 cell death are therefore relatively similar 
to those observed when NB1 cells were exposed to the 
pro-apoptotic drug etoposide. However, clear differences 
were detected at the ultrastructural level between TAT-
RasGAP317-326- and etoposide-treated NB1 cells. For 
example, the peptide never induced pyknosis in NB1 
cells while etoposide almost always did so. Moreover, 
cytoplasmic materials often accumulated close to the 
nucleus in response to TAT-RasGAP317-326, while this was 
rarely the case when cells were incubated with etoposide. 
As seen in Raji cells, the inactive TAT-RasGAP317-326 
(W317A) mutant had no effect on the ultrastructure of 
NB1 cells.
The data shown in Figures 2 and 3 indicate that TAT-
RasGAP317-326 is inducing a form of death that is sharing 
some characteristics with apoptosis, at least in some cell 
lines, but which does not seem to be strictly equivalent to 
this mode of death. We therefore aimed to determine if 
other types of cell death were triggered by the RasGAP-
derived peptide.
Apoptosis inhibition does not protect against 
TAT-RasGAP317-326-induced cell death in Raji 
cells and only partially in NB1 cells
TAT-RasGAP317-326 induced caspase-3 activation 
and PARP1 cleavage in both Raji and NB1 cells (Figure 
4A), indicating that the peptide can trigger an apoptotic 
program. However, inhibition of caspase activity with 
the pan-caspase Z-VD-fmk inhibitor [15, 16] (Figure 
4A), while efficiently blocking apoptosis triggered 
by FasL, had no effect on death induced by TAT-
RasGAP317-326 in Raji cells (Figure 4B). In NB1 cells, 
however, a partial protection was observed (Figure 4B). 
Intrinsic mitochondrial apoptosis is characterized by the 
release of cytochrome c into the cytosol, which depends 
on the pore forming proteins Bax and Bak. Unlike tBid, 
TAT-RasGAP317-326 did not induce cytochrome c release 
from isolated mitochondria (Supplementary Figure S5), 
suggesting no direct action at the mitochondria level. 
The activity of Bax and Bak can be inhibited by over-
expression of anti-apoptotic Bcl-2 family members, 
such as Bcl-XL [17, 18]. Bcl-XL over expression (Figure 
4C) partially prevented TAT-RasGAP317-326-induced 
apoptosis in NB1 cells (Figure 4D). In Raji cells, 
etoposide, even at high doses, only induced a slight 
increase in apoptosis, most probably because Raji cells 
express high basal level of Bcl-2 [19]. However, Bcl-
XL overexpression did not protect Raji cells against 
TAT-RasGAP317-326 (µM)
Cell line 10 20 40 60 80 Ref
TC252 (Ewing sarcoma) - ND ND ND ND [12]
THP-1 (acute myeloid leukemia) - - ++ ++ ++ [12] / Unpublished
U2OS (osteosacroma) - - - - - [7] / Unpublished
Vero (monkey kidney) - - - ND + Unpublished
WM1366 (melanoma) ND + ++ ND ++ Unpublished
WM3248 (melanoma) ND + ++ ND ++ Unpublished
ND: not determined. -: not killed. +: < 20% killed. ++: > 20% killed.
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TAT-RasGAP317-326-induced death (Figure 4D). Similar 
results were obtained when Bax and Bak expression 
were removed by gene disruption using the CRISPR/
Cas9 technology (Figure 4E-4F). Combining Bcl-XL 
overexpression and Z-VD-fmk treatment did not induce 
a stronger inhibition of TAT-RasGAP317-326-induced 
death in NB1 cells as compared to individual inhibitor 
applications (Figure 4G).
Figure 1: TAT-RasGAP317-326 directly kills Raji and NB1 cells A. Raji cells and NB1 cells were treated for 16 and 24 hours, 
respectively, with 0, 20 and 40 µM TAT-RasGAP317-326, TAT or TAT-RasGAP317-326(W317A). Cell death, corresponding to the percentage of 
propidium iodide (PI)-positive cells, was determined by flow cytometry. Results correspond to the mean +/- 95% confidence interval (CI) 
of 3 independent experiments. B. Raji and NB1 cells were treated with 20 µM and 40 µM TAT-RasGAP317-326, respectively, for the indicated 
periods of time. Phosphatidylserine exposure and plasma membrane permeabilization were then analyzed by flow cytometry using Annexin-V 
and 7AAD staining, respectively. C. Double stain analysis of 7AAD- and Annexin-V positive cells in Raji and NB1 cells after the indicated 
periods of time of TAT-RasGAP317-326 treatment. D. Raji and NB1 cells were treated with 150 ng/mL FasL for 16 hours and 10 µg/mL etoposide 
for 9 hours, respectively. Cell death was analyzed as in panel B. The results correspond to the mean +/- 95% CI of 3 independent experiments.
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Figure 2: Ultrastructural analysis of TAT-RasGAP317-326-induced cell death in Raji cells. Representative electron micrographs 
showing the morphological ultrastructural features in Raji cells left untreated (Ctrl) or incubated with 20 μM TAT-RasGAP317-326 (W317) (24 
hours), 20 μM TAT-RasGAP317-326 (24 hours) or with 150 ng/mL FasL (16 hours). Scale bars: 5 µm. n: nucleus; m: mitochondria.
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Figure 3: Ultrastructural analysis of TAT-RasGAP317-326-induced cell death in NB1 cells. Representative electron micrographs 
showing the morphological ultrastructural features in NB1 cells in control condition (Ctrl) or after 40 μM TAT-RasGAP317-326 (w317A) (24 
hours), 40 μM TAT-RasGAP317-326 (24 hours) or 10 μg/mL etoposide (8 hours) treatments. Scale bar: 5 µm. n: nucleus; m: mitochondria.
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Figure 4: Inhibition of apoptosis does not prevent TAT-RasGAP317-326-induced cell death. A. Raji cells and NB1 cells were 
pre-incubated or not 1 hour with 10 µM of the pan-caspase inhibitor Z-VD-fmk. Raji cells were then treated with 20 µM TAT-RasGAP317-326 
for 16 hours and NB1 cells with 40 µM TAT-RasGAP317-326 for 24 hours. Cells were lysed and cleavage of PARP and caspase-3 analyzed 
by Western blotting. B. Raji and NB1 cells were pre-incubated or not 1 hour with 10 µM of the pan-caspase inhibitor Z-VD-fmk. Raji 
cells were then treated with 20 µM TAT-RasGAP317-326 (P20) and 150 ng/mL Fas-ligand (FasL) for 16 hours. NB1 cells were treated with 
40 µM TAT-RasGAP317-326 (P40) and 30 µM 4-HC, the active form of cyclophosphamide, for 24 hours. Cell death (corresponding to the % 
of Annexin-V positive cells) was determined by FACS. Results correspond to the mean +/- 95% CI of 3 independent experiments. C. Raji 
and NB1 cells were infected with empty viruses or viruses encoding Bcl-XL. Bcl-XL expression levels were assessed by Western blotting. 
D. Raji cells overexpressing or not Bcl-XL were treated with 20 μM TAT-RasGAP317-326 and 250 μM etoposide (eto) for 16 hours. NB1 cells 
overexpressing or not Bcl-XL were treated with 40 μM TAT-RasGAP317-326 and 50 μM etoposide for 24 hours. Cell death (corresponding 
to the % of 7AAD positive cells) was determined by FACS. The results correspond to the mean +/- 95% CI of at least three independent 
experiments. E. Bax and Bak were disrupted in Raji and NB1 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed 
by Western blotting. F. Wild-type and Bax/Bak double-knock-out Raji and NB1 cells were treated with 20 µM TAT-RasGAP317-326 for 16 
hours and 40 µM TAT-RasGAP317-326 for 24 hours, respectively. Cell death (corresponding to the % of PI-positive cells) was determined 
by FACS. Results correspond to the mean +/- 95% CI of 3 independent experiments. G. NB1 cells overexpressing or not Bcl-XL were pre-
incubated or not 1 hour with 10 μM of the pan-caspase inhibitor Z-VD-fmk and then treated with 40 μM TAT-RasGAP317-326. After 24 hours 
incubation, cell death (corresponding to the % of 7AAD-positive cells) was determined by FACS.
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TAT-RasGAP317-326 does not trigger necroptosis
As apoptosis was not, or only partially, involved in 
the death induced by TAT-RasGAP317-326, we investigated 
whether other forms of death could be involved. 
Necroptosis, also called programmed necrosis, is a form 
of cell death that differs from apoptosis at morphological 
and signaling levels [20, 21]. It is characterized by cell 
rounding, gain in cell volume, organelle swelling and 
plasma membrane rupture. Necroptosis requires receptor-
interacting protein (RIP) 1 and 3. The downstream target 
of the complex formed by RIP1/RIP3 was identified 
as mixed lineage kinase domain-like protein (MLKL) 
[22, 23]. Activation of MLKL leads to its translocation 
from the cytosol to plasma and intracellular membranes, 
and subsequent loss of membrane integrity [24]. In 
cells such as the HT29 colorectal adenocarcinoma, 
necroptosis can be triggered by tumor necrosis factor 
alpha (TNF-α) stimulation when caspases and translation 
are inhibited [25]. We were however unable to induce 
Raji and NB1 necroptosis using this protocol. This 
could be the consequence of a low MLKL expression 
(Figure 5A). To assess the involvement of necroptosis in 
TAT-RasGAP317-326-induced death, Raji cells were treated 
with necrosulfonamide (NSA), an MLKL inhibitor [23]. 
NSA efficiently prevented necroptosis in HT29 cells 
(Figure 5B) but had no effect on the death provoked by 
the RasGAP-derived peptide (Figure 5C). One could 
argue that NSA might not be efficient in Raji cells, even 
at concentrations shown to be efficient in sensitive cell 
lines such as HT29. We therefore knocked out MLKL 
in Raji and NB1 cells as another approach to prevent 
necroptosis. Because endogenous levels of MLKL in these 
cells were low and could not be detected in Raji and NB1 
cells (Figure 5A), the targeted DNA region by the Cas9 
endonuclease was sequenced. Figure 5D shows that both 
alleles of Raji clones #2 and #6 and NB1 clones #B3 and 
#A6 were disrupted, engendering frameshift mutations. 
These MLKL disrupted clones were then treated with the 
TAT-RasGAP317-326 peptide but this did not prevent cell 
death (Figure 5E). Collectively, these data demonstrate 
that TAT-RasGAP317-326 does not require the molecular 
machinery of necroptosis to kill Raji and NB1 cells.
TAT-RasGAP317-326 does not trigger pyroptosis
We next examined the implication of pyroptosis. 
This form of programmed cell death is stimulated by 
microbial and viral infections but also by stroke and cancer 
[26]. Morphological features displayed by pyroptotic 
cells are common with apoptosis and/or necrosis [26, 27]. 
Defined as a caspase-1-dependent cell death, pyroptosis 
results in the production of inflammatory cytokines such 
as interleukin-1β (IL-1β) and IL-18 and ends up in cell 
lysis. To determine whether pyroptosis is a type of cell 
death induced by TAT-RasGAP317-326, Raji and NB1 cells 
lacking caspase-1 were generated. Loss of caspase-1 
expression was confirmed in different clones by Western 
blotting (Figure 6A). The ability of the peptide to cause 
cell death was not abrogated in caspase-1 knock-out Raji 
and NB1 cells (Figure 6B). This is in line with the caspase 
inhibition results shown above (Figure 4B) as Z-VD-
fmk is also expected to prevent caspase-1 activity [16]. 
Altogether, this indicates that the RasGAP-derived peptide 
does not elicit pyroptosis.
TAT-RasGAP317-326 does not trigger parthanatos
Parthanatos is a cell death mode that is initiated 
by over-activation of poly (ADP-ribose)-polymerase 
1 (PARP1). Under physiological conditions, PARP1 is 
involved in DNA repair. To maintain genomic homeostasis, 
PARP1 detects single strand DNA breaks, uses NAD+ to 
synthetize poly (ADP-ribose) (PAR) and attaches PAR on 
itself and other target proteins [28, 29]. This leads to the 
recruitment of critical proteins for DNA repair [30, 31]. 
Hyperactivation of PARP1 contributes to NAD+ and ATP 
depletion and translocation of apoptosis-inducing factor 
(AIF) from the mitochondria to the nucleus [32-34]. To 
investigate if TAT-RasGAP317-326 triggers parthanatos, 
PARP1 knock-out cells were generated. Loss of PARP1 
expression was controlled by Western blotting (Figure 
6C). Figure 6D shows that in the absence of PARP1, Raji 
and NB1 cells are still killed by the peptide. Hence, the 
peptide does not trigger parthanatos.
Autophagy and TAT-RasGAP317-326-induced 
death
Autophagy is a process of self-degradation. During 
starvation, it allows cells to maintain energy levels via 
the degradation and recycling of cellular cytoplasmic 
constituents, allowing cell survival. Autophagosome 
formation involves the lipidation of the LC3 protein [35]. 
This pro-survival function of autophagy is well accepted 
[36, 37]. Autophagy may in some conditions trigger cell 
death [38]. To test if the peptide modulates autophagy, 
the autophagic marker lipidatino of LC3 was examined 
by Western blotting. Figure 7A shows that conversion of 
the LC3-I unlipidated form to the LC3-II lipidated form 
is similar in untreated cells and in cells treated with TAT-
RasGAP317-326. To rule out the involvement of autophagy 
in TAT-RasGAP317-326-triggered death, two autophagic 
genes, ATG5 and ATG6, were disrupted (Figures 7B and 
7D). Disruption of ATG5 fully prevented autophagy in 
Raji cells, as assessed by the absence of LC3 lipidation 
in serum deprivated conditions (Figure 7F). Moreover, 
autophagy induced by serum starvation fully prevented 
in cells lacking ATG6 (Figure 7F). However, the absence 
of ATG5 and ATG6 did not prevent TAT-RasGAP317-326-
induced cell death in Raji and NB1 cells (Figures 7C 
and 7E), suggesting that autophagy plays no role in TAT-
RasGAP317-326-mediated death.
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Figure 5: TAT-RasGAP317-326-induced cell death does not require the necroptosis machinery. A. Expression of MLKL 
in wild-type HT29 cells, Raji cells and NB1 cells assessed by Western blotting. B. HT29 cells were pretreated for 1 hour with 10 μM 
necrosulfonamide (NSA) and necroptosis was induced by the addition of 30 ng/ml TNF-α (T), 2 μg/ml cycloheximide (C) and 10 μM 
Z-VD-fmk (Z). After 24 hours, cell death was determined by FACS after staining with PI. C. Raji cells were pretreated for 1 hour with 10 
μM NSA before the addition of 20 μM TAT-RasGAP317-326 (P). After 16 hours incubation, cell death (corresponding to the % of PI-positive 
cells) was determined by FACS. The results correspond to the mean +/- 95% CI of three independent experiments. D. DNA sequences of 
wild-type MLKL gene and MLKL alleles of clones 2 and 8 and clones B3 and A6 of Raji cells and NB1 cells, respectively. Differences 
with the wild-type MLKL sequence are highlighted in bold. The sgRNAs directed against MLKL are highlighted in grey. E. Wild-type and 
MLKL disrupted Raji and NB1 cells were treated for 16 and 24 hours, respectively. Cell death (corresponding to the % of PI-positive cells) 
was measured by FACS. The results correspond to the mean +/- 95% CI of minimum three independent experiments.
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It is possible that the peptide triggers cell death 
via the activation of several pathways in parallel. We 
therefore investigated the effect of multiple cell death 
inhibition on TAT-RasGAP317-326 toxicity. Figure 7G 
shows that inhibition of apoptosis and necroptosis 
in autophagy-deficient Raji and NB1 cells did not 
protect against the cytotoxic effect of the peptide. 
Taken together, these results indicate that none of the 
“classical” death pathways mediate the killing activity 
of TAT-RasGAP317-326.
Figure 6: TAT-RasGAP317-326-induced cell death is caspase-1- and PARP1-independent. A. Caspase-1 was disrupted in Raji 
and NB1 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed by Western blotting. B. Wild-type and caspase-1 
knock-out Raji cells were treated or not with 20 µM TAT-RasGAP317-326 (P) for 16 hours. Wild-type and caspase-1 knock-out NB1 cells were 
treated or not with 40 µM TAT-RasGAP317-326 (P) for 24 hours. Cell death was then assessed by flow cytometry after PI staining. Results 
correspond to the mean +/- 95% CI of 3 independent experiments. C. PARP1 was disrupted in wild-type Raji and NB1 cells using CRISPR/
Cas9 technology. Loss of expression was confirmed by Western blotting. D. Wild-type and PARP1 knock-out Raji cells were treated or not 
with 20 µM TAT-RasGAP317-326 (P) for 16 hours. NB1 cells were treated or not with 40 µM TAT-RasGAP317-326 (P) for 24 hours. Cell death 
was then assessed by flow cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent experiments.
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Figure 7: Autophagy is not involved in TAT-RasGAP317-326-induced cell death. A. Raji cells were treated during 16 hours 
with 20 μM TAT-RasGAP317-326 (P) or not (N/T) and LC3 expression was analyzed by Western blotting. NB1 cells were treated during 
the indicated periods of time with 40 μM TAT-RasGAP317-326 and LC3 expression was analyzed by Western blotting. B. and D. ATG5 and 
ATG6 were individually disrupted in Raji and NB1 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed by Western 
blotting. C. Wild-type and ATG5 knock-out Raji cells were treated or not with 20 μM TAT-RasGAP317-326 (P) for 16 hours. Wild-type and 
ATG5 knock-out NB1 cells were treated or not with 40 µM TAT-RasGAP317-326 (P) for 24 hours. Cell death was then assessed by flow 
cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent experiments. E. Wild-type and ATG6 knock-
out Raji and NB1 cells were treated as described in panel D. Cell death was then assessed by flow cytometry after PI staining. Results 
correspond to the mean +/- 95% CI of 3 independent experiments. F. Wild-type, ATG5 knock-out and ATG6 knock-out Raji cells were 
cultured for 48 hours in presence or absence of serum. LC3 conversion was analyzed by Western blotting. G. Wild-type, ATG5 knock-out 
and ATG6 knock-out Raji cells were pretreated or not with 10 µM Z-VD-fmk and 10 μM necrosulfonamide (NSA) for 1 hour and then 
treated or not with 20 μM TAT-RasGAP317-326 (P) for 16 hours. Wild-type, ATG5 knock-out and ATG6 knock-out NB1 cells were pretreated 
or not with 10 µM Z-VD-fmk and 10 μM necrosulfonamide (NSA) for 1 hour and then treated or not with 40 µM TAT-RasGAP317-326 (P) 
for 24 hours. Cell death was then assessed by flow cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent 
experiments.
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DISCUSSION
Apoptosis had been the most intensively studied 
mode of regulated cell death for years. Thus, apoptotic 
inducers were and are largely used in the clinic as cancer 
therapies. However, tumor cell resistance to apoptosis, 
leading to cancer progression, is currently a major clinical 
problem. Some strategies could overcome this problem. 
For example, restoring the sensitivity of cancer cells to 
apoptosis might improve the efficacy of anti-tumor drugs. 
Another possibility would be to trigger alternate modes of 
death to which cancer cells are not resistant. The results 
presented here indicate that the TAT-RasGAP317-326 peptide 
has the capacity to kill some tumor cells in a manner 
distinct from the known characterized forms of death.
Our data show that necroptosis, autophagy, 
parthanatos and pyroptosis are neither activated nor 
involved in the toxicity induced by TAT-RasGAP317-326. 
In contrast, the apoptotic pathway is efficiently 
stimulated by the peptide. However, inhibiting 
apoptosis, either pharmacologically or genetically, 
did not (Raji cells), or only partially (NB1 cells), 
prevent TAT-RasGAP317-326 cytotoxicity. Hence, TAT-
RasGAP317-326 has the potential to activate apoptosis and 
another form of cell death that is distinct from the above 
mentioned death pathways. The ability of triggering 
multiple forms of death has been reported for other 
compounds. Indeed, shikonin and cisplatin, depending 
on the concentrations used, stimulate either apoptosis 
or necroptosis/necrosis [39, 40]. Another example is 
the lipophilic mitochondria-targeted F16 compound that 
was shown to elicit death via apoptosis [41]. However, 
Bcl-2 overexpression did not block the capacity of F16 
to trigger a necrotic cell death, demonstrating that one 
compound can have a dual ability to kill through both 
apoptosis and necrosis.
Our results clearly indicate that TAT-RasGAP317-326 
has the potential to stimulate both apoptosis and an 
alternative form of death in tumor cells of various origins. 
However, it is currently not known whether these two 
forms of death are activated independently or whether the 
triggering event leading to the alternative form of death 
has the capacity to also stimulate apoptosis.
In Raji cells, the sensitivity to the alternative 
form of death stimulated by TAT-RasGAP317-326 is 
seemingly high and the apoptotic pathway can be blocked 
without affecting the overall death response. In NB1 
cells, activation of the alternate form of death appears 
suboptimal and efficient killing requires concomitant 
activation of apoptosis. Consequently, it seems that there 
is a continuum of sensitivities among cancer cell lines to 
the direct killing action of TAT-RasGAP317-326.
Only a fraction of the tested cell lines were found 
to be sensitive to the killing activity of the peptide. 
To assess if those cells share common biological 
features that were not present in the resistant cell 
lines, we performed mutational and transcriptomics 
bioinformatical analyses on six sensitive and 
six resistant cell lines (subjected to 40 µM TAT-
RasGAP317-326). Supplementary Figure S6A lists the 6 
genes with the strongest differential mutational status 
between resistant and sensitive cell lines. Even in these 
genes, there was no strict association between the 
mutation status and the sensitivity of the cell lines to 
the peptide. It is unlikely that these genes, individually 
at least, drive the peptide sensitivity of a cell line. 
In agreement with this is the absence of correlation 
between their expression and the sensitivity of a cell 
line to be killed by the peptide (Supplementary Figure 
S6B). Moreover, there is no statistical support for a 
difference in the overall mutational rate of these cell 
lines (Supplementary Figures S6C-S6D). Gene profiling 
analysis revealed that cell lines cluster according 
to their origin rather than their sensitivity to TAT-
RasGAP317-326 (Supplementary Figure S6E). We finally 
performed a differential expression analysis to find 
whether the expression of certain genes was specifically 
associated with TAT-RasGAP317-326 sensitivity but failed 
to detect any (Supplementary Figure S6F). These 
results suggest that neither mutation nor transcriptional 
regulation are involved in the regulation of TAT-
RasGAP317-326 sensitivity. However, we should take into 
account that the cell lines were not always tested in 
identical experimental conditions (e.g. different culture 
media used for the experimentation). Moreover, as the 
peptide requires entry into cells via the HIV-TAT48-57 
portion, it is also possible that variations in peptide 
intake could explain some of the differences in the 
sensitivity observed between the cell lines.
At present, we cannot rule out the possibility that 
the alternate form of death triggered by the peptide is a 
form of necrosis. One hypothesis that we cannot dismiss 
is that TAT-RasGAP317-326 enters cells and then once 
in the cytoplasm alters, directly or indirectly, plasma 
membrane integrity by interacting with specific molecules 
that are enriched in the inner leaflet of the membrane. 
This mode of action has been reported for defensin 
NaD1, a host defense peptide [42]. NaD1 was shown to 
enter mammalian cells and bind to phosphatidylinositol 
4,5-bisphosphate (PIP2), leading to rapid membrane 
destabilization and permeabilization. As highlighted in 
this example, cell death induced by a peptide may not, or 
not only, depend on protein binding but also on specific 
membrane lipid interaction.
To conclude, our finding could potentially have 
interesting clinical relevance since current anti-cancer 
therapies are mostly based on drugs that induce tumor 
cell apoptosis. Consequently, determining that a 
peptide is able to induce a distinct form of death in 
tumor cells could lead to the generation of innovative 
anti-cancer drugs that complement or be combined 
with existing ones.
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MATERIALS AND METHODS
Cell lines
All cell lines were cultured in 5% CO2 at 37 °C. 
293T, 501Mel, PC3, HT29, U2OS and Vero were cultured 
in DMEM (Invitrogen, ref. no. 61965) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS; 
Invitrogen, ref. no. 10270-106). Raji, A375, Daudi, HeLa, 
IGr37, IPC298, Jurkat, MelJuso, Namalwa, Ramos, 
RPMI-8226, SKMel30, SKW6.4, THP-1, WM1366 
and WM3248 were cultured in RPMI (Invitrogen, ref. 
no. 61870) supplemented with 10% FBS. The NB1 
neuroblastoma cells were maintained in neural basic 
medium composed of DMEM/F12 (Invitrogen, ref. no. 
31331-028) supplemented with 2% B27 serum-free 
supplement (Invitrogen, ref. no. 17504044), 20 ng/ml 
human recombinant basic fibroblast growth factor (bFGF) 
(Peprotech, ref. no. 100-18B) and 20 ng/ml human 
recombinant epidermal growth factor (EGF) (Peprotech, 
ref. no. AF-100-15). Human peripheral blood lymphocytes 
(PBLs) were isolated by density centrifugation over 
a Ficoll-Paque gradient (Lymphoprep; Stemcell 
Technologies) from buffy coats of healthy human donors, 
obtained from the state of Vaud blood transfusion service. 
The donors gave written consent for potential use of their 
blood for medical research. B cells present in PBLs were 
positively stained with mouse FITC-labelled anti-CD19 
antibody for 30 min at 4°C before flow cytometry analysis.
Chemicals
TNFα and the protease inhibitor tablets were from 
Roche (ref. no. 11088939001 and 4693132001, respectively). 
Cycloheximide and etoposide were from Sigma (ref. no. 
C7698 and E1383 respectively). Necrosulfonamide was from 
Tocris bioscience (ref. no. 5025). The pan-caspase inhibitor 
Z-VD-fmk was a kind gift from Maxim Pharmaceuticals. 
Hexameric Fas ligand, resulting from the aggregation of 6 
fusion proteins between Fas ligand and the Fc portion of 
IgG1 [43], was provided by Pascal Schneider (University of 
Lausanne). Puromycin was from Life technologies (ref. no. 
A11138-02) and 4-hydroperoxycyclophosphamide (4-HC) 
was from Niomech, (ref. no. D-18864).
Peptides
TAT and TAT-RasGAP317–326 are retro-inverso 
peptides (i.e. synthesized with D-amino acids in the 
opposite direction compared to the natural sequence). The 
TAT moiety corresponds to amino acids 48–57 of the HIV 
TAT protein (RRRQRRKKRG) and the RasGAP317–326 
moiety corresponds to amino acids 317–326 of the human 
RasGAP protein (DTRLNTVWMW). These two moieties 
are separated by two glycine linker residues in the 
TAT-Ras-GAP317–326 peptide. TAT-RasGAP317-326(W317A) 
has the tryptophan at position 317 mutated into an alanine. 
The peptides were synthesized at the department of 
biochemistry, University of Lausanne, Switzerland, using 
FMOC technology, purified by HPLC and tested by mass 
spectrometry.
Cell death measurement
Cell death was measured with an Annexin-V-FITC 
/ 7AAD kit (Beckman Coulter, ref. no. IM3614) or with 
propidium iodide (PI) (Sigma, ref. no. 81845) and used 
according to the manufacturer’s instructions. Cells were 
scanned using a Beckman Coulter FC500 flow cytometer 
and data were analyzed with the Kaluza Version 1.3 
software (Beckman Coulter).
Cell cycle analysis
Cells were collected, washed once in PBS and 
fixed in 70 % ethanol at 4°C for 2 hours and then washed 
twice with PBS. DNA was stained with PI solution (10 
μg/mL PI, 150 μg/mL RNase A in water) at 37°C for 30 
minutes. Samples were analyzed by flow cytometry using 
a Beckman Coulter FC500 flow cytometer.
TMRM staining
Cells were collected, washed once in PBS and 
stained with 100 µL of 150 nM tetramethylrhodamine 
methyl ester (TMRM) solution by incubating during 
20 min at 37°C. 500 µL of PBS were added and then 
transferred to a sample tube which was analyzed by 
flow cytometry using a Beckman Coulter FC500 flow 
cytometer.
Mitochondria isolation and cytochrome c release
Cells were harvested in PBS and centrifuged 
10 min at 1,000xg. Cells were then resuspended in 
isotonic mitochondrial buffer (MB) (10 mM HEPES pH 
7.4, 210 mM mannitol, 70 mM sucrose, 1 mM EDTA 
supplemented with one tablet of protease inhibitor 
cocktail per 50 mL), broken by five passages through a 
25G1 0.5- by 2.5-mm needle fitted on a 2 mL syringe 
and centrifuged at 1,500xg for 5 min. This procedure 
was repeated twice and supernatants from each step were 
pooled and centrifuged 5 min at 1,500xg. Supernatant 
was collected, centrifuged 5 min at 2,000xg and further 
centrifuged 10 min at 9,000xg. Pellet was resuspended 
in MB (100 µL), centrifuged 10 min at 7,000xg and 
the pellet, representing the mitochondrial fraction, was 
finally resuspended in a volume of 100 µL of MB. 40 µg 
of mitochondria were incubated in KCl buffer (10 mM 
HEPES pH 7.4; 125 mM KCl; 0.5 mM EGTA; 4 mM 
MgCl2; 5 mM KH2PO4) and left untreated or treated with 
20 µM TAT-RasGAP317–326, 20 µM TAT-RasGAP317–326 
(W317A) or 40 nM tBid for 30 min at 37°C. Samples 
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were then centrifuged 5 min at 16,000xg and supernatant 
and pellet analyzed by Western blotting for the presence 
of cytochrome c.
Antibodies
The rabbit anti-Bcl-XL, the rabbit anti-caspase-3, 
the rabbit anti-LC3, the mouse anti-PARP1, the rabbit 
anti-actin antibodies were from Cell Signaling (ref. no. 
2764, 9662, 2775, 9546, 4970 respectively). The rabbit 
anti-ATG6, the rabbit anti-total Bax and the rabbit 
anti-total Bak were from Santa Cruz Biotechnology 
(ref. no. sc-11427, sc-493 and sc-832 respectively). 
The mouse anti-caspase-1 was from Adipogen (ref. 
no. AG-20B-0048). The rabbit anti-ATG5 was from 
Abcam (ref. no. ab108327). The rat anti-MLKL was 
from Merck Millipore (ref. no. MABC604). The mouse 
FITC-labelled anti-CD19 was from Beckman Coulter 
(ref. no. A07768).
Detection of cellular and mitochondrial ROS
Intracellular levels of cytosolic and mitochondrial 
superoxide as well as H2O2 production were determined 
by flow cytometry using live-cell permeant-specific 
fluorogenic probes, dihydroethidium (DHE; Marker 
Gene Technologies Inc, ref. no MGT-M1241-M010), 
MitoSOX (Molecular Probes, ref. no M36008) and 
6-carboxy-20,70-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA; Molecular Probes, ref. no C-400), 
respectively. DHE is oxidized to red fluorescent ethidium 
by cytosolic superoxide, MitoSOX is selectively 
targeted to mitochondria, where it is oxidized by 
superoxide and exhibits red fluorescence and carboxy-
H2DCFDA becomes green-fluorescent when oxidized 
with intracellular H2O2. After drug treatment, cells were 
harvested and transferred to flow cytometry tubes and 
incubated with 5 µM of specific probe at 37 oC for 30 min. 
Cells were washed twice with PBS, resuspended in 500 µL 
PBS and, for visualization of the intracellular fluorescence, 
probes were excited at 488 nm and fluorescence emission 
were analyzed by flow cytometry.
Determination of intracellular ATP content
Intracellular ATP content was measured with 
the ATP determination kit (Molecular Probes, ref. no 
A22066) according to manufacturer’s instructions. 
Briefly, after drug treatment, cells were collected, 
washed twice in PBS, resuspended in 100 µL lysis buffer 
(NaHCO3 20 mM + Na2CO3 100 mM) and kept at -80°C 
for at least 4h. Cell lysates and ATP standards (10 µL) 
were mixed with standard reaction solution (90 µL) and 
luminescence was determined using an automatized 
bioluminometer (Promega Glomax 96 microplate 
luminometer). ATP level for each sample was normalized 
to protein content.
Plasmids
The lentiviral vector lentiCRISPRv2 [44] was 
obtained from Addgene (#868, Addgene, ref. no. 
52961). The pMD2.G plasmid (#554, Addgene, ref. no. 
12259) encodes the envelope of lentivirus. The psPAX2 
plasmid (#842, Addgene, ref. no. 12260) encodes the 
packaging system. The hBclXL.LEGO-iG2 plasmid 
(#863) was constructed by subcloning the 771 bp EcoRI 
fragment from hBcl-XL. dn3 (#274) into LeGO-iG2 
(#807; Addgene: plasmid 27341).
Lentivirus production
Recombinant lentiviruses hBclXL.LEGO-iG2 
were produced as described [45] with the following 
modifications: pMD.G (#218) and pCMVDR8.91 (#219)
were replaced by pMD2.G and psPAX2 respectively.
Genome editing by CRISPR method
Single guide RNAs targeting the early exon 
of the protein of interest were chosen in the sgRNA 
library [46] and are listed in Table 2. LentiCRISPR 
plasmids specific for a gene were created according 
to the provided instructions. Oligos were designed as 
follow: Forward 5’-CACCGnnnnnnnnnnnnnnnnnn
nn-3’; Reverse-3’-CnnnnnnnnnnnnnnnnnnnnCAA-5’, 
where nnnnnnnnnnnnnnnnnnnn in the forward oligo 
corresponds to the 20 bp sgRNA. Oligos were synthetized, 
then phosphorylated and annealed to form oligo 
complexes. LentiCRISPR vector was BsmBI digested 
and dephosphorylated. Linearized vector was purified 
and gel extracted and ligated to oligo complexes. The 
lentiCRISPR vector containing the sgRNA was then used 
for lentivirus production. Cells were infected and selected 
with the appropriate dose of puromycin (2 µg/ml for Raji, 
1 µg/ml for NB1). Clone isolation was performed by 
limiting dilution in 96 well-plate.
TA cloning
TA cloning kit (Life technologies, ref. no. K202020) 
was used according to manufacturer’s instructions to 
sequence DNA fragment containing the region where Cas9 
was guided by a sgRNA.
Electron microscopy
NB1 cells were plated in poly-L-lysine (0.01%, 
Sigma-Aldrich, ref. no. P4832)-coated glass slides 
(LabTek Chamber Slides, ref. no. 177399) at a density 
of 300,000 cells per slide (area = 1.8 cm2), cultured 
for 24 hours. The Raji Burkitt lymphoma cells were 
cultured at a density of 200,000 cells per ml. The cells 
were treated as described in the figures. Cells were 
then fixed 2 hours in 2.5% glutaraldehyde (Electron 
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Microscopy Sciences, ref. no. 16220) dissolved in 
100 mM phosphate buffer (PB), pH7.4. After three 
washes in PB, cells were postfixed for 1 hour in 1% 
osmium tetroxide (Electron Microscopy Sciences, 
ref. no. 19150) in PB and then stained with ethanol 
70% containing 1% uranyl acetate (Sigma-Aldrich, 
ref. no. 73943) for 20 min. Raji and NB1 cells were 
dehydrated in graded alcohol series and embedded in 
epon (Electron Microscopy Sciences, ref. no. 13940). 
Ultrathin sections (with silver to gray interference) 
were cut with a diamond knife (Diatome), mounted 
on Formvar-coated single slot grids, and then 
counterstained with 3% uranyl acetate for 10 min and 
then with lead citrate (0.2%, Sigma-Aldrich, ref. no. 
15326) for 10 min. Sections were visualized using a 
Philips CM100 transmission electron microscope.
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The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, 
apoptosis-, and necroptosis-independent manner
SUPPLEMENTARY FIGURES
Supplementary Figure S1: Effect of TAT-RasGAP317-326 on the survival of PBLs and B cells. PBLs from 3 different healthy 
donors were left untreated or treated with 20 µM TAT-RasGAP317–326 for 16 hours. Then, cells were washed twice with PBS and B cells were 
stained with FITC-labelled anti-CD19 antibody. Cell death was assessed by flow cytometry after PI staining.
Supplementary Figure S2: Effect of TAT-RasGAP317-326 on cell cycle. Raji cells and NB1 cells were treated for the indicated 
periods of time with 20 and 40 μM TAT-RasGAP317-326, respectively. Cells were collected and cell cycle analyzed by flow cytometry. Results 
correspond to the mean +/- 95% CI of 3 independent experiments.
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Supplementary Figure S3: Sensitivity of Raji and NB1 cells to TAT-RasGAP317-326-mediated death and effect of the 
peptide on mitochondrial potential. A. Raji cells were treated with different concentrations of TAT-RasGAP317-326 for 72 hours and 
cell death was determined by trypan blue exclusion. NB1 cells were treated with different concentrations TAT-RasGAP317-326 for 24 hours 
and cell death was determined by flow cytometry using 7AAD. B. Raji and NB1 cells were treated with 0, 20 and 40 μM TAT-RasGAP317-326 
for 16 and 24 hours, respectively. Cell death and mitochondrial membrane potential were then analyzed by PI and TMRM staining using 
flow cytometry. Results correspond to the mean +/- 95% CI of 3 independent experiments.
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Supplementary Figure S4: Effect of TAT-RasGAP317-326 on ROS production. A. Intracellular ROS production was detected in 
Raji or NB1 cells after treatment with 20 and 40 μM TAT-RasGAP317-326, respectively. Cell death (corresponding to the % of Annexin-V and/
or 7AAD-positive cells) was determined by flow cytometry. H2O2, cO2
.- and mO2
.- superoxides were detected for the indicated periods of 
time by flow cytometry staining using carboxy-H2DCFDA, DHE and MitoSOX fluorescent probe, respectively. B. Jurkat cells were treated 
for 48 hours with 10 nM APO866 (a potent ROS inducing agent). Cell death and ROS production were determined by flow cytometry 
using specific probes as described above. C. Cells were pretreated for 2 hours with or without the indicated concentrations of MitoTEMPO 
and then treated or not with 40 μM TAT-RasGAP317-326 for 24 hours. Cell death and mO2
.- were measured by flow cytometry using PI and 
MitoSox, respectively. The results are expressed as percentage of cells that are PI-positive (PI) or MitoSox-positive. D. Intracellular ATP 
levels were determined at the indicated periods of time for Raji and NB1 cells treated with 20 and 40 μM TAT-RasGAP317-326, respectively. 
Each sample was normalized to protein content and to the mean basal ATP level (T0). Cell death was assessed by flow cytometry after PI 
staining. Results correspond to the mean +/- 95% CI of 3 independent experiments.
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Supplementary Figure S5: Effect of TAT-RasGAP317-326 on isolated mitochondria. Isolated mitochondria were left untreated or 
treated with 20 µM TAT-RasGAP317–326 (P), 20 µM TAT-RasGAP317–326 (W317A) (W) or 40 nM tBid for 30 min at 37°C. After centrifugation, 
supernatant and pellet were analyzed by Western blotting.
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Supplementary Figure S6: Comparison of mutational count and gene expression profiles between TAT-RasGAP317-326- 
sensitive and -resistant cell lines. A. Assessment of mutational enrichment according to TAT-RasGAP317-326 sensitivity with black 
representing mutated genes and white denoting no mutation. The six most highly enriched genes are displayed. B. Heatmap representing the 
expression of the six most mutated genes. C. Number of non-synonymous somatic mutations among the twelve cell lines. D. Distribution 
of somatic mutation number in resistant and sensitive cell lines. E. Heatmap representing gene expression of the twelve different cell lines, 
with a gradient from blue (low expression) to red (high expression). F. Heatmap displaying the ten most differentially expressed genes 
between resistant and sensitive cell lines.
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RELATED UNPUBLISHED DATA 
 
To characterize the mode of cell death induced by TAT-RasGAP317-326, I performed several 
experiments that were not published and that I report here.  
 
Does TAT-RasGAP317-326-induced cell death require the translation process? 
To define at which level the peptide acts, transcription and translation were inhibited by actinomycin D 
and cycloheximide (CHX), respectively. Figure R1A shows that TAT-RasGAP317-326-induced cell death 
still occurs in the presence of CHX at a concentration allowing the inhibition of c-Myc translation, as 
illustrated by the dose-dependent decrease of its protein abundance (Figure R1B). Results obtained 
with actinomycin D are not depicted due to the basal high toxicity of this compound rendering results 
hardly interpretable. Nevertheless, these data suggest that TAT-RasGAP317-326 acts post-
translationally. To better characterize at which step the RasGAP-derived peptide works, the 
requirement of the proteasome (using the MG-132 proteasome inhibitor) or the involvement of the 
kinases (using staurosporine) remain to be investigated.  
 
 
 
 
Figure R1. TAT-RasGAP317-326 does not require the translation process. A. WT NB1 cells were 
preincubated or not (N/T) for 1 hour with cycloheximide (CHX), before being treated or not (CTRL) with 20 µM 
TAT-RAsGAP317-326 (P) for 9 hours. Cell death, corresponding to the percentage of Annexin-V positive cells 
(apoptosis) or the percentage of 7-AAD positive cells (necrosis and late apoptosis), was determined by flow 
cytometry. Results correspond to the mean +/- 95% CI of at least 3 independent experiments. B. Abundance of c-
Myc in NB1 cells treated or not for 9 hours with cycloheximide at the indicated concentrations was assessed by 
western blotting.  
 
 
 
Does TAT-RasGAP317-326 trigger necroptosis? 
In order to answer this question, we used in parallel two approaches. First, we inhibited necroptosis 
using two different pharmacological inhibitors, a RIPK1 inhibitor called necrostatin-1 (Nec-1) and a 
MLKL inhibitor termed necrosulfonamide (NSA). Figures R2A and R2B indicate that NB1 cells treated 
with Nec-1 and NSA were not protected against the peptide toxicity. However, as mentioned in the 
Oncotarget paper, we were unable to induce necroptosis in NB1 cells rendering the generation of a 
positive control for these two experiments difficult. Consequently, the second approach was to 
generate MLKL knockout cells and to test them in the presence of the peptide as depicted in Figure 5 
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of the Oncotarget paper [196]. Results acquired with the MLKL knockout cells were in agreement with 
those obtained with the pharmacological inhibitors. 
 
 
 
 
 
Figure R2. Inhibition of necroptosis does not prevent TAT-RasGAP317-326-induced cell death. A. 
WT NB1 cells were preincubated or not (N/T) for 1 hour with necrostatin-1 (Nec-1), before being treated or not 
(CTRL) with 20 µM TAT-RAsGAP317-326 (P) for 24 hours. Cell death, corresponding to the percentage of Annexin-
V positive cells (apoptosis) or the percentage of 7-AAD positive cells (necrosis), was determined by flow 
cytometry. B. WT NB1 cells were preincubated or not (N/T) for 1 hour with 1 μM or 10 μM necrosulfonamide 
(NSA), before being treated or not (CTRL) with 40 μM TAT-RasGAP317-326 (P). After 24 hours incubation, cell 
death (corresponding to the % of PI positive cells) was determined by flow cytometry. Results correspond to the 
mean +/- 95% CI of at least 3 independent experiments. 
 
 
 
Does TAT-RasGAP317-326 require CAPNS1 to kill NB1 cells or to sensitize HCT116 cells to 
cisplatin? 
The calpains are a family of calcium-dependent cysteine proteases that are implicated in several 
physiological processes, such as cell motility and apoptosis [197]. Furthermore, it has been 
demonstrated that calpain activity may affect cancer progression and anti-tumour therapies [198, 199]. 
Although the calpain family consists of more than ten members, the best characterized ones are the 
ubiquitously expressed μ-calpain and m-calpain. They are heterodimers consisting of an unique large 
subunit (CAPN1 and CAPN2 respectively) and a common small regulatory subunit (CAPNS1) [200]. 
CAPNS1 was identified as a RasGAP SH3 binding protein [201]. In order to investigate whether TAT-
RasGAP317-326 targets calpains to mediate cell death, CAPNS1 knockout NB1 and HCT116 cells were 
generated (Figure R5A). As illustrated in Figure R5B, the deletion of CAPNS1 in NB1 did not protect 
cells against the toxicity of the peptide. In addition, CAPNS1 disruption in HCT116 cell line did not 
abrogate the chemosensitizing activity of TAT-RasGAP317-326 in the presence of cisplatin (Figure R5C). 
However, as already described in the literature, the absence of CAPNS1 in HCT116 renders those 
cells partially resistant to cisplatin (Figure R5C) [199].   
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Figure R5. CAPNS1 is not required to sensitize HCT116 cells neither to kill NB1 cells. A. CAPNS1 
was disrupted in NB1 and HCT116 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed 
by western blotting. B. Wild-type (WT) and CAPNS1 knockout (KO) NB1 cells were treated or not with 40 µM 
TAT-RAsGAP317-326 (P) for 24 hours. Cell death, corresponding to the % of PI positive cells, was determined by 
flow cytometry. The experiment was performed only once. C. WT and CAPNS1 KO HCT116 cells were treated or 
not with 30 µM cisplatin in the presence or in the absence of 20 µM TAT-RAsGAP317-326 (P). After 24 or 48 hours, 
Hoechst 33342 staining was performed to determine the proportion of apoptotic cells by manually counting 
pycnotic nuclei. This experiment was performed only once.  
 
 
 
Does TAT-RasGAP317-326 induce cell death in HEK293T, Vero, HeLa, WM3248, and WM1366 
cells? 
In order to complete the Table 1 published in the Oncotarget paper, we tested several different cell 
lines for their sensitivity to TAT-RasGAP317-326-induced cell death. Figure R6 depicts the sensitivity of 
five cell lines (293T, Vero, HeLa, WM3248, and WM1366) to the peptide. Of note, 293T and Vero cells 
were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), whereas the three other 
cell lines were grown in RPMI supplemented with 10% FBS. 
 
 
 
 
 
 
Figure R6. TAT-RasGAP317-326 toxicity in 293T, Vero, HeLa, WM3248, and WM1366 cells. 293T, 
Vero, HeLa, WM3248, and WM1366 cell lines were treated with the indicated concentrations of TAT-RasGAP317-
326 for 24 hours. Cell death was then assessed using the Cytation 3 cell imaging multi-mode reader after PI and 
Hoechst 33342 staining. Results correspond to the mean +/- 95% CI of 3 independent experiments.
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PART III 
 
The third part of the results is dedicated to the identification of regulators of TAT-RasGAP317-326-
induced cell death. As reported in the previous part, the RasGAP-derived peptide can kill some tumour 
cells in a manner that differs from known regulated forms of death. To identify proteins involved in the 
killing activity of the peptide, a CRISPR/Cas9 screening was performed on two cell lines (SKW6.4 and 
Raji). Results of CRISPR/Cas9 screens, the validation of the top candidate genes, and the role of their 
proteins in the activity of TAT-RasGAP317-326 are presented in the following manuscript.  
 
This study was carried out in collaboration with several colleagues. The work was shared as following: 
Mathieu Heulot performed the screening on Raji cells and most of the experiments with those cells, 
except the cytosolic access assay (TAT-PNA), and the membrane potential and intracellular 
potassium measurements that were done by Dr. Sébastien Michel. Giulia Torriani, a PhD student in 
Prof. Stefan Kunz laboratory at the Institute of Microbiology, generated all the data with pseudotyped 
viruses. I performed the CRISPR/Cas9 screen on the SKW6.4 cells and validated all the yielded 
candidates of this screening. I did most of the experiments in SKW6.4 cells, except the cytosolic 
access assay (TAT-PNA) and the membrane potential measurement that were done by Dr. Sébastien 
Michel. In addition, I performed the majority of the experiments presented in the supplementary figures 
of the manuscript. Finally, I wrote the following manuscript. 
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GENOME-WIDE CRISPR/CAS9 SCREEN IDENTIFIES THE INVOLVEMENT OF 
POTASSIUM CHANNELS AND THE NA+/K+-ATPASE PUMP IN THE CYTOSOLIC 
ACCESS OF TAT-CONSTRUCTS AND VIRUSES.  
 
 
INTRODUCTION 
Drug delivery into cells remains a challenge due to selective permeability of the cell membrane. To 
improve the intracellular carriage of promising therapeutic molecules, such as proteins or nucleic 
acids, cell-penetrating peptides (CPPs) can be conjugated to these compounds of interest. CPPs are 
short peptides (usually less than 30 amino acids) able to spontaneously and ubiquitously transport 
various biochemically active molecules inside living cells. The first CPP described was the full length 
Trans-Activator of Transcription (TAT) protein of the HIV, in 1988 [140]. Some years later, it was found 
that a truncated version of TAT, TAT48-57, was sufficient to deliver cargoes into cells [142]. Although 
the TAT CPP has been studied for almost 30 years, its mechanism of entry into cells remains debated 
due to the disparity of results among the different authors. It has been reported that the internalization 
of TAT can occur by direct translocation, endocytosis, or both simultaneously [153, 188-190, 193]. 
This discrepancy is mainly attributed to the fact that a CPP enters cells via a singular mechanism 
according to its sequence, structure, or amphipathicity. Moreover, cellular uptake of a single CPP is 
dependent on variable factors such as peptide concentration, time of incubation, local lipid 
composition, or characteristics of the cargo [147].  
Direct translocation can happen at 4°C and in ATP depletion condition. It requires destabilization of 
the plasma membrane through different ways that result most of the time in the formation of pores 
allowing the passage of the CPP. In contrast to direct translocation, endocytosis is a generic name 
describing different processes that allow cells to absorb material via an ATP-depend manner [160]. 
Molecules can trigger endocytosis by the direct contact with the cell membrane, its binding to a 
receptor, or by their electrostatic interactions with the proteoglycans. There are several endocytic 
routes to reach the cytoplasm including macropinocytosis, clathrin-mediated endocytosis, caveolae-
mediated endocytosis, or clathrin- and caveolae-independent endocytosis [161]. According to its size 
and biochemical properties, a cargo is internalized through specifically one or several of these routes. 
Once the cargo is sequestered into a vesicle, it is then internalized and sorted into a series of 
tubulovesicular compartments, named endosomes. Cargoes can have various fates including their 
recycling back to the cytoplasmic membrane, their delivery and degradation to the lysosomes, or their 
endosomal escape to reach the cytosol [180].  
In this study, we performed gene disruption CRISPR-based genetic screens to better understand the 
mode of action of a peptide called TAT-RasGAP317-326. The latter was derived from the p120 Ras 
GTPase-activating protein (RasGAP) and was fused to the TAT48-57 CPP. TAT-RasGAP317-326 has 
various anti-cancer properties. It potently sensitizes tumour cells to various chemotherapeutic agents 
and hampers metastatic progression in vitro and in vivo [122-124, 202]. Recently, we have shown that 
this RasGAP-derived peptide possesses also the ability to directly kill some neoplastic cells [196]. 
Moreover, in these cells blocking any known mode of cell death, such as apoptosis, necroptosis, 
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autophagy, parthanatos, or pyroptosis, did not (or only partially) inhibit the toxicity of the peptide [196]. 
By using the CRISPR/Cas9 approach, we expected to decipher which genes were involved in TAT-
RasGAP317-326-induced cell death. The screens yielded as the top candidates several potassium 
channels (KCNQ5, KCNN4, and KCNK5) and a subunit of the Na+/K+-ATPase pump (ATP1B3), whose 
loss rendered the cells resistant to the peptide toxicity. However, we showed that the disruption of 
these genes hampers the cytosolic access of the RasGAP-derived peptide rather than inhibits its pro-
death activity. In addition, we validated the involvement of these targets in the regulation of the 
cytosolic access of two other TAT-constructs called TAT-PNA and TAT-Cre. Finally, this ability to 
inhibit the intracellular delivery was also validated for several viruses.  
This new property of potassium channels and the Na+/K+-ATPase pump could allow a better 
understanding of the mode of entry of TAT CPP and could lead to development of prophylactic 
inhibition of viral infections.   
 
 
MATERIALS AND METHODS 
Cell lines 
All cell lines were cultured in 5 % CO2 at 37 °C. The Raji and Daudi Burkitt lymphoma cells, the HeLa 
cervical cancer cells, the THP-1 acute monocytic leukemia cells, and the SKW6.4 lymphoblastoid cells 
were cultured in RPMI (Invitrogen, ref. no. 61870) supplemented with 10 % heat-inactivated fetal 
bovine serum (FBS; Invitrogen, ref. no. 10270-106). The NB1 neuroblastoma cells were maintained in 
neural basic medium composed of DMEM/F12 (Invitrogen, ref. no. 31331-028) supplemented with 2% 
B27 serum-free complement (Invitrogen, ref. no. 17504044), 20 ng/ml human recombinant basic 
fibroblast growth (bFGF) (Peprotech, ref. no. 100-18B) and 20 ng/ml human recombinant epidermal 
growth factor (EGF) (Peprotech, ref. no. AF-100-15). Human lung carcinoma alveolar epithelial (A549) 
cells were grown in DMEM (Invitrogen, ref. no. 61965) supplemented with 10 % heat-inactivated FBS, 
glutamine, and penicillin-streptomycin.  
 
Chemicals 
Puromycin was from Life technologies (ref. no. A11138-02). Blasticidin was from Applichem (ref. no. 
A3784). TRAM-34 and XE991 were from Alomone labs (ref. no. T-105 and X-100, respectively). 
Ouabain, digoxin, pyrenebutyrate, gramicidin, Live Hoechst 33342, and dasatinib were from Sigma 
(ref. no. O3125, O4599, 257354, 50845, B3361, and CDS023389, respectively). Okadaic acid was 
from LC laboratories (ref. no. O-2220).  
  
Peptides 
TAT-RasGAP317–326 is a retro-inverso peptide (i.e. synthesized with D-amino acids in the opposite 
direction compared to the natural sequence). The TAT moiety corresponds to amino acids 48–57 of 
the HIV TAT protein (RRRQRRKKRG) and the RasGAP317–326 moiety corresponds to amino acids 
317–326 of the human RasGAP protein (DTRLNTVWMW). These two moieties are separated by two 
glycine linker residues in the TAT-Ras-GAP317–326 peptide. TAT-RasGAP317-326 (W317A) has the 
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tryptophan at position 317 mutated into an alanine. All the peptides, including the FITC-TAT-
RasGAP317-326 ([FITC]DTRLNTVWMWGGRRRQRRKKRG), were synthesized at the department of 
biochemistry, University of Lausanne, Switzerland, using FMOC technology, purified by HPLC and 
tested by mass spectrometry.  
 
Cell death measurement  
Cell death was measured with propidium iodide (PI) (Sigma, ref. no. 81845). Cells were analyzed 
using a Beckman Coulter FC500 flow cytometer and data were analyzed with the Kaluza Version 1.2 
software (Beckman Coulter). 
 
Plasmids 
The lentiviral vector lentiCRISPR [203] was obtained from Addgene (#868, Addgene, ref. no. 52961). 
The pMD2.G plasmid (#554, Addgene, ref. no. 12259) encodes the envelope of lentivirus. The 
psPAX2 plasmid (#842, Addgene, ref. no. 12260) encodes the packaging system. pLUC705 (#876, gift 
from Bing Yang) [204] was HindIII/XhoI digested and blunted with T4 DNA polymerase. LeGOIG2 
(#807, Addgene, ref. no. 27341) was StuI digested, dephosphorylated and ligated to the blunted insert 
to make LeGOiG2-LUC705 (#875). pTAT-Cre (#917, Addgene, ref. no. 35619) encodes the Histidine-
tagged TAT-Cre recombinase. Cre-reporter plasmid (#918, Addgene, ref. no. 62732) encodes a 
LOXP-RFP-STOP-LOXP-GFP. After infection, cells are red. If Cre-recombinase is able to reach the 
nucleus, recombination will occur and the RFP-STOP fragment will be excised and GFP will be 
produced. 
 
Lentivirus production 
Recombinant lentiviruses were produced as described [205] with the following modification: pMD.G 
and pCMVDR8.91 were replaced by pMD2.G and psPAX2, respectively. 
 
Genome-scale CRISPR/Cas9 Knockout screening 
The human GeCKO v2 library (2 plasmid system) (Addgene ref. no. 1000000049) was amplified by 
electroporation using the electroporation system (Bio-Rad Gene Pulser II ref. no. 165-2105) and the 
Lucigen Endura cells (ref. no. 60242). Cells were plated on LB Agar plate containing 100 µg/ml 
ampicillin. After 14 h at 32°C, colonies were scrapped and plasmids recovered with the Plasmid Maxi 
kit (Qiagen, ref. no. 12162). To produce lentivirus library, 12 T-225 flasks were seeded with 12x106 of 
HEK293T cells / flask. The day after, each flask was treated as follows: 10 µg pMD2.G, 30 µg psPAX2 
and 25 µg GeCKO plasmid library were mixed with 250 mM CaCl2. This solution was mixed (v/v) with 
2x HEPES buffer (NaCl 280 mM, KCl 10 mM, Na2HPO4 1.5 mM, D-glucose 12 mM, HEPES 50 mM), 
incubated for 1 minute and added to the culture medium. Seven hours later, the medium was removed 
and replaced by DMEM supplemented with 10 % FBS and 1 % penicillin-streptomycin. Forty-eight 
hours later, the medium was collected and centrifuged for 5 min at 2000 g to pellet the cells. 
Supernatant was filtered through a 0.45 µm HV/PVDF (Millipore, ref. no. SE1M003M00) and 
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concentrated 100x by ultracentrifugation (Beckman) at 24.000 rpm for 2 hours at 4°C. Virus pellet was 
resuspended in ice-cold PBS, aliquoted and stored at -80°C. 
To express the Cas9 endonuclease, SKW6.4 and Raji cells were infected with lentiCas9-Blast 
(Addgene, ref. no. 52962) and selected with 10 µg/ml blasticidin for a week.  
The multiplicity of infection (MOI) of the GeCKO virus library was determined as follows: different 
volumes of virus library were added to 3x106 cells expressing Cas9 plated in a 12-well plate. Twenty-
four hours later, each well was split into duplicate and one replicate received 10 µg/ml puromycin for 3 
days. Cell viability was determined by trypan blue exclusion and MOI was considered as the 
percentage of living cells. The virus volume yielding to MOI close to 0.3 was chosen. Large-scale 
infection of 12x107 cells was carried out in 12-well plates with 3x106 cells per well. Twenty-four hours 
later, wells were pooled in a T-225 flask and infected cells selected with 10 µg/ml puromycin for a 
week. 3x107 infected untreated SKW6.4 and Raji cells were frozen for genomic DNA analysis. 1x108 
infected SKW6.4 cells and 6x107 infected Raji cells were treated with 60 µM and 40 µM TAT-
RasGAP317-326 for 17 days and 8 days respectively, with a medium and peptide renewal every 2-3 
days. 3x107 peptide-selected SKW6.4 and Raji cells were frozen for genomic DNA analysis. Genomic 
DNA was extracted with Blood & Cell Culture DNA Midi Kit according to manufacturer’s instructions 
(Qiagen, ref. no. 13343). A first PCR was performed to amplify the lentiCRISPR sgRNA region with 
the following primers: 
F1: 5’-AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG-3’ 
R1: 5’-CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCC-3 
 
A second PCR was performed to attach Illumina adaptors and barcodes (green) to samples. 5 µL of 
the first PCR product was used. Primers for the second PCR include both a variable length sequence 
(red) to increase library complexity and an 8bp barcode for multiplexing of different biological samples. 
Of note, R2_iA_06 and R2_iA_12 were used for the PCR in SKW6.4 samples, whereas R2_iA_12 and 
R2_iC_26 were used for the PCR in Raji samples.  
Table I. Primer sequences for the second PCR 
 
Both PCR were performed in 100 µL with the Herculase II Fusion DNA Polymerase (Agilent, ref. no. 
600675). Amplicons were gel extracted, quantified, mixed and sequenced with a MiSeq (Illumina). 
Raw FASTQ files were demultiplexed and processed to contain only the unique sgRNA sequence. 
The number of reads of each sgRNA was normalized as described [206]. The MAGeCK algorithm 
F2a AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTTGTGGAAAGGACGAAACACCG 
F2b AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCTCTTGTGGAAAGGACGAAACACCG 
F2c AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGAGCTCTTGTGGAAAGGACGAAACACCG 
F2d AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCATAACCTCTTGTGGAAAGGACGAAACACCG 
F2e AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCTAACGTCTTGTGGAAAGGACGAAACACCG 
R2_iA_06 CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT 
R2_iA_ 12 CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT 
R2_iC_26 CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT 
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[207] was used to rank screening hits by the consistent enrichment among multiple sgRNAs targeting 
the same gene. 
 
Genome editing by CRISPR/Cas9 system 
Single guide RNAs targeting the early exon of the protein of interest were chosen in the sgRNA library 
[206] and are listed in table I. LentiCRISPR plasmids specific for a gene were created according to the 
provided instructions. Oligos were designed as follow: Forward 5’-CACCGnnnnnnnnnnnnnnnnnnnn-3’; 
Reverse-3’-CnnnnnnnnnnnnnnnnnnnnCAA-5’, where nnnnnnnnnnnnnnnnnnnn in the forward oligo 
corresponds to the 20 bp sgRNA. Oligos were synthetized, then phosphorylated and annealed to form 
oligo complex. LentiCRISPR vector was BsmBI digested and dephosphorylated. Linearized vector 
was purified and gel extracted and ligated to oligo complex. The lentiCRISPR vector containing the 
sgRNA was then used for virus production. Cells were infected and selected with the appropriate dose 
of puromycin (0.5 µg/ml for SKW6.4, 2 µg/ml for Raji). Clone isolation was performed by limiting 
dilution in 96 well-plate. 
 
Table I. List of sgRNAs used to disrupt target genes 
Target gene sgRNA name sgRNA sequence 
KCNN4 sgKCNN4.1 CTGCCCGAGTGCTACAAGAA 
KCNN4 sgKCNN4.2 CATGGTGCCCGGCACCACGT 
KCNK5 sgKCNK5.1 ATGGTGGTAATGACGGTCGC 
KCNK5 sgKCNK5.2 CTCTGCCTGACGTGGATCAG 
ATP1B3 sgATP1B3.1 ATGCGGTCACTGGTTTTGGA 
ATP1B3 sgATP1B3.2 ACTTCGTATGCAGGGTACAT 
SLC39A14 sgSLC39A14.1 ATATCAGAGTAGCGGACACC 
SLC39A14 sgSLC39A14.2 CGACTGCTCGCTGAAATTGT 
KCNQ5 sgKCNQ5.1 TCTAGGAATTAATTCACAGC 
KCNQ5 sgKCNQ5.2 ACAGATCCTCCGCATGGTCG 
PIP5K1A sgPIP5K1A.1 CATGCAAGATTTCTACGTGG 
PIP5K1A sgPIP5K1A.2 GGATACTACATGGTAAGGGA 
 
 
Antibodies 
The rabbit anti-PIP5K1A, anti-pSrc Tyr416, anti-pAKT S473, anti-pAKT T308, and anti-actin antibodies 
were purchased from Cell Signaling (ref. no. 9693, 6943, 9271, 9275, and 4970, respectively). The 
mouse anti-PP2Ac and anti-ATP1B3 antibodies were purchased from Santa Cruz (ref.no. sc56950 
and sc135998, respectively). The mouse anti-vinculin antibody was purchased from Sigma (ref. no. 
v9131). 
 
TA cloning 
TA cloning kit (Life technologies, ref. no. K202020) was used according to manufacturer’s instructions 
to sequence DNA fragment containing the region where Cas9 was guided by a sgRNA. 
 
RESULTS - PART III 
  98 
 
Cytosolic access assay  
WT, KCNN4 KO, KCNK5 KO, and ATP1B3 KO SKW6.4 cells, as well as WT, KCNQ5 KO and 
PIP5K1A Raji cells were infected with the LeGOiG2-LUC705 lentivirus. Then, 200,000 cells were 
treated with 5 μM peptide nucleic acid (PNA) GRKKRRQRRR-CCTCCTACCTCAGTTACA (PNAbio). 
This PNA is composed of the protein TAT sequence and the oligonucleotide sequence able to mask 
the aberrant splicing site at the position 705 in order to restore proper luciferase splicing and 
expression. After 16 hours incubation, cells were washed twice in HKR buffer (119 mM NaCl, 2.5 mM 
KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1.3 mM MgCl2, 20 mM HEPES, 11 mM dextrose, pH 7.4) and 
lysed in 40 μL HKR + 0.1 % Triton X-100 for 15 min at room temperature. Luciferase activity was 
measured using Dual-Luciferase Reporter Assay (Promega) and normalized to the protein content. 
Results are expressed as the ratio of PNA treated over PNA untreated luciferase activity. Signals were 
detected with GLOMAXTM 96 Microplate Luminometer (Promega), analyzed with Glomax version 
1.7.0 program. 
 
TAT-Cre-recombinase production, purification and recombination 
WT and KCNQ5 KO Raji cells were infected with the lentivirus encoding Cre-reporter described in 
[208]. TAT-Cre-recombinase was produced as described in [188]. Briefly, E. coli BL21 transformed 
with pTAT-Cre were grown overnight in LB containing 100 µg/ml kanamycin. Overnight culture was 
used to inoculate fresh LB medium at OD600 nm 0.2. Protein production was induced at OD600 nm 
0.6 with 500 µM IPTG for 3 hours. Bacteria were collected by centrifugation at 5000xg and kept at -
20°C. Purification was performed on Äkta prime (GE, Healthcare, USA) equipped with a 1 ml HisTrap 
FF column equilibrated with binding buffer (20 mM sodium phosphate, 500 mM NaCl, 5 mM imidazole 
pH 7.4). The day of the purification, bacterial pellet was resuspended in lysis buffer (Binding buffer + 
protease inhibitor tablets (Roche, ref. no. 4693132001) + DNase 1 (Roche, ref. no. 04716728001) + 
Lysozyme 2 mg/ml (Roche, ref. no. 10 837 059 001)) and sonicated 6 x 30sec. After 20 minutes 
centrifugation at 5000xg, the supernatant was filtered with Steriflip 0.45 µm and loaded on the column. 
Elution buffer (20 mM sodium phosphate, 500 mM NaCl, 500 mM imidazole pH 7.4) was used to 
detach His-tagged proteins from the column. Imidazole was removed from collected fractions by 
overnight dialysis using 10K MWCO cassette (Thermo Scientific, ref. no. 66807) in PBS. WT and 
KCNQ5 KO Raji cells encoding the Cre-reported were treated for 48 hours with 20 µM TAT-Cre-
recombinase. Fluorescence was observed using a Nikon Eclipse TS100 microscope. 
 
Confocal microscopy 
Cells were seeded onto glass bottom culture dishes (MatTek, corporation ref. no. P35G-1.5-14-C) and 
treated with FITC-TAT-RasGAP317-326. For nuclear staining, 1 μl/ml live Hoechst 33342 (Molecular 
probes, ref. no. H21492) was added into culture medium 15 minutes before washing cells twice with 
PBS. After washing, cells were examined under a Zeiss LSM 710 Quasar laser scanning fluorescence 
confocal microscope. 
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Direct translocation with pyrenebutyrate 
Cells were washed twice with serum-free medium and treated for 10 minutes with 50 µM 
pyrenebutyrate at 37°C. Then cells were treated with TAT-RasGAP317-326 or the inactive point mutant 
TAT-RasGAP317-326 (W317A) for the indicated period of time. 
 
Potassium-rich buffer 
40 mM KCl, 100 mM potassium glutamate, 1 mM MgCl2, 1 mM CaCl2, 5 mM glucose, 20 mM HEPES, 
pH7.4 from [193]. 
 
Membrane potential and intracellular potassium measurements  
The membrane potential (Vm) was determined by incubating the cells with the fluorescent probe 
DiBAC4(3) 100 nM during 40 minutes (molecular probe, ref. no. B438) Median fluorescence intensity 
was directly assessed by flow cytometry. For intracellular potassium concentration [K+]i determination, 
cells were incubated with the K+-sensistive probe Asante Potassium Green 2 (APG-2) (Abcam, ref. 
no. ab142806) 1 uM during 30 minutes, followed by flow cytometry analysis. 
 
Virus infection 
WT and KCNN4 KO HeLa cells or A549 cells were plated in 96-well plates at a density of 2x104 cells 
per well and grown into confluent monolayers in 16 to 20 h. The cells were treated or not with 10 µM 
TRAM-34 or 10 µM  XE991 for 1 hour, followed by infection with the indicated pseudotyped virus that 
contained a luciferase reporter in their genome for 1 h at 37°C. Unbound virus was removed, the cells 
were washed twice with DMEM, and fresh medium was added. Sixteen hours after the infection, cells 
were lysed in 1X Cell Culture Lysis Reagent (Promega) according to the manufacturer’s instructions. 
The activity of the Luciferase gene reporter was measured using the Luciferase Assay System 
(Promega) according to manufacturer’s instructions and using a Lumat LB 9507 (Berthold 
Technologies) luminometer. 
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RESULTS 
CRISPR/Cas9 screening highlighted several genes involved in the modulation of TAT-
RasGAP317-326 toxicity 
 
To identify proteins required for the peptide toxicity, we performed CRISPR/Cas9 screens on two cell 
lines, the SKW6.4 B-lymphoblastoid EBV-transformed cells and the Raji Burkitt lymphoma cells. Both 
cell lines were directly killed by the peptide (Figures 1A and 1B). The CRISPR/Cas9 system uses 
single-guide RNAs (sgRNAs) that direct the Cas9 DNA endonuclease to their complementary 
sequences, located at specific loci, and disrupt them [209, 210]. We used the GeCKO v2 human 
CRISPR/Cas9 lentiviral library, where each plasmid encodes a different sgRNA, targeting a total of 
19,050 human genes (with 6 sgRNAs per target) and 1,864 miRNAs (with 4 sgRNAs per target) [203] 
(Figure 1C). The two cell lines were infected with the lentivirus library. Half of the infected SKW6.4 or 
Raji cells were treated with TAT-RasGAP317-326 for 17 or 8 days with 60 µM or 40 µM TAT-RasGAP317-
326 respectively, a dose of peptide known to induce close to 100% cell death within 48 hours. This 
allowed to positively select only the cells bearing sgRNAs that target genes required for the toxicity of 
the peptide. The other half of the cells was left untreated to serve as a control. Then, the sgRNAs in 
the resistant population and those of the control population were sequenced by high-throughput 
sequencing, to determine their relative abundance. The initial distribution of the sgRNAs observed in 
the control population is expecting to change in the treated one. This is because the positive selection 
leads to the enrichment of the resistant subpopulation and therefore to an overall increase abundance 
of only the sgRNAs which confer resistance against the peptide (Figure 1C). Figures 1D and 1E 
represent the TAT-RasGAP317-326-induced cell death sensitivity of both cell lines infected with the 
CRISPR/Cas9 library before and after selection with the peptide. As expected, after positive selection 
with TAT-RasGAP317-326, the two cell lines were rendered resistant to its toxicity.  
Results of massively parallel sequencing for SKW6.4 and Raji cells in both the control and the peptide 
selected populations are presented in Supplementary Table S1. The screens identified several 
candidate genes. The frequency of each sgRNA in both control and peptide selected populations for 
the two cell lines is displayed in Figures 1F and 1G. The four top candidate genes with the highest 
sgRNA enrichment in the treated population are labeled. The dots with the same color indicate 
sgRNAs targeting the same gene. The plots of Figures 1H and 1I depict the four top genes in SKW6.4 
and in Raji cells respectively obtained using the Model-based Analysis of Genome-wide CRISPR-
Cas9 Knockout (MAGeCK) algorithm. Interestingly, three potassium channels were found among the 
top candidates (KCNN4, KCNK5, and KCNQ5). In addition, the screen on SKW6.4 cells identified  one 
subunit of the Na+/K+-ATPase pump (ATP1B3) and a divalent metal transporter for zinc, manganese, 
iron, and cadmium (SLC39A14). In Raji cells, an enzyme that catalyzes the phosphorylation of 
phosphatidylinositol 4-phosphate (PI4P) to form phosphatidylinositol 4,5-biphosphate (PI(4,5)P2) 
called PIP5K1A, an adaptor protein termed Arrestin domain-containing protein 3 (ARRDC3), and a 
MAGE family member protein (MAGEB5) were highlighted as putative regulators of the peptide. The 
absence of these candidates is expected to render SKW6.4 cells and Raji cells resistant to the peptide 
toxicity.  
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Figure 1. Identification of candidate genes, whose depletion confers TAT-RasGAP317-326 
resistance. A. SKW6.4 cells were treated for 24 hours with indicated concentrations of TAT-RasGAP317-326. Cell 
death, corresponding to the percentage of propidium iodide (PI)-positive cells, was assessed using flow 
cytometry. B. Raji cells were treated for 16 hours as described in panel A. Cell death was then assessed by flow 
cytometry after PI staining. C. The lentiCRISPR library is a pool of lentiviruses used to infect wild-type (WT) cells. 
Half of the infected knockout cell population is then treated with TAT-RasGAP317-326 to select the resistant cells, 
while the other half remains untreated. The abundance of each sgRNA is then compared between the two 
populations using high-throughput sequencing. D-E. SKW6.4 WT, SKW6.4 GeCKO library control, and SKW6.4 
GeCKO library TAT-RasGAP317-326 (P)-selected cells, or Raji WT, Raji GeCKO library control, and Raji GeCKO 
library TAT-RasGAP317-326 (P)-selected cells were treated or not with 40 μM or 20 μM TAT-RasGAP317-326 for 24 
or 16 hours, respectively. Cell death was then assessed by flow cytometry after PI staining. Results correspond to 
the mean +/- 95% CI of three independent experiments. F-G. Scatterplot showing enrichment of specific sgRNAs 
after TAT-RasGAP317-326 treatment in SKW6.4 and Raji cells, respectively. Dots with the same color indicate 
sgRNAs targeting the same gene. The blue dashed-line represents the equal frequency in both control (CTRL) 
and TAT-RasGAP317-326 (P) populations. H-I. Identification of the four top candidate genes implicated in resistance 
to TAT-RasGAP317-326 in SKW6.4 and Raji cells respectively using the Model-based Analysis of Genome-wide 
CRISPR/Cas9 Knockout (MAGeCK) p-value.   
 
 
 
To validate the top candidates, we knocked them out in the two corresponding cell lines using the 
CRISPR/Cas9 technology. The level of expression of ATP1B3 in wild-type and knockout SKW6.4 cells 
was detected by western blot (Figure 2D), however, endogenous levels of KCNN4, KCNK5, and 
SLC39A14 could not be assessed in that way. Consequently, the DNA region targeted by the Cas9 
endonuclease was sequenced for these genes (Figures 2A and 2G and Supplementary Figure S1A). 
Of note, KCNK5 disrupted clone #2 and SLC39A14 disrupted clone #1 bear a frameshift on allele 2 
and on allele 1 respectively, which could mean that KCNK5 and SLC39A14 might still be functional in 
these clones.  
All the knockout clones were treated with TAT-RasGAP317-326. The absence of each of the four top 
genes yielded by the CRISPR/Cas9 screening in SKW6.4 cell line protects, at least partially, against 
the peptide toxicity (Figures 2B, 2E, 2H, and Supplementary Figure S1B). As a complementary 
approach, we used pharmacological inhibitors whenever they were available, such as TRAM-34, a 
KCNN4 blocker and digoxin/ouabain, two Na+/K+-ATPase pump potent inhibitors (Figures 2C and 2F) 
[211-213].  
As shown in Figures 2J and 2M, only the two candidates KCNQ5 and PIP5K1A were validated in Raji 
cells. Knockout cells for both genes (Figures 2I and 2L) fully prevent TAT-RasGAP317-326-induced cell 
death. Moreover, the pharmacological inhibitor XE991, which acts on the five members of the KCNQ 
family, was able to block the peptide toxicity in Raji cells (Figure 2K) [214].  
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Figure 2. Validation of the top candidate genes in SKW6.4 and Raji cells. A, G. DNA sequences of 
WT KCNN4 and KCNK5 genes in SKW6.4 cells and KCNN4 and KCNK5 alleles of corresponding knockout 
clones #1 and #2. Differences with WT and disrupted clones are in blue. The sgRNAs directed against each gene 
are highlighted in grey. B, E, H. WT and KCNN4, ATP1B3, KCNK5 disrupted SKW6.4 cells respectively were 
treated or not with 40 μM TAT-RasGAP317-326 for 24 hours. Cell death was then assessed by flow cytometry after 
PI staining. C, F. SKW6.4 WT cells were pretreated or not with 10 μM TRAM-34 (C) and 100 nM digoxin or 100 
nM ouabain (F) for 1 hour and then treated with 40 μM TAT-RasGAP317-326 for 24 hours. Cell death was assessed 
by flow cytometry after PI staining. D, L. Expression of ATP1B3 and PIPK1A in WT and knockout SKW6.4 and 
Raji cells, respectively. I. Same as panel A for KCNQ5 gene in Raji cells. J, M. WT and KCNQ5, PIP5K1A 
disrupted Raji cells respectively were treated or not with 40 μM TAT-RasGAP317-326 for 16 hours. Cell death was 
assessed as in panel B. K. Raji cells were pretreated or not with 10 μM XE991 for 1 hour and then treated with 40 
μM TAT-RasGAP317-326 for 16 hours. Cell death was assessed by flow cytometry after PI staining. Results for 
panels B, C, E, F, H, J, K, and M correspond to the mean +/- 95% CI of three independent experiments.   
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To determine if the candidates generated by the two CRISPR/Cas9 screens were required for the 
peptide to exert its toxicity on other cell lines, we tested the inhibitors on several cell types which were 
also killed by the RasGAP-derived peptide. Supplementary Figure S1C depicts that the KCNN4 
inhibitor TRAM-34 can prevent TAT-RasGAP317-326-induced cell death in the acute monocytic leukemia 
THP-1 cell line and the cervix adenocarcinoma HeLa cell line, but not in Raji cells. However, ouabain 
and digoxin, by inhibiting the Na+/K+-ATPase pump, were able to block the toxicity of the peptide in 
three (Raji, THP-1, and Daudi) out of the four cell lines tested (Supplementary Figure S1D). Of note, 
Raji, THP-1, and Daudi (Burkitt Lymphoma) cells all belong to the peripheral blood mononuclear cell 
type, whereas the non-responder NB1 cell line is derived from a neuroblastoma tumour. Finally, the 
KCNQ inhibitor XE991 was able to reduce the killing efficiency of the peptide in SKW6.4 and Daudi 
cells, but not in NB1 and HeLa cell lines (Supplementary Figure S1E). To confirm some of these 
results KCNQ5, ATP1B3, and KCNN4 disrupted clones were generated in NB1, Raji, and HeLa cells, 
respectively (Supplementary Figures S1F, S1H, and S1H). Supplementary Figures S1G, S1I, and S1K 
support the conclusion that disruption of KCNQ5 does not protect NB1 cells against TAT-RasGAP317-
326, whereas in ATP1B3 knockout Raji cells and in KCNN4 knockout HeLa cells the killing efficiency of 
the peptide is decreased. These results suggest that the involvement of the top candidates in TAT-
RasGAP317-326-induced cell death is cell type dependent.  
 
 
Regulators of TAT-RasGAP317-326-induced cell death are not involved in the pro-death activity of 
the peptide 
 
KCNN4, KCNK5, ATP1B3, SLC39A14, KCNQ5 and PIP5K1A can be implicated in the activity of TAT-
RasGAP317-326 at three different cellular steps, which are the entry of the peptide into the cell either 
through direct translocation or endocytosis, its endosomal escape (only if it gains access to the cytosol 
by endocytosis), and the pro-death activity of the peptide once having reached the cytoplasm (Figure 
3A).  
To determine how these proteins participate in the inhibition of the peptide toxicity, we first assessed 
whether they were implicated in the pro-death activity of the peptide. To bypass the step of the 
intracellular delivery of the peptide, we used the counteranion pyrenebutyrate (PB). The latter allows 
the direct membrane translocation of arginine-rich peptides such as TAT within a few minutes, through 
an electrostatic interaction between the guanidium groups of arginines and the negative charges of PB 
[215]. We first compared the kinetics of TAT-RasGAP317-326-induced death in the presence or in the 
absence of PB. Figures 3B and 3C show that in the presence of PB death occurs within ten minutes, 
while in the absence of the counteranion it takes about 24 hours for the peptide to exert the same 
killing efficiency. These results reveal that the forced direct translocation of TAT-RasGAP317-326 by PB 
accelerates the capacity of the peptide to kill SKW6.4 and Raji wild-type cells. As shown in Figure 3D, 
PB leads to the rapid diffuse cytosolic accumulation of FITC-labeled TAT-RasGAP317-326 in Raji cells. 
However, when treated only with fluorescent peptide, the signal consists of punctate endocytic-like 
structures. 
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Figure 3. The disrupted cells for regulators of TAT-RasGAP317-326-induced cell death are not 
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anymore protected when the peptide enters through forced direct translocation. A. Scheme 
depicting the three different cellular steps, on which the regulators of TAT-RasGAP317-326-induced cell death can 
potentially act. They could modulate the entry of the peptide into the cells (step 1), its endosomal escape (step 2), 
or the pro-death activity of the peptide once having reached the cytoplasm (step 3). B. WT SKW6.4 cells were 
treated with 40 μM TAT-RasGAP317-326 (TP) and 50 µM pyrenebutyrate (PB) alone or in combination. Cell death 
was analyzed by flow cytometry using PI as membrane permeabilization marker. C. Same than in panel B in Raji 
cells. D. Confocal images of Raji cells treated with 40 µM TAT-RasGAP317-326-FITC (P-FITC) for 30 minutes in the 
presence or in the absence of 50 µM PB. Of note, in conditions where PB was added, experiments were 
performed in serum-free medium. E. WT Raji cells were treated with 50 µM PB and the indicated concentration of 
peptide, either TAT-RasGAP317-326 or TAT-RasGAP317-326 (W317A) for 30 minutes. Cell death was analyzed by 
flow cytometry using PI. F. WT, KCNN4 KO, KCNK5 KO, and ATP1B3 KO SKW6.4 cells were treated or not with 
40 µM TAT-RasGAP317-326 and 50 µM PB for 30 minutes and cell death was determined using PI. G. Same as 
panel F in WT, KCNQ5 KO, and PIP5K1A KO Raji cells. H. WT SKW6.4 cells were treated with 40 µM TAT-
RasGAP317-326 for indicated periods of time in PBS containing or not 10% serum. Cell death was analyzed by flow 
cytometry using PI. I. Same as H with WT Raji cells. Cell death was analyzed by flow cytometry using PI. J. WT, 
KCNN4 KO, KCNK5 KO, and ATP1B3 KO SKW6.4 cells were incubated in medium containing or not 10% serum 
and treated for 3 hours with 40 µM TAT-RasGAP317-326. Cell death was analyzed by flow cytometry using PI. K. 
Same as J with WT, KCNQ5 KO, and PIP5K1A KO cells treated for 1h30 with 40 µM TAT-RasGAP317-326. Results 
represent 3 independent experiments +/- 95% CI. 
 
Importantly, forced translocation of the inactive point mutant TAT-RasGAP317-326 (W317A) with PB did 
not lead to significant increase of cell death (Figure 3E). We then assessed the effect of TAT-
RasGAP317-326 direct translocation on the SKW6.4 and Raji knockout cells. Figures 3F and 3G show 
that in the presence of PB TAT-RasGAP317-326-induced death occurs to the same extent in wild-type 
and KCNN4, KCNK5, ATP1B3 knockout SKW6.4 cells or in wild-type and KCNQ5 and PIP5K1A Raji 
cells, respectively. Furthermore, Supplementary Figure S2A supports the same conclusion for 
SLC39A14 knockout clone and wild-type SKW6.4 cells pretreated with TRAM-34, digoxin, or ouabain. 
 
In addition, as a complementary approach, we investigated the toxicity of the RasGAP-derived peptide 
in serum-free conditions. Indeed, it was reported that serum proteins act on the internalization 
mechanism of arginine-rich peptides, inducing their cellular uptake preferentially through endocytosis.  
[216]. On the contrary, serum-free media have been shown to favor the direct translocation process of 
these peptides [217]. To verify this assertion, HeLa cells were incubated in phosphate-buffered saline 
(PBS) with or without serum and treated with the FITC-labeled peptide. Supplementary Figure S2B 
shows that the cytoplasmic accumulation of the fluorescent RasGAP-derived peptide is much more 
pronounced in cells in serum-free medium compared to the ones in medium supplemented with 
serum. Of note, the same observation was shown in SKW6.4 cells (Supplementary Figure S2B).  
We, therefore, examined the effect of serum in SKW6.4 and Raji cells treated with the peptide. When 
incubated in PBS without serum, death kinetics in both wild-type SKW6.4 and Raji cells were 
accelerated compared to the serum-rich conditions (Figures 3H and 3I). Figures 3J and 3K show that 
in the absence of serum, the KCNN4, KCNK5, and ATP1B3 disrupted clones in SKW6.4 cells and the 
KCNQ5 and PIP5K1A disrupted clones in Raji cells were efficiently killed within 3 and 1.5 hours, 
respectively. The same result was depicted in SLC39A14 knockout SKW6.4 cells (Supplementary 
Figure S2C).  
 
Altogether these results indicate that the regulators of TAT-RasGAP317-326-induced cell death are not 
involved in the pro-death activity of the peptide. Indeed, knockout clones for six different targets can 
be killed if the route taken by TAT-RasGAP317-326 to reach the cytosol is forced translocation. 
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Nevertheless, our data do not allow us to conclude if these observations are due to an increased 
amount of peptide reaching the cytoplasm, or a change in the route of entry of the peptide, or both.  
 
 
Regulators of TAT-RasGAP317-326-induced cell death prevent its cytosolic access and that of 
other TAT-constructs 
  
After having shown that the six validated candidates were not involved in the pro-death activity of TAT-
RasGAP317-326, we investigated if they were implicated in its cytosolic access. We used the fluorescent 
FITC-coupled version of TAT-RasGAP317-326 to assess the peptide uptake into wild-type and knockout 
cells. Of note, the FITC-coupled peptide increases cell adhesion and directly kills cells with the same 
efficiency as the TAT-RasGAP317-326 peptide. As illustrated by confocal microscopy images in Figure 
4A, in wild-type cells the fluorescent peptide accumulates with time, whereas in KCNQ5 knockout Raji 
cells, no or only a slight distribution of the FITC-peptide is observed. These results were confirmed by 
the measurement of the median fluorescence intensity by flow cytometry in wild-type and KCNQ5 
knockout Raji cells treated with the fluorescent version of the peptide (Figure 4B).  
Moreover, to assess the mode of entry of the peptide, we performed the same experiment at 4°C, the 
temperature at which active cellular processes such as endocytosis are blocked (Figure 4B). In low 
temperature, the signal of FITC-TAT-RasGAP317-326 was greatly reduced in both wild-type and KCNQ5 
knockout Raji cells compared to the conditions at 37°C (Figure 4B). This suggests that the peptide 
enters cells mainly through endocytosis. To exclude a potential membrane-bound defect of the peptide 
in KCNQ5 knockout Raji clone that could induce misinterpretation of the results, we assessed the 
fluorescent intensity at shorter time points (Figure 4C). The increased fluorescence present in both 
wild-type and knockout cells after 1 minute of incubation with the labeled peptide suggests indirectly 
that the capacity of the peptide to bind to plasma membrane is not affected in knockout cells. 
Observations made in Raji cells were partially supported in wild-type and knockout SKW6.4 cells. 
Indeed, the inhibition of the FITC-peptide intracellular delivery was less pronounced at 37°C in the 
KCNN4, KCNK5, and ATP1B3 knockout SKW6.4 cells than in KCNQ5 knockout Raji cells (Figure 4G). 
Finally, the confocal microscopy images of HeLa wild-type cells pretreated or not with TRAM-34 and 
HeLa KCNN4 knockout cells show that at 4°C the peptide is blocked at the membrane 
(Supplementary Figure 3A). Though, at 37°C, the intracellular accumulation of the peptide with time is 
diminished and delayed in KCNN4 knockout and TRAM-34 pretreated cells compared to wild-type 
HeLa cells. In addition, the plasma membrane is partially delimited by the fluorescent peptide after one 
hour of incubation in the knockout and pretreated cells, but not in the wild-type cells (Supplementary 
Figure 3A). This observation suggests that some of the peptide accumulates at the membrane and its 
entry is partially prevented when the KCNN4 potassium channel is non-functional.  
Thus far, data indicate that the FITC-TAT-RasGAP317-326 peptide mainly enters through endocytosis. 
However, the slight increase in the median fluorescence intensity in Raji and SKW6.4 cells at 4°C 
suggests that the labeled peptide can marginally translocates directly into cells (Figures 4B and 4G). 
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Consequently, we cannot formally rule out the possibility that both direct translocation and endocytosis 
happen simultaneously at 37°C.  
 
As the uptake of TAT-RasGAP317-326 was affected in the knockout cells, we next assessed if the 
candidates could also be involved in the intracellular delivery of other TAT-constructs such as TAT-
PNA and TAT-Cre (Supplementary Figures S4A and S4B).  
For the former construct, wild-type and knockout SKW6.4 and Raji cells were infected with a virus 
encoding for a luciferase gene disrupted by the mutated β-globin intron 2. These cells produce a 
mRNA that encodes a truncated non-functional luciferase. However, the luciferase pre-mRNA can be 
properly processed if the splice site generated by the mutation at position 705 is masked by a 
matching oligonucleotide (ON-705) (Supplementary Figure S4A). ON-705 was covalently coupled to 
the cell-permeable peptide TAT. The resulting so-called TAT-peptide nucleic acid (TAT-PNA), when 
incubated with cells, triggers the correct splicing of the mutated luciferase pre-RNA but only if the PNA 
is gaining access to the cytosol [204, 218]. Figure 4D shows that in Raji KCNQ5 and PIP5K1A 
knockout cells, the fold induction of luciferase is decreased compared to wild-type Raji cells. This 
result was confirmed in Raji wild-type cells treated with XE991 (Figure 4E). However, as expected, 
there was no reduction of the luciferase activity in Raji wild-type cells treated with the KCNN4 inhibitor 
TRAM-34 (Figure 4E). Moreover, the luciferase activity was restored with TAT-PNA in wild-type 
SKW6.4 cells, whereas in KCNN4 as well as in SKW6.4 wild-type cells treated with TRAM-34 the 
activity of the luciferase was not fully restored (Figures 4H and 4I). In contrast to KCNN4, the 
disruption of KCNK5 and ATP1B3 as well as the chemical inhibition of KCNQ5 in SKW6.4 did not 
significantly decrease the fold induction of luciferase compared to wild-type cells. Finally, we observed 
in wild-type HeLa cells pretreated with the KCNN4 inhibitor a decrease of the luciferase activity 
compared to the non-treated wild-type HeLa cells (Supplementary Figure S4C). These results indicate 
that the absence of KCNQ5 and KCNN4 prevent at least partially the cytosolic access of the TAT-PNA 
construct, whereas the disruption of the other candidates do not affect significantly the intracellular 
delivery of the TAT-construct. 
To investigate the delivery into cells of the TAT-Cre construct, we used a second assay based on the 
TAT-Cre-mediated recombination of a loxP-RFP-STOP-loxP-GFP construct (Supplementary Figure 
S4B) [188, 208]. Cells stably infected with the loxP-RFP-STOP-loxP-GFP construct express the red 
fluorescence protein. When exogenous TAT-Cre recombinase enters cells and translocates to the 
nucleus, RFP-STOP is excised and GFP expression is initiated. The switch from red to green 
fluorescence consequently attests for cytosolic access of TAT-Cre recombinase. Accordingly, the 
lentiviral loxP-RFP-STOP-loxP-GFP construct was stably introduced into wild-type, KCNQ5, and 
PIP5K1A knockout Raji cells. These cells were then left untreated or treated with TAT-Cre 
recombinase. As expected, the absence of TAT-Cre did not induce GFP production (Figure 4F). After 
48 hours of treatment, many GFP-positive cells were visible in wild-type Raji cells, while only one or 
two GFP-positive cells were observed in the knockout Raji clones (Figure 4F). These preliminary data 
suggest that KCNQ5 and PIP5K1A are required for efficient cytosolic access of TAT-Cre recombinase 
in Raji cells.  
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Taken together, the above experiments indicate that regulators of TAT-RasGAP317-326-induced death 
play a role in the regulation of the cytosolic access of the RasGAP-derived peptide but also of other 
TAT-constructs of different sizes, ranging from 3.3 kDa to ~40 kDa.  
 
 
 
 
Figure 4. Regulators of TAT-RasGAP317-326 toxicity prevent its cytosolic access and that of 
other TAT-constructs. A. Confocal microscopy images of WT and KCNQ5 KO Raji cells treated for indicated 
periods of time with 40 μM FITC-coupled TAT-RasGAP317-328 (green) at 37°C. The nucleus is stained with live 
Hoechst 33342 1 μg/ml for 15 minutes (blue). B. WT and KCNQ5 KO Raji cells were treated with 40 μM TAT-
RasGAP317-326-FITC for indicated periods of time at 37°C (left panel) or 4°C (right panel). Cells were then 
collected and washed three times with cold phosphate-buffered saline (PBS). The median fluorescence intensity 
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of viable cells was then measured by flow cytometry. C. WT and KCNQ5 KO Raji cells were treated with 40 μM 
TAT-RasGAP317-326-FITC for indicated periods of time at 37°C and then washed once with ice-cold PBS. Cells 
were then analyzed by flow cytometry. D. Cytosolic access was assessed using a luciferase rescue reporter 
assay [204]. WT, KCNQ5 KO, and PIP5K1A KO Raji cells were infected with a virus encoding for the luciferase-
coding sequence, interrupted by a mutated human β-globin intron and treated with 10 μM TAT-ON-705, a TAT-
peptide nucleic acid (TAT-PNA). After 24 hours, luciferase activity was measured and normalized to the protein 
content. E. WT Raji cells were pretreated or not with 10 μM XE991 or 10 μM TRAM-34 for 1 hour and treated for 
24 hours with TAT-PNA. The cells were then processed as in panel D.F. WT, KCNQ5 KO and PIP5K1A KO Raji 
cells stably expressing loxP-RFP-STOP-loxP-GFP construct were treated or not with TAT-Cre for 48 hours. 
Fluorescence was observed on microscope. G. WT, KCNN4 KO, KCNK5 KO, and ATP1B3 KO SKW6.4 cells 
were treated with 40 μM TAT-RasGAP317-326-FITC for indicated periods of time at 4°C or 37°C. Cells were then 
processed as for panel B. H. WT, KCNN4 KO, KCNK5 KO, and ATP1B3 KO SKW6.4 cells expressing the 
mutated luciferase mRNA were treated with 10 μM TAT-PNA and analyzed as in panel D. I. Same as panel E with 
SKW6.4 cells. Results for panels B, C, D, E, G, H and I correspond to the mean +/- 95% CI of 3 independent 
experiments. 
 
 
The plasma membrane depolarization induced by the disruption of the KCNQ5 potassium 
channel in Raji cells hampers the cytosolic access of TAT-RasGAP317-326 
To better understand the mechanisms by which the proteins revealed by CRISPR/Cas9 screens 
hamper the intracellular delivery of TAT-constructs, we investigated the effect of plasma membrane 
potential and intracellular potassium [K+]i modulations. Indeed, the candidate proteins mainly regulate 
the potassium flux either because they are potassium channels (KCNN4, KCNK5, and KCNQ5) or a 
subunit of the Na+/K+-ATPase pump (ATP1B3). Potassium plays a predominant role in the 
establishement of the resting cell membrane potential. Indeed, Rothbard and colleagues proposed a 
membrane potential-driven direct plasma membrane penetration hypothesis, whereas the rate of 
passage of molecules through the bilayer is directed by the membrane potential [219]. Moreover, 
another study showed that endocytosis depends on the membrane resting potential through a 
potential-dependent reorganization of actin [220]. Consequently, to disrupt the plasma membrane 
polarization, we incubated the SKW6.4 and Raji wild-type cells in a K+-rich buffer and investigated 
whether TAT-RasGAP317-326 was still able to kill cells. Figure 5A indicates that in Raji cells, but not in 
SKW6.4 cells, the disruption of the bilayer potential prevents the peptide toxicity. As a complementary 
approach to explore whether the candidate proteins were involved in the regulation of the membrane 
resting potential, we used the DiBAC4(3) potential-sensitive probe, where increased depolarization 
results in an increase in fluorescence. Although the gold standard to measure membrane potential is 
electrophysiology, this probe was shown to obtain similar values [221, 222].  We used the K+/Na+ 
ionophore gramicidin as a positive control for cell depolarization [223]. Figure 5B shows that KCNQ5 
knockout Raji cells are more depolarized than wild-type cells. In addition, in the presence of the KCNQ 
family inhibitor XE991, wild-type cells are also depolarized. However, no significant changes in the 
plasma membrane potential of KCNN4, KCNK5, and ATP1B3 knockout SKW6.4 cells were observed 
compared to wild-type cells, although gramicidin was greatly able to depolarize those cells (Figure 
5C). In order to study if the increase membrane potential of KCNQ5 knockout cells was correlated with 
an increase of [K+]i due to a decrease of K+ export in disrupted cells, we employed the K+-sensitive 
probe Asante Potassium Green 2 (APG-2). Figures 5D and 5E report that there is no significant 
variation of the [K+]i in KCNQ5 knockout or Raji wild-type cells treated with XE991 compared to non-
treated wild-type cells. The same observation was made in KCNN4 knockout or SKW6.4 wild-type 
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cells treated with TRAM-34 (Figure 5F). As a positive control for the APG2 probe, we observed a slight 
decrease of the [K+]i in wild-type SKW6.4 treated with gramicidin, which is known to allow the efflux of 
K+ out of the cells. Finally, to investigate a putative link between the plasma membrane potential and 
the peptide uptake, we assessed FITC-TAT-RasGAP317-326 accumulation in cell depolarized with K+-
rich buffer or gramicidin. Figure 5G indicates that the Raji wild-type cells depolarization, due to both 
K+-rich buffer and gramicidin, hampers the cytosolic access of TAT-RasGAP317-326 independently of 
the [K+]i. These results suggest that the disruption of KCNQ5 induces a depolarization of the 
membrane potential responsible for the inhibition of the peptide entry into the cells. However, the 
KCNN4, KCNK5 and ATP1B3 SKW6.4 disrupted cells did not prevent TAT-RasGAP317-326-induced cell 
death through the modulation of the membrane resting potential. Accordingly, the mechanism by 
which those knockout cells are protected remains to be resolved.    
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Figure 5. The disruption of KCNQ5, but not KCNN4, induces the depolarization of the plasma 
membrane preventing the cytosolic access of the TAT-RasGAP317-326 peptide. A. To affect the 
resting potential of the plasma membrane, SKW6.4 WT and Raji WT cells were incubated in PBS or K+-rich buffer 
before being treated with 0, 20, or 40 μM TAT-RasGAP317-326 during 1h30. Cell death was then assessed by flow 
cytometry using PI as cell membrane permeabilization marker. B. Plasma membrane potential (Vm) in Raji WT 
and KCNQ5 KO cells that were pretreated or not with 10 μM XE991 or 2 μg/ml gramicidin for 30 or 5 minutes, 
respectively. The Vm was determined by incubating the cells with 100 nM fluorescent probe DiBAC4(3) for 40 
minutes and median fluorescence intensity was directly assessed by flow cytometry. C. Same than in panel B, but 
in WT, KCNN4, KCNK5, and ATP1B3 SKW6.4 cells and WT cells were pretreated with 10 μM TRAM-34 (TRAM) 
instead of XE991. D. For the intracellular potassium concentration [K+]i in Raji WT and KCNQ5 KO cells, they 
were incubated with 1 μM K+-sensitive probe Asante Potassium Green 2 (APG-2) for 30 minutes, followed by flow 
cytometry analysis. E. Same than in panel D, but in Raji WT cells that were pretreated for 30 minutes with 10 μM 
XE991. F. Same than in panels D and E but in WT and KCNN4 KO SKW6.4 cells treated or not with 10 μM 
TRAM-34. G. Cells incubated in K+-rich buffer and/or treated with 2 μg/ml gramicidin were pre-incubated during 
30 or 5 minutes, respectively, before the addition of the fluorescent probes. To monitor Vm, [K+]i and peptide 
uptake, cells were incubated with 100nM DiBAC4(3) for 40 minutes, 1 μM APG-2 for 30 minutes and 40 μM TAT-
RasGAP317-326-FITC for 1 hour, respectively. Fluorescence intensity was then assessed by flow cytometry, directly 
for DiBAC4(3) or APG2 and after one washing step with cold-PBS for peptide uptake. Results represent at least 3 
independent experiments +/- 95% CI. 
 
 
Disruption of KCNN4 hampers the cytosolic access of several arenaviruses 
 
After having shown that regulators of TAT-RasGAP317-326-induced death mediate the intracellular 
delivery of different TAT-constructs, we hypothesized that they might also be functionally required for 
proper internalization of other cargos, such as viruses. Indeed, many pathogens hijack the existing 
endocytic routes to mediate their internalization into the cytoplasmic compartment, thus maintaining 
their survival and activity [194, 195].  
Here, we used the well-characterized human lung carcinoma alveolar epithelial A549 cell line that 
shares key characteristics with human epithelia and has been used extensively to study viral entry. 
We employed a safe pseudotyped vesicular stomatitis virus (VSV) system bearing the envelope 
glycoproteins (GPs) of viruses of interest. Such viral particles possess the tropism of the virus from 
which the GP was derived. We selected VSV and several arenaviruses, originating from both Old 
World (Eastern Hemisphere, e.g. Lassa, lymphocytic choriomeningitis virus (LCMV), and Lujo viruses) 
and New World (Western Hemisphere, e.g. Junin, Guanarito, Tacaribe, and Amapari viruses), 
because they gain access to the cytosol through different endocytic pathways (Supplementary Figures 
5A and 5B). VSV associates to the low-density lipoprotein receptor (LDLR), as its principal receptor to 
enter cells via clathrin-mediated endocytosis (CME), and escapes from early endosomes at pH 6.2 to 
reach the cytoplasm (Supplementary Figure 5B) [224-226].  The New World arenaviruses utilize 
human transferrin receptor-1 (hTfR1) (Junin and Guanarito) or animal orthologs of TfR1 (Amapari and 
Tacaribe) to enter cells via CME and then exit late endosome at pH≈5.5 (Supplementary Figure 5B) 
[227-229]. The Old World LCMV and Lassa viruses use the cellular receptor α-dystroglycan (DG) to 
infect cells via a macropinocytosis-related pathway [230-232]. The latter belong both to acid-activated 
viruses, escaping late endosomes by acid-induced membrane fusion (pH <5). However, they are 
transported to intermediate multivesicular bodies (MVBs) by an unidentified organelle, which is not 
early endosomes as demonstrated by the persistence of infection in cells lacking the early endosome 
markers Rab5 and EEA1 (Supplementary Figure 4B) [231, 233]. Of note, Lassa virus has to engage 
the late endosomal resident protein LAMP-1 for efficient fusion, which is not the case for LCMV [234]. 
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Finally, mechanisms of entry, including the receptor, have still not been highlighted for the newly 
identified Old World arenavirus Lujo, although Tani and colleagues demonstrated that TfR1 and DG 
were not involved [235]. Consequently, because those viruses use different endocytic routes to enter 
cells, they are valuable tools for characterizing at which step potassium channels regulate the 
cytoplasmic access.  
To study the entry of the selected viruses in the presence of KCNN4 and KCNQ5 inhibitors, the viral 
genome employed encodes luciferase gene, and successful internalization into the cytosol of the host 
cell can be determined by luciferase activity measurement. Figure 6A shows that in A549 cells, the 
KCNN4 inhibitor TRAM-34 prevented entry of LCMV, Junin, Lujo, Guanarito, Tacaribe, and Amapari 
viruses in a dose-dependent manner. However, infections by VSV and Lassa viruses were not blocked 
by TRAM-34. These results suggest that KCNN4 could inhibit transferrin-mediated clathrin 
endocytosis, prevent LAMP-1-independent late endosomal escape, or both. Finally, we cannot rule out 
the possibility that TRAM-34 exerts a virucidal activity.  Unlike TRAM-34, inhibition of KCNQ5 with 
XE991 in A549 did not protect significantly cells against tested virus infections (VSV, Lassa, LCMV, 
Junin, and Guanarito) (Figure 6B). 
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Figure 6. Inhibition of KCNN4 but not KCNQ5 prevents cytosolic access of certain viruses in 
A549 cells. A. A549 cells were pretreated for 1 hour with indicated concentration of TRAM-34 and infected with 
the mentioned pseudotyped virus containing a luciferase reporter in their genome. Luciferase activity was 
measured 16 hours post-infection. B. Same as in A with X991. Results represent 3 technical triplicate 
experiments +/- 95% CI. 
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DISCUSSION 
In order to unravel the mechanism of action of the TAT-RasGAP317-326 anti-cancer peptide, we 
performed genome-wide CRISPR/Cas9 screens in two distinct cell lines. The identified mediators of 
TAT-RasGAP317-326-induced cell death in the SKW6.4 B-lymphoblastoid EBV-transformed cells are 
mainly involved in the regulation of potassium flux, as illustrated by the two potassium channels 
KCNN4, KCNK5 and the subunit of the Na+/K+-ATPase pump ATP1B3. In addition, we validated one 
more candidate in these cells, which is a divalent metal transporter SLC39A14 for which no 
association with potassium has yet been reported. The screen in the Raji Burkitt lymphoma cells 
identified another potassium channel named KCNQ5 and the PIP5K1A lipid kinase. As PIP5K1A 
generates the membrane lipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), which is required for 
KCNQ family channels opening, the two proteins revealed by screening Raji cells are probably both 
involved in the modulation of potassium flux [236, 237]. Furthermore, we show that the inhibition of 
KCNN4, KCNQ5, and ATP1B3 can prevent cell death induced by the peptide in other cell lines (Daudi, 
THP-1, NB1, and HeLa), meaning that the effect of these candidates can be transferred to cells from 
diverse origins. Nevertheless, although almost all the tested cell lines were protected by at least one of 
the three candidates, no relation can be deduced between the origin of cells and the protein able to 
rescue them from the peptide toxicity. This could be explained by cell line-dependent differences in the 
level of expression or in the activity of each candidate. Of note, the only refractory cell line to the 
protective effect of the validated targets is the neuroblastoma NB1 cells, which are cultured in the 
absence of serum. As shown in this study, in serum-free conditions the protection of knockout clones 
against the killing activity of the peptide is lost.    
      
However, instead of being implicated in the death induction process per se as expected, we 
demonstrated that regulators of potassium flux are involved in the cytosolic access of TAT-RasGAP317-
326 and two other TAT-constructs, TAT-Cre and TAT-PNA. Indeed, when we force the entry of the 
peptide via direct translocation using PB or serum deprivation, cells lacking the validated targets are 
not anymore protected against the toxicity of the anti-cancer peptide. Thenceforth, the candidates can 
prevent the intracytoplasmic delivery of the TAT-constructs at two different levels, either they inhibit 
direct translocation and/or endocytosis or they hamper endosomal escape. The latter possibility can 
occur only if TAT-constructs gain access to the cytosol by an active vesicular uptake. Although 
endocytosis has been proposed as the general mode of entry of CPP constructs into cells, several 
studies show that TAT CPP can gain access to the cytoplasm by vesicular uptake, direct translocation, 
or both simultaneously depending mainly on the size, the biochemical nature of the cargo, and on the 
concentration used [188-190, 238, 239]. Our results indicate that TAT-RasGAP317-326 penetrates the 
cell via both endocytosis and direct translocation. Indeed, confocal microscopy detects early diffuse 
distribution (after less than 5 minutes) followed by the accumulation of the fluorescent peptide in small 
vesicles. In addition, although there is a decrease of peptide uptake at 4°C, temperature at which 
endocytosis is blocked, the fluorescence does not go back to the basal intensity, meaning that a low 
amount of the peptide translocates directly into cells. Of note, although still occurring, it is well-
established that the direct translocation is lowered at low temperatures due to decreases in cell 
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membrane dynamics and fluidity [240]. Another possibility to explain the slight increase in the 
fluorescence intensity at 4°C could be that the FITC-coupled peptide remains attached to the plasma 
membrane despite several washes. To exclude this hypothesis, trypan blue can be used to quench 
membrane-bound fluorescence instead of washes. Trypan blue is a non-permeant dye that was 
shown to quench the green fluorescence of membrane bound particles [241]. 
In contrast, TAT-Cre recombinase internalization was reported to occur purely by endocytosis via 
macropinocytosis [188, 242]. Although we cannot rule out that the targets revealed by the screens 
mediate the direct translocation of the peptide, we can argue that the KCNQ5 potassium channel and 
its regulator PIP5K1A block either endocytosis or endosomal escape as the disrupted clones for these 
genes hamper the cytosolic access of TAT-Cre. To better decipher the involvement of each candidate 
in the cytosolic access of some cargoes, the requirement of the candidates for different endocytosis 
pathways will have to be investigated. To this purpose, we could use fluorescent probe, such as 
dextran (70kDa) and transferrin, which have been shown to be internalized specifically via 
macropinocytosis and clathrin-mediated endocytosis, respectively [243-245]. 
Interestingly, the size of TAT-constructs studied here, ranging from 3.3 kDa to ~40kDa, does not affect 
the capacity of the candidates (at least KCNQ5 and PIP5K1A) to modulate their intracellular delivery. 
Though, it is well-described that the mechanism of entry depends on the size of the molecule fused to 
TAT, with smaller cargoes distributing throughout the cell and the bigger ones ending up in 
cytoplasmic vesicles [242]. 
The candidates highlighted in the screen performed on SKW6.4 prevent the cytosolic access of TAT-
constructs to a lesser extent than KCNQ5 and PIP5K1A. Hypotheses to explain those results could be 
that they do not act at the same level, to the same efficiency, or depending on the cell line the mode of 
entry used by TAT-constructs can vary. Indeed, the composition of the plasma membrane, which 
differs from a cell line to another, affects the efficiency of cytosolic access [246]. Finally, although 
literature reports that the identified regulators are mainly sited in the plasma membrane, defining their 
exact location might shed light on the specific step of the cytosolic access where they act [247-250].  
  
In order to better understand how the regulators of potassium flux modulate the cytosolic access of 
TAT, we show that the disruption of potassium channel KCNQ5 hampers the cytosolic access of the 
anti-cancer peptide via cytoplasmic membrane depolarization. The effect of the membrane potential 
on molecule internalization by endocytosis or direct translocation was already previously reported by 
incubating the cells with potassium-rich buffer [219, 251]. Strikingly, in Raji wild-type cells, incubation 
with potassium-rich buffer inducing depolarization of the bilayer membrane does not go with an 
increased intracellular potassium concentration. However, these results should be interpreted with 
caution due to the suboptimal specificity of the APG2 probe for potassium. Furthermore, 
electrophysiology would be required to confirm results obtained with the DiBAC4(3) potential-sensitive 
probe.   
Interestingly, KCNN4, KCNK5, and ATP1B3 do not prevent the intracellular delivery of TAT-
RasGAP317-326 through the regulation of the membrane resting potential. Ben-Dov et al. demonstrated 
that intracellular uptake depends on the membrane resting potential through a potential-dependent 
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reorganization of actin [220]. Consequently, one can hypothesize that KCNN4, KCNK5, and ATP1B3 
regulate cytosolic access by preventing actin depolymerization via another mechanism than 
depolarization of the plasma membrane. Indeed, it was reported that Ca2+-sensitive K+ channels, such 
as KCNN4, and the Na+/K+-ATPase pump modulate actin cytoskeleton [252, 253]. If the potassium 
flux regulators act on the actin cytoskeleton, it would suggest that their absence prevents endocytosis 
rather than endosomal escape. This assumption is supported by the stronger membrane association 
of the FITC peptide in HeLa cells treated with TRAM-34 or in KCNN4 knockout HeLa cells than in 
HeLa wild-type cells.    
 
Finally, as a potential clinical relevance, we demonstrate that the KCNN4 inhibitor TRAM-34 blocks 
the cytosolic access of some arenaviruses. Among them Junin, Guanarito, and Lujo viruses are 
responsible for clinical disease associated with fever and bleeding referred to as viral hemorrhagic 
fevers (VHFs) [254]. VHFs have significant clinical and public health impact with high case mortality 
rate (10-30%) and only limited therapies and vaccines [255-257]. In the light of the results obtained 
with several viruses and because they use different endocytic routes, we can postulate that either the 
inhibition of KCNN4 potassium channel hamper transferrin-mediated clathrin endocytosis or modulate 
shared downstream processes of the endocytic pathway, including endosome maturation (i.e. 
acidification) or endosomal escape. It is nevertheless unlikely that TRAM-34 affects acidification of 
endosomes since Lassa virus infection, which exits from late endosome (pH≈5.5), was not hampered 
by the KCNN4 inhibitor [258]. It is, therefore, possible that TRAM-34 prevents the cytosolic access of 
viruses by blocking LAMP-1-independent late endosomal escape. Of note, it has been reported that 
some viruses can utilize several endocytic pathways to reach the cytosol, making the analysis of these 
data more complex [259]. However, one hypothesis that we cannot dismiss yet is the potential 
virucidal activity of TRAM-34. The KCNN4 inhibitor could indeed inactivate viral particles outside the 
cell. Furthermore, it has been reported that TRAM-34 can block the activity of other proteins such as 
cytochrome P450  [260]. Consequently, to exclude possible off-target effects, results should be 
confirmed in A549 KCNN4 knockout cells. In addition, these preliminary data obtained with 
pseudotyped viruses have to be confirmed with authentic viruses. Finally, the absence of protection 
against viral infection in cells treated with the KCNQ5 inhibitor XE991 suggests that either the 
expression of this potassium channel is not predominant in A549 cells or the activity of KCNQ5 is not 
required to regulate viral infections.  
 
To conclude, we demonstrated that regulators of potassium flux play a key role in the cytosolic access 
of some TAT-constructs and arenaviruses. Although we show that the regulation of intracellular entry 
by KCNQ5 potassium channel is dependent on the plasma membrane potential, how the other 
candidates work remains still to be unravelled. Consequently, further experiments need to be 
performed in order to decipher at which steps the different validated targets act.  
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SUPPLEMENTARY TABLE AND FIGURES 
 
 
 
 
 
Supplementary Table S1. Counts summary metrics of the CRISPR/Cas9 screens in SKW6.4 and 
Raji cells. SKW6.4 and Raji GeCKO library control populations and SKW6.4 and Raji GeCKO library TAT-
RasGAP317-326 (P) selected populations were sequenced with a MiSeq (Illumina). Raw FASTQ files were 
demultiplexed and processed to contain only the unique sgRNA sequence. The total number of reads, the 
number of reads for each sgRNA, and the number of reads per targeted genes are shown in this table. 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S1. The involvement of candidate proteins in TAT-RasGAP317-326-induced 
cell death is tumour type dependent. A. DNA sequences of WT SLC39A14 gene in SKW6.4 cells and 
SLC39A14 alleles of corresponding knockout clone #1. Differences between WT and the disrupted clone are in 
blue. The sgRNA directed against the gene is highlighted in grey. B. WT and SLC39A14 disrupted SKW6.4 cells 
were treated or not with 40 μM TAT-RasGAP317-326 for 24 hours. Cell death was then assessed by flow cytometry 
after PI staining. C. Raji, THP-1, and HeLa WT cells were pretreated or not with 1 μM or 10 μM TRAM-34 for 1 
hour and then treated with the indicated concentration of TAT-RasGAP317-326 (P) for 16 (Raji) or 24 (THP-1/HeLa) 
hours. Cell death was assessed by flow cytometry after PI staining. D. Raji, THP-1, Daudi, and NB1 WT cells 
were preincubated with 100 nM digoxin or 100 nM ouabain for 1 hour and then treated with 40 μM TAT-
RasGAP317-326 for 16 (Raji) or 24 hours. Cell death was assessed by flow cytometry after PI staining. E. SKW6.4, 
HeLa, Daudi, and NB1 WT cells were preincubated with 10 μM XE991 for 1 hour and then treated with 40 or 80 
(HeLa) μM TAT-RasGAP317-326 for 24 hours. Cell death was assessed by flow cytometry after PI staining. F. 
Same as Panel A for KCNQ5 gene in NB1 cells. G. WT and KCNQ5 disrupted NB1 cells were treated or not with 
40 μM TAT-RasGAP317-326 for 24 hours. Cell death was then assessed by flow cytometry after PI staining. H. 
Expression of ATP1B3 in WT and knockout Raji cells. I. WT and ATP1B3 disrupted Raji cells were treated or not 
with 40 μM TAT-RasGAP317-326 for 16 hours. Cell death was then assessed by flow cytometry after PI staining. J. 
Same as Panel A for KCNN4 gene in HeLa cell. K. WT and KCNN4 disrupted HeLa cells were treated or not with 
80 μM TAT-RasGAP317-326 for 24 hours. Cell death was then assessed by flow cytometry after PI staining. Results 
for panels B, C, D, E, G, I, and K correspond to the mean +/- 95% CI of three independent experiments.   
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Supplementary Figure S1. The involvement of candidate proteins in TAT-RasGAP317-326-induced 
cell death is tumour type dependent. (see legend on the previous page) 
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Supplementary Figure S2. Forced TAT-RasGAP317-326 direct translocation induced death in 
SKW6.4 WT, SLC39A14 KO and treated with TRAM-34, digoxin, or ouabain. A. WT, SLC39A14 KO, 
and SKW6.4 cells pretreated with TRAM-34, digoxin, or ouabain were treated or not with 40 µM TAT-RasGAP317-
326 and 50 µM PB for 30 minutes and cell death was determined using PI. B. Live confocal microscopy imaging of 
HeLa and SKW6.4 WT cells incubated in medium containing or not 10% serum and treated for 1 hour with 20 μM 
FITC fused TAT-RasGAP317-328 (green). The nuclei of HeLa cells are stained with live Hoechst 33342 1 μg/ml for 
15 minutes (blue). C. WT and SLC39A14 KO SKW6.4 cells were incubated in medium containing or not 10% 
serum and treated for 3 hours with 40 µM TAT-RasGAP317-326. Cell death was analyzed by flow cytometry using 
PI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S3. Assessment of the FITC-TAT-RasGAP317-326 cytosolic access in 
KCNN4 KO, HeLa cells treated with TRAM-34 and WT HeLa cells. A. Live confocal microscopy 
imaging of HeLa WT, HeLa WT pretreated with 10 μM TRAM-34 for 1 hour, and HeLa KCNN4 KO treated for the 
indicated periods of time with 80 μM FITC fused TAT-RasGAP317-328 (green) at 4°C and 37°C. The nucleus is 
stained with live Hoechst 33342 1 μg/ml for 15 minutes (blue).  
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Supplementary Figure S3. Assessment of the FITC-TAT-RasGAP317-326 cytosolic access in 
KCNN4 KO, HeLa cells treated with TRAM-34 and WT HeLa cells. (see legend on the previous page) 
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Supplementary Figure S4. Cytosolic access assays. A. The scheme represents the luciferase rescue 
reporter assay. This assay employs cells expressing a plasmid carrying the luciferase-coding sequence 
interrupted by a mutated human β-globin intron 2. This mutation creates a new splicing site that is targeted by the 
splicing machinery of the cells, together with a cryptic site that is now also used, to produce an mRNA that 
encodes a truncated non-functional luciferase. However, the luciferase pre-mRNA can be properly processed if 
the splice site generated by the mutation at position 705 is masked by a matching oligonucleotide (ON-705). ON-
705 can be covalently coupled to a cell-penetrating peptide (CPP) (e.g. TAT). The resulting so-called peptide 
nucleic acid (PNA), when incubated with cells, triggers the correct splicing of the mutated luciferease pre-RNA but 
only if the PNA is gaining access to the cytosol. B. TAT-Cre mediated excision of transcriptional RFP-STOP 
region flanked by two loxP sites induces constitutive GFP expression. Pr, promoter. C. Cytosolic access was 
assessed using a luciferase rescue reporter assay [261]. WT HeLa cells were infected with a virus encoding for 
the luciferase-coding sequence, interrupted by a mutated human β-globin intron. They were then pretreated or not 
with 10 μM TRAM-34 for 1 hour and treated for 24 hours with 10 μM TAT-PNA. After 24 hours, luciferase activity 
was measured and normalized to the protein content. Results correspond to the mean +/- 95% CI of three 
independent experiments.  
 
 
 
 
 
 
 
 
Supplementary Figure S5. VSV and Arenaviruses entry and transport. A. Phylogenic tree of 
Arenaviruses. Modified from Urata et al., Viruses, 2012, [262]. B. Viruses bind to specific receptors before 
entering the cell by hijacking endocytic pathways. VSV (in green) associates to the low-density lipoprotein 
receptor (LDLR) to enter cells via clathrin-mediated endocytosis (CME), and escapes from early endosomes to 
reach the cytoplasm. The New World arenaviruses (in blue) utilize transferrin receptor-1 to enter cells via CME 
and then exit late endosome. The Old World (in purple) LCMV and Lassa viruses use the cellular receptor α-
dystroglycan to infect cells via a macropinocytosis-related pathway and escape late endosomes by acid-induced 
membrane fusion. However, they are transported to intermediate multivesicular bodies by an unidentified 
organelle, which is not early endosomes. Of note, Lassa virus has to engage the late endosomal resident protein 
LAMP-1 for efficient fusion, which is not the case for LCMV. Finally, mechanisms of entry, including the receptor, 
have still not been highlighted for the newly identified Old World arenavirus Lujo (in purple). 
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Supplementary Figure S5. VSV and Arenaviruses entry and transport. (see legend on the previous 
page) 
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RELATED DATA 
 
This part is dedicated to results that I obtained by working on the mode of action of TAT-RasGAP317-326 
and the involvement of the candidates highlighted by CRISPR/Cas9 screens in the cytosolic access of 
the peptide. As they are either negative results or preliminary data, they were not added to the 
previous manuscript.  
 
  
CRISPR/Cas9 screening in NB1 cells 
As we did not succeed in the Oncotarget paper to decipher how TAT-RasGAP317-326 could kill NB1 
cells (Figure R1A), a gene disruption CRISPR/based genetic screen was performed to identify genes 
whose loss increases resistance to the peptide in this cell line. The rational of using the NB1 cells for 
the screen, in addition to the SKW6.4 and the Raji cells, was to favor the identification of the core 
proteins required for the peptide to kill in cell lines of different origins. Table R1 compares the results 
of massive parallel sequencing for NB1 and Raji cells in both control and peptide-selected 
populations. The screen identified more than 20,000 targeted genes with more than 100,000 targeted 
sgRNAs in the control population of Raji and NB1 cells (in grey and red respectively in Table R1). 
These data demonstrate that the infection with the CRISPR/Cas9 GeCKO library worked well. 
However, whereas the number of targeted genes and sgRNAs in control and peptide selected 
populations are quite similar in Raji cells (in grey and bold grey respectively in Table R1), they differ in 
NB1 control and peptide selected populations (in red and bold red respectively in Table R1). One 
explanation for the loss of around 40% of targeted genes in the NB1 peptide selected population could 
be that these genes were not involved in inducing cell resistance to the peptide toxicity. Another 
explanation would be that a large number of cells were lost during the splitting steps of the treated 
population. Indeed, one of the properties of TAT-RasGAP317-326 is to greatly increase cell adherence 
rendering the cells very difficult to be detached with trypsin. The latter explanation seems to be the 
right one, according to the large and unexpected decrease of the targeted sgRNAs number in the 
peptide-selected population compared to the control population (>80%). As a consequence of this 
technical issue, the results of the sequencing performed on NB1 cells are not directly interpretable as 
shown in Figure R1. Although after positive selection with TAT-RasGAP317-326, the NB1 cells infected 
with the library were rendered resistant to its toxicity (Figure R1B), SNAP29, the top candidate yielded 
by the screen, was not required for the peptide to kill NB1 cells (Figures R1C, D, and E).  
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Figure R1. Identification of candidate genes, whose loss-of-function should confer TAT-
RasGAP317-326 resistance. A. NB1 cells were incubated for 24 hours with indicated concentrations of TAT-
RasGAP317-326 or TAT, as a control. Cell death was then assessed by flow cytometry after 7-AminoActinomycin D 
(7-AAD) staining. B. NB1 WT, NB1 GeCKO library control and NB1 GeCKO library TAT-RasGAP317-326 (P) 
selected cells were treated or not with 40 μM TAT-RasGAP317-326 for 24 hours. Cell death was then assessed by 
flow cytometry after PI staining. Results correspond to the mean +/- 95% CI of 3 independent experiments. C. 
Identification of the four top candidate genes implicated in resistance to TAT-RasGAP317-326 in NB1 cells using the 
Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) p-value. D. Expression of SNAP29 in 
NB1 WT and KO clones #1 and #2. E. WT and SNAP29 disrupted NB1 cells were treated or not with 40 μM TAT-
RasGAP317-326 for 24 hours. Cell death was then assessed by flow cytometry after PI staining.  
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Table RI. Counts summary metrics of the CRISPR-Cas9 screen in Raji and NB1 cells. Raji and 
NB1 GeCKO library control populations and Raji and NB1 GeCKO library TAT-RasGAP317-326 (P) selected 
populations were sequenced with a MiSeq (Illumina). Raw FASTQ files were demultiplexed and processed to 
contain only the unique sgRNA sequence. The total number of reads, the number of reads for each sgRNA, and 
the number of reads per targeted genes are shown in this table.  
 
 
 
Are ATP1A1 knockout SKW6.4 clones resistant to TAT-RasGAP317-326-induced cell death? 
Na+/K+-ATPase pump transforms the energy of ATP to maintain the sodium and potassium gradients 
across the plasma membrane. This pump transports three Na+ from inside the cell to the outside and 
two K+ from outside to the inside. The minimal functional Na+/K+-ATPase pump is composed of two 
subunits: the alpha subunit that hydrolyses ATP and transports the cations, and the beta subunit that 
is required for the stability and trafficking of the pump [263]. Whereas three different isoforms of the 
beta subunit have been found in humans, the alpha subunit possesses four isoforms (ATP1A1, 
ATP1A2, ATP1A3 and ATP1A4) [264, 265]. In contrast to the other subunits, ATP1A1 is expressed in 
all tissues.  
As the CRISPR/Cas9 screen on SKW6.4 cells highlighted ATP1B3, which is an isoform of the beta 
subunit of the Na+/K+-ATPase pump, we then investigated if the alpha subunit of the pump was 
equally able to regulate TAT-RasGAP317-326-induced cell death. We, therefore, generated ATP1A1 
knockout clones in parallel to ATP1B3 knockout cells (Figure R2A). Figure R2B indicates that the 
alpha subunit ATP1A1 of the Na+/K+-ATPase pump is also involved in the regulation of the peptide 
toxicity.  
Figure R2. ATP1A1 knockout SKW6.4 cells are protected against TAT-RasGAP317-326 toxicity. A. 
ATP1A1 was disrupted in SKW6.4 cells using the CRISPR/Cas9 technology. Loss of expression was confirmed 
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by western blotting. B. Wild-type (WT) and ATP1A1 knockout (KO) SKW6.4 cells were treated or not with 40 µM 
TAT-RAsGAP317-326 for 24 hours. Cell death, corresponding to the % of PI positive cells, was determined by flow 
cytometry. Results correspond to the mean +/- 95% CI of 3 independent experiments. 
 
 
 
Does TAT-RasGAP317-326 colocalize with Rab5 in HeLa cells? 
To assess if TAT-RasGAP317-326 enters cells through endocytosis, we investigated whether the FITC 
fluorescent-labelled peptide colocalized with the marker of early endosomes, Rab5. As depicted in 
Figure R3, TAT-RasGAP317-326 and Rab5 colocalize, suggesting that the peptide enters cells at least 
partially through endocytosis.  
 
    
 
 
 
Figure R3. TAT-RasGAP317-326 colocalizes with the early endosome marker Rab5. A. Fluorescent 
confocal microscopy analysis of HeLa cells treated with 40 µM FITC-TAT-RasGAP317-326 (upper left panel, green) 
for 12 hours and then stained with an anti-Rab5 antibody (upper central panel, purple) indicates that TAT-
RasGAP317-326 and Rab5 colocalize (upper right panel, white). A histogram (lower panel) showing colocalization of 
FITC-TAT-RasGAP317-326 with Rab5 along a line that was drawn on one of the cells was generated from the 
image using ImageJ software. Black arrows indicate colocalization in aggregates.  
 
  
 
Does TAT-RasGAP317-326 colocalize with LAMP1 in HeLa cells? 
Once trapped into endosomes, TAT-RasGAP317-326 has to escape them to access to the cytoplasm 
and exerts its activity. Endosomal escape can occur in early or late endosomes. One way to assess if 
the peptide gains access to the cytosol from early endosomes is to determine whether it is or not 
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present in the late endosomes. Therefore, we studied if the peptide colocalized with the late 
endosomal marker, LAMP-1. Figure R4 illustrates that TAT-RasGAP317-326 and LAMP-1 colocalize. 
This suggests that the peptide does not escape early endosomes. Consequently, either the peptide is 
able to escape late endosomes or it is sequestrated into endosomes, hampering it to reach the 
cytosol. The second hypothesize would mean that the killing efficiency of the peptide is only based on 
its entry via direct translocation.  
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Figure R4. TAT-RasGAP317-326 colocalizes with the late endosome marker LAMP-1. A. Fluorescent 
confocal microscopy analysis of HeLa cells treated with 80 µM FITC-TAT-RasGAP317-326 (upper right panel, 
green) for 24 hours and then stained with an anti-LAMP-1 antibody (upper left panel, purple) and with the nuclei 
marker Hoechst 33343 (lower right panel, blue) indicates that TAT-RasGAP317-326 and LAMP-1 partially colocalize 
(lower left panel, white). B. Picture magnifications of what was represented in panel A. 
 
 
 
Does the absence of KCNN4 and KCNQ5 potassium channels inhibit endocytosis of TAT-
RasGAP317-326 through the activation of PP2A? 
Recently, Eil and colleagues demonstrated that increased intracellular potassium concentration could 
limit the activation of T cells through the activation of the serine/threonine phosphatase PP2A and the 
subsequent inhibition of Akt [266]. Moreover, by overexpressing KCNN4 as well as another potassium 
channel KCNA3 in T-cells, the intracellular potassium concentration was reduced and consequently 
PP2A was inhibited. Consequently, they have demonstrated that potassium channels, via the 
modulation of intracellular potassium concentration, can regulate T-cell activation through PP2A.  
PP2A is known to negatively regulate Akt activity as well as Src kinase, two proteins that were shown 
to be involved in endocytosis [267-271]. The PP2A protein consists of the structural subunit (A), 
catalytic subunit (C), and a variable regulatory subunit (B) [272].  
Consequently, we hypothesized that the absence of KCNN4 or KCNQ5 would increase the 
intracellular potassium concentration and subsequently stimulates PP2A activation that represses Akt 
or Src kinase. This would result finally in the inhibition of TAT-RasGAP317-326 endocytosis (Figure R5).  
 
In order to validate this assumption, we used a serine/threonine phosphatase (PP1 and PP2A) 
inhibitor named okadaic acid (OA). Figures R5B and R5C show that, in the presence of OA, the 
KCNN4 and KCNQ5 knockout cells are re-sensitized to TAT-RasGAP317-326-induced cell death at the 
same extent as wild-type cells treated with the peptide. Then, to investigate if the absence of KCNN4 
and KCNQ5 potassium channels impacted the abundance of the catalytic subunit of PP2A (PP2Ac) or 
the extent of Src and Akt phosphorylation, we performed western blot analyses. The first 
phosphorylation site of Akt at the threonine 308 residue stimulates only partially the kinase, which 
requires a second phosphorylation at serine 473 residue for its full activation [273, 274]. Figures R5D 
and R5E illustrate that neither the abundance of PP2Ac nor Src or Akt phosphorylation are 
deregulated in knockout cells or wild-type cells treated with the KCNN4 inhibitor TRAM-34 or the 
KCNQ5 inhibitor XE991 compared to the non-treated wild-type cells. These results suggest that the 
effect of OA is independent of Akt or Src kinase phosphorylation. Of note, although it seems that there 
is a decrease of Src and Akt (at S473 residue only) phosphorylation in Raji treated with XE991 or in 
KCNQ5 knockout Raji cells (Figure R5E), it is an artifact due to an inefficient exposure of the 
membrane. In addition, the increased phosphorylation of Akt at T308 residue in KCNN4 knockout 
SKW6.4 cells was not related to the protective effect against the peptide toxicity observed in those 
cells, as no similar observation was made in wild-type cells treated with the TRAM-34 inhibitor (Figure 
R5D). The same assertion can be done regarding to the increased abundance of PP2Ac in KCNQ5 
knockout Raji cells (Figure R5E). Finally, we treated wild-type SKW6.4 and Raji cells with an efficient 
dose of the Src kinase inhibitor dasatinib (Figure R5F) in the presence of TAT-RasGAP317-326. Figure 
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R5G shows that the inhibition of Src kinase does not protect wild-type cells against the peptide 
toxicity, supporting western blotting results. 
Ultimately, we assessed if the re-sensitizing effect of OA in knockout cells was associated with an 
increased intracellular uptake of the peptide. Strikingly, in the presence of OA, the entry of the FITC-
coupled TAT-RasGAP317-326 peptide remained blocked in KCNQ5 knockout Raji cells (Figure R5H). 
This suggests that, upon OA treatment, the peptide is able to kill cells directly from the outside. 
Another assumption would be that OA is able to very efficiently potentiate the effect of the peptide 
which, therefore, requires only very few molecules inside the cell to induce its death.   
In order to better understand how OA is able to rescue the phenotype of knockout cells, we could 
silence PP2A. This would allow us to assess if the observed effect of OA is due to PP2A inhibition. 
Alternatively, we could stimulate PP2A in wild-type cells and assess whether its activation prevents 
TAT-RasGAP317-326-induced cell death.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure R5. Okadaic acid can re-sensitize KCNN4 and KCNQ5 knockout cells to TAT-RasGAP317-
326 independently of Akt and Src kinase modulation. A. Scheme depicting the possible mechanisms by 
which okadaic acid (OA) could re-sensitize KCNN4 and KCNQ5 knockout cells to TAT-RasGAP317-326-induced cell 
death. OA is a specific inhibitor of PP1 and PP2A. Src as well as Akt kinases are inhibited by PP1 and PP2A. The 
sequential inhibitions activate Src and Akt kinases that induce endocytosis. The presence of potassium channels 
could inhibit PP2A activation or stimulate both kinases, either directly or by modulating the intracellular potassium 
concentrations, resulting in endocytosis stimulation. Consequently, in cells specifically disrupted for KCNN4 or 
KCNQ5, endocytosis could not occur correctly. According to this hypothesize, Dasatinib, a Src Kinase inhibitor, 
should protect wild-type cells against the peptide toxicity via the TAT-RasGAP317-326 endocytosis inhibition. B. 
KCNN4 KO or WT SKW6.4 cells were preincubated one hour with different concentrations (0, 12.5, 25, 50, and 
100 µM) of OA, before being treated or not (CTRL) with 40 µM TAT-RasGAP317-326 for 24 hours. Cell death, 
corresponding to the % of PI positive cells, was determined by flow cytometry. C. KCNQ5 KO or WT Raji cells 
were preincubated one hour with different concentrations (0, 50, 100, 200, and 400 µM) of OA, before being 
treated or not (CTRL) with 40 µM TAT-RasGAP317-326 for 16 hours. Cell death was assessed as in panel B. D. 
SKW6.4 WT cells were pretreated one hour with 10 µM TRAM-34 (TRAM) or 10 µM XE991. The abundance of 
PP2Ac as well as the extent of Src and Akt phosphorylation at serine 473 and threonine 308 were assessed by 
western blot in the indicated cells. Vinculin was used as protein loading control. E. Same as panel D with WT and 
KCNQ5 KO Raji cells. F. Abundance of Src kinase in SKW6.4 and Raji WT cells treated or not for 1 hour with 
dasatinib at the indicated concentrations was assessed by western blotting. G. WT SKW6.4 and Raji cells were 
preincubated or not (N/T) one hour with 125 nM or 1 µM dasatinib, before being treated or not with 40 µM TAT-
RasGAP317-326 for 24 hours (SKW6.4) or 16 hours (Raji). Cell death was assessed as in panel B. H. KCNQ5 KO 
and WT Raji cells were treated as in panel C with FITC-TAT-RasGAP317-326 for 1 hour. Cells were then collected 
and washed three times with cold phosphate-buffered saline (PBS). The median fluorescence intensity of viable 
cells was then measured by flow cytometry. Results of panel B and C correspond to the mean +/- 95% CI of 3 
independent experiments.    
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Figure R5. Okadaic acid can resensitize KCNN4 and KCNQ5 knockout cells to TAT-RasGAP317-
326 independently of Akt and Src kinase modulation. (see legend on the previous page) 
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DMEM protects cells against TAT-RasGAP317-326-induced cell death. 
By working with several cell lines that were cultured in different media, we observed that the sensitivity 
of cells toward TAT-RasGAP317-326 toxicity was medium-dependent. Figure R6A show that SKW6.4 
wild-type cells are partially protected against the peptide in DMEM compared to RPMI. Same results 
were observed in other cell lines such as here in the melanoma cell lines WM3248 and WM1366 
(Figure R6B). Comparison of media composition revealed that the concentration of calcium was higher 
in DMEM than in RPMI. Consequently, the complementation of RPMI with calcium partially blocked 
TAT-RasGAP317-326-induced death (Figure R6C).  
To investigate if DMEM was still able to protect cells once the peptide has gained access to the 
cytoplasm, we used pyrenebutyrate (PB) to force its direct translocation. Figure R6C shows that in the 
presence of PB, cells were not any more protected in DMEM. This suggests that the calcium 
concentration of the medium is an important parameter modulating the peptide toxicity, although it 
does not regulate its direct pro-death activity.  
 
 
Figure R6. DMEM protects against TAT-RasGAP317-326-induced cell death. A. SKW6.4 cells cultured 
in RPMI or in DMEM were treated or not (CTRL) with 40 µM TAT-RasGAP317-326 (P40) for 24 hours. Cell death, 
corresponding to the % of PI positive cells, was determined by flow cytometry. B. Same as Panel A in WM3248 
and WM1366 cell lines treated with 40 or 80 µM TAT-RasGAP317-326. C. SKW6.4 cells cultured in RPMI were 
treated or not (CTRL) with 1.38mM CaCl2 and 40 µM TAT-RasGAP317-326 for 24 hours. Cell death was determined 
using PI. D. SKW6.4 cells cultured in RPMI or in DMEM were treated or not with 40 µM TAT-RasGAP317-326 and 
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50 µM PB for 30 minutes and cell death was determined using PI. Results of panel A, C and D correspond to the 
mean +/- 95% CI of at least 3 independent experiments.    
 
 
 
A549 is the only tested cancer cell line that is not killed by TAT-RasGAP317-326. 
Among about 40 tested cell lines, the human lung carcinoma A549 cells are the only ones that were 
not killed by the peptide when cultured in RPMI. Of note, the scale of the y-axis goes only until 4% cell 
death. Accordingly, these cells could be useful for future experiments designed to find the mechanism 
of action of the peptide or its mode of entry. As a first experiment, we could assess the uptake of the 
FITC-TAT-RasGAP317-326 in those cells.  
 
 
 
Figure R7. A549 cells are not killed by TAT-RasGAP317-326. A. A549 cells cultured in RPMI or in DMEM 
were treated or not (CTRL) with 20, 40, and 80 µM TAT-RasGAP317-326 for 24 hours. Cell death, corresponding to 
the % of PI positive cells, was determined by flow cytometry. 
 
 
 
There is no difference in intracellular calcium concentration between wild-type and KCNN4 or 
KCNQ5 knockout cells. 
Perturbations of intracellular calcium compartmentalization and concentration have been shown to 
induce cytotoxicity [275]. Moreover, we showed that cells cultured in DMEM, which contains more 
calcium than RPMI, are protected against the peptide toxicity. Finally, the absence of KCNN4, which is 
a potassium calcium-activated channel, blocks TAT-RasGAP317-326-induced death. We, therefore, 
hypothesize that calcium could play a key role in the mode of action of the RasGAP-derived peptide. 
We used the chemical calcium indicator Fluo-4/AM to assess intracellular calcium concentration in 
various conditions [276]. We employed the ionophore ionomycin and the intracellular calcium chelator 
Bapta/AM as positive and negative control, respectively [277, 278]. Figure R8A shows that there is no 
difference in intracellular calcium concentration between wild-type and KCNN4 knockout SKW6.4 
cells. Furthermore, cells preincubated in OA, calcium chloride (CaCl2), and DMEM did not display any 
changes in intracellular calcium concentration compared to non-treated cells. Same observations were 
reported in wild-type and KCNQ5 knockout Raji cells (Figure R8B).  
These results do not exclude that calcium is involved in TAT-RasGAP317-326-induced cell death. 
Indeed, as Fluo-4 is blocked in the cytoplasm, it cannot measure precisely perturbation of calcium 
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compartmentalization. Moreover, Fluo-4 probe might not be enough sensitive to detect small localized 
variations of calcium that could be sufficient to modulate the peptide toxicity. We could, therefore, 
perform confocal microscopy to better investigate calcium localization.  
 
 
 
Figure R8. There is no difference in intracellular calcium concentration between wild-type and 
KCNN4 or KCNQ5 knockout cells. A. WT and KCNN4 KO SKW6.4 cells were preincubated one hour in 10 
µM Bapta/AM, 200 µM okadaic acid (OA), 200 µg/ml CaCl2, or DMEM. 5 µM Fluo-4/AM was then added for 1 
hour. The cells were washed once and 20 minutes later, the median fluorescence intensity of viable cells was 
measured by flow cytometry. For the positive control, ionomycin plus 200 µg/ml CaCl2 were added five minutes 
before analyzing the cells by flow cytometry. B. As in panel A with WT and KCNQ5 KO Raji cells. Results 
correspond to the mean +/- 95% CI of 3 independent experiments.    
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PART IV 
 
The fourth part of the results is dedicated to a recent project unrelated to TAT-RasGAP317-326.  
In this part, we took advantage of the well-implemented CRISPR/Cas9 technology in the lab to apply it 
to a project about resistance mechanisms of hepatocellular carcinoma (HCC) to sorafenib. In addition, 
we used exome sequencing analysis to identify novel pathways that lead to sorafenib resistance. The 
latter could be targeted to treat HCC. Preliminary results obtained with the two technologies are 
presented in the following section in form of manuscript.  
Of note and as illustrated in the manuscript, we have encountered some technical issues in the course 
of this project. This study was based on three HCC cell lines that were rendered resistant to sorafenib 
by our collaborators. Once we received them, we directly performed exome sequencing analyses. In 
the meantime, we assessed if cells were still resistant to sorafenib in our hands. Unexpectedly, two 
out of the three cell lines had lost their resistant phenotype suggesting the occurrence of a genetic 
drift. However, the latter happened most probably after we had performed exome sequencing. Indeed, 
the results depict some mutations already described in the literature suggesting that cells were still 
resistant at that time. Unfortunately, as our collaborators did not keep frozen resistant cells, we were 
unable to validate mutations highlighted by exome sequencing analyses. Accordingly, certain results 
presented in this part should be cautiously interpreted.  
 
This study was carried out in collaboration with Dr. Olivier Dormond from the department of Visceral 
Surgery of Centre Hospitalier Universitaire Vaudois (CHUV). Dr. Emilie Uldry, from his laboratory, 
established and validated the three sorafenib resistant cell lines used in this study (Figure 1 of the 
following manuscript). Dr. David Barras from the Swiss Institute of Bioinformatics (SIB) analyzed the 
exome sequencing data. I performed all the other experiments. 
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IDENTIFICATION OF GENES INVOLVED IN ACQUIRED SORAFENIB 
RESISTANCE IN HEPATOCELLULAR CARCINOMA.  
 
 
INTRODUCTION 
Worldwide, liver cancer is the second most common cause of cancer death and the fifth most common 
tumour [39]. The five-year survival rate of hepatocellular carcinoma (HCC), which is the most frequent 
liver cancer, is around 10%. The global mortality rate is proportional to the global incidence, 
highlighting the aggressiveness of the tumour and the poor efficacy of current therapies. Sorafenib, a 
multikinase inhibitor (VEGFR, PDGFR, RET, c-KIT, C-Raf, B-Raf), is the sole approved drug for 
patients with advanced HCC. In addition to its ability to induce cancer cell death, sorafenib is a potent 
anti-proliferative agent via the inhibition of growth factor receptors [279]. However, despite clinical 
trials showing that the median overall survival time with sorafenib is higher than with placebo (10.7 
months vs 7.9 months), the outcomes are far from satisfactory [52]. Genetic heterogeneity of HCC and 
resistance to sorafenib are part of the explanations of the poor prognosis. To date, many mechanisms 
have been implicated in the failure to respond to sorafenib [57]. One of them is activation of the 
escape pathway of canonical RAF/MERK/ERK cascade. In addition, EGFR aberrant activation and the 
subsequent stimulation of PI3K/AKT pathway are such examples [58]. In this context, other 
mechanisms, such as JNK, Mcl-1, Mapk14, SDF-1α, Galectin-1, and Sirtuin 1 activations, have been 
reported as well [59-64]. Sorafenib resistance can also be acquired through its antiangiogenic activity 
as sustained sorafenib treatment induces an increased intratumour hypoxia, which leads to cell 
survival in a HIF-1α-dependent manner [65]. 
Despite the fact that several signalling pathways have been shown to be implicated in sorafenib 
primary and acquired resistance, the exact mechanisms are still incompletely understood. A better 
knowledge of chemoresistance mechanisms is primordial to improve the outcome of advanced-stage 
HCC patients. Indeed, unraveling new genes involved in sorafenib resistance in HCC could lead to the 
identification of new targetable candidates to treat HCC. In this study, we rendered three different 
HCC cell lines (HUH-7, PLC/PRF/5, and HepG2/C3A) resistant to sorafenib by long-term exposure to 
the drug. To identify novel mutations responsible for the resistance to sorafenib, exome sequencing 
was conducted on the parental cell lines and their matched sorafenib resistant counterpart. The results 
highlighted two already known genetic alterations, including p53 Y220C structural mutation and EGFR 
amplification. As a complementary approach, we performed a CRISPR/Cas9 screen to identify 
additional potential regulators of sorafenib-induced resistance. The screen highlighted KEAP1 as the 
top candidate. Dysregulation of KEAP1 cellular pathway has been shown to promote proliferation and 
chemoresistance in several cancer types including HCC [112, 280, 281].   
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MATERIALS AND METHODS 
Cell lines 
All cell lines were cultured in 5 % CO2 at 37 °C. HepG2/C3A, PLC/PRF/5, and HUH-7 cells were 
cultured in Dulbecco’s modified Eagle Medium (DMEM) (Gibco, Paisley, UK) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS; Invitrogen, ref. no. 10270-106). The sorafenib resistant 
HepG2/C3A, PLC/PRF/5, and HUH-7 cells were maintained in DMEM plus 10% FBS with 5 μM 
sorafenib. They were rendered resistant by three months exposure to 5 μM sorafenib, a clinically 
relevant dose. 
 
Chemical and antibodies 
Sorafenib was purchased from LC laboratories (ref. no. S8502). The mouse anti-vinculin and the goat 
anti-vimentin antibodies were purchased from Sigma (ref. no. v9131 and v4630, respectively). The 
goat anti-EGFR antibody was purchased from Santa Cruz (ref. no. sc-03-G). The rabbit anti-p53 and 
anti-E-cadherin antibodies were purchased from Cell Signaling (ref. no. 9282 and 3195, respectively).  
 
MTS (3-[4,5 dimethylthiazol-2-yl]-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay 
The MTS is a colorimetric assay that functions as an indicator of cell metabolic activity. The assay 
determines the presence of live cells with functional mitochondria and is commonly used to detect cell 
growth and proliferation. Briefly, cells were placed into 96-well plates. Subsequent to incubation 
overnight, the cultured cells were treated with varying concentrations of sorafenib for 72 hours. The 
combined MTS/PMS (phenazine methosulfate) solution (Promega ref. no. G5421) was added to each 
well and incubated for an additional 1 hour at 37ºC. The absorption was then measured at a 
wavelength of 490 nm by the Cytation 3 cell imaging multi-mode reader (BioTek Instruments). 
 
Cell death measurement 
Cell death was measured with propidium iodide (Sigma, ref. no. 81845). Cells were analyzed using a 
Beckman Coulter FC500 flow cytometer and data were analyzed with the Kaluza Version 1.2 software 
(Beckman Coulter). 
 
Exome sequencing  
All six cell lines were subjected to exome sequencing. Genomic DNA was extracted with Blood & Cell 
Culture DNA Midi Kit according to manufacturer’s instructions (Qiagen, ref. no. 13343). Nucleic acid 
quality was assessed using the Fragment Analyzer (Advances Analytical Technologies Inc., Ankeny, 
USA). Exome sequencing libraries were performed as follows: 3 µg of genomic DNA was fragmented 
into 150-200 base pair fragments using the Covaris Sample Preparation System (S-series). Samples 
were prepared using SureSelectXT library prep kit (Agilent, Santa Clara, USA). The resulting adaptor-
tagged libraries were then hybridized with exons biotin-coated baits from the SureSelect V5 kit 
(Agilent) for 24 hours at 65°C. Hybrids were captured with streptavidin-coated beads, PCR amplified 
and indexed. Cluster generation was performed with the libraries using the Illumina HiSeq PE Cluster 
Kit v4 cBot reagents (Catalog number PE-401-400) and sequenced on the Illumina HiSeq 2500 using 
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HiSeq SBS Kit V4 reagents (Catalog number FC-401-4002). Sequencing data were processed using 
the Illumina Pipeline Software version 1.84. 
 
Somatic mutation and copy number variation calling 
Exome sequences were processed according to the Genome Analysis Toolkit (GATK) best practices 
pipeline, which involves trimming, alignment using BWA-MEM, marking of duplicates, local 
realignment around indels, and base recalibration [282]. Somatic single nucleotide polymorphisms 
(SNP) calling for each cell line was then achieved by comparing every resistant cell lines to its 
matched sensitive counterpart using both MuTect [283] and VarScan 2 [284] with default settings. 
Only the variants that were shared between MuTect and Varscan2 filtered output were kept and 
annotated using ANNOVAR [285]. Somatic copy number variation between resistant cell lines and 
their sensitive counterparts was achieved using the VEGAWES R package [286] and these calls were 
then used to create Circos plots [287]. In order to determine whether important genes were contained 
in the amplified and lost chromosomal regions, we made the intersection between the gain/lost genes 
and a cancer curated driver gene database from Rubio-Perez et al. [288].  
 
Lentivirus production 
Recombinant lentiviruses were produced as described [205] with the following modification: pMD.G 
and pCMVDR8.91 were replaced by pMD2.G and psPAX2, respectively. 
 
Genome-scale CRISPR/Cas9 Knockout screening 
The human GeCKO v2 library (2 plasmid system) (Addgene ref. no. 1000000049) was amplified by 
electroporation using the electroporation system (Bio-Rad Gene Pulser II ref. no. 165-2105) and the 
Lucigen Endura cells (ref. no. 60242). Cells were plated on LB Agar plate containing 100 µg/mL 
ampicillin. After 14 hours at 32°C, colonies were scrapped and plasmids recovered with the Plasmid 
Maxi kit (Qiagen, ref. no. 12162). To produce lentivirus library, 12 T-225 flasks were seeded with 
12x106 of HEK293T cells/flask. The day after, each flask was treated as follows: 10 µg pMD2.G, 30 µg 
psPAX2 and 25 µg GeCKO plasmid library were mixed with 250 mM CaCl2. This solution was mixed 
(v/v) with 2x HEPES buffer (NaCl 280 mM, KCl 10 mM, Na2HPO4 1.5 mM, D-glucose 12 mM, HEPES 
50 mM), incubated for 1 minute and added to the culture medium. Seven hours later, the medium was 
removed and replaced by DMEM supplemented with 10 % FBS and 1 % penicillin-streptomycin. Forty-
eight hours later, the medium was collected and centrifuged for 5 min at 2000 g to pellet the cells. The 
supernatant was filtered through a 0.45 µm HV/PVDF (Millipore, ref. no. SE1M003M00) and 
concentrated 100x by ultracentrifugation (Beckman) at 24.000 rpm for 2 hours at 4°C. Virus pellet was 
resuspended in ice-cold PBS, aliquoted and stored at -80°C. 
To express the Cas9 endonuclease, HUH-7 SR cells were infected with lentiCas9-Blast (Addgene, ref. 
no. 52962) and selected with 35 µg/mL blasticidin for a week.  
The multiplicity of infection (MOI) of the GeCKO virus library was determined as follows: different 
volumes of virus library were added to 250,000 HUH-7 SR cells expressing Cas9 plated in a 6-well 
plate. Twenty-four hours later, each well was split into duplicate and one replicate received 10 µg/mL 
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puromycin for 3 days. Cell viability was determined by trypan blue exclusion and MOI was considered 
as the percentage of living cells. The virus volume yielding to MOI close to 0.3 was chosen. Large-
scale infection of 12x107 HUH-7 cells was carried out in 6-well plates with 250,000 cells per well. 
Twenty-four hours later, wells were pooled in a T-225 flask and infected cells selected with 10 µg/mL 
puromycin for a week. After puromycin selection, the cells were split into two. One part (6x107 cells) 
was left untreated. The second part (6x107 cells) was treated with 5 µM Sorafenib for 12 population 
doublings with a sorafenib renewal every 3 days. After 12 doubling times, control and sorafenib-
treated surviving cells were collected, and their genomic DNA was extracted with Blood & Cell Culture 
DNA Midi Kit according to manufacturer’s instructions (Qiagen, ref. no. 13343). A first PCR was 
performed to amplify the lentiCRISPR sgRNA region with the following primers: 
F1: 5’-AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG-3’ 
R1: 5’-CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTCTTTCC-3 
A second PCR was performed to attach Illumina adaptors and barcodes (green) to samples. 5 µL of 
the first PCR product was used. Primers for the second PCR include both a variable length sequence 
(red) to increase library complexity and an 8bp barcode for multiplexing of different biological samples. 
 
Table 1. Primer sequences for the second PCR 
F2a AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTTCTTGTGGAAAGGACGAAACACCG 
F2b AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTAGCTCTTGTGGAAAGGACGAAACACCG 
F2c AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCGAGCTCTTGTGGAAAGGACGAAACACCG 
F2d AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTCATAACCTCTTGTGGAAAGGACGAAACACCG 
F2e AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCTGTGCTAACGTCTTGTGGAAAGGACGAAACACCG 
R2_iC_26 CAAGCAGAAGACGGCATACGAGATGCTCATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT 
R2_iA_12 CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTACTATTCTTTCCCCTGCACTGT 
 
Both PCR were performed in 100 µL with the Herculase II Fusion DNA Polymerase (Agilent, ref. no. 
600675). Amplicons were gel extracted, quantified, mixed and sequenced with a MiSeq (Illumina). 
Raw FASTQ files were demultiplexed and processed to contain only the unique sgRNA sequence. 
The number of reads of each sgRNA was normalized as described [206]. The MAGeCK algorithm 
[207] was used to rank screening hits by the consistent enrichment among multiple sgRNAs targeting 
the same gene. 
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RESULTS 
Establishment of sorafenib resistant PLC/PRF/5, HepG2/C3A, and HUH-7 cell lines 
 
To investigate mechanisms of acquired sorafenib resistance, we established three sorafenib resistant 
(SR) HCC cell lines derived from wild-type PLC/PRF/5, HepG2/C3A, and HUH-7 cells by three months 
exposure to 5 μM sorafenib, a clinically relevant dose. As sorafenib can induce both decreased 
proliferation and tumour cell death, acquired resistance can target one of these two properties 
separately or at the same time. However, firstly only the acquisition of an anti-proliferative resistance 
was confirmed in the three populations using cell growth as a readout. Figure 1 shows that even 
though sorafenib affects greatly the growth of the wild-type cells in a dose-dependent manner, the 
matched resistant ones are almost not sensitive to the drug. These data indicate that after three 
months of treatment with sorafenib, PLC/PRF/5, HepG2/C3A, and HUH-7 became resistant to the 
drug. Of note, results depicted in Figure 1 are technical triplicates from a single experiment.  
 
 
Figure 1. Validation of sorafenib resistant cell lines. Specified HCC cell lines were treated with 
sorafenib at indicated concentrations for 72 hours. Cell growth was assessed by MTS assay. Results correspond 
to the mean of technical triplicates compared to the respective control. 
 
 
 
 
Genetic changes in sorafenib resistant cell lines compared to the matched sensitive ones 
 
To assess the genetic alterations responsible for acquired resistance to sorafenib, we extracted DNA 
from three HCC wild-type cell lines (PLC/PRF/5, HepG2/C3A, and HUH-7) and their matched 
sorafenib resistant derivatives. We then conducted exome sequencing using the Illumina technology 
to compare mutation profiling of baseline and matched resistant cell lines. We achieved a median 
coverage above 50x. Supplementary figure S1 depicts the distribution of the depth of sequencing 
coverage. Characteristics of non-synonymous mutations present in sorafenib resistant cell lines are 
shown in the Supplementary Table S1. 
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Exome sequencing data revealed genetic alterations such as ATP7A and p53 Y220C structural 
mutations as putative causes of sorafenib resistance in HepG2/C3A SR cells 
 
Exome sequencing analyses on HepG2/C3A SR and wild-type cells identified four somatic mutations. 
Among them, there was the p53 Y220C structural mutation (Figure 2). Y220C missense mutation 
causes conformational instability of p53 protein [289]. This genetic alteration has been reported to 
induce chemoresistance in many tumour types such as neuroblastoma or ovarian cancer [290, 291]. 
Although it has not been described to be involved in acquired resistance specifically, loss-of-function 
mutations in p53 were reported to confer intrinsic sorafenib resistance [292].  
To study the involvement of p53 mutation in the resistant phenotype of HepG2/C3A SR cells, we 
planned to rescue mutated p53. In order to assess the effect of the rescue experiment in both anti-
proliferative and cell death resistance to sorafenib, we measured cell death and cell growth in the 
presence of the drug. Unexpectedly, Supplementary Figure S2A illustrates that HepG2/C3A SR and 
PLC/PRF/5 SR cell lines lost their resistant phenotype, although all three SR cell lines were always 
kept in culture in the presence of sorafenib. Of note, results showed in Figure 1 and those represented 
in Supplementary Figure S2 were obtained in two different laboratories by two different experimenters 
at three months interval. To reach the same growth inhibitory effect in the three HCC wild-type cells as 
in Figure 1, the dose of sorafenib was 4-fold higher in Supplementary Figure S2A.  We used, 
nevertheless, the same batch of sorafenib in both experiments. However, at concentrations where the 
wild-type cells have reduced cell growth, the HepG2/C3A SR and PLC/PRF/5 SR cells did not display 
any resistance to sorafenib. We observed the same effect regarding the cell death induced by the 
multikinase inhibitor, except in HepG2/C3A at 20 μM sorafenib (Supplementary Figure 2B). Two main 
hypotheses that are not mutually exclusives could explain these results. Either a genetic drift occurred 
in the two SR cell lines, or wild-type cells were not sensitive to sorafenib anymore, despite the fact that 
they have never been in contact with this drug previously. One could hypothesize that the serum used 
in the experiment depicted in Supplementary Figure S2 was less prone to promote the cellular entry of 
sorafenib than the one employed in the experiment illustrated in Figure 1. Interestingly, HUH-7 SR 
cells were still resistant to the drug compared to their sensitive counterpart (Supplementary Figures 
S2A and S2B). 
Although we were unable to validate the involvement of p53 Y220C mutation by a rescue experiment, 
exome sequencing results in HepG2/C3A SR cells are not called into question by a potential genetic 
drift. Indeed, we extracted the DNA that was used to conduct exome sequencing directly after having 
received cells from Olivier Dormond laboratory. Henceforth, the contribution of the destabilised p53 in 
sorafenib resistance remains to be validated.  
 
Importantly, Supplementary Table S1 reports that the frequency of the p53 Y220C mutation in the SR 
population is 21.57%. This means that only about one-fifth of HepG2/C3A SR cells bear the mutation. 
Accordingly, other genetic alterations should be involved in the acquired resistance to sorafenib. 
Among mutations revealed by exome sequencing data, the ATP7A copper-transporting P-type 
adenosine triphosphatase has been described to confer multidrug resistance [293-296]. Although it 
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was not reported to be directly implicated in sorafenib resistance, it could be a good candidate to 
investigate in more detail. These preliminary results suggest that sorafenib resistance is a complex, 
heterogeneous, and multifactorial phenomenon.      
 
 
  
Figure 2. Circos plot depicting copy number variations and somatic mutations in HepG2/C3A 
SR cell line. Outer ideogram runs clockwise from chromosome 1 (chr1) to chromosome Y (chry) with labels in 
Mb of physical distance. The data are represented in several tracks. The innermost track represents somatic 
mutations with their respective variant allele frequency (VAF) detected in the exome sequencing data. The next 
central track shows exon segmentation (in log2 of the resistant/sensitive depth ratio). The outer track depicts 
somatic copy number variation (CNV) calls. Green bands represent amplifications and red bands represent 
loss/deletions.  
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PLC/PRF/5 acquired sorafenib resistance is probably due to several concomitant mutations 
including EGFR amplification 
 
Exome sequencing results obtained from PLC/PRF/5 SR and wild-type cell lines identified several 
somatic mutations as well as the amplification and deletion of several regions of the exome (Figure 4).  
 
 
 
 
Figure 4. Circos plot depicting copy number variations and somatic mutations in PLC/PRF/5 
SR cell line. Outer ideogram runs clockwise from chromosome 1 (chr1) to chromosome Y (chry) with labels in 
Mb of physical distance. The data are represented in several tracks. The innermost track represents somatic 
mutations with their respective variant allele frequency (VAF) detected in the exome sequencing data. The next 
central track shows exon segmentation (in log2 of the resistant/sensitive depth ratio). The outer track depicts 
somatic copy number variation (CNV) calls. Green bands represent amplifications and red bands represent 
loss/deletions. Potential driver genes contained within amplified or deleted regions are highlighted in green or red, 
respectively. 
RESULTS - PART IV 
  147 
 
Among these genetic alterations, the amplification of the epidermal growth factor receptor (EGFR) 
gene has been already shown to be involved in primary and acquired resistance of HCC to sorafenib 
[58, 297, 298]. Unfortunately, likewise in HepG2/C3A cells, we were unable to validate the 
involvement of EGFR amplification in sorafenib resistance because of the occurrence of a potential 
genetic drift in PLC/PRF/5 SR cells (Supplementary Figure S2). 
In addition, PREX1, DAPK3, NR4A1, LRPPRC, and NSD1, whose genomic alterations in PLC/PRF/5 
SR cells were highlighted by exome sequencing, have been previously reported to play a role in 
resistance to several chemotherapeutic agents [299-304]. As the frequency of each specific mutation 
was not higher than 42% of PLC/PRF/5 SR cells, this means that the resistant phenotype of the 
population was secondary to several concomitant mutations. Consequently, further experiments are 
required to investigate the involvement of each genetic alteration in sorafenib resistance specifically. 
 
 
The epithelial to mesenchymal transition is not involved in HUH-7 acquired sorafenib 
resistance 
 
The circos plot of exome sequencing data conducted on HUH-7 wild-type and SR cells depicts 
numerous mutations induced by sorafenib treatment (Figure 6). Among them, we identified mutations 
in genes involved in the epithelial-mesenchymal transition (EMT) such as E-cadherin (CDH1), 
collagen (COL15A1), and laminin (LAMA4) (Figure 6). EMT referrers to the conversion of cells with an 
epithelial phenotype into cells with a mesenchymal phenotype [305]. It is the consequence of the loss 
of E-cadherin adhesion receptors that mediate cell-to-cell interaction [306]. The extracellular matrix 
(ECM), which is a network composed of proteoglycans, polysaccharides, and fibers mainly constituted 
by fibronectin, vitronectin, collagen, and laminin, plays a crucial role in EMT [307]. Indeed, ECM 
proteins promote EMT and are used as biomarkers of this process [308]. Finally, several reports 
highlight the major contribution of EMT to cancer drug resistance including sorafenib [59, 309-311]. 
In order to investigate whether EMT contributes to sorafenib resistance in HUH-7 cells, we evaluated 
the expression of EMT markers between HUH-7 SR cells and their matched sensitive counterpart. 
EMT is characterized by decrease in the expression of the epithelial marker E-cadherin and an 
increased expression of the mesenchymal marker vimentin. Western blot analyses indicated no 
change in the abundance of E-cadherin and vimentin proteins between both HUH-7 wilde-type and SR 
cell lines (Figures 7A and 7B). The absence of E-cadherin downregulation observed by western blot in 
HUH-7 SR cells, whereas exome sequencing results depicted a deletion of CDH1 in those cells, could 
be explained by the occurrence of some mechanisms of compensation (e.g. increased RNA stability, 
increased expression of other remaining gene copies).    
Moreover, we tested the contribution of EMT in the two other SR cell lines and the matched wild-type 
cells. Figures 7A and 7B show that the SR cell lines do not display any EMT phenotype.  
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Figure 6. Circos plot depicting copy number variations and somatic mutations in HUH-7 SR cell 
line. Outer ideogram runs clockwise from chromosome 1 (chr1) to chromosome Y (chry) with labels in Mb of 
physical distance. The data are represented in several tracks. The innermost track represents somatic mutations 
with their respective variant allele frequency (VAF) detected in the exome sequencing data. The next central track 
shows exon segmentation (in log2 of the resistant/sensitive depth ratio). The outer track depicts somatic copy 
number variation (CNV) calls. Green bands represent amplifications and red bands represent loss/deletions. 
Potential driver genes contained within amplified or deleted regions are highlighted in green or red, respectively. 
 
 
 
As for the two previous HCC cell lines, other genetic alterations that are illustrated in the HUH-7 circos 
plot have been shown to be involved in mechanisms of cancer resistance, such as NTN4, COL15A1, 
ROS1, and CACNA1E [312-315].  
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Figure 7. SR cell lines do not display an epithelial to mesenchymal transition phenotype. A. 
Western blot analyses of E-cadherin abundance in indicated cell lines. β-actin was used as protein loading 
control. B. Western blot analyses of vimentin abundance in indicated cell lines. Vinculin was used as protein 
loading control. 
 
 
 
CRISPR/Cas9 screen identifies KEAP1 as a putative gene involved in sorafenib anti-
proliferative activity 
 
As a complementary approach to exome sequencing, we performed a loss-of-function CRISPR/Cas9 
screen on HUH-7 SR cell line. By using a negative selection screen, we sought to identify genes 
whose inactivation is detrimental to the resistant cells. Such genes can be recognized by a decrease 
in the abundance of corresponding sgRNAs during the course of the sorafenib treatment. 
Consequently, genes for which the targeted sgRNAs would be depleted compared to the control are 
those required for the cell to be resistant to sorafenib.  
HUH-7 SR cells were infected with the GeCKO v2 human CRISPR/Cas9 lentiviral library [203]. Half of 
the infected cells were treated with 5 µM sorafenib for 12 population doublings. According to the 
literature, this number of doubling times should ensure sufficient depletion of genes required for 
resistance [316]. The other half of the cells was left untreated for 12 population doublings to serve as a 
control. Then, the sgRNAs present in both the resistant and the control populations were sequenced 
by high-throughput sequencing to determine their relative abundance. As a supplementary control, the 
sgRNAs of 3x106 HUH-7 SR infected cells were sequenced before starting the experiment. This 
ensures that the difference seen between both treated and non-treated HUH-7 SR after 12 doubling 
times is due to the effect of sorafenib, and not to a depletion of sgRNAs in the control population 
secondary to several splitting steps and long-term culture conditions.  
Results of massively parallel sequencing did not reveal any significantly depleted genes in HUH-7 SR 
treated with sorafenib compared to the non-treated population. Nevertheless, one candidate gene 
named KEAP1 was significantly enriched in the sorafenib treated population after 12 doubling times. 
The plot of Figure 8A depicts the only significant candidate gene obtained using the Model-based 
Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm. The frequency of each 
sgRNA in both untreated and treated populations is displayed in Figure 8B. The six sgRNAs for 
KEAP1 are labeled in blue.         
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Figure 8. GeCKO screen in HUH-7 SR cells reveals KEAP1 whose loss confers sorafenib 
resistance. A. Identification of KEAP1 gene implicated in sorafenib resistance using the MAGeCK p-value in 
HUH-7 SR cells. B. Scatterplot showing enrichment of six sgRNAs targeting KEAP1 gene after sorafenib 
treatment in HUH-7 SR cells. Blue dots indicate the six sgRNAs targeting KEAP1 gene. The blue dashed line 
represents the equal frequency in both untreated and treated populations. 
 
 
As the dose of sorafenib used for the screen (5 μM) was shown to not induce cell death in HUH-7 SR 
population (Supplementary Figure S2), the enrichment of sgRNAs targeting KEAP1 gene is due to the 
selective advantage of KEAP1 knockout cells to proliferate in sorafenib-rich conditions. Accordingly, in 
HUH-7 SR cells, KEAP1 is not responsible for acquired resistance to the killing activity of sorafenib but 
is involved in the anti-proliferative resistance to the tyrosine kinase inhibitor. Supplementary Figure S3 
shows that there is no enrichment of sgRNAs targeting KEAP1 in untreated HUH-7 SR cells after 12 
population doublings compared to the population that did not undergo any doublings. This means that 
the deletion of KEAP1 confers a proliferative advantage only in the presence of sorafenib.  
To validate the involvement of KEAP1 in the anti-proliferative activity of sorafenib, HUH-7 as well as 
PLC/PRF/5 and HepG2/C3A KEAP1 knockout clones are currently being generated. 
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DISCUSSION 
Intrinsic and acquired resistances to sorafenib are mainly responsible for the poor outcome of patients 
suffering from advanced-stage HCC. As the exact mechanisms of sorafenib resistance remain to be 
better understood, we conducted an analysis of genetic alterations occurring in cell lines that were 
previously rendered resistant to the multi-targeted tyrosine kinase inhibitor. 
 
Results of exome sequencing in PLC/PRF/5 cell lines highlighted EGFR amplification as a potential 
genomic alteration responsible for sorafenib resistance. This mutation was already described to be 
involved in primary and acquired resistance of HCC to sorafenib [58, 297, 298]. Although these results 
lack innovation, they nevertheless validate the efficiency of exome sequencing approach to bring out 
genomic modification due to acquired sorafenib resistance. Unfortunately, we were unable to validate 
the involvement of EGFR amplification in sorafenib resistance, probably due to an occurrence of a 
genetic drift in two (PLC/PRF/5 and HepG2/C3A) out of the three cell types studied.  
 
In HepG2/C3A SR cells, we identified Y220C mutation of p53 as a putative mechanism of sorafenib 
resistance. P53 is the most frequently altered gene in human cancers and up to 58% of HCCs may 
harbour mutations in this tumour suppressor gene [317]. Its role in treatment resistance was described 
in many cancer types [290, 291, 318]. Loss-of-function p53 mutations are responsible for intrinsic 
sorafenib resistance. Indeed, the inactivation of p53 gene decreases the susceptibility of cells to 
apoptosis in a hypoxic environment. Therefore, in the absence of p53, tumours may be less 
dependent on their vascular supply rendering them less responsive to antiangiogenic therapies [292]. 
Nevertheless, to our knowledge, this mutation was not yet described to be implicated in acquired 
sorafenib resistance. Again, because of the existence of a potential genetic drift, we could not perform 
the rescue experiment that would allow us to validate the role of p53 mutation in HepG2/C3A 
resistance to sorafenib. As an alternative approach, we could overexpress the Y220C p53 mutant in 
wild-type cells and assess whether it is sufficient to induce resistance. 
 
Finally, exome sequencing data revealed several mutations present in HUH-7 SR cells but not in their 
wild-type sensitive counterpart. Except for mutations in E-cadherin, laminin, and collagen genes, none 
of them have been described in the literature to be involved in sorafenib resistance. E-cadherin, 
laminin, and collagen are known to mediate EMT process [305]. However, results suggest that the 
mechanism of sorafenib resistance in HUH-7 SR cells is independent of EMT. Consequently, to 
decipher which one(s) of all the mutations highlighted by exome sequencing is (are) more prone to 
mediate sorafenib resistance, we are going to use two Web open platforms cBioPortal 
(www.cbioportal.org) and COSMIC (cancer.sanger.ac.uk) that provide large-scale cancer genomics 
data sets, including annotations of mutations defined in the literature as resistance mutations [319, 
320]. Of note, the same approach will be used for the mutations revealed in HepG2/C3A SR and 
PLC/PRF/5 SR cell lines. 
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As a complementary approach to exome sequencing, we performed genome-wide CRISPR/Cas9 
screen on HUH-7 SR cell line. The aim was to identify genes required for the acquired resistance to 
sorafenib. However, the negative selection screen did not reveal any significantly depleted genes. 
Several reasons could explain this result. First, the dose of sorafenib used (5 µM) was shown (later) to 
be too low to induce cell death even in the wild-type sensitive HUH-7 cells (Supplementary Figure S2). 
Consequently, cells carrying the sgRNAs targeting genes involved in sorafenib resistance will not be 
killed by sorafenib at this concentration. Then, negative selection screen has to be carried out a large 
scale to guarantee that entire library is represented multiple times over, ensuring sufficient sensitivity 
for depleted sgRNAs to be deducted from the final cell population. Presumably, using 6x107 cells per 
condition was not satisfactory to reach enough sensitivity. Finally, negative selection screen requires 
efficient sgRNAs. Indeed, depletion of a sgRNA can only be recognized if the targeted gene is cleaved 
and inactivated in a large proportion of the cells carrying the sgRNA. This third possibility seems less 
likely to be the cause of the screen failure since several papers report the use of the same 
CRISPR/Cas9 library to perform their successful negative selection screens [203, 209]. Nevertheless, 
the screening performed in HUH-7 SR cells revealed a significant enrichment of KEAP1 sgRNAs in 
the treated population. This suggests that KEAP1 knockout cells bear a selective advantage to 
proliferate under sorafenib treatment. Accordingly, KEAP1 seems to be involved in the anti-
proliferative activity of sorafenib rather than in its capacity to induce cancer cell death.  
The KEAP1-NRF2 regulatory pathway plays a central role in cell defense against oxidative damage. 
Upon exposure to oxidative stress, the nuclear factor erythroid 2-related factor 2 (NRF2) transcription 
factor activates the expression of many cytoprotective proteins, including drug-efflux pumps, 
antioxidant proteins, and drug-metabolizing enzymes [321-324]. The intracellular level of NRF2 is 
regulated by the Cul3-KEAP1 ubiquitin E3 ligase complex, which degrades NRF2 in proteasomes 
preventing it from moving to the nucleus [325, 326]. KEAP1 somatic mutations were detected in many 
tumour types including HCCs [327-329]. Cancer cells bearing loss-of-function KEAP1 mutations 
display NRF2 overexpression and subsequent transcriptional upregulation of cytoprotective proteins 
[329, 330].  The constitutive activation of NRF2, that stimulates detoxification and antioxidant 
enzymes, increases resistance against anti-cancer treatment including sorafenib [112, 280, 281]. 
Moreover, Zhang et al. report that NRF2 promotes proliferation in HCC [331]. Consequently, our 
results are in line with the literature and suggest that loss-of-function mutation of KEAP1 upregulates 
NRF2 that promotes cell proliferation in HCC. To validate this hypothesis HUH-7 as well as 
PLC/PRF/5 and HepG2/C3A KEAP1 knockout clones are currently being generated. In addition, we 
will assess if the proliferative effect of KEAP1 mutation depends on NRF2 activity.  
 
To conclude, using exome sequencing analysis we identified EGFR amplification and Y220C 
destabilized mutation of p53 as already known causes of sorafenib resistance. In addition, we showed 
that, in the presence of sorafenib, KEAP1 knockout HUH-7 SR cells display selective proliferation 
advantage. Finally, we are still working on the analysis of the different genomic mutations revealed in 
the three SR HCC cell lines. Hopefully, we will unveil a novel mechanism of sorafenib resistance. 
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Interestingly, none of the genetic alterations was common to the three SR cell lines. These data shed 
light on the complexity and the multifactorial process of acquired sorafenib resistance. 
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SUPPLEMENTARY TABLE AND FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S1. Characteristics of nonsynonymous mutations present in sorafenib 
resistant cell lines. Var_Freq represents the frequency of the specific mutation in corresponding SR cell line 
(TumVar/(TumRef+TumVar)). Norm denotes wild-type cells and Tum denotes SR cells. Var represents the fold 
number that the mutation was detected either in wild-type (NormVar) or in SR (TumVar) cells. Ref represents the 
fold number that the non-mutated version of the gene was detected either in wild-type (NormRef) or in SR 
(TumRef) cells. 
chromosome gene exon nt_normal nt_variant aa comments
5 ADAMTS12 23 C A p.K1532N Var_Freq=25.53% ; NormRef=57;NormVar=0;TumRef=35;TumVar=12 ; pval=3.02276334925652e-05
17 TP53 6 T C p.Y220C Var_Freq=21.57% ; NormRef=43;NormVar=0;TumRef=40;TumVar=11 ; pval=0.000689808997416789
17 KRTAP4-5 1 A T p.C79S Var_Freq=52.94% ; NormRef=12;NormVar=0;TumRef=8;TumVar=9 ; pval=0.00242735774969656
X ATP7A 10 C T p.H741Y Var_Freq=44.93% ; NormRef=63;NormVar=0;TumRef=38;TumVar=31 ; pval=2.75786606748935e-11
1 OR2T4 1 C T p.H208Y Var_Freq=21.32% ; NormRef=205;NormVar=0;TumRef=107;TumVar=29 ; pval=3.60522885059006e-13
2 LRPPRC 36 C T p.E1313K Var_Freq=25% ; NormRef=43;NormVar=0;TumRef=33;TumVar=11 ; pval=0.000273853549899687
2 SCG2 2 A G p.M147T Var_Freq=25.84% ; NormRef=119;NormVar=0;TumRef=66;TumVar=23 ; pval=5.18518296722473e-10
3 COL8A1 5 C A p.L236I Var_Freq=31.58% ; NormRef=92;NormVar=0;TumRef=52;TumVar=24 ; pval=5.13625445082996e-10
3 COL6A5 24 C T p.P1611L Var_Freq=28% ; NormRef=26;NormVar=0;TumRef=18;TumVar=7 ; pval=0.00415201541609537
3 ASTE1 3 T G p.I372L Var_Freq=31.48% ; NormRef=45;NormVar=0;TumRef=37;TumVar=17 ; pval=8.54287570245387e-06
4 FAT4 17 G T p.R4814M Var_Freq=41.38% ; NormRef=33;NormVar=0;TumRef=17;TumVar=12 ; pval=2.40241927500685e-05
5 MAST4 5 T C p.L134S Var_Freq=28.77% ; NormRef=86;NormVar=0;TumRef=52;TumVar=21 ; pval=1.3010717388905e-08
5 PCDHGC5 1 C A p.P569Q Var_Freq=21.21% ; NormRef=68;NormVar=0;TumRef=52;TumVar=14 ; pval=2.26529529099562e-05
6 BRPF3 5 C G p.P610A Var_Freq=25.32% ; NormRef=67;NormVar=0;TumRef=59;TumVar=20 ; pval=1.30233798023623e-06
9 TMEM245 8 T C p.S462G Var_Freq=20% ; NormRef=27;NormVar=0;TumRef=16;TumVar=4 ; pval=0.0271634008914299
12 NR4A1 3 C G p.L39V Var_Freq=21.43% ; NormRef=111;NormVar=1;TumRef=99;TumVar=27 ; pval=1.22698734976333e-07
16 EXOC3L1 5 C T p.A282T Var_Freq=21.21% ; NormRef=45;NormVar=0;TumRef=26;TumVar=7 ; pval=0.00161703492633542
18 TXNDC2 2 C A p.A394E Var_Freq=22.02% ; NormRef=121;NormVar=1;TumRef=85;TumVar=24 ; pval=5.02051569717353e-08
19 DAPK3 3 T C p.D81G Var_Freq=31.58% ; NormRef=84;NormVar=0;TumRef=52;TumVar=24 ; pval=1.81421261591585e-09
20 PREX1 30 T G p.Y1299S Var_Freq=21.43% ; NormRef=22;NormVar=0;TumRef=22;TumVar=6 ; pval=0.0237082066869291
1 LEPROT 2 A G p.D3G Var_Freq=38.14% ; NormRef=133;NormVar=0;TumRef=120;TumVar=74 ; pval=1.29621420350843e-20
1 TCHH 3 T C p.D70G Var_Freq=30.99% ; NormRef=67;NormVar=0;TumRef=49;TumVar=22 ; pval=6.8578681997738e-08
1 FLG 3 T C p.K123R Var_Freq=26.97% ; NormRef=104;NormVar=0;TumRef=65;TumVar=24 ; pval=1.24713756600968e-09
1 CACNA1E 47 G T p.R2111I Var_Freq=24.36% ; NormRef=60;NormVar=0;TumRef=59;TumVar=19 ; pval=6.58009999749085e-06
1 CACNA1E 47 A C p.R2111S Var_Freq=24.36% ; NormRef=58;NormVar=0;TumRef=59;TumVar=19 ; pval=8.85937690874239e-06
2 PSD4 2 A T p.E124V Var_Freq=21.61% ; NormRef=135;NormVar=0;TumRef=156;TumVar=43 ; pval=2.68391108649089e-11
2 ACKR3 2 C T p.T341I Var_Freq=21.05% ; NormRef=50;NormVar=0;TumRef=45;TumVar=12 ; pval=0.000285335917714085
5 PCDHGA1 1 C T p.L505F Var_Freq=27.94% ; NormRef=116;NormVar=1;TumRef=98;TumVar=38 ; pval=7.54555642503331e-11
6 HMGCLL1 6 G T p.A209E Var_Freq=51.43% ; NormRef=26;NormVar=0;TumRef=17;TumVar=18 ; pval=3.45784975955139e-06
6 LAMA4 9 G A p.A326V Var_Freq=21.59% ; NormRef=78;NormVar=0;TumRef=69;TumVar=19 ; pval=2.07936069440011e-06
6 ROS1 29 G A p.P1607L Var_Freq=20.48% ; NormRef=177;NormVar=0;TumRef=167;TumVar=43 ; pval=4.25113072871995e-13
7 TMEM168 2 A C p.L20R Var_Freq=22.92% ; NormRef=62;NormVar=0;TumRef=74;TumVar=22 ; pval=5.91900293031971e-06
9 FREM1 17 C G p.G937R Var_Freq=37.74% ; NormRef=61;NormVar=0;TumRef=33;TumVar=20 ; pval=2.10461395401582e-08
9 COL15A1 16 G T p.E680X Var_Freq=22.54% ; NormRef=59;NormVar=0;TumRef=55;TumVar=16 ; pval=2.63470174010994e-05
11 LRRC4C 7 G T p.P389T Var_Freq=36.89% ; NormRef=132;NormVar=0;TumRef=77;TumVar=45 ; pval=2.60838342230116e-17
12 PTPRQ 2 A G p.I32M Var_Freq=41.38% ; NormRef=39;NormVar=0;TumRef=17;TumVar=12 ; pval=7.12657956578534e-06
14 MIPOL1 6 A G p.K41E Var_Freq=34.19% ; NormRef=122;NormVar=1;TumRef=102;TumVar=53 ; pval=8.75765871130879e-15
14 PTPN21 17 C G p.R1055T Var_Freq=33.33% ; NormRef=66;NormVar=0;TumRef=58;TumVar=29 ; pval=6.73146329822748e-09
14 TTC8 13 T G p.F383L Var_Freq=29.41% ; NormRef=52;NormVar=0;TumRef=60;TumVar=25 ; pval=1.3335172208777e-06
15 ISLR2 4 C T p.R458C Var_Freq=33.33% ; NormRef=75;NormVar=0;TumRef=62;TumVar=31 ; pval=7.29446226296915e-10
16 ZP2 19 T C p.E676G Var_Freq=36.76% ; NormRef=66;NormVar=0;TumRef=43;TumVar=25 ; pval=2.97400278886949e-09
16 HYDIN 74 G T p.Y4187X Var_Freq=38.78% ; NormRef=53;NormVar=0;TumRef=30;TumVar=19 ; pval=9.4107509254498e-08
17 MYH8 33 C A p.Q1510H Var_Freq=33.09% ; NormRef=105;NormVar=1;TumRef=93;TumVar=46 ; pval=2.42556161290772e-12
17 NBR1 21 A G p.T951A Var_Freq=29.17% ; NormRef=63;NormVar=0;TumRef=51;TumVar=21 ; pval=3.73219376124505e-07
19 ZNF432 5 C T p.G111R Var_Freq=24.72% ; NormRef=45;NormVar=0;TumRef=67;TumVar=22 ; pval=4.48443891196936e-05
20 VSX1 1 G A p.P46S Var_Freq=21.62% ; NormRef=27;NormVar=0;TumRef=29;TumVar=8 ; pval=0.00872267906642771
22 ZNF74 6 G A p.V249M Var_Freq=34.19% ; NormRef=94;NormVar=1;TumRef=77;TumVar=40 ; pval=2.84743621850786e-11
X DCAF8L2 1 A G p.I346V Var_Freq=27.4% ; NormRef=60;NormVar=0;TumRef=53;TumVar=20 ; pval=1.56870595424578e-06
HepG2/C3A
PLC/PRF/5
HUH-7
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Supplementary Figure S1. Distribution of the depth of sequencing coverage. The lines depict the 
cumulative fraction of the target bases covered at or above the specified coverage. This shows that around 70% 
of target bases were covered with at least 50x sequencing reads.   
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Supplementary Figure S2. HepG2/C3A and PLC/PRF/5 are subjected to a genetic drift inducing 
the loss of sorafenib resistant phenotype. A. Specified HCC cell lines were treated with sorafenib at 
indicated concentrations for 72 hours. Cell growth was assessed by MTS assay and compared to the control 
(CTRL). B. Specified HCC cell lines were treated with sorafenib at indicated concentrations for 48 hours. Cell 
death was assessed by flow cytometry after PI staining. Results correspond to the mean +/- 95% CI of three 
independent experiments. 
 
 
 
 
 
 
 
Supplementary Figure S3. GeCKO screen in HUH-7 SR PDT 0 vs PDT 12 reveals no enrichment 
of KEAP1. A. Identification of KEAP1 gene using the MAGeCK p-value in HUH-7 SR cells. B. Scatterplot 
showing the six sgRNAs targeting KEAP1 gene in HUH-7 SR cells at population doubling time (PDT) 0 versus 
PDT 12. Blue dots indicate the six sgRNAs targeting KEAP1 gene. The blue dashed line represents the equal 
frequency in both PDT 0 and PDT 12. 
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DISCUSSION 
 
Cancer is one of the most dreadful diagnoses a patient can receive. Although many types of tumour 
are now considered curable thanks to advances in research, screening methods, and treatment 
modalities, cancer remains one of the deadliest diseases in the world. Fighting cancer starts with 
prevention strategies through the avoidance of risk factors (e.g. tobacco use, alcohol abuse, lack of 
physical activity, infection by HPV/HBV). However, whereas efficient, prevention is often not sufficient. 
Once diagnosed, several therapeutic strategies exist to treat malignant disease. Though, yet too many 
tumours are refractory to known treatments. To improve cancer outcome several approaches can be 
undertaken, including the improvement of the current anti-cancer therapies, the development of novel 
more efficient drugs, or the reduction of treatment associated long-term side effects.  
 
Our laboratory developed more than ten years ago a peptide with anti-cancer potentials termed TAT-
RasGAP317-326. This ten amino acid peptide, derived from the RasGAP protein and coupled to the TAT 
cell-penetrating peptide, sensitizes adult cancer cells to various chemotherapies and radiotherapy 
[122]. In addition, it possesses the ability to prevent metastasis formation by hampering cell migration 
and invasion [124]. The present thesis reports the identification of two new features of TAT-
RasGAP317-326: its capacity to sensitize pediatric tumours to several chemotherapeutic agents and its 
ability to directly kill some cancer cells.  
The biology and genetic of childhood cancers differ from adulthood tumours. Thus, most anti-cancer 
treatments developed to target specific pathways in adult malignancies may have only little or no 
benefit in pediatric patients. Moreover, childhood tumours are rare diseases with a subsequent slow 
rate of drug development [332]. One approach to overcome this hurdle is to study an anti-cancer drug 
for pediatric patients at the preclinical stage. We used this strategy in the first part of this thesis by 
studying the in vitro efficacy of TAT-RasGAP317-326 to sensitize childhood tumours from various origins 
to chemotherapies. We show that the peptide sensitizes childhood cancer cells to genotoxins. 
However, it was not possible to predict the efficacy of this sensitization based on the tumour type and 
the drug used. 
Moreover, we discovered a new feature of the RasGAP-derived peptide which is its ability to directly 
kill some adult and pediatric cancer cells. This novel property gave us the opportunity to investigate 
the mechanism of action of the peptide, which remained to be precisely determined, through the 
characterization of the mode of cell death triggered by it. Using pharmacological and genetic 
approaches, we found that cell death was not fully prevented when regulated forms of death including 
apoptosis, necroptosis, autophagy, parthanatos, and pyroptosis were inhibited. As a second approach 
to decipher the mode of action of the peptide, we performed a genome-scale knockout screen using 
CRISPR/Cas9 technology. The validated candidates highlighted by the screen were shown to be 
dispensable for the pro-death activity of the peptide. Indeed, results reported in the third part of this 
manuscript suggest that they are involved in the cytosolic access of the anti-cancer peptide. 
Consequently, how TAT-RasGAP317-326 kills cancer cells remains unanswered. Our original hypothesis 
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that it induces regulated cell death rather than accidental death seems to be invalidated by our recent 
results. Some evidence suggest that the peptide triggers a form of necrosis. Thus, a new assumption 
is that TAT-RasGAP317-326 once penetrated inside the cell could interact with some lipids of the inner 
leaflet of the plasma membrane, leading to membrane destabilization and cell lysis. NaD1, another 
cationic peptide is known to induce cell death by this mechanism [333]. This could explain the death 
kinetic of the peptide, which does not kill within minutes but requires few hours (between four and six) 
to induce cell death. Indeed, the peptide has to enter the cell and to accumulate sufficiently into the 
cytoplasm to display its cytotoxic activity. Another indication supporting the necrotic hypothesis is that 
the peptide is able to bind to several phosphatidylinositols (e.g. PIP2, PIP3, phosphatidylserine, and 
cardiolipin). These recent results were obtained by one of my colleague using membrane lipid strips. 
The peptide target being a lipid rather than a protein could explain the results obtained with the 
CRISPR/Cas9 screen, a technology not adapted to screen lipids. However, the absence of any 
proteins required for the pro-death activity in CRISPR/Cas9 screens could alternatively be explained 
by the fact that the target of TAT-RasGAP317-326 is part of the pool of essential genes. Therefore, it will 
not be detectable through this unbiased approach. Of note, the results showing that the NB1 
neuroblastoma cells treated with the peptide partially die through apoptosis are not necessarily in 
contradiction with the necrotic hypothesis. Indeed, it is possible that, in those particular cells, damages 
of the plasma membrane induced by the peptide trigger subsequently low level of apoptosis. 
Moreover, it has been described that changes in plasma membrane lipid composition occur in cancer 
cells [334-336]. This could explain why they are killed by the peptide, whereas healthy cells are not. 
Finally, another assumption to explain the peptide selectivity for cancer cells could be related to its 
uptake mechanism. Indeed, we have demonstrated that ion channels and pumps are involved in the 
cytoplasmic access of the peptide. They are also known to be implicated in the driving malignant 
cancer cell behaviour [337]. Accordingly, changes in their expression in tumour cells compared to 
normal cells have been described [338-341]. Thenceforward, their dysregulation in cancer cells could 
increase TAT-RasGAP317-326 uptake allowing it to be in sufficient quantity to exert its toxicity. To 
investigate which one of the two speculations is correct, we could assess if the fluorescent version of 
the peptide is able to reach the cytoplasm of healthy cells as efficiently as it does in cancer cells.  
One question that remains unanswered is to know whether the mechanisms used by TAT-RasGAP317-
326 to sensitize to chemotherapies are similar to those used to directly kill cancer cells. One evidence 
in favour of a distinct mechanism would be to find a cell line that is directly killed but not sensitize by 
the peptide or a cell line that is not killed even at high TAT-RasGAP317-326 concentrations, but that is 
sensitized to chemotherapies. To address this point A549 cells could be used, since they are 
insensitive to high doses of peptide, and assess whether they are sensitized by it to chemotherapy. If 
the answer is positive this would argue in favour of a distinct mechanism. However, one hypothesis 
that would support a similar mode of action is that chemotherapeutic agents or radiotherapy could 
render peptide-induced cell death more efficient, for instance by lowering its IC50. According to this 
assumption, it would be chemotherapeutic agents that would act as a sensitizer and not the opposite 
as we have always hypothesized. This would also explain why to sensitize cancer cells we usually use 
about four times lower dosage than to directly kill them. 
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One very interesting aspect revealed in the paper published in Oncotarget is that TAT-RasGAP317-326 
can kill in an apoptosis-independent manner. Indeed, most of the current non-surgical anti-cancer 
strategies are designed to induce cancer cell death, mainly through apoptosis. However, a cancer cell 
can mutate and adapt to become resistant to apoptosis. To decrease this risk of acquired resistance 
and consequently the relapse of the tumour, combinations of anti-cancer drugs have improved the 
success of some therapies. Another way to overcome cancer cell resistance to pro-apoptotic stimuli 
would be to trigger non-apoptotic cell death. Consequently, as TAT-RasGAP317-326 has the ability to kill 
in a way distinct from apoptosis, it could efficiently complement the current anti-cancer strategies and 
hopefully would be less prone to treatment resistance. 
Finally, TAT-RasGAP317-326 could potentially have interesting clinical relevance. Indeed, it may benefit 
pediatric cancer patients by increasing the efficacy of anti-cancer therapies notably by allowing 
reductions in anti-cancer drug dosage and the associated treatment-induced side effects. As a direct 
cancer cell killer, it could also complement or be combined with existing anti-cancer drugs. However, 
some limitations still hamper its potential clinical use. As for peptides of less than 5 kDa, it is mostly 
extracted via the renal or hepatic routes preventing its sufficient accumulation into the tumour [342]. 
The bioavailability of the peptide has already been studied in nude mice bearing a xenograft HCT116 
subcutaneous tumour. Although only 0.2% of the injected TAT-RasGAP317-326 dose went into the 
tumour, this faint percentage was nevertheless sufficient to sensitize cancer cells to cisplatin toxicity 
[343]. However, the efficiency of this anti-cancer agent could be improved by preventing renal and 
hepatic excretion and by increasing the biodelivery of the peptide specifically into the tumour. Another 
major concern precluding the translation of this peptide into the clinics is the high concentration that 
we should use to reach an anti-tumour activity in vitro. Finally, we have recently observed that different 
calcium concentrations in the media can affect the direct killing activity of the peptide. This information 
is of importance since the calcemia can differ from one patient to another. Additional investigations are 
therefore required to improve the stability and the delivery of the peptide as well as the increase of our 
understanding of how it works with the final aim to one day translate this anti-cancer peptide into 
clinical applications.        
 
One major concern in anti-cancer therapies is treatment resistance. An important factor behind 
treatment failure due to intrinsic and acquired resistance is intratumoral heterogeneity [344, 345]. Few 
remaining cells to certain treatment are then able to rebuild a tumour and their resistance is often 
associated with an increased aggressiveness and invasive behaviour. Cancer relapse secondary to 
drug resistance underscores the urgent need to better understand the mechanisms of resistance that 
could ultimately lead to the development of alternative therapies. In the fourth part of the present 
thesis, we aimed at finding out new genes involved in sorafenib resistance in hepatocellular carcinoma 
(HCC) using exome sequencing and CRISPR/Cas9 loss-of-function screening. Sorafenib is the only 
FDA-approved chemotherapeutic agent to treat advanced HCC. However, its efficacy is far from 
satisfactory with an overall survival of 11 months mostly due to its intrinsic and acquired resistance. 
Among the genetic alterations highlighted by exome sequencing data, p53 Y220C structural mutation 
and EGFR amplification have been already described to be involved in sorafenib resistance [58, 292, 
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297, 298]. Interestingly, the Y220C missense mutation causing conformational instability of the p53 
protein is druggable. Indeed, the compounds PhiKan083 and PK7088 bind Y220C mutant with high 
affinity and stabilize the p53 protein [346-349]. Although they are not yet in clinical trials, they are very 
promising drugs, that could be used in combination with sorafenib. This strategy has been already 
applied to erlotinib, a potent EGFR inhibitor. A phase III clinical trial of sorafenib plus erlotinib in 
patients with advanced HCC concludes that erlotinib does not improve survival in patients with 
advanced HCC [350]. Although erlotinib does not seem to be indicated in first-line treatment, it could 
potentially benefit to patients with EGFR amplification as a second-line therapy. Therefore, tumour 
cells of each relapsed cancer should be sequenced in order to assess if the patient bears the EGFR 
amplification or not. Such therapeutic approach raised the new concept of personalized cancer 
medicine. Thanks to the drop in the cost of genome sequencing (from 1,000,000 in 2001 to around 
1,000 nowadays), this concept will be achievable in a near future.   
One limitation of our study is that we should have generated for each type of HCC cell line more than 
one sorafenib resistant derivative cell line. This would have allowed us to investigate whether, for a 
given cell line, it is always the same mutation that is responsible for the resistant phenotype or 
whether mutations are randomly acquired independently of the type of cell line.   
Finally, in order to capture the full complexity of HCC, data generated by exome sequencing have to 
be ideally integrated with transcriptomic, proteomic, metabolic, and methylome analyses. Although we 
did not perform these analyses, as a complementary approach to exome sequencing we employed a 
CRISPR/Cas9 screening. It revealed the involvement of the KEAP1 protein in the anti-proliferative 
activity of sorafenib. Though, it was already reported that loss-of-function mutation of KEAP1 
upregulates NRF2, that promotes cell proliferation in HCC [329-331].  
Another CRISPR-based approach, using this time the CRISPR/deadCas9 transcriptional activation 
genome-wide screen, could provide a better understanding of the molecular mechanisms inducing 
sorafenib resistance [351]. This system can increase transcription of a gene through an inactive Cas9 
(deadCas9) fused to a transcription activator peptide. A defined sgRNA is used to target the 
deadCas9-activator to a specific genomic sequence and subsequently to achieve high expression 
levels. Consequently, at a lethal concentration of sorafenib, a gain-of-function screen would detect 
genes whose overexpression lead to sorafenib resistance. 
To bring innovation and consequently to increase the interest of this project, future experiments are 
planned to test the effect of a new multi-targeted tyrosine kinase inhibitor Lenvatinib (lenvima®) [352]. 
It has more potent inhibitory activity than sorafenib against several kinases including VEGFR, RET, 
FGFR, c-KIT, and PDGFR [353]. It is now FDA-approved for recurrent or metastatic thyroid cancer 
and a phase III clinical trial comparing lenvatinib to sorafenib has just been completed in HCC [354]. 
Accordingly, very few are known about its resistance mechanisms. Thenceforward, it is of high 
importance to assess whether the resistance mechanisms are similar to those of sorafenib. If 
lenvatinib is efficient in conditions where sorafenib is not, it could represent a breakthrough in the 
current crisis affecting advanced HCC treatment.  
 
DISCUSSION 
  161 
Whereas CRISPR/Cas9 negative selection screen in HCC cells was technically unsuccessful, the 
positive selection screens performed in order to identify regulators of TAT-RasGAP317-326 were an 
accomplishment. As mentioned above, instead of being required in the death induction process per 
se, we demonstrated that validated candidates were involved in the cytosolic access of TAT-
RasGAP317-326 and two other TAT-constructs, TAT-Cre and TAT-PNA. This interesting discovery 
opens new fields of investigations and generates further questions. Indeed, how KCNN4, KCNK5, 
ATP1B3, SLC39A14, KCNQ5, and PIP5K1A which are mostly regulators of potassium flux manage 
cytosolic access, remains to be fully characterized. The preliminary results suggest that the absence 
of KCNQ5 prevents cytosolic access of the anti-cancer peptide through the depolarization of the 
plasma membrane. This observation was however not confirmed for the other candidates. Different 
experiments that could be done to elucidate what is the exact role of each candidate in the regulation 
of the cytosolic access of TAT-constructs are proposed in the discussion of the third part of the results. 
A better understanding of how TAT CPP enters cells is crucial for its clinical application and could lead 
to a subsequent modulation of its uptake or endosomal escape [355]. Indeed, although TAT has 
proceeded to different phases of clinical trials, no therapy employing this CPP has been yet approved 
by the FDA [356]. As a future perspective, it would be of interest to assess if the candidates yielded by 
the CRISPR-based screen modulate also the delivery of other CPP from different origins. 
Finally, we demonstrated the property of the KCNN4 inhibitor TRAM-34 to efficiently prevent the 
cytosolic access of some arenaviruses. Among this family of viruses, some of them are causative 
agents of various severe viral hemorrhagic fevers with a high rate of mortality in humans [255]. Only 
suboptimal therapies and limited vaccines for some of these viruses exhibit the urgent need for novel 
therapeutic strategies [255-257]. Although these results are preliminary, they highlight a potential 
clinical relevance of KCNN4 chemical inhibitors to prevent viral infection. Therefore, it could be 
interesting to investigate whether the absence of KCNN4 can also inhibit the infection of other 
microorganisms, such as bacteria or other types of viruses.   
 
To conclude, a better understanding of the mode of action of TAT-RasGAP317-326 as well as the 
discovery of some new features could one day lead to the development of a compound with multiple 
anticancer properties. Furthermore, this work paves the ground to a better knowledge of sorafenib 
resistance. This could ultimately lead to the development of alternative therapies. 
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A WxW MOTIF IS REQUIRED FOR THE ANTICANCER ACTIVITY OF THE TAT-
RasGAP317-326 PEPTIDE.  
 
Contribution: 
This work has been published in the Journal of Biological Chemistry in 2014. I performed all the 
revisions of the paper. 
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Background: TAT-RasGAP317–326 is a Ras GTPase-activating protein (RasGAP)-derived peptide that requires deleted in
liver cancer-1 (DLC1) for its antimetastatic activities.
Results: AWXWmotif within TAT-RasGAP317–326 mediates RasGAP-DLC1 interaction.
Conclusion: The tryptophan residues of TAT-RasGAP317–326 are crucial for its activity
Significance: The WXWmotif could be used to design anticancer small molecules bearing TAT-RasGAP317–326 activities.
TAT-RasGAP317–326, a cell-permeable 10-amino acid-long
peptide derived from the N2 fragment of p120 Ras GTPase-ac-
tivating protein (RasGAP), sensitizes tumor cells to apoptosis
induced by various anticancer therapies. This RasGAP-derived
peptide, by targeting the deleted in liver cancer-1 (DLC1) tumor
suppressor, also hampers cell migration and invasion by pro-
moting cell adherence and by inhibiting cell movement. Here,
we systematically investigated the role of each amino acidwithin
the RasGAP317–326 sequence for the anticancer activities of
TAT-RasGAP317–326. We report here that the first three amino
acids of this sequence, tryptophan, methionine, and tryptophan
(WMW), are necessary and sufficient to sensitize cancer cells to
cisplatin-induced apoptosis and to reduce cell migration. The
WMWmotif was found to be critical for the binding of fragment
N2 to DLC1. These results define the interactionmode between
the active anticancer sequence of RasGAP and DLC1. This
knowledge will facilitate the design of small molecules bearing
the tumor-sensitizing and antimetastatic activities of TAT-
RasGAP317–326.
Cancer is the second leading cause of death worldwide (1).
Ninety percent of cancer-related death is attributed to metas-
tases (1). Surgery, chemotherapy, and radiotherapy remain at
present the main clinical therapeutic tools to treat cancer.
These treatments are very efficacious against some cancers but
are of limited long term efficacy against others. Besides devel-
oping new anticancer modalities, increasing the efficacy of cur-
rent therapies is of clear and timely interest.
p120 Ras GTPase-activating protein (from now on referred
to as RasGAP)2 is amultidomain protein. It was first reported as
a negative modulator of the Ras signaling pathway (2). This
activity requires the GAP domain of the protein (2). It was
found later that other domains of the protein had signaling
activities that were not related to its function as a GAP. For
example, the N-terminal moiety of RasGAP can positively reg-
ulate MAP kinase kinases such as Ras and Mos (3). RasGAP is
also a specific caspase-3 substrate (4). Because of the presence
of two sites within RasGAP that have differential sensitivities
toward caspase-3-mediated cleavage, the RasGAP/caspase-3
module acts as a stress sensor in cells (5). In the presence of low
stresses, caspase-3 is mildly activated, and this leads to the par-
tial cleavage of RasGAP into anN-terminal fragment that exerts
potent, Akt-dependent, antiapoptotic activities (4, 6, 7). When
cells are subjected to strong stresses, RasGAP is fully processed
by caspase-3, further cleaving the N-terminal fragment and
henceforth destroying its ability to protect cells.
One of the fragments generated by the full cleavage of Ras-
GAP by caspase-3, fragment N2 (RasGAP158–455), has the
capacity to increase the sensitivity to anticancer treatments of
various tumor cell lines, both in vitro and in vivo (6, 8). Similarly
to fragment N2, a cell-permeable 10-amino acid peptide con-
tained within the SH3 domain of fragment N2, called TAT-
RasGAP317–326, was found to efficiently sensitize cancer cells to
anticancer agent-induced apoptosis (9) and to inhibit tumor
growth when combined with chemotherapy (8). We recently
reported that fragmentN2was an efficient inhibitor of themet-
astatic cascade (10). TAT-RasGAP317–326 also inhibited cell
migration and invasion into basement membrane matrix by
strengthening adhesiveness of the cells to their substratum (11).
However, in an attempt to use TAT-RasGAP317–326 as an anti-
metastatic tool, we found, using mouse models, that this pep-
tide was not always delivered efficiently to tumors (10). This
delivery issue would call for the development of small mole-
cules bearing the activity of RasGAP317–326. However, such
* This work was supported by a grant fromOncosuisse (KFS-02543-02-2010).
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developmentwould greatly benefit fromabetter understanding
of the mode of action of TAT-RasGAP317–326.
Actin cytoskeleton dynamics controls adhesion, migration,
and invasion and is mainly regulated by the small GTPases of
the Rho family (e.g. Rho itself, Rac, and Cdc42 (12, 13)). We
found that the TAT-RasGAP317–326 molecular properties by
which it induces adhesion and inhibits migration rely on mod-
ulation of the actin cytoskeleton and requires deleted in liver
cancer-1 (DLC1), a RhoGAP that functions as a tumor and
metastasis suppressor (11, 14). Therefore, understanding
whether and howTAT-RasGAP317–326 engages DLC1 is of cru-
cial interest.
Although peptide therapeutics are gathering increasing
interest for the treatment of tumors (15), classical issues asso-
ciated with peptide-based therapy are impeding their develop-
ment. These issues consist of the rapid clearance from the body,
the lack of targetable ability, their short half-lives, and their
expensive production costs. Consistent with this, the Lipinski’s
rule-of-five, a model that predicts the likeliness of a compound
to be translated into an orally active drug, is of bad prognosis for
peptide development (16).
The goal of the present study was to characterize the impor-
tance of each of the RasGAP317–326 amino acids for its sensitiz-
ing activity and its ability to increase cell adhesiveness. This was
performed to better understand the mode of action of the pep-
tide and to gather structure-function information that could be
used for pharmacological development to facilitate the devel-
opment of a small molecule that mimics TAT-RasGAP317–326.
Our recent finding that fragmentN2 requires DLC1 for its anti-
metastatic activities prompted us to dissect how these twomol-
ecules interact. Here, we report the exact binding mode
between DLC1 and TAT-RasGAP317–326 and we identify a
shortWXWmotif located at the N-terminal end of the peptide
that carries its anticancer activities.
EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture—The osteosarcoma cell line used
in this study is U2OS (ATCC; HTB-96). HEK-293T cells were
used for protein interaction studies as reported previously (11).
The cells were cultured at 37 °C and 5% CO2 and were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco; 61965) supplemented with 10% fetal bovine serum
(FBS) (Gibco; 10270) for not more than 2 months and were
constantly checked for their morphology.
Peptide Synthesis—The peptides used in this study were
made of D-amino acids, which provide resistance to proteases
and therefore increase their stability. In order for the side chains
to be similarly exposed as in L-form peptides (8), the D-form pep-
tides were synthesized starting with the last C-terminal residue
(retro-inversopeptides).TheTAT-RasGAP317–326 (GRKKRRQR-
RRGGWMWVTNLRTD), the TAT (HIV-TAT48–57) (GRK-
KRRQRRR), and all the peptides mentioned in the figures were
synthesized at theDepartmentofBiochemistry,University ofLau-
sanne, Switzerland using the Fmoc (N-(9-fluorenyl)methoxycar-
bonyl) technology, purified by HPLC, and tested by mass spec-
trometry as reported earlier (9). Two glycine residues were
inserted as a linker between TAT and the peptides of interest.
Trypsin-mediated Detachment Assays, Transfection, Immuno-
precipitation, and Western Blotting—Trypsin-mediated detach-
ment assays, Giemsa staining, calcium-phosphate transfection,
immunoprecipitation, andWestern blottingwere performed as
reported previously (11). The primary antibodies used were
anti-HA (Covance; MMS-101r), anti-V5 (Invitrogen; 46-1157)
and anti-GFP (Clontech; 632380).
Wound-healing Scratch Assay—Five hundred thousand
U2OSwere grown in 3.5-cmplates. The day after, the cells were
pretreated as indicated in the figures for 3 h. Awound in the cell
layer was made with a tip (0.4-mm diameter at its extremity).
Five pictures per wound were taken just after wounding (0 h),
and then 24 and 48 h after wounding (the same five fields per
wound were photographed at each time point). Wound areas
were measured using the ImageJ software. The migration area
was calculated by subtracting the 48 h value by the 0 h value,
and the data were normalized against the untreated condition.
For time-course experiments, the data obtained after 24 h were
treated similarly than for 48 h.
Apoptosis Measurements—One hundred and fifty thousand
U2OS cells were grown in 3.5-cm plates. The day after, the cells
were treated for 22 h with 20 !M TAT-coupled peptides in the
presence or in the absence of 30 !M cisplatin (Sigma-Aldrich;
P4394) as indicated in the figures. The cells were then fixed, and
the nuclei were stained in 2% paraformaldehyde containing 10
!g/ml Hoechst 33342 (Molecular Probes; H1399) for 15 min.
The pyknotic nuclei were visualized using the Nikon Eclipse
TS100 microscope equipped with fluorescence; they were then
scored and reported in percentage over total number of cells.
Greyscale Heat Map—Heat map was performed by semi-
quantitative evaluation of the effects of the alanine-substituted
peptides as compared with wild-type 317–326 peptide. The
results onwhich the heatmap is based appear in Fig. 1B (adher-
ence; 20!Mvalues), Fig. 2A (migration), and Fig. 2B (apoptosis).
This heat map is a greyscaled representation of whether the
alanine-substituted peptides recapitulate the effects of 317–
326. Specifically for apoptosis, theminimal effect (in black) was
set to the “cisplatin alone” condition, and themaximal effect (in
white) was set to the “cisplatin ! 317–326” condition; for
adherence, the minimal effect (in black) was set to the
“untreated ! trypsin” condition, and the maximal effect (in
white) was set to the “317–326! trypsin” condition; for migra-
tion, the minimal effect (in white) was set to the “317–326”
condition, and the maximal effect (in black) was set to the
“untreated” condition.
Plasmids—The extension .dn3 indicates that the backbone
plasmid is pcDNA3 (plasmid 1) from Invitrogen. The Stag-HA-
hRasGAP[158–455].dn3 (plasmid 644) (here called HA-N2),
Stag-HA-hRasGAP[158–455](W317A).dn3 (plasmid 793)
(here called HA-N2 (W317A)), and V5-mDLC1[1–1092].dn3
(plasmid 791) (here called V5-DLC1) plasmids were described
earlier (11). The Stag-HA-hRasGAP[158–455](W319A).dn3
(plasmid 803) (here calledHA-N2 (W319A)) plasmid encodes a
Stag- and HA-tagged form of fragment N2 bearing a mutation
of tryptophan 319 into an alanine residue (W319A). The tem-
plate vector used for starting the mutagenesis is the HA-N2
plasmid. Mutagenesis was performed using the mega-primer
procedure (17) as follows. (i) TheW319Amutation was gener-
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ated by PCR amplification of HA-N2 using oligonucleotide
(oligo) 1019 (human RasGAP nucleotides 1052–1097 (NCBI
entryM23379) except for nucleotides (underlined) that create a
W319A mutation and a silent mutation generating a Bsu36I
restriction site: (GAA TTA GAA GAT GGA TGG ATG GCG
(W319A)GTTACAAACC (N1-N2of Bsu36I) TAAGG (N7of
Bsu36I) ACAGATG)) and oligo 62 (TACCTAGCATGAACA-
GATTG (random sequence) AGGGGCAAACAACAGATG
(pcDNA3 nucleotides 1080–1063)). (ii) The PCR product
obtained in (i) was purified and elongated on the HA-N2 tem-
plate. (iii) The PCR reaction was resumed after the addition of
oligo 28 and oligo 70. The PCR in (iii) was digested with BsiWI
and NotI and ligated into plasmid HA-N2 digested with the
same enzymes. The DLC1 mutant plasmids were generated
using the same methodology. The V5-mDLC1[1–1092]
(R677A).dn3 (plasmid 804) (here called V5-DLC1 (R677A))
plasmid encodes a V5-tagged form of theMus musculus DLC1
transcript variant 2 (NM_015802.3) bearing a mutation of argi-
nine 677 into an alanine residue (R677A). The template vector
used for starting the mutagenesis is the V5-DLC1 plasmid.
Mutagenesis was performed as follows. (i) TheR677Amutation
was generated by PCR amplification of V5-DLC1 using oligo
1016 (mouse Dlc1 nucleotides 2368–2411 (NCBI entry
NM_015802.3) except for nucleotides (underlined) that create
a R677A mutation and a silent mutation generating an EcoRI
restriction site: (GTC GGG CTC TTC GCG (R677A) AAG
TCA GGT GTC AAA TCC CG A (N2 of EcoRI) AT T (N5 of
EcoRI) CAGGCT) and oligo 62. (ii) The PCR product obtained
in (i) was purified and elongated on the V5-DLC1 template. (iii)
The PCR reaction was resumed after the addition of oligo 28
(TAATACGACTCACTATAGGGAGA (pcDNA3 sequence
863–885)) and oligo 70 (TACCTAGCATGAACAGATTG
(same random sequence as in nucleotide oligo 62)). The PCR in
(iii) was digestedwith EcoRV andXhoI and ligated into plasmid
V5-DLC1 digestedwith the same enzymes. TheV5-mDLC1[1–
1092](N829A,L830A).dn3 (plasmid 805) (here called V5-DLC1
(N829A,L830A)) plasmid encodes a V5-tagged form of the
M. musculus DLC1 transcript variant 2 (NM_015802.3) bear-
ing a mutation of asparagine 829 and leucine 830 into alanine
residues (N829A,L830A). The template vector used for starting
the mutagenesis is the V5-DLC1. Mutagenesis was performed as
follows. (i) The N829A and L830A mutations were generated by
PCR amplification of V5-DLC1 using oligo 1017 (mouse Dlc1
nucleotides 2821–2859 (NCBI entry NM_015802.3) except for
nucleotides (underlined) that create theN829A and L830Amuta-
tions and a newNotI restriction site: (AAAGACCTGAATGAA
GCGGCC (N829A,L830A and (N1–6) of NotI) GCGGCGACT
CAAGGGCTG) and oligo 62). (ii) The PCR product obtained in
(i) was purified and elongated on the V5-DLC1 template. (iii) The
PCR reaction was resumed after the addition of oligo 28 and oligo
70. The PCR in (iii) was digested with EcoRI and XhoI and ligated
into plasmid V5-DLC1 digested with the same enzymes. The
extension .gfp indicates that the backbone plasmid is pEGFP-C1
(plasmid 6) fromClontech and encodes the green fluorescent pro-
tein. The pEGFP-hDLC1.gfp (plasmid 811) (here called GFP-
DLC1),pEGFP-hDLC2.gfp (plasmid812) (herecalledGFP-DLC2)
and pEGFP-hDLC3.gfp (plasmid 813) (here called GFP-DLC3)
plasmids encode GFP-tagged versions of human DLC1, DLC2",
and DLC3", respectively, and were described earlier (18, 19).
The extension .pgx indicates that the backbone plasmid is
pGEX-4T-1 from GE Healthcare. GST-hDLC1[625–878].pgx
(plasmid 816) (here called GST-DLC1-GAP) is an expression
vector encoding the GST fusion human DLC1 GAP domain
corresponding to nucleotide 1873–2634 of the human DLC1
gene (GenBank: AAK97501.1).
In Silico Prediction of Protein Interaction—The rigid docking
of p120 RasGAP to DLC1 was performed using the PatchDock
web server (20, 21), version beta 1.3, with the default complex
type and a 4.0 Å clustering root mean square deviation. The
DLC1 GAP domain (Protein Data Bank (PDB) ID: 3KUQ (22,
23)) was used as the receptor and the RasGAP SH3 domain
(PDB ID: 2J05 (24)) as the ligand. The receptor and ligand bind-
ing sites were not imposed, and no additional constraint was
applied during the docking. The best-scored calculated binding
mode was retained for structural analysis.
Recombinant Protein Production and Isothermal Titration
Calorimetry—RecombinantGST-DLC1-GAPdomainwas pro-
duced as reported previously using BL21 transformed with the
GST-GAP-DLC1.pgx construct (25). Elution of the GST-
DLC1-GAP domain in 30 mM reduced L-glutathione (Sigma-
Aldrich, G4251, in 50 mM Tris (pH:7.4), 100 mM NaCl) was
followed by 2 h of dialysis in 4 liters of PBS. The dialysis buffer
was then used as titration buffer and to resuspend TAT-
RasGAP317–326 and the corresponding tryptophan mutants.
Isothermal titration calorimetry was performed as reported
previously using the ITC200 system (GE Healthcare Life Sci-
ences) unless otherwise mentioned (26). The sample cell (200
!l) was loadedwith 50!MGST-DLC1-GAP, whereas the TAT-
RasGAP317–326 and the tryptophanmutant concentrations in the
syringe were 500 !M. The titration experiment started with an
injection of 0.5!l followed by 15 injections of 2.49!l, each lasting
5 s, with a 3-min interval between each injection. Controls and
measurements were performed as reported earlier (26).
Statistical Analysis—All experiments were performed inde-
pendently. The results were expressed as mean " 95% confi-
dence intervals. One-way ANOVAs and repeated measure-
ment ANOVAs were performed using the R software (version
2.11.0) and were followed by a Tukey test for multiple compar-
isons. Asterisks denote statistically significant differences (p
value# 0.05).
RESULTS
The individual contribution of each amino acid of the Ras-
GAP 317–326 sequence was evaluated through an alanine-
scanning approach. This approach has been successfully used
to identify several protein-protein interactions (27). For exam-
ple, it has been employed to map the binding between the
human immunodeficiency virus (HIV)GP120 glycoprotein and
the human CD4 receptor (28). This methodology consists of
substituting amino acids of interest into alanine residues (27).
Alanine that has a methyl side chain is considered as neutral
and, in contrast to glycine that is also a small amino acid with
only a hydrogen side chain, prevents introduction of conforma-
tional flexibility. Alanine substitutions therefore tend to keep
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intact the overall secondary structure of the investigated pro-
tein (27).
We first evaluated the consequence of these mutations on
adhesion induced by TAT-RasGAP317–326 (from now on
referred to as 317–326). Alanine substitutions of the trypto-
phan residues at positions 317 and 319 abrogated the capacity
of the peptide to increase cell adherence (Fig. 1, A and B). Sub-
stitutions at positions 318, 320, 323, 324, and 325 strongly
reduced the pro-adherence activity of 317–326, but some resid-
ual adherence was nevertheless observed. Replacement of
amino acids 321, 322, and 326 had no or only limited effect on
the ability of the peptide to increase cell adherence. These
results indicate that the tryptophan and leucine residues of
317–326 are critically required for the pro-adhesion activity of
the peptide. Residues 318, 320, and 324–325 are also important
for this activity but do not appear as indispensable as the tryp-
tophan residues because their replacement does not totally
abolish the activity of 317–326. One could therefore generate a
consensus sequence for RasGAP317–326-mediated adhesion
increase, WMWVXXLRTX, where the X represents residues
that are not required for this activity and where the bold resi-
dues are those that seem the most important for the pro-adhe-
sive activity of the peptide. Interestingly, this consensus
sequence is almost identical to the amino acids that are con-
served between vertebrates and insects in the RasGAP 317–326
sequence (WXWVTXXRTX) (Fig. 1C). Hence the data pre-
sented in Fig. 1 indicate that most evolutionary conserved
amino acids are important for the increase cell adherencemedi-
ated by the 317–326 sequence of RasGAP.
We next assessed whether the amino acids identified to be
required for the pro-adhesion activity of 317–326 were also
playing a role in the capacity of the peptide to inhibit migration
and to sensitize tumor cells to genotoxins. Similarly to the
adhesion increase, alanine substitutions of the Trp-317, Trp-
319, Leu-323, Arg-324, and Thr-325 amino acids completely or
partially abrogated the capacity of 317–326 to inhibit cell
migration (Fig. 2A) or to favor cell death induced by cisplatin, a
commonly used chemotherapeutic agent (Fig. 2B). The Met-
318 and Val-320 residues seem, however, to be differentially
required for 317–326-mediated effects on apoptosis, adhesion,
and migration (Fig. 2C). This differential requirement of Met-
318 and Val-320 could be the consequence of 317–326mediat-
ing its effects on apoptosis, adhesion, and migration via differ-
ent signaling pathways. Alternatively, this could be explained
by a difference in the sensitivity of the assays used to measure
apoptosis, adhesion, and migration and/or a difference in the
sensitivity of these biological processes themselves. We there-
fore performed a dose response with 317–326 and measured
apoptosis sensitization, adhesion increase, and migration inhi-
bition. Fig. 2D shows that these three assays or biological pro-
cesses do not display similar sensitivities to the RasGAP-de-
rived peptide. Indeed, the EC50 for apoptosis sensitization (5
!M)was lower than the EC50 for adhesion promotion (11.5!M),
whichwas lower than the EC50 formigration (16.5!M). In other
words, less 317–326 is required to render tumor cells more
sensitive to cisplatin-induced apoptosis than is required to
mediate increased adhesiveness and even less so to inhibit cell
migration. This indicates that a decrease in the activity of the
peptide will first impact on its capacity to inhibit migration,
then on its ability to increase cell adherence, and lastly on its
capacity to sensitize cells to anticancer treatments. Hence a
mutation that partially affects the activity of 317–326 should
have a stronger impact on migration inhibition than on cell
adherence promotion and tumor sensitization. This is particu-
larly obvious with the V320A mutation. This can also be seen
somewhat with the M318A and L323A mutations. Therefore,
these results are not contradictory with the possibility that
modulation of apoptosis, adhesion, and migration by 317–326
is the consequence of one protein ormolecule being targeted by
the peptide.
If the twoN-terminal tryptophan residues of 317–326 are the
only crucial residues for the activity of the peptide, it should be
possible to shorten the 317–326 sequence without losing its
activity. Hence, truncated versions of 317–326 were analyzed
for their effects on adhesion, migration, and sensitization to
apoptosis. Fig. 3,A and B, show that 317–323 and 317–321 still
induce increased adherence, although to a lower extent than
the parental 317–326 peptide. In contrast, 322–326 failed to
augment cell adhesiveness. This indicates that the 317–321
sequence is sufficient to increase cell adherence. Although the
322–326 sequence lacked activity, it still may be required for
optimal 317–326 activity as revealed by the point mutations
within this sequence (Figs. 1 and 2). It was reported that the
322–326 sequence participates in the formation of a #-sheet
required for dimerization of the RasGAP SH3 domains. One
could therefore hypothesize that the 322–326 fulfills structural
functions to constrain the 317–321 stretch in a conformation
that is optimal for its activity. Co-incubation of 317–321 and
322–326 failed to potentiate 317–321-induced adhesion, indi-
cating that both domains have to be carried by the same entity
to be physiologically fully active. When the active peptides are
narrowed down to four (317–320) and three (317–319) amino
acids, their pro-adhesive property is even more decreased (Fig.
3B). We also tested the ability of the truncated peptides to
inhibit migration (Fig. 3C) and to sensitize to cisplatin-induced
apoptosis (Fig. 3D). The slight 317–323-mediated increase of
adherence was translated into a weak but statistically signifi-
cant inhibition of migration, whereas smaller peptides did not
affect migration or affected it to a much lesser extent (Fig. 3C).
On the other hand, the apoptosis-sensitizing effect of the trun-
cated versions, including the 317–319 tripeptide, was similar to
the one induced by the full-length peptide (Fig. 3D). Of note,
theDrosophila peptide that carries a leucine residue at position
318 was highly efficient in recapitulating the effects of the
human version (Fig. 3, A–D). Altogether, these results indicate
that the WXWmotif within the 317–326 sequence carries the
anticancer activities of the peptide.
To better understand why the 317–319 tripeptide sensi-
tizes tumor cells to apoptosis but does not recapitulate the
effects on adhesion and more importantly on migration, we
evaluated the effects of increased dose of 317–319 on migra-
tion. Wound closure was measured over a 48-h period to
have a longer window for the evaluation of migration
dynamics. At a 40 !M concentration, the 317–319 tripeptide
significantly inhibited migration (Fig. 4A). When the 317–
319 concentration increased to 60 !M, the effect on migra-
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tion was not stronger than with 40 !M, indicating that 40 !M
is already a saturating dose and that 317–319 cannot reach
the inhibitory effect obtained with the full-length peptide. In
contrast, the dose-response experiment depicted in Fig. 4B
shows that 317–319 is as efficient as 317–326 in sensitizing
tumor cells to cisplatin-induced apoptosis. This finding may
indicate that two different molecules are targeted by 317–
326 to mediate inhibition of migration and to sensitize
tumor cells to death.
The DLC family consists of three isoforms (DLC1, DLC2,
and DLC3) with nonredundant activity (14). DLC1 regulates
cell migration (29). DLC2 couldmodulate apoptosis as it can be
localized at the mitochondria level (30). Fragment N2, the
parental polypeptide from which 317–326 is derived, can bind
FIGURE 1. Cell adherence induced by alanine-substituted RasGAP317–326 peptides. A and B, U2OS cells were cultured overnight and then treated for 8 h
with 20 !M TAT or 20 !M of the indicated TAT-coupled peptides or left untreated. The cells were then subjected to trypsin-mediated detachment assays. The
images shown in panel A correspond to 20 !M peptide-treated cells (n$ 4 independent experiments). Scale bar: 200 !M for all images. w/o trypsin, without
trypsin. B, dose-response quantitation (n$ 4 independent experiments). C, alignment of the p120 RasGAP317–326 sequences fromdifferent species. The amino
acids conserved during evolution are shaded in gray. Drosoph., Drosophila.
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DLC1 (11) but whether fragment N2 also binds the other DLC
isoformswas not investigated. Fig. 4C shows thatDLC2, but not
DLC3, interacts with fragment N2. As fragment N2 binds both
DLC1 and DLC2, this raises the possibility that 317–326 mod-
ulates adhesion/migration through DLC1 and apoptosis
through DLC2 (model 1 in Fig. 4D). Another possibility would
be that DLC1 and DLC2 are both required for the effects on
adhesion/migration and that a still unidentified protein medi-
ates the apoptotic response (model 2 in Fig. 4D). Jaiswal et al.
(31) have shown that the SH3 domain of RasGAP binds to the
DLC1 GAP domain using isothermal titration calorimetry
(ITC). However, whether 317–326 directly binds DLC proteins
FIGURE 2. Ability of alanine-substituted RasGAP317–326 peptides to inhibit cell migration and sensitize cancer cells against cisplatin-induced
apoptosis. A, U2OS cells were grown to confluence and were pretreated for 3 h with 20 !M of the indicated TAT-coupled peptides. The cells were then
subjected to wound healing scratch assays. The graph displays the percentage of migration over untreated cells. Asterisks and number signs denote
statistical significant differences after one-way ANOVA (asterisk: different from untreated condition; number sign: different from 317–326 treatment; n$
7 independent experiments). Error bars indicatemean" 95% confidence intervals. B, U2OS cells were cultured overnight andwere subsequently treated
for 22 h with 20 !M of the indicated TAT-coupled peptides in the presence or in the absence of 30 !M cisplatin. The number of pyknotic nuclei was then
scored and reported as the percentage of apoptosis. The light gray region displays the level of apoptosis induced by cisplatin alone, and the dark gray
region shows the apoptosis sensitization zone. Asterisks and number signs denote statistical significant differences after one-way ANOVA with the
cisplatin-only treatment and with the cisplatin ! 317–326 treatment, respectively (n $ 6 independent experiments). Error bars indicate mean " 95%
confidence intervals, C, schematic representation of the importance of each amino acid within the wild-type sequence for the apoptosis sensitization,
adhesion promotion, and migration inhibition processes. D, comparison of the dose-dependent effect of 317–326 on apoptosis sensitization, adhesion
(prevention of detachment), and inhibition of migration. Each experiment was performed as described in earlier figures and panels except that here all
the responses are reported as the percentage of the maximum observed effect. Error bars indicate mean" 95% confidence intervals.
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has not been reported. We used ITC to assess this point. ITC
records temperature changes generated when two molecules
interact (32). Repeated injection of 317–326 into the cell con-
taining the DLC1 GAP domain led to a marked variation in
temperature (endergonic reaction) that was progressively
reduced with subsequent 317–326 injections (indicative of
binding site saturation and hence the specificity of the interac-
tion) (Fig. 4E, upper panel). In contrast, injections of the two
tryptophan peptide mutants (W317A andW319A) in the incu-
bation cell of the ITC device containing theDLC1GAP domain
induced minimal temperature changes (these changes are
caused by the injection of a given volume in the cell) (Fig. 4F).
FIGURE3.Ability of truncatedandvariantRasGAP317–326peptides to increaseadherence, inhibit cellmigration, and sensitize cancer cells to cisplatin-
induced apoptosis. A, sequences of the peptides tested. Residues shaded in gray are those that are found required for adhesion based on the alanine-
scanningperformed in Fig. 1. The residues inwhiteon a black background are those that differ from the residues shaded in gray.Droso,Drosophila. B, U2OS cells
were culturedovernight andwere subsequently treated for 8 hwith 20!MTATor 20!Mof the indicated TAT-coupledpeptides or left untreated. The cellswere
then subjected to trypsin-mediated detachment assays. Error bars indicatemean" 95% confidence intervals, C, U2OS cells were subjected to wound-healing
scratch assays in the presence of 20 !M of the indicated TAT-coupled peptides. Asterisks and number signs denote statistical significant differences after
one-way ANOVA from the untreated condition and from the 317–326 treatment, respectively (n$ 7 independent experiments). Error bars indicate mean"
95% confidence intervals,D, U2OS cells were cultured overnight andwere subsequently treated for 22 h with 20!M of the indicated TAT-coupled peptides in
the presence or in the absence of 30!M cisplatin. The number of pyknotic nuclei was then scored and reported as the percentage of apoptosis. The light gray
regiondisplays the level of apoptosis inducedby cisplatin alone, and thedark gray region shows the zonewhere sensitizationoccurs.Asterisks andnumber signs
denote statistical significant differences after one-wayANOVAwith the cisplatin-only treatment andwith the cisplatin! 317–326 treatment, respectively (n$
6 independent experiments). Error bars indicate mean" 95% confidence intervals.
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FIGURE 4.Direct interaction of 317–326withDLC1 requires aWXWmotif that is sufficient tomediate the tumor sensitization effect of 317–326.A and
B, effect of increasing doses of 317–319 on U2OS cell migration over time (A) and on sensitization to apoptosis induced by 30 !M cisplatin (B) (n $ 3
independent experiments). Asterisks denote statistical significance after repeated measurement ANOVAs (A). Error bars indicate mean " 95% confidence
intervals,C, HEK-293T cellswere transfectedwith the indicated combinations of plasmids. Twomilligramsof cell lysateswere immunoprecipitated (IP) using an
anti-HA antibody. Forty!g of total lysates (TL) were also loaded.Western blotting (WB) against theHA tag (N2) andGFP (DLC1–3)was performed. The cropped
blot is representative of three independent experiments.D, workingmodels. Model 1 suggests that DLC1 andDLC2mediate every 317–326 anticancer effects,
whereasmodel 2 includes a third player thatwouldmediate the effects of 317–326 on apoptosis. E, isothermal titration calorimetrywas used to investigate the
binding between 317–326 and the GAP domain of DLC1. This panel displays the raw data of the heat pulses resulting from titration of the recombinant
GST-DLC1-GAPdomain (50!M) in the calorimetric cell with serial injections of 317–326 at a 500!M concentration. The lower paneldisplays the integrated heat
pulses (in kcal), normalized per mole of 317–326, as a function of the molar ratio (317–326 concentration/DLC1-GAP concentration). The resulting curve was
fitted to a model equation allowing the determination of the KD. The dissociation constant and the molar ratio displayed here are the mean of three
experiments. F, as controls, the recombinantGST-DLC1-GAPdomainwas titratedwith theRasGAPW317Amutant peptide (upper right) and theRasGAPW319A
mutant peptide (lower right) (n$ 3 independent experiments).
AWXWMotif with Anticancer Activities
23708 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 34•AUGUST 22, 2014194
The dissociation constant (KD) of the interaction between the
RasGAP 317–326 sequence and the DLC1 GAP domain was
calculated to be %5 !M (Fig. 4E, lower panel). This KD is in
agreement with the functional TAT-RasGAP317–326 EC50 val-
ues obtained for apoptosis (5 !M), adhesion (11.5 !M) and
migration (16.5 !M) (Fig. 2D).
We next wanted to determine the binding mode of 317–326
to DLC1. In silico docking experiments of the RasGAP SH3
domain (PDB: 2JO5) to the DLC1 GAP domain (PDB: 3KUQ)
revealed a preferred binding mode involving polar and nonpo-
lar interactions of RasGAPTrp-317 to DLC1 Leu-830 andAsn-
829, as well as a cation-$ interaction between RasGAPTrp-319
and DLC1 Arg-677 (Fig. 5A). This in silico prediction was in
agreement with the immunoprecipitation assays using DLC1
mutants bearing point mutations at position 677 and at posi-
tions 829 and 830. Fig. 5B (left blot) shows that these mutated
DLC1 proteins have impaired fragment N2 binding abilities.
Conversely, alanine substitutions of Trp-317 and Trp-319 in
fragment N2 greatly reduced its capacity to bind wild-type
DLC1 (Fig. 5B, right blot).
Fig. 5A was derived from the structure of the RasGAP
sequence in its natural L-form. One could question whether the
FIGURE 5. Structural model of RasGAP binding to DLC1. A, in silico docking of DLC1 GAP domain (PDB ID: 3KUQ; in blue) and RasGAP SH3 domain (PDB ID:
2JO5; inorange) interaction. The right paneldisplays the interactionbetween the SH3domainof RasGAPand theGAPdomainofDLC1. This interaction involves
the Trp-317 and Trp-319 residues of RasGAP and the Arg-677, Asn-829, and Leu-830 residues of DLC1. The left panel shows a lowermagnification image of this
interaction. This binding mode had a geometric shape complementarity score of 10024. See Refs. 20 and 21 for score interpretation. The next best binding
mode (not shown) had a score of 9804. The spatially nearest calculated pose (not shown) had a root mean square deviation of 15.1 Å as compared with the
binding mode displayed in the figure and had a geometric shape complementarity score of 9488. B, immunoprecipitation assays displaying the interaction
between wild-type fragment N2 and mutants of DLC1 (left blot) and between wild-type DLC1 and mutants of fragment N2 (right blot). HEK 293T cells were
transfected with the indicated combinations of plasmids. Two milligrams of cell lysates were immunoprecipitated (IP) using an anti-V5 antibody. Forty !g of
total lysates (TL) were also loaded. Western blotting (WB) against the HA tag (N2) and the V5 tag (DLC1) was performed. The left blot was cropped, but all the
lanes originate from the same exposure of one given blot. Cropped blots are representative of three independent experiments. C, retro-inversoWMWpeptide
(D-aminoacids) superimposedon the conformationof theWMWresiduesof RasGAP (L-aminoacids). The twopeptides are coloredaccording to theatomtypes.
Lighter colors have been applied to the retro-inverso peptide.
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TAT-RasGAP317–326 peptide, synthesized with D-amino acids,
adopts a similar configuration. To assess this point, we per-
formed an in silico superimposition between the WMW
sequences in D-amino acids and the one derived from the SH3
domain of RasGAP (L-form, PDB ID: 2J05). Fig. 5C shows a
virtual identical structure for both conformations, indicating
that the D-amino acid version of 317–326 is likely to engage
DLC1 as the corresponding natural L-form does.
DISCUSSION
Increasing the rate of death induced by chemotherapy spe-
cifically in cancer cells and impairing their invasiveness are
prime strategies to fight cancer. We previously reported that a
cell-permeable peptide derived from RasGAP, 317–326, had
the ability to act as a dual anticancer peptide by sensitizing
tumor cells to anticancer therapy-induced cell death and by
hampering invasiveness (8, 9, 11). The mode of action of this
peptide is still imprecisely defined. However, recent data dem-
onstrated that the DLC1 tumor suppressor binds to the paren-
tal molecule (fragment N2) that contains 317–326 and that
DLC1 is required for some of the anticancer activities of 317–
326 (11). This new information allowed us to evaluate whether
317–326 is able to bind the DLC1 GAP domain using ITC and
their mode of binding using site-directed mutagenesis and in
silicomodeling approaches. The KD of this interaction is about
10-fold higher than the KD calculated for the interaction
between the SH3 domain of RasGAP with the DLC1 GAP
domain (0.6 !M) (31). The weaker binding affinity of 317–326
with the DLC1 GAP domain could be explained by the number
of amino acids involved in the interaction. Indeed, it appears
that only two amino acids are necessary for this binding,
whereas it has been reported that three amino acids are
involved in the interaction between the RasGAP SH3 domain
and the DLC1 GAP domain (31).
In this study, we show that sensitization to apoptosis, migra-
tion, and adhesion was differentially modulated by 317–326
(Fig. 2D) but that this globally required the same crucial amino
acids (Fig. 2C). The full-length RasGAP peptide could be nar-
rowed down to a three-amino acid peptide, 317–319, that still
bears most of the anticancer activities of the longer construct
(Fig. 4, A and B). However, in contrast to its effect on apoptosis
sensitization, the ability of 317–319 to inhibit migration was
reduced as compared with that of the 10 amino acid 317–326
sequence. This suggests that two targets are involved in trans-
ducing the RasGAP peptide anticancer properties. Here, we
show that another DLC isoform, DLC2, is also engaged by frag-
ment N2 (Fig. 4E), raising the possibility that the second target
is DLC2.However, this remains to be demonstrated. It has been
previously reported that the SH3 of RasGAP inhibits the GAP
activity of DLC1 (33). These results have been confirmed very
recently by the observation that RasGAP SH3 domain inhibits
the GAP activity of DLC1 in vitro (31). Therefore, a reasonable
assumption is that 317–319, by engaging the Arg-677 finger of
DLC1, also inhibits the GAP activity of DLC1. However, DLC1
exerts some of its functions in a GAP-independent manner
(29), and it remains possible that 317–326 mediates its effects
by modulating the GAP-independent activities of DLC1. In
favor of this second possibility is our recent observation that
Rho inhibition using the C3 exoenzyme does not prevent 317–
326 from increasing adhesion (11).
We have demonstrated here that the Trp-317 and Trp-319
residues are required for 317–326 to mediate its anticancer
effects. The importance of these residues for protein-protein
interaction is consistent with previously published structural
data showing that Trp-317 and Trp-319 establish a hydropho-
bic pocket allowing the dimerization of the SH3 domain of Ras-
GAP (24). Data collected in the present study suggest that other
amino acids, although not strictly required for the biological
activity of the RasGAP-derived peptide, are nevertheless of
importance, in particular as structural scaffolding residues
(amino acids 323–325). Interestingly, the hydrophilic residues
of 317–326 (Thr-321, Asn-322, and Asp-326), known to be
exposed at the surface of the RasGAP SH3 crystal (24), are dis-
pensable for 317–326-mediated anticancer effects. This sug-
gests that hydrophobicity is a key chemical property through
which 317–326 (and likely the endogenous p120 RasGAP SH3
domain) functions. Met-318, a residue that is not strictly con-
served during evolution but whose hydrophobicity is however
evolutionary conserved (leucine in insects), could be indeed
replaced by a hydrophobic leucine residue without any loss in
activity of 317–326. Another important question is whether a
WaW motif (where a represents an aliphatic residue) can be
found elsewhere within the human proteome and be a putative
target of DLC1/2. Not surprisingly, hundreds of proteins bear
such a motif, but none of them correspond to known DLC-
interacting proteins or are predicted to be involved in biological
functions potentially modulated by the DLC proteins (data not
shown) (29).
The discovery that a very short peptidic motif, consisting of
only two tryptophan amino acids separated by a spacer residue
(WXW), still bears, at least to some extent, the anticancer activ-
ities of the parental molecule provides the basis to undertake
the rational design of small molecules with similar activities.
Such drugs, by potentiating chemotherapy and impinging on
metastatic progression, may be of considerable benefit to can-
cer patients.
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Aldehyde dehydrogenase activity plays a
Key role in the aggressive phenotype of
neuroblastoma
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Abstract
Background: The successful targeting of neuroblastoma (NB) by associating tumor-initiating cells (TICs) is a major
challenge in the development of new therapeutic strategies. The subfamily of aldehyde dehydrogenases 1 (ALDH1)
isoenzymes, which comprises ALDH1A1, ALDH1A2, and ALDH1A3, is involved in the synthesis of retinoic acid, and
has been identified as functional stem cell markers in diverse cancers. By combining serial neurosphere passages
with gene expression profiling, we have previously identified ALDH1A2 and ALDH1A3 as potential NB TICs markers
in patient-derived xenograft tumors. In this study, we explored the involvement of ALDH1 isoenzymes and the
related ALDH activity in NB aggressive properties.
Methods: ALDH activity and ALDH1A1/A2/A3 expression levels were measured using the ALDEFLUOR™ kit, and by
real-time PCR, respectively. ALDH activity was inhibited using the specific ALDH inhibitor diethylaminobenzaldehyde
(DEAB), and ALDH1A3 gene knock-out was generated through the CRISPR/Cas9 technology.
Results: We first confirmed the enrichment of ALDH1A2 and ALDH1A3 mRNA expression in NB cell lines and
patient-derived xenograft tumors during neurosphere passages. We found that high ALDH1A1 expression was
associated with less aggressive NB tumors and cell lines, and correlated with favorable prognostic factors. In
contrast, we observed that ALDH1A3 was more widely expressed in NB cell lines and was associated with poor
survival and high-risk prognostic factors. We also identified an important ALDH activity in various NB cell lines and
patient-derived xenograft tumors. Specific inhibition of ALDH activity with diethylaminobenzaldehyde (DEAB)
resulted in a strong reduction of NB cell clonogenicity, and TIC self-renewal potential, and partially enhanced NB
cells sensitivity to 4-hydroxycyclophosphamide. Finally, the specific knock-out of ALDH1A3 via CRISPR/Cas9 gene
editing reduced NB cell clonogenicity, and mediated a cell type-dependent inhibition of TIC self-renewal properties.
Conclusions: Together our data uncover the participation of ALDH enzymatic activity in the aggressive properties
and 4-hydroxycyclophosphamide resistance of NB, and show that the specific ALDH1A3 isoenzyme increases the
aggressive capacities of a subset of NB cells.
Background
Neuroblastoma (NB), which arises from neural crest-
derived sympatho-adrenal progenitors, is one of the
most life-threatening solid tumors of childhood [1–3].
The hallmark of NB is its extreme biological, genetic,
and clinical heterogeneity. This leads to a broad spectrum
of clinical outcomes, ranging from spontaneous regression
to an aggressive life-threatening disease for high-risk NB,
with only 40% long-term survival despite intensive multi-
modal therapy [1–3]. While only few recurrent gene
mutations have been found in NB tumors, a large number
of recurrent somatic genetic alterations have been
described, which includes numerical or segmental
chromosomal alterations [1, 2, 4–6].
Like their tumor of origin, NB cell lines display
important biological heterogeneity. Three cell subtypes
arise spontaneously in NB cell line cultures: a) neuro-
blastic (N-type), displaying properties of embryonic
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sympathoblasts, b) substrate-adherent (S-type), resem-
bling Schwannian, glial or melanocytic progenitor cells,
and c) intermediate (I-type) subtype [7]. I-type cells
express markers of both N and S subtypes and display
bidirectional differentiation potential when treated with
specific agents [8–10]. Moreover, I-type cells are signifi-
cantly more aggressive than N- or S-type cells, and were
proposed to represent NB stem cells (SCs) or malignant
neural crest SCs [9, 11].
In recent years, emerging evidence has suggested that
tumor progression, metastasis, and chemotherapeutic
drug resistance are driven by a minor cell subpopulation,
designed as cancer stem cells (CSCs) or tumor-initiating
cells (TICs) [12–14]. These are capable of self-renewal
and differentiation into heterogeneous phenotypic and
functional lineages, and are characterized by plasticity
[14–16]. In a previous study aiming to identify NB TIC
markers, we combined serial neurosphere (NS) passage
assays, which allow the enrichment of TICs, with gene
expression profiling. This allowed the identification of a
gene expression signature associated to NB TICs [17].
Among this gene profile, ALDH1A2 and ALDH1A3
were selected for further investigations of their role in
maintaining NB TIC properties. The rationale behind
this selection is based on the demonstration of the im-
plication of ALDH activity in the biology of normal SCs
and CSCs in other settings [18–21].
ALDHs belong to a superfamily of 19 genes coding for
NAD(P)+-dependent enzymes involved in the detoxifica-
tion of a large number of endogenous and exogenous
aldehydes [22, 23]. The ALDH1 subfamily, which includes
A1, A2 and A3 isoforms, is involved in the synthesis of
retinoic acid, playing therefore an important role in devel-
oping tissues [22]. Elevated ALDH activity was first
demonstrated in normal hematopoietic progenitor/stem
cells and is now commonly used for the isolation of CSCs
in multiple tumor settings [24, 25]. Moreover, several
ALDH isoenzymes were associated to TICs properties,
such as ALDH1A1 in melanoma and lung adenocarcin-
oma [20, 26], ALDH1B1 in colon cancer [27], ALDH1A3
in breast cancer and NSCLC [28, 29], and ALDH7A1 in
prostate cancer [30]. ALDH1 expression was also
correlates with cyclophosphamide resistance [23, 31, 32], a
chemotherapeutic drug widely used for the treatment of
many cancers, including NB. So far, ALDH activity has
not been linked to NB tumor initiation or progression.
However, a recent paper described the involvement of
ALDH1A2 in the regulation of CSC properties in NB [33].
In this study, we aimed at exploring the expression
pattern of the three ALDH1 isoforms in NB cell lines
and patient-derived xenograft (PDX) tumors. ALDH
activity was found to play a role in NB cell aggressive
properties, such as clonogenicity, TIC proliferation, and
cyclophosphamide resistance. In addition, we revealed
that ALDH1A3 is associated with poor prognosis, and
ALDH1A3 gene disruption negatively impacted the
aggressiveness of a subset of NB cell lines, suggesting
that it can enhance NB tumorigenic properties.
Methods
Ethics statement
All in vivo procedures were performed under the guide-
lines of the Swiss Animal Protection Ordinance and the
Animal Experimentation Ordinance of the Swiss Federal
Veterinary Office (FVO). Animal experimentation proto-
cols were approved by the Swiss FVO (authorization
number: 1564.6). All reasonable efforts were made to
ameliorate suffering, including anesthesia for painful
procedures.
Patient-derived xenograft
Tumor material was collected from NB patients, diag-
nosed in the Hemato-Oncology Unit of the University
Hospital of Lausanne (Switzerland), after informed
consent and in agreement with local institutional ethical
regulations (Protocol 26/05, 07/02/2005). Patient-derived
xenografts (PDX) NB1, NB2 and NB4 were produced by
in vivo serial subcutaneous transplantations of bone-
marrow derived tumor cells in athymic Swiss nude mice
(Crl:NU(Ico)-Foxn1nu) from Charles River Laboratory
(France) [17]. PDX tumors were dissociated as
previously described [17].
Cell culture
All well-characterized NB cell lines [34–36] were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco,
Paisley, UK) supplemented with 10% Fetal Bovine Serum
(FBS) (Sigma-Aldrich, St Louis, USA) and 1% penicillin/
streptomycin (Gibco). The NB1-C cell line [17] was
established from the dissociated NB1 PDX tumor
derived from bone marrow metastatic cells (stage 4,
NMYC not amplified). NB1-C cells were maintained in
Neural Basic Medium (NBM) [DMEM/F12 supple-
mented with 1% penicillin/streptomycin, 2% B27
(Invitrogen, Carlsbad, USA), 20 ng/ml human recombin-
ant bFGF (Peprotech, Rocky Hill, USA), and 20 ng/ml
EGF (Peprotech)].
RNA extraction, reverse transcription, and PCR
Total RNAs from NB cells (1 × 106 cells) was obtained
using the RNeasy Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. RNAs (0.2-
1 μg) were reverse transcribed with the PrimeScriptTM
RT reagent Kit (TAKARA Bio, St.Germain-en-Laye,
France) using random primers and oligo dT primers
according to the manufacturer’s instructions.
The expression levels of ALDH1A1, ALDH1A2,
ALDH1A3, and MYC mRNAs were measured by real-
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time PCR using specific primers (QuantiTect primer
assay, Qiagen), QuantiFast SYBRgreen assay (Qiagen),
and the Corbett Rotor-Gene 6000 real-time cycler
(Qiagen), as previously described [37]. The cycling con-
ditions comprised 3 min polymerase activation at 95°C,
followed by 40 cycles of 3 s at 95°C, 20s at 60°C and 1 s
at 72°C for fluorescence acquisition. The ratio of each
gene of interest to HPRT1 gene expression and the rela-
tive gene expression were evaluated using the ΔCt and
ΔΔCt methods, respectively.
NANOG, SOX2, and MYC expression levels were ana-
lyzed by PCR using GoTaq Hot Start Kit (Promega,
Madison, USA) with the following primers: NANOG-for
5’-CAGCCCCGATTCTTCCACCAGTCCC-3’, NANOG-
rev 5’-CGGAAGATTCCCAGTCGGGTTCACC-3’, SOX
2-for 5’GGGAAATGGGAGGGGTGCAAAAGAGG-3,
SOX2-rev 5’-TTGCGTGAGTGTGGATGGGATTGGT
G-3’, MYC-for 5’-GCGTCCTGGGAAGGGAGATCCGG
AGC-3’, MYC-rev 5’-TTGAGGGGCATCGTCGCGGG
AGGCTG-3’. Cycling reactions were 2 min at 95°C
followed by 35 cycles of 30s at 95°C, 30s at 60°C and 30s
at 72°C, and 5 min at 72°C.
ALDEFLUOR assay
ALDH activity was analyzed using the ALDEFLUOR™ kit
according to manufacturer’s instructions (Stem Cell
Technologies, Grenoble, France). Briefly, 1×106 NB cells
or PDX-dissociated cells were resuspended in 1 ml
ALDEFLUOR assay buffer. The ALDH substrate BOD-
IPY™-aminoacetaldehyde (BAAA) was added to the cells.
Immediately after mixing, half of the suspension was
used as the negative control, by adding 5 μl of the
ALDH inhibitor diethylaminobenzaldehyde (DEAB,
3 μM). Cells were incubated for 30–45 minutes at 37°C,
then washed twice, and suspended in ALDEFLUOR™
assay buffer containing 1 μg/ml of DAPI (Life Technologies,
Switzerland) for viable cells selection. The brightly fluores-
cent ALDH+ cells were detected in the FL1-channel of a
GalliosTM Flow Cytometer (Beckman Coulter, Inc., USA)
and data were analyzed using KALUZA™ software
(Beckman Coulter, Inc., USA).
ALDH activity inhibition
Cells were pre-treated with DEAB (Sigma-Aldrich) at 50
or 100 μM according to the cell line tested, or for control
cells with Dimethyl sulfoxide (DMSO, Sigma-Aldrich) for
3 days prior functional assays, while maintaining the same
amount of DEAB or DMSO during the assay.
Proliferation assay
Cell proliferation was assessed using the MTS/PMS cell
proliferation kit (Promega). Briefly, 104 SK-N-Be2c cells
and 2*104 NB1-C cells per well were seeded in a
96-wells plate in DMEM/FCS or in NBM, respectively.
Proliferation was monitored by measuring the OD at
405 nm immediately after seeding and after 24, 48, 72
and 96 h in presence of DEAB or DMSO for ALDH
inhibition experiments, or without treatment.
Methylcellulose clonogenic assay
Clonogenic assays in semi-solid conditions were
performed as described [38]. Briefly, NB cells (1*103)
were grown in 500 μl semi-solid medium containing
53% methylcellulose (Fluka), and 47% DMEM/FCS (for
SK-N-Be2c) or 47% NBM (for NB1-C) in poly-Hema
(poly2-hydroxyethyl methylacrylate, 16 mg/ml in EtOH;
Sigma-Aldrich) -coated 24-wells plates. For ALDH activ-
ity inhibition assay, DEAB or DMSO was added in the
semi-solid medium, and supplemented every 4 days in
100 μl of medium. After 2 weeks, colonies were counted
using an optic microscope (Olympus, Volketswil,
Switzerland).
NB neurosphere culture and self-renewal assay
NS culture was performed as described in neural crest
stem cell medium (NCSCm) in poly-Hema-coated six
wells plates to prevent cell adhesion [17, 39]. For the
production of serial NS passages, NB cells (1×105 cells/ml)
were plated, and spheres were dissociated every 7 days in
0.05% trypsin-EDTA (Invitrogen), subsequently inhibited
with Trypsin inhibitor (v/v) (Sigma-Aldrich). At each
sphere passage, a part of the dissociated cells were tested
for ALDH activity and for ALDH1A1/2/3 mRNA expres-
sion. For self-renewal assay, 1×104 cells were plated in
500 μl NCSCm in triplicates without treatment, or in
presence of DEAB or DMSO for ALDH inhibition
experiments.
Cell viability assays
Cells (2×104 for SK-N-Be2c, IGR-N91 and IGR-N91R, or
4*104 for NB1-C) were plated in 96-wells plates 24 h
before treatment with 4-hydroxycyclophosphamide (4-
HCPA, Niomech, Bielefeld, Germany) for 48 h. Cell
viability was measured in quadruplicates using the MTS/
PMS cell proliferation kit from Promega according to
manufacturer’s instructions as described [40].
ALDH1A3 knock out through CRISPR/Cas9 technology
Two sgRNAs targeting the early exon of the ALDH1A3
gene were chosen in the published sgRNA library [41].
Oligos were designed as follow: sgALDH1A3.1:
forward 5’-CACCGCTACATGTAACCCTTCAACT-3’,
reverse 5’-AAACAGTTGAAGGGTTACATGTAGC-3’,
sgALDH1A3.2: forward 5’- CACCGCGCTCAGCCCG
ACGTGGACA-3’, reverse 5’- AAACTGTCCACGTCG
GGCTGAGCGC-3’. The lentiviral vector lentiCRISPR
v2 [42] was obtained from Adgene (Cambridge, USA).
LentiCRISPR v2-sgALDH1A3 plasmids were constructed
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according to the manufacturer’s instructions (Adgene).
Virus production and lentiviral infections were performed
as previously described [43] with the following modifica-
tion: pCMVDR8.91 was replaced by psPAX2 (Adgene).
Transduced SK-N-Be2c and NB1-C cells were selected
24 h post-infection with 5 μg/ml or 1 μg/ml of puromycin
(Sigma-Aldrich), respectively. Control cells were trans-
duced with virus containing the empty lentiCRIPR v2
vector. Clone isolation was performed by limiting dilution
in 96-wells plate.
Validation of the ALDH1A3 KO by immunoblotting
could not be performed due to the detection (using 3
different anti-ALDH1A3 antibodies) of a non-specific
band migrating with a similar velocity as ALDH1A3 in
the negative control SH-EP cell line lacking ALDH1A3
mRNA expression. Thus, genome editing in clones was
verified by NGS sequencing. PCR amplicons were
designed across the ALDH1A3 genomic regions targeted
by the sgRNAs to examine generation of indels. A
second PCR was performed to attach Illumina adaptors
and barcodes to samples according to manufacturer’s
instructions. Primers for the second PCR include both a
variable length sequence to increase library complexity
and an 8 bp barcode for multiplexing of different
biological samples. Amplicons were gel extracted,
quantified, mixed and sequenced with a MiSeq SR300
(Illumina Inc., San Diego, USA). Sequencing reads were
then processed with the following bioinformatic tools to
quantify the occurrence of indels in the selected clones.
Universal Illumina adapter and quality trimming of the
sequencing reads was achieved using Cutadapt [44]. The
trimmed reads were then aligned to the human refer-
ence genome (build GRCh37) using bwa [45] and then
visualized using Integrative Genomics Viewer (IGV,
Broad Institute). In parallel, to quantify the exact
number of genetic variants for each CRISPR clone, we
developed an R script that quantifies the percentage of
each detected variant.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5.04 (GraphPad Software, Inc., La Jolla, USA).
Unpaired two-tailed parametric t-test or non parametric
Mann Whitney test were carried out to compare two
different conditions, as specified in the Figure Legends.
Results
ALDH1A2 and ALDH1A3 expression are enhanced in NB
TICs
We have previously identified ALDH1A2 and ALDH1A3
genes as potential NB TIC markers as their expression
was upregulated during NS selection of NB TICs derived
from NB PDX tumors (181x and 9x baseline, respect-
ively by Affymetrix microarray analysis) [17]. To confirm
the enrichment in stem-like cells by serial NS passages
of NB cell lines, the expression levels of various SC-
associated markers were analyzed by RT-PCR and real-
time PCR at different sphere passages in the SK-N-Be2c
and NB1-C cell lines. NANOG, SOX2, and MYC mRNA
expression levels were already increased at the second
sphere passage (Additional file 1: Figure S1), confirming
the rapid enrichment of NB TICs through serial NS
culture.
To validate the prior microarray data and to provide a
closer insight into ALDH1 isoenzyme expression status
along the NB TIC selection, we analyzed the mRNA
expression levels of the three ALDH1 isoforms in four
successive NS passages and in parental cells (T0) grow-
ing in adherent conditions (Fig. 1). ALDH1A1 mRNA
expression levels during TIC selection varied depending
on the cell type and NS passages analyzed. In contrast,
ALDH1A2 mRNA expression was strongly increased, in
early steps of the TIC selection process (s1-s2) and
remained elevated in later NS passages (s3-s4) in the
I-type SK-N-Be2c cell line, as well as in the NB1 PDX
tumor and the related NB1-C cell line (Fig. 1). Moreover,
ALDH1A3 mRNA expression was also highly upregu-
lated in the NB1 PDX tumor and in the SK-N-Be2c cell
line during TIC selection, while it remained stable in the
NB1-C cell line (Fig. 1). Altogether, these results confirm
the enrichment of ALDH1A2 and ALDH1A3 mRNA
expression observed in the NS microarray profiling
derived from the NB PDX tumors [17].
ALDH activity was also measured during successive
NS passages from T0 to NS passage 4 (s4) in the SK-N-
Be2c and NB1-C cell lines, and in cells derived from the
NB1 PDX. The percentage of ALDH+ cells remained
stable during TIC selection in all cells analyzed; simi-
larly, the relative fluorescence intensity remained more
or less constant during NS passages except for a slight
increase in the NB1-C cell line (Fig. 2a and b). These
results indicate a lack of correlation between ALDH
activity (as measured using the ALDEFLUOR kit) and
ALDH1 isoform expression in NB TICs (see Discussion).
NB cell lines and PDX tumors display cell-specific ALDH1
isoenzyme expression profiles and elevated ALDH activity
Next, the expression profile of each ALDH1 isoform was
evaluated by real-time PCR in a large panel of NB cell
lines and NB PDX tumors. Most NB cell lines analyzed
expressed ALDH1A1 and/or ALDH1A3, but rarely
ALDH1A2 (Fig. 3a). The less aggressive S-type cell lines
expressed significantly higher levels of ALDH1A1
mRNA relative to N/I-type NB cells (Fig. 3a and b).
Interestingly, the NB1-C cell line and the related NB1-
PDX tumor displayed a similar expression pattern of
ALDH1 isoenzymes, with elevated expression levels of
ALDH1A1 and A3. Furthermore, the expression level of
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ALDH1A3 was significantly enhanced in the three PDX
tumors as compared to NB cell lines, suggesting a role of
this isoenzyme in in vivo grown tumors (Fig. 3a and b).
Further analysis of ALDH activity revealed elevated,
yet heterogeneous, percentages of ALDH+ cells in NB
cell lines and PDX tumors, ranging from 1.2 to 69%
(Fig. 4a and b).
High ALDH1A3 expression in NB tumors correlates with
poor outcome and high-risk prognostic markers
To identify the link between ALDH1 expression and NB
aggressiveness, the ALDH1A1/A2/A3 expression patterns
were analyzed in NB tumors using the R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl).
Analysis of the published dataset of Versteeg and
colleagues [5] revealed that high ALDH1A1 expression is
significantly associated with good prognosis, while
elevated expression of ALDH1A3 is strongly correlated
with poor survival (Fig. 5a). The expression level of
ALDH1A2 is globally reduced in NB tumors compared to
ALDH1A1 and A3 isoforms, but the rare tumors with
high ALDH1A2 expression level displayed a very poor
survival rate (Fig. 5a). Moreover, low expression levels of
ALDH1A1 (Fig. 5b) or high expression levels of
ALDH1A3 (Fig. 5c) are associated with unfavorable
prognostic factors in NB (i.e., age at diagnosis >18 months,
and stage 4 disease).
Inhibition of ALDH activity affects NB aggressive
properties
We next investigated whether the inhibition of ALDH
activity in NB cell lines affects the NB cell properties
associated with aggressiveness, such as proliferation,
anchorage-independent growth, and TIC self-renewal.
First, we confirmed that subtoxic doses of DEAB, a well-
known specific inhibitor of ALDH activity [21], fully
inhibit ALDH activity, which can be recovered by DEAB
removal (Additional file 1: Figure S2). Treatment with
DEAB had no impact on the 2D-proliferation capacities
of SK-N-Be2c and NB1-C cell lines (Fig. 6a). However,
ALDH activity inhibition strongly affected NB cell
clonogenic properties (Fig. 6b), and negatively impacted
on TIC self-renewal capacities of SK-N-Be2c and NB1-C
cell lines by 43 and 88%, respectively (Fig. 6c).
As ALDH activity was shown to mediate resistance to
4-hydroxycyclophosphamide (4-HCPA), NB cell sensitiv-
ity to this chemotherapeutic agent was also measured in
presence or absence of DEAB. We observed that ALDH
inhibition partly sensitized SK-N-Be2c and NB1-C cell
lines to 4-HPCA (Fig. 6d). In addition, we analyzed two
cell lines, the drug-sensitive IGR-N91, and the multidrug
resistant IGR-N91R, previously established in our lab
[35]. Interestingly, ALDH enzymatic inhibition was able
to almost completely sensitize the IGR-N91 cells to
4-HCPA and had a strong sensitizing impact on the
multidrug resistant IGR-N91R cells (Fig. 6e). Altogether
Fig. 1 ALDH1A2 and A3 isoform expression are enhanced during NB self-renewal process. The mRNA expression levels of the three ALDH1
isoforms (ALDH1A1, ALDH1A2 and ALDH1A3) were analyzed by real-time PCR in parental cells (T0) and four sphere passages (s1 to s4) of
SK-N-Be2c, NB1-C, and NB1 PDX-derived cells. Data are plotted as ALDH1 mRNA expression relative to the T0 parental cells in pooled s1-s2 and
s3-s4 ± SD (unpaired t-test: * correspond to p < 0.05, ** p < 0.01, *** p < 0.0001)
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these results demonstrate that endogenous ALDH activ-
ity plays a role in NB cell aggressive properties and me-
diates NB cell resistance to the chemotherapeutic drug
4-HCPA.
ALDH1A3 knock out affects NB clonogenic properties
Although ALDH activity measured by the ALDEFLUOR
assay was initially mainly attributed to the ALDH1A1
isoform, other ALDH isoenzymes, such as ALDH1A2,
ALDH1A3, ALDH2, ALDH3A1, and ALDH9A1, could
be involved in the measured ALDH activity [21, 25, 28,
29]. As the ALDH1A3 isoform is associated with poor
survival in NB and is the most widely expressed ALDH1
isoform in our panel of NB cell lines and PDX tumors
(Figs. 5a and 3a, respectively), we asked whether
ALDH1A3 activity plays a functional role in NB aggres-
sive phenotype. To answer this question, ALDH1A3
knock-out (KO) SK-N-Be2c and NB1-C cell lines were
generated by CRISPR/Cas9 gene editing (Additional file
1: Figure S3). Similarly, as for the observations after
DEAB-mediated ALDH inhibition, ALDH1A3 KO did
not affect the 2D-cell proliferation properties, but de-
creased the 3D-anchorage-independent growth of both
NB cell lines (Fig. 7a and b). While, ALDH1A3 KO only
impaired the TIC self-renewal properties of the SK-N-
Be2c cell line, but had no effect on NB1-C cells (Fig. 7c).
Discussion
In this study, we first confirmed the enrichment of
ALDH1A2 and ALDH1A3 expression during NB TICs
Fig. 2 ALDH activity remains stable during NB TICs selection. ALDH activity was measured using the ALDEFLUOR kit in parental cells (T0) and
successive sphere passages (s1 to s4) in SK-N-Be2c, NB1-C, and NB1 PDX-derived cells. a The percentage of ALDH+ cells (black bars) and the mean
fluorescence intensity (MFI) ratio (MFI of the test tube/control tube, red bars) are plotted as mean ± SD of more than 3 experiments according to
cell availability at each sphere passage (unpaired t-tests: ***p < 0.0005). b Representative dot plots showing the ALDH activity in SK-N-Be2c and
NB1-C parental cells (T0) and in sphere passages 4 (s4) in presence (control tube) or absence (test tube) of DEAB. The percentage of ALDH+ cells
are indicated in the dot plots
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selection in one PDX tumor (NB1), as well as in two dis-
tinct cell lines, the NB1-C cells derived from the NB1
PDX tumor, and/or the I-type SK-N-Be2c cell line. The
enhancement of ALDH1A2 and ALDH1A3 mRNA ex-
pression levels during TIC selection of NB1-PDX derived
cells was in accordance with the fold increase (181x and
9x, respectively) as observed in our previous microarray
analysis [17]. Interestingly, the implication of ALDH1A2
in the regulation of CSC properties in NB has recently
been reported [33]. Moreover, high ALDH1A2 expression
in NB correlates with poor survival, suggesting a role for
this ALDH1 isoenzyme in NB tumor aggressiveness.
ALDH activity has been demonstrated to select CSCs
in leukemia and breast, lung, liver, prostate, brain, and
colon cancer [23–25]. However, despite significant over-
expression of ALDH1A2 and ALDH1A3 during TIC
selection, no increase in the percentage of ALDH+ cells
could be observed during NS-passages by ALDEFLUOR
assay measurements. This suggests that ALDH enzym-
atic activity may not be a valuable functional marker of
TICs in NB. Similar findings were previously described
in melanoma [46].
Our analysis of ALDH1 isoform expression profiles in
NB cell lines and PDX tumors revealed differential
Fig. 3 NB cell lines and PDX tumors display various ALDH isoenzyme expression patterns. a Basal endogenous mRNA expression levels of each
ALDH1 isoform were measured in 10 NB cell lines (* = serum-free medium) and 3 NB PDX tumors by real-time PCR. Mean ratio of ALDH1 isoform/
HPRT1 ± SD are plotted in the bar graphs. Experiments were performed in tri- or quadruplicates (nd: not detected). b Comparison of ALDH1A1/
A2/A3 mRNA expression levels between S-type versus N/I-type cell lines (left panel) and NB cell lines versus PDX tumors (right panel). Individual
values and mean values ± SD of ALDH1 isoform/HPRT1 ratio are plotted in the dot plots (Mann Whithney test *p = 0.033, **p = 0.007)
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expression patterns which may rely on the strong het-
erogeneity of NB tumors and cell lines. The higher
expression levels of ALDH1A1 in the less aggressive
S-type cell lines is in accordance with the finding that
elevated ALDH1A1 expression in NB tumors correlates
with a better survival rate and favorable prognostic
factors. In other neoplasms, ALDH1A1 has been shown
to correlate either with favorable or poor prognosis
depending on the tumor setting or on tumor sample sets
[23]. Moreover, we observed that ALDH1A3 is strongly
expressed in PDX tumors, and that higher ALDH1A3
expression correlates with poor survival and high-risk
Fig. 4 Heterogeneous ALDH activity is detected in NB cell lines and PDX tumors. a The percentage of ALDH+ cells (black bars) and the MFI ratio
(MFI of the test tube/control tube, red bars), measured using the ALDEFLUOR kit, are given as mean ± SD of 1 to 8 experiments for the NB cell
lines and 3 to 4 experiments for the PDX-dissociated tumor cells. b Representative dot plots showing the ALDH activity in SK-N-Be2c, NB1-C cell
lines, and cells dissociated from the 3 PDX tumors in presence (control tube) or absence of DEAB (test tube). The percentages of ALDH+ cells
are indicated
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prognostic markers. These observations, as well as the
ALDH1A3 enrichment in NB TICs, suggest that
ALDH1A3 isoenzyme could be linked to NB progression
and aggressiveness. This correlates with other studies
showing that high ALDH1A3 expression is associated
with more aggressive forms of breast, glioblastoma,
glioma, and pancreatic cancer [28, 47–49].
NB PDX tumors and cell lines also displayed a strong
and heterogeneous ALDH enzymatic activity. However,
no correlation between the expression levels of a specific
ALDH1 isoform and ALDH activity could be identified
in these samples, as well as during NB TIC selection.
Although the ALDH enzymatic activity measured by the
ALDEFLUOR kit was initially mainly attributed to
ALDH1A1, other ALDH isoenzymes were also involved
[21, 25, 28, 29]. Further investigations are needed to
determine if the ALDH activity detected in NB cells can
be associated with a specific ALDH isoenzyme. Yet, we
observed that ALDH1A3 gene disruption had no major
impact on the ALDH enzymatic activity in SK-N-Be2c
and NB1-C clones (Additional file 1: Figure S4). These
data suggest that ALDH1A3 isoenzyme play a negligible
role in the conversion of the ALDH substrate, BODIPY-
aminoacetaldehyde, to fluorescent BODIPY-aminoacetate
reaction products in NB cells, in contrast to breast cancer
and non-small cell lung carcinoma [28, 29].
Drug resistance is a hallmark of CSCs or TICs and is
considered as a major contributing factor of relapse. Vari-
ous mechanisms of chemoresistance have been identified
in CSCs, including ALDH activity [50]. Indeed, ALDH
activity has been associated for a long time with normal
SC and CSC resistance to oxazaphosphorines such as
Fig. 5 ALDH1A3 expression is associated with unfavorable prognostic markers and reduced survival, while ALDH1A1 expression correlates with
less aggressive NB. a-c Graphs were generated from the Versteeg database (n = 88 NB patients) using the R2: Genomics Analysis and Visualization
Platform (http://r2.amc.nl). a Kaplan Meier overall survival curves. b-c ALDH1A1 (b) and ALDH1A3 (c) mRNA expression levels in NB tumors
according to age≤ or > 18 month at diagnosis (left panels) or with stage 4 versus stage 4 s (right panels)
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cyclophosphamide [23, 25, 51–53], a drug commonly used
during NB patient therapy. A cyclophosphamide-resistant
phenotype in relation with high ALDH activity has not yet
been described in NB. In this study, we demonstrate a sig-
nificant sensitization of NB cell lines to 4-HCPA, the ac-
tive metabolite of cyclophosphamide, upon ALDH activity
inhibition with DEAB, which represents an original find-
ing. Importantly, the multidrug resistant IGR-N91R cells
could be efficiently resensitized to 4-HCPA using DEAB.
As DEAB was shown to most potently inhibit ALDH1A1,
followed by ALDH2, ALDH1A2, ALDH1B1, ALDH1A3
and ALDH5A1 [54], further studies will be required to
determine the specific involvement of individual ALDH
isoenzyme in ALDH-mediated resistance to 4-HCPA in
NB.
Interestingly, we also demonstrate in this present study
that treatments of NB cells with DEAB induced a
significant decrease in their anchorage-independent growth
and TIC self-renewal properties. ALDH1A3 gene disruption
also impaired the clonogenic properties of both cell lines
analyzed. However, ALDH1A3 KO only affected the TIC
self-renewal capacities of the SK-N-Be2c cell line, but not
that of NB1-C cells. This observation correlates with the
lack of enrichment of the ALDH1A3 isoenzyme in the
NB1-C cell line during self-renewal assays, in contrast to
ALDH1A3 enrichment in the SK-N-Be2c cells and the NB1
PDX-derived cells (Fig. 1). This suggests that the ALDH1A3
isoenzyme may not play a major role in TIC self-renewal in
the NB1-C cell line.
The limitations of the present work are partly due to
the difficulty to precisely assess both global ALDH activ-
ity and particular isoform inhibition. This is an issue
shared by all prior reports on ALDH function. In fact,
the ALDEFLUOR kit has been thought to faithfully
Fig. 6 DEAB-mediated ALDH inhibition affects NB aggressive properties and sensitizes NB cells to 4-hydroxycyclophosphamide. Analyses of the
impact of ALDH activity inhibition by DEAB treatment on NB cell proliferation (2D-growth, a), clonogenicity (3D-growth, b), TICs self renewal (c),
and sensitivity to 4-HCPA (a-e). SK-N-Be2c and NB1-C cell lines were pre-treated with 100 or 50 μM of DEAB, respectively, for three days before
starting functional assays performed in presence of DEAB or DMSO as control. a Mean OD at 405 nm± SD of 4 (SK-N-Be2c) or 2 (NB1-C) experiments
performed in quadruplicates. b Mean of relative colony numbers ± SD of 3 experiments performed in duplicates (unpaired t-test *p < 0.05, ***p≤
0.0005). c Mean ratio of cell number/cell plated ± SD of 2 experiments performed in triplicates (unpaired t-test ***p≤ 0.0001). d Cell viability of
SK-N-Be2c and NB1-C cells treated for 48 h with indicated doses of 4-HCPA in presence or absence of DEAB (100 μM and 50 μM, respectively). Mean
values ± SD of 3 experiments performed in quadruplicates (unpaired t-test *p < 0.02, ***p≤ 0.0001). e Cell viability of IGR-N91 and IGR-N91R cells
treated for 48 h with indicated doses of 4-HCPA in presence or absence of DEAB (100 μM). Mean values ± SD of 3 experiments performed in
quadruplicates (unpaired t-test ***p≤ 0.0005)
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measure ALDH1A1 isoform activity, a presumption
which has subsequently been shown not be entirely
correct (see above). Moreover, DEAB selectively inhibits
specific ALDH isoenzymes, and this at various levels of
efficiency. In this study, we addressed these limitations
by performing genetic knock-outs that (from our previ-
ous work on TICs) appeared to influence the biology of
NB, and investigated their impact. Similarly, as for other
metabolic pathways involved in oncogenesis, the func-
tional redundancy of multiple enzymatic isoforms limits
the investigation of the mechanistic underpinnings
behind the effects we and other observed. Nonetheless,
we feel that, while our findings are mostly focused on in
vitro assays for oncogenic potential, this study opens
new avenues for in vivo investigations. In particular, the
ALDH-associated re-sensitization of NB to frequently
used chemotherapeutic agents (i.e., cyclophosphamide)
will need to be further detailed as it constitutes a poten-
tial translational avenue. In addition, the data linking
ALDH variation with clinical outcomes in NB patients
correlate with our prior work and the current results.
We feel they constitute an encouraging step towards
further work addressing the role of ALDH isoforms in
murine models of NB, in particular PDX.
Conclusions
Our results highlight the impact of ALDH enzymatic
activity on the aggressive properties of NB in addition to
Fig. 7 Specific ALDH1A3 KO impairs NB cell clonogenic properties. a-c Impact of ALDH1A3 specific KO was analyzed on the proliferation (a),
clonogenic (b), and TIC self-renewal (c) capacities. a Mean OD at 405 nm ± SD of 3 experiments performed in quadruplicates. b Mean of relative
colony numbers ± SD of 3 experiments performed in duplicates (unpaired t-test *p < 0.05). c Mean ratio of cell number/cell plated ± SD of 3
experiments performed in duplicates in pooled s1 to s3 passages (s1-s3) (unpaired t-test **p≤ 0.005)
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its resistance to 4-HCPA. Further work is needed to
identify the specific ALDH isoenzyme(s) involved as they
may be considered for future therapeutic strategies for
high-risk NB.
Additional file
Additional file 1: Figure S1. Stem cell markers are enriched during
neurosphere culture. Figure S2. DEAB treatment is efficient to transitory
inhibit ALDH activity. Figure S3. Illustration of the insertions/deletions in
the different ALDH1A3 KO clones. Figure S4. ALDH1A3 KO has no
impact on the percentage of ALDH+ cells. (ZIP 1853 kb)
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Additional Files 
Fig S1. Stem cell markers are enriched during neurosphere culture. (A) The expression levels of the 
stem cell markers Nanog, Sox2 and Myc were analyzed by RT-PCR in total RNA obtained from SK-N-
Be2c and NB1-C parental cells (T0) and the sphere passage s2. The HPRT1 gene was used as control. 
(B) MYC mRNA expression was analyzed by real-time PCR in the sphere passages s2, and s5 relative to 
parental cells (T0). Mean relative expression ± SD of two experiments performed in duplicates were 
plotted in the bare graph (unpaired t-test, *p<0.05). 
Fig S2. DEAB treatment is efficient to transitory inhibit ALDH activity. ALDH activity was analyzed in 
untreated SK-N-Be2c cells, after prolonged treatment with 100  M DEAB for 5 days, or after 3 days in 
presence of DEAB followed by 2 days in absence of DEAB. Representative dot plots are shown. 
Fig S3. Illustration of the insertions/deletions in the different ALDH1A3 KO clones. DNA sequences 
of WT ALDH1A3 gene and mutated alleles of 2 clones of SK-N-Be2c cells and 2 clones NB1-C cells 
identified by MiSeq Illumina sequencing. Insertions/deletions are indicated in red.  The sgALDH1A3.1 and 
sgALDH1A3.2 are highlighted in light grey and in dark grey, respectively, and the PAM sequence is 
labeled in black bold. The number of reads and percentage of each allele/total number of reads are 
indicated, as well as the total coverage. Note that three alleles were found in the SK-N-Be2c clone 1.9, 
indicating a triploidy of this genomic region, which was confirmed by the ratio of 2 different indels found in 
clone 1.18. The alleles 1 and 2 have the same indel. In addition, only one indel could be identified in each 
NB1-C clone, suggesting LOH in this genomic region. All indels lead to premature stop codons in the N-
term end of the ALDH1A3 protein as indicated.  
Fig S4. ALDH1A3 KO has no impact on the percentage of ALDH+ cells. ALDH activity was measured 
using the ALDEFLUOR kit in control and ALDH1A3 KO SK-N-Be2c and NB1-C clones. (A) The 
percentage of ALDH+ cells are plotted as mean ± SD of 2 experiments. 
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